


**CUMULATIVE
SUPPLEMENT 10
October 2023**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2023

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

**Cumulative Supplement 10
October 2023**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	ix
1.5	AVAILABILITY OF THE EDITION.....	x
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	xi
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xii

DRUG PRODUCT LISTS

Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Products Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

43rd EDITION

**CUMULATIVE SUPPLEMENT 10
October 2023**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPR) of any changes or corrections. The DOBPR can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME (NEW ABBREVIATED NAME)</u>
AKORN OPERATING CO LLC (AKORN)	EPIC PHARMA LLC (EPIC PHARMA LLC)
AKORN OPERATING CO LLC (AKORN)	HIKMA PHARMACEUTICALS USA INC (HIKMA)
AKORN OPERATING CO LLC (AKORN)	RISING PHARMA HOLDINGS INC (RISING)
ALEOR DERMACEUTICALS LTD (ALEOR DERMACEUTICALS)	ALEMBIC PHARMACEUTICALS LTD (ALEMBIC)
ALLERGAN (ALLERGAN)	ABBVIE INC (ABBVIE)

ALLERGAN HOLDINGS UNLTD CO (ALLERGAN HOLDINGS)	ABBVIE INC (ABBVIE)
ALLERGAN INC (ALLERGAN)	ABBVIE INC (ABBVIE)
ALLERGAN SALES LLC (ALLERGAN)	ABBIE (ABBVIE)
ALLERGAN SALES LLC (ALLERGAN)	ABBVIE INC (ABBVIE)
EMCURE PHARMACEUTICALS LTD (EMCURE PHARMS)	AVET LIFESCIENCES LTD (AVET LIFESCIENCES)
EMCURE PHARMACEUTICALS LTD (EMCURE PHARMS LTD)	AVET LIFESCIENCES LTD (AVET LIFESCIENCES)
EPIC PHARMA INC (EPIC PHARMA)	EPIC PHARMA LLC (EPIC PHARMA LLC)
EPIC PHARMA INC (EPIC PHARMA INC)	EPIC PHARMA LLC (EPIC PHARMA LLC)
HERITAGE PHARMA LABS INC (HERITAGE PHARMA)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
HERITAGE PHARMA LABS INC DBA AVET PHARMACEUTICALS LABS INC (HERITAGE PHARMA AVET)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
MAYNE PHARMA INC (MAYNE PHARMA INC)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA INTERNATIONAL PTY LTD (MAYNE PHARMA)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA INTERNATIONAL PTY LTD (MAYNE PHARMA INTL)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA LLC (MAYNE PHARMA)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
NEXUS PHARMACEUTICALS INC (NEXUS PHARMS)	NEXUS PHARMACEUTICALS LLC (NEXUS)
STRIDES PHARMA GLOBAL PTE LTD (STRIDES PHARMA)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
TORRENT PHARMA INC (TORRENT)	APOZEAL PHARMACEUTICALS INC (APOZEAL PHARMS)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	App1 No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	–

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	–	RS
-----	-----------------------------------	-------	-------	---------	---	----

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2022</u>	<u>MAR</u> <u>2023</u>	<u>JUN</u> <u>2023</u>	<u>SEP</u> <u>2023</u>	<u>DEC</u> <u>2024</u>
DRUG PRODUCTS	21983	22398	22632	22925	
LISTED SINGLE	2718	2759	2779	2771	
SOURCE	(12.4%)	(12.3%)	(12.3%)	(12.1%)	
MULTISOURCE	19265	19639	19853	20154	
	(87.6%)	(87.7%)	(87.7%)	(87.9%)	

THERAPEUTICALLY EQUIVALENT	19165 (87.2%)	19554 (87.3%)	19781 (87.4%)	20083 (87.6%)
NOT THERAPEUTICALLY EQUIVALENT	100 (0.5%)	85 (0.4%)	72 (0.3%)	71 (0.3%)
EXCEPTIONS ⁴	46 (0.2%)	46 (0.2%)	46 (0.2%)	46 (0.2%)
NEW MOLECULAR ENTITIES APPROVED	8	19	11	20
NUMBER OF APPLICANTS	1211	1222	1217	1216

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ABIRATERONE ACETATE

TABLET; ORAL							
ABIRATERONE ACETATE							
AB	DR REDDYS	500MG	A208416	002	Sep 01, 2023	Aug	NEWA
AB	FLORIDA	500MG	A215086	001	Mar 23, 2023	Mar	NEWA
AB	TEVA PHARMS USA	500MG	A210726	001	Jan 26, 2023	Jan	NEWA

ABIRATERONE ACETATE; NIRAPARIB TOSYLATE

TABLET; ORAL							
AKEEGA							
+	JANSSEN BIOTECH	500MG; EQ 50MG BASE	N216793	001	Aug 11, 2023	Aug	NEWA
+	!	500MG; EQ 100MG BASE	N216793	002	Aug 11, 2023	Aug	NEWA

ACARBOSE

TABLET; ORAL							
ACARBOSE							
@	DASH PHARMS	25MG	A091053	001	Jan 06, 2011	Feb	CAHN
@		50MG	A091053	002	Jan 06, 2011	Feb	CAHN
@		100MG	A091053	003	Jan 06, 2011	Feb	CAHN

ACETAMINOPHEN

SOLUTION; INTRAVENOUS							
ACETAMINOPHEN							
AP	WOCKHARDT BIO AG	1GM/100ML (10MG/ML)	A205746	001	Apr 18, 2023	Apr	NEWA
	@ ZYDUS PHARMS	1GM/100ML (10MG/ML)	A216467	001	Oct 25, 2022	Mar	DISC

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET; ORAL							
APADAZ							
+	@ KVK TECH INC	325MG; EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Mar	DISC
+	@	325MG; EQ 6.12MG BASE	N208653	001	Feb 23, 2018	Mar	DISC
+	@	325MG; EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Mar	DISC
+	@ ZEVRA THERAP	325MG; EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Jun	CAHN
+	@	325MG; EQ 6.12MG BASE	N208653	001	Feb 23, 2018	Jun	CAHN
+	@	325MG; EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Jun	CAHN

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL							
BUTALBITAL AND ACETAMINOPHEN							
AA	@ ALVOGEN	300MG; 50MG	A207635	001	Jun 05, 2017	Aug	DISC
AA	NE RX PHARMA	300MG; 50MG	A214955	001	Aug 16, 2022	Sep	CAHN
AA	SENORES PHARMS	300MG; 50MG	A214088	001	Apr 07, 2022	Jan	CAHN
AA		325MG; 25MG	A214088	002	Apr 07, 2022	Jan	CAHN
AA		325MG; 50MG	A214088	003	Apr 07, 2022	Jan	CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL							
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
AA	RISE PHARMA	300MG; 50MG; 40MG	A214087	001	Aug 13, 2021	Sep	CAHN
AA		325MG; 50MG; 40MG	A214087	002	Aug 13, 2021	Sep	CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL							
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE							
>D>	LARKEN LABS INC	325MG; 30MG; 16MG	A204209	001	Sep 30, 2016	Oct	DISC
>A>	@	325MG; 30MG; 16MG	A204209	001	Sep 30, 2016	Oct	DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL							
ACETAMINOPHEN AND CODEINE PHOSPHATE							
AA	! GENUS LIFESCIENCES	120MG/5ML; 12MG/5ML	A087508	001		Sep	CAHN
TABLET; ORAL							
ACETAMINOPHEN AND CODEINE PHOSPHATE							
	@ NOSTRUM LABS INC	300MG; 15MG	A088629	002	Mar 06, 1985	Apr	DISC
	@	300MG; 30MG	A088629	003	Mar 06, 1985	Apr	DISC
	+ @	300MG; 60MG	A088629	001	Mar 06, 1985	Apr	DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ SUN PHARM INDS INC 325MG; 5MG

A090118 001 Dec 23, 2008 Jun DISC

@ 325MG; 7.5MG

A090118 002 Dec 23, 2008 Jun DISC

@ 325MG; 10MG

A090118 003 Dec 23, 2008 Jun DISC

ACETAMINOPHEN; IBUPROFEN

TABLET; ORAL

COMBOGESIC

+ @ AFT PHARMS LTD 325MG; 97.5MG

N209471 001 Mar 01, 2023 Aug DISC

+! 325MG; 97.5MG

N209471 001 Mar 01, 2023 Mar NEWA

ACETAMINOPHEN; IBUPROFEN SODIUM

SOLUTION; INTRAVENOUS

COMBOGESIC IV

>A> +! HIKMA 1GM/100ML (10MG/ML); EQ 300MG
BASE/100ML (EQ 3MG BASE/ML)

N215320 001 Oct 17, 2023 Oct CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

@ DR REDDYS LABS SA 500MG; 7.5MG

A090177 005 Oct 20, 2008 Apr CAHN

@ 650MG; 10MG

A090177 006 Oct 20, 2008 Apr CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

>A> AB ! AMNEAL PHARMS 325MG; 37.5MG

A090485 001 Dec 09, 2009 Mar CHRS

>D> @ CHARTWELL RX 325MG; 37.5MG

A076475 001 Apr 21, 2005 Oct CAHN

@ STRIDES PHARMA 325MG; 37.5MG

A076475 001 Apr 21, 2005 Oct CAHN

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

AB INDICUS PHARMA 500MG

A090779 001 Jul 14, 2011 Feb CMFD

TABLET; ORAL

ACETAZOLAMIDE

AB AARKISH PHARMS NJ 125MG

A217197 001 May 09, 2023 Apr NEWA

AB 250MG

A217197 002 May 09, 2023 Apr NEWA

AB AJANTA PHARMA LTD 125MG

A211151 001 Sep 11, 2023 Sep NEWA

AB 250MG

A211151 002 Sep 11, 2023 Sep NEWA

@ BRECKENRIDGE 125MG

A207503 001 Apr 30, 2020 Jan DISC

@ 250MG

A207503 002 Apr 30, 2020 Jan DISC

AB NE RX PHARMA 125MG

A217197 001 May 09, 2023 Sep CAHN

AB 250MG

A217197 002 May 09, 2023 Sep CAHN

AB ZYDUS 125MG

A211069 001 Apr 04, 2023 Mar NEWA

AB 250MG

A211069 002 Apr 04, 2023 Mar NEWA

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETIC ACID

@ CHARTWELL RX 2%

A040166 001 Jul 26, 1996 Jan CAHN

VOSOL

AT ! HIKMA 2%

N012179 001 Sep CAHN

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

HYDROCORTISONE AND ACETIC ACID

@ COSETTE 2%; 1%

A040609 001 Feb 06, 2006 Jun DISC

AT +! TARO 2%; 1%

A088759 001 Mar 04, 1985 Jun CHRS

AT + 2%; 1%

A088759 001 Mar 04, 1985 Jun CRLD

VOSOL HC

>D> AT +! AKORN 2%; 1%

N012770 001 Oct CAHN

>A> AT +! SAPTALIS PHARMS 2%; 1%

N012770 001 Oct CAHN

ACETYLCYSTEINEINJECTABLE; INTRAVENOUS
ACETYLCYSTEINE

AP	STERISCIENCE	6GM/30ML (200MG/ML)	A217182	001	Apr 19, 2023	Apr	NEWA
	SOLUTION; INHALATION, ORAL						
	ACETYLCYSTEINE						

>A>	AN	EXELA PHARMA	20%	A205643	001	Nov 01, 2023	Oct	NEWA
-----	----	--------------	-----	---------	-----	--------------	-----	------

ACYCLOVIRCAPSULE; ORAL
ACYCLOVIR

AB	@ AUROBINDO PHARMA USA	200MG	A074727	001	Apr 22, 1997	May	CAHN
	INDOCO	200MG	A075090	001	Jan 26, 1999	Sep	CAHN

CREAM; TOPICAL
ACYCLOVIR

AB	ZYDUS LIFESCIENCES	5%	A206770	001	Feb 28, 2023	Feb	NEWA
----	--------------------	----	---------	-----	--------------	-----	------

SUSPENSION; ORAL
ACYCLOVIR

>D>	@ AUROBINDO PHARMA	200MG/5ML	A216331	001	Mar 31, 2022	Oct	CMFD
-----	--------------------	-----------	---------	-----	--------------	-----	------

>A>	AB		A216331	001	Mar 31, 2022	Oct	CMFD
-----	----	--	---------	-----	--------------	-----	------

AB	CHARTWELL RX	200MG/5ML	A212718	001	Apr 23, 2020	Aug	CAHN
----	--------------	-----------	---------	-----	--------------	-----	------

AB	MSN	200MG/5ML	A217393	001	Mar 09, 2023	Mar	NEWA
----	-----	-----------	---------	-----	--------------	-----	------

AB	! NOVITIUM PHARMA	200MG/5ML	A212252	001	Jul 10, 2020	May	CHRS
----	-------------------	-----------	---------	-----	--------------	-----	------

>D>	AB	VISTAPHARM	200MG/5ML	A213951	001	Jan 11, 2021	Oct	DISC
-----	----	------------	-----------	---------	-----	--------------	-----	------

>A>	@	200MG/5ML	A213951	001	Jan 11, 2021	Oct	DISC
-----	---	-----------	---------	-----	--------------	-----	------

ZOVIRAX

+ @ MYLAN 200MG/5ML

N019909	001	Dec 22, 1989	May	DISC
---------	-----	--------------	-----	------

TABLET; BUCCAL
SITAVIG

+! LNHC 50MG

N203791	001	Apr 12, 2013	Sep	CAHN
---------	-----	--------------	-----	------

TABLET; ORAL
ACYCLOVIR

@ AUROBINDO PHARMA USA 400MG

A075211	001	Sep 28, 1998	Apr	CAHN
---------	-----	--------------	-----	------

@ 800MG

A075211	002	Sep 28, 1998	Apr	CAHN
---------	-----	--------------	-----	------

ADAPALENEGEL; TOPICAL
ADAPALENE

AB	ENCUBE ETHICALS	0.3%	A200298	001	Jun 14, 2012	Apr	CMFD
----	-----------------	------	---------	-----	--------------	-----	------

ADAPALENE; BENZOYL PEROXIDEGEL; TOPICAL
ADAPALENE AND BENZOYL PEROXIDE

AB	ENCUBE	0.1%; 2.5%	A206164	001	May 23, 2018	Aug	CMFD
----	--------	------------	---------	-----	--------------	-----	------

>A> ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

>A> GEL; TOPICAL

>A> CABTREO

>A>	+!	BAUSCH	0.15%; 3.1%; 1.2%	N216632	001	Oct 20, 2023	Oct	NEWA
-----	----	--------	-------------------	---------	-----	--------------	-----	------

ADENOSINESOLUTION; INTRAVENOUS
ADENOSINE

AP	! HONG KONG	60MG/20ML (3MG/ML)	A077425	001	Aug 29, 2013	Sep	CAHN
----	-------------	--------------------	---------	-----	--------------	-----	------

AP	!	90MG/30ML (3MG/ML)	A077425	002	Aug 29, 2013	Sep	CAHN
----	---	--------------------	---------	-----	--------------	-----	------

ALBENDAZOLETABLET; ORAL
ALBENDAZOLE

@ CHARTWELL RX 200MG

A211636	001	Jun 10, 2020	May	CAHN
---------	-----	--------------	-----	------

@ CIPLA LTD 200MG

A210434	001	Sep 21, 2018	Sep	DISC
---------	-----	--------------	-----	------

ALBUTEROL SULFATESOLUTION; INHALATION
ACCUNEB

+ @ MYLAN SPECIALITY LP EQ 0.021% BASE

N020949	002	Apr 30, 2001	Jun	DISC
---------	-----	--------------	-----	------

ALBUTEROL SULFATE

AN	! RITEDOSE CORP	EQ 0.021% BASE	A214531	001	Dec 28, 2021	Jun	CHRS
----	-----------------	----------------	---------	-----	--------------	-----	------

AN	SENTISS	EQ 0.5% BASE	A074543	001	Jan 15, 1998	Jul	CAHN
----	---------	--------------	---------	-----	--------------	-----	------

TABLET;ORAL

ALBUTEROL SULFATE

AB	DASH PHARMS NATCO	EQ 2MG BASE	A072894	002	Jan 17, 1991	Feb CAHN
AB	!	EQ 4MG BASE	A072894	001	Jan 17, 1991	Feb CAHN

ALBUTEROL SULFATE; BUDESONIDE

AEROSOL, METERED; INHALATION

AIRSUPRA

+	ASTRAZENECA	EQ 90MCG BASE/INH;80MCG/INH	N214070	001	Jan 10, 2023	Feb CAHN
+	BOND	EQ 90MCG BASE/INH;80MCG/INH	N214070	001	Jan 10, 2023	Jan NEWA

ALENDRONATE SODIUM

SOLUTION;ORAL

ALENDRONATE SODIUM

AA	!	HIKMA	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013	May CTEC
AA		NOVITIUM PHARMA	EQ 70MG BASE/75ML	A214512	001	May 11, 2023	May NEWA

TABLET;ORAL

ALENDRONATE SODIUM

@ ANDA REPOSITORY

@

@

@

TABLET, EFFERVESCENT;ORAL

BINOSTO

>D>	+	ASCEND THERAPS US	EQ 70MG BASE	N202344	001	Mar 12, 2012	Oct CAHN
>A>	+	RADIUS	EQ 70MG BASE	N202344	001	Mar 12, 2012	Oct CAHN

ALFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION

ALFENTA

AP	+	RISING	EQ 0.5MG BASE/ML	N019353	001	Dec 29, 1986	Sep CAHN
----	---	--------	------------------	---------	-----	--------------	----------

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

AB		ACCORD HLTHCARE	300MG	A203154	002	May 06, 2013	Jul CHRS
AB		HETERO LABS LTD V	100MG	A217748	001	Aug 03, 2023	Jul NEWA
AB			300MG	A217748	002	Aug 03, 2023	Jul NEWA
AB	!	UNICHEM	300MG	A211820	002	Mar 12, 2019	Jul CHRS

ALPROSTADIL

INJECTABLE;INJECTION

ALPROSTADIL

AP		HONG KONG	0.5MG/ML	A075196	001	Apr 30, 1999	Sep CAHN
----	--	-----------	----------	---------	-----	--------------	----------

ALVIMOPAN

CAPSULE;ORAL

ALVIMOPAN

AB		HIKMA	12MG	A217753	001	Aug 31, 2023	Aug NEWA
AB		PAR PHARM	12MG	A216843	001	Jan 24, 2023	Jan NEWA
AB	!	WATSON LABS TEVA	12MG	A208295	001	Dec 19, 2019	Jun CHRS
		ENTEREG					
	+	@ CUBIST PHARMS	12MG	N021775	001	May 20, 2008	Jun DISC

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB		RISING	100MG	A210129	001	Mar 02, 2020	Sep CAHN
AB		STRIDES PHARMA	100MG	A209047	001	Jun 07, 2017	Feb CTEC

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

AA	!	AUROBINDO PHARMA USA	50MG/5ML	A074170	001	Oct 28, 1994	Jul CAHN
AA		ELYSIUM	50MG/5ML	A214178	001	Aug 20, 2021	Sep CAHN

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

AB		ATHEM	100MG	A210215	001	Mar 10, 2020	Sep CAHN
AB		STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017	Feb CTEC

AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINE

@ SUN PHARM

500MG/VIAL

A077126 001 Mar 14, 2008 Jul DISC

ETHYOL

+! CLINIGEN

500MG/VIAL

N020221 001 Dec 08, 1995 Jul CTEC

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

! HIKMA

EQ 50MG BASE/ML

A063313 001 Apr 11, 1994 Feb CTEC

@ HONG KONG

EQ 50MG BASE/ML

A064045 001 Sep 28, 1993 Sep CAHN

AP

EQ 250MG BASE/ML

A064045 002 Sep 28, 1993 Sep CAHN

AMINOCAPROIC ACID

SOLUTION; ORAL

AMICAR

AA +! HIKMA

0.25GM/ML

N015230 002

Sep CAHN

AMINOCAPROIC ACID

AA TARO

0.25GM/ML

A214458 001 Mar 24, 2023 May CAHN

AA TARO PHARMS

0.25GM/ML

A214458 001 Mar 24, 2023 Mar NEWA

@ VISTAPHARM

0.25GM/ML

A212814 001 Feb 26, 2020 Mar DISC

TABLET; ORAL

AMICAR

AB + HIKMA

500MG

N015197 001

Sep CAHN

AB +

1GM

N015197 002 Jun 24, 2004

Sep CAHN

AMINOCAPROIC ACID

AB MSN

1GM

A212938 002 Sep 13, 2023 Sep NEWA

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

@ CHARTWELL MOLECULAR

100MG

A084588 001

Jul CAHN

@

200MG

A084588 002

Jul CAHN

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB CHARTWELL RX

100MG

A077069 003 Oct 04, 2016 Jun CAHN

AB

200MG

A077069 001 Apr 08, 2005 Jun CAHN

AB

400MG

A077069 002 Apr 08, 2005 Jun CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB CHEMISTRY HLTH

10MG

A216243 001 Jun 06, 2022 Sep CAHN

AB

25MG

A216243 002 Jun 06, 2022 Sep CAHN

AB

50MG

A216243 003 Jun 06, 2022 Sep CAHN

AB

75MG

A216243 004 Jun 06, 2022 Sep CAHN

AB

100MG

A216243 005 Jun 06, 2022 Sep CAHN

AB

150MG

A216243 006 Jun 06, 2022 Sep CAHN

AB GRAVITI PHARMS

10MG

A217411 001 May 19, 2023 May NEWA

AB

25MG

A217411 002 May 19, 2023 May NEWA

AB

50MG

A217411 003 May 19, 2023 May NEWA

AB

75MG

A217411 004 May 19, 2023 May NEWA

AB

100MG

A217411 005 May 19, 2023 May NEWA

AB

150MG

A217411 006 May 19, 2023 May NEWA

AB RISING

10MG

A217411 001 May 19, 2023 Aug CAHN

AB

25MG

A217411 002 May 19, 2023 Aug CAHN

AB

50MG

A217411 003 May 19, 2023 Aug CAHN

AB

75MG

A217411 004 May 19, 2023 Aug CAHN

AB

100MG

A217411 005 May 19, 2023 Aug CAHN

AB

150MG

A217411 006 May 19, 2023 Aug CAHN

AB RUBICON

10MG

A215376 001 May 01, 2023 Apr NEWA

AB

25MG

A215376 002 May 01, 2023 Apr NEWA

AB

50MG

A215376 003 May 01, 2023 Apr NEWA

AB

75MG

A215376 004 May 01, 2023 Apr NEWA

AB

100MG

A215376 005 May 01, 2023 Apr NEWA

AB

150MG

A215376 006 May 01, 2023 Apr NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@ ANDA REPOSITORY EQ 12.5MG BASE;5MG

A070765 001 Dec 10, 1986 Sep CAHN

@ EQ 25MG BASE;10MG

A070766 001 Dec 10, 1986 Sep CAHN

LIMBITROL

+ @ CHARTWELL RX EQ 12.5MG BASE;5MG

N016949 001 Mar CAHN

LIMBITROL DS

+ @ CHARTWELL RX EQ 25MG BASE;10MG

N016949 002 Mar CAHN

AMLODIPINE BENZOATE

SUSPENSION; ORAL

AMLODIPINE BENZOATE

@ AMNEAL EQ 1MG BASE/ML

A215035 001 Jun 13, 2023 Jun DISC

AB EQ 1MG BASE/ML

A215035 001 Jun 13, 2023 Jun NFTG

KATERZIA

+! AZURITY EQ 1MG BASE/ML

N211340 001 Jul 08, 2019 Jun CTEC

AB +! EQ 1MG BASE/ML

N211340 001 Jul 08, 2019 Jun CFTG

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB COREPHARMA EQ 2.5MG BASE

A076719 001 May 23, 2007 Feb CAHN

AB EQ 5MG BASE

A076719 002 May 23, 2007 Feb CAHN

AB EQ 10MG BASE

A076719 003 May 23, 2007 Feb CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

LOTREL

AB + SANDOZ EQ 2.5MG BASE;10MG

N020364 002 Mar 03, 1995 Sep CAHN

AB + EQ 5MG BASE;10MG

N020364 003 Mar 03, 1995 Sep CAHN

AB + EQ 5MG BASE;20MG

N020364 004 Mar 03, 1995 Sep CAHN

AB + EQ 5MG BASE;40MG

N020364 007 Apr 11, 2006 Sep CAHN

AB + EQ 10MG BASE;20MG

N020364 005 Jun 20, 2002 Sep CAHN

AB +! EQ 10MG BASE;40MG

N020364 006 Apr 11, 2006 Sep CAHN

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

@ SOFIE 18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)

A204667 001 Apr 22, 2015 May DISC

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

@ CHARTWELL RX 125MG/5ML

A062059 001 Jan CAHN

@ 250MG/5ML

A062059 002 Jan CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB DEVA HOLDING AS 600MG/5ML; EQ 42.9MG BASE/5ML

A209351 001 Sep 13, 2023 Sep NEWA

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB DEVA HOLDING AS 500MG; EQ 125MG BASE

A209992 001 Sep 15, 2023 Sep NEWA

AB 875MG; EQ 125MG BASE

A209991 001 Sep 15, 2023 Sep NEWA

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

ADZENYS XR-ODT

AB + NEOS THERAPS EQ 3.1MG BASE

N204326 001 Jan 27, 2016 Jun CFTG

AB + EQ 6.3MG BASE

N204326 002 Jan 27, 2016 Jun CFTG

AB + EQ 9.4MG BASE

N204326 003 Jan 27, 2016 Jun CFTG

AB + EQ 12.5MG BASE

N204326 004 Jan 27, 2016 Jun CFTG

AB + EQ 15.7MG BASE

N204326 005 Jan 27, 2016 Jun CFTG

AB +! EQ 18.8MG BASE

N204326 006 Jan 27, 2016 Jun CFTG

AMPHETAMINE

AB ACTAVIS LABS FL INC EQ 3.1MG BASE

A209253 001 Jun 22, 2023 Jun NFTG

AB EQ 6.3MG BASE

A209253 002 Jun 22, 2023 Jun NFTG

AB EQ 9.4MG BASE

A209253 003 Jun 22, 2023 Jun NFTG

AB EQ 12.5MG BASE

A209253 004 Jun 22, 2023 Jun NFTG

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
AMPHETAMINE

AB	EQ 15.7MG BASE	A209253	005	Jun 22, 2023	Jun NFTG
AB	EQ 18.8MG BASE	A209253	006	Jun 22, 2023	Jun NFTG

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ANI PHARMS	2.5MG; 2.5MG; 2.5MG; 2.5MG	A205401	002	Jan 22, 2019	Feb CMFD
AB	ASCENT PHARMS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214959	001	Sep 29, 2021	Feb CTNA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A214959	002	Sep 29, 2021	Feb CTNA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A214959	003	Sep 29, 2021	Feb CTNA
AB		5MG; 5MG; 5MG; 5MG	A214959	004	Sep 29, 2021	Feb CTNA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A214959	005	Sep 29, 2021	Feb CTNA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A214959	006	Sep 29, 2021	Feb CTNA
AB	GRANULES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A217027	001	Jan 23, 2023	Feb CTNA
AB		1.25MG; 1.25MG; 1.25MG; 1.25MG	A217027	001	Jan 23, 2023	Jan NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A217027	002	Jan 23, 2023	Feb CTNA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A217027	002	Jan 23, 2023	Jan NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A217027	003	Jan 23, 2023	Feb CTNA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A217027	003	Jan 23, 2023	Jan NEWA
AB		5MG; 5MG; 5MG; 5MG	A217027	004	Jan 23, 2023	Feb CTNA
AB		5MG; 5MG; 5MG; 5MG	A217027	004	Jan 23, 2023	Jan NEWA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A217027	005	Jan 23, 2023	Feb CTNA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A217027	005	Jan 23, 2023	Jan NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A217027	006	Jan 23, 2023	Jan NEWA
AB	LANNETT CO INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214403	001	Nov 26, 2021	Feb CMFD
AB	@	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214403	001	Nov 26, 2021	Feb CTNA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A214403	002	Nov 26, 2021	Feb CMFD
AB	@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A214403	002	Nov 26, 2021	Feb CTNA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A214403	003	Nov 26, 2021	Feb CMFD
AB	@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A214403	003	Nov 26, 2021	Feb CTNA
AB		5MG; 5MG; 5MG; 5MG	A214403	004	Nov 26, 2021	Feb CMFD
AB	@	5MG; 5MG; 5MG; 5MG	A214403	004	Nov 26, 2021	Feb CTNA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A214403	005	Nov 26, 2021	Feb CMFD
AB	@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A214403	005	Nov 26, 2021	Feb CTNA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A214403	006	Nov 26, 2021	Feb CMFD
AB	@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A214403	006	Nov 26, 2021	Feb CTNA
AB	SPECGX LLC	3.125MG; 3.125MG; 3.125MG; 3.125MG	A211546	001	Aug 31, 2023	Aug NEWA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211546	002	Aug 31, 2023	Aug NEWA
AB		9.375MG; 9.375MG; 9.375MG; 9.375MG	A211546	003	Aug 31, 2023	Aug NEWA
AB		12.5MG; 12.5MG; 12.5MG; 12.5MG	A211546	004	Aug 31, 2023	Aug NEWA
AB	SUN PHARM INDS INC	3.125MG; 3.125MG; 3.125MG; 3.125MG	A215997	001	Sep 27, 2023	Sep NEWA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A215997	002	Sep 27, 2023	Sep NEWA
AB		9.375MG; 9.375MG; 9.375MG; 9.375MG	A215997	003	Sep 27, 2023	Sep NEWA
AB		12.5MG; 12.5MG; 12.5MG; 12.5MG	A215997	004	Sep 27, 2023	Sep NEWA
AB	TEVA PHARMS USA	3.125MG; 3.125MG; 3.125MG; 3.125MG	A210876	001	Jan 31, 2022	Sep CMFD
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A210876	002	Jan 31, 2022	Sep CMFD
AB		9.375MG; 9.375MG; 9.375MG; 9.375MG	A210876	003	Jan 31, 2022	Sep CMFD
AB		12.5MG; 12.5MG; 12.5MG; 12.5MG	A210876	004	Jan 31, 2022	Sep CMFD
AB	MYDAYIS					
AB	+ TAKEDA PHARMS USA	3.125MG; 3.125MG; 3.125MG; 3.125MG	N022063	001	Jun 20, 2017	Aug CTEC
AB	+	6.25MG; 6.25MG; 6.25MG; 6.25MG	N022063	002	Jun 20, 2017	Aug CTEC
AB	+	9.375MG; 9.375MG; 9.375MG; 9.375MG	N022063	003	Jun 20, 2017	Aug CTEC
AB	+	12.5MG; 12.5MG; 12.5MG; 12.5MG	N022063	004	Jun 20, 2017	Aug CTEC

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ALKEM LABS LTD	1.25MG; 1.25MG; 1.25MG; 1.25MG	A217787	001	Oct 06, 2023	Sep NEWA
AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A217787	002	Oct 06, 2023	Sep NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A217787	003	Oct 06, 2023	Sep NEWA
AB		3.125MG; 3.125MG; 3.125MG; 3.125MG	A217787	004	Oct 06, 2023	Sep NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A217787	005	Oct 06, 2023	Sep NEWA
AB		5MG; 5MG; 5MG; 5MG	A217787	006	Oct 06, 2023	Sep NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A217787	007	Oct 06, 2023	Sep NEWA
AB	LANNETT CO INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A215565	001	Jul 08, 2022	Feb CMFD
AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A215565	002	Jul 08, 2022	Feb CMFD
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A215565	003	Jul 08, 2022	Feb CMFD
AB		3.125MG; 3.125MG; 3.125MG; 3.125MG	A215565	004	Jul 08, 2022	Feb CMFD
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A215565	005	Jul 08, 2022	Feb CMFD
AB		5MG; 5MG; 5MG; 5MG	A215565	006	Jul 08, 2022	Feb CMFD
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A215565	007	Jul 08, 2022	Feb CMFD

AMPICILLIN SODIUM

INJECTABLE; INJECTION							
AMPICILLIN SODIUM							
	@ STERISCIENCE	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Jan	CAHN
	@	EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A202198	001	Apr 07, 2014	Jan	CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION							
AMPICILLIN AND SULBACTAM							
AP	STERISCIENCE	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A201024	001	Apr 07, 2014	Jan	CAHN
AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A201024	002	Apr 07, 2014	Jan	CAHN
AP		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	A202197	001	Apr 07, 2014	Jan	CAHN

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL							
AMPICILLIN TRIHYDRATE							
>A>	AUROBINDO PHARMA	EQ 250MG BASE	A216554	001	Oct 31, 2023	Oct	NEWA
>A> AB		EQ 500MG BASE	A216554	002	Oct 31, 2023	Oct	NEWA
>D>	! SANDOZ	EQ 500MG BASE	A064082	002	Aug 29, 1995	Oct	CTEC
>A> AB	! PRINCIPEN '250'	EQ 500MG BASE	A064082	002	Aug 29, 1995	Oct	CTEC
	+ @ APOTHECON	EQ 250MG BASE	N050056	001		Jul	CRLD
	PRINCIPEN '500'						
	+ @ APOTHECON	EQ 500MG BASE	N050056	002		Jul	CRLD

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL							
ANAGRELIDE HYDROCHLORIDE							
	@ NATCO PHARMA USA	EQ 0.5MG BASE	A076811	001	Apr 18, 2005	Aug	CAHN
	@	EQ 1MG BASE	A076811	002	Apr 18, 2005	Aug	CAHN

ANASTROZOLE

TABLET; ORAL							
ANASTROZOLE							
	@ ANDA REPOSITORY	1MG	A090732	001	Jun 28, 2010	Sep	CAHN

APALUTAMIDE

TABLET; ORAL							
ERLEADA							
	+ JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Feb	CHRS
	+!	240MG	N210951	002	Feb 17, 2023	Feb	NEWA

APIXABAN

TABLET; ORAL							
APIXABAN							
	@ AUROBINDO PHARMA LTD	2.5MG	A210026	001	May 26, 2023	Jun	DISC
AB		2.5MG	A210026	001	May 26, 2023	May	NEWA
	@	5MG	A210026	002	May 26, 2023	Jun	DISC
AB		5MG	A210026	002	May 26, 2023	May	NEWA
	@ ZYDUS PHARMS	2.5MG	A210185	001	Feb 27, 2023	Jul	DISC
AB		2.5MG	A210185	001	Feb 27, 2023	Feb	NEWA
	@	5MG	A210185	002	Feb 27, 2023	Jul	DISC
AB		5MG	A210185	002	Feb 27, 2023	Feb	NEWA

APOMORPHINE HYDROCHLORIDE

FILM; SUBLINGUAL							
KYNMOBI							
	+ @ SUMITOMO PHARMA AM	10MG	N210875	001	May 21, 2020	Jul	CAHN
	+ @	15MG	N210875	002	May 21, 2020	Jul	CAHN
	+ @	20MG	N210875	003	May 21, 2020	Jul	CAHN
	+ @	25MG	N210875	004	May 21, 2020	Jul	CAHN
	+ @	30MG	N210875	005	May 21, 2020	Jul	CAHN
	+ @ SUNOVION PHARMS INC	10MG	N210875	001	May 21, 2020	Jul	DISC
	+ @	15MG	N210875	002	May 21, 2020	Jul	DISC
	+ @	20MG	N210875	003	May 21, 2020	Jul	DISC
	+ @	25MG	N210875	004	May 21, 2020	Jul	DISC
	+ @	30MG	N210875	005	May 21, 2020	Jul	DISC

APRACLONIDINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
IOPIDINE

AT	+	HARROW EYE	EQ 0.5% BASE	N020258	001	Jul 30, 1993	May CAHN
	+		EQ 1% BASE	N019779	001	Dec 31, 1987	May CAHN

APREMILASTTABLET;ORAL
APREMILAST

AB		ANNORA	10MG	A211878	001	Jul 26, 2023	Jul NEWA
AB			20MG	A211878	002	Jul 26, 2023	Jul NEWA
AB			30MG	A211878	003	Jul 26, 2023	Jul NEWA
	@	AUROBINDO PHARMA LTD	10MG	A211716	001	Jul 19, 2023	Aug DISC
AB			10MG	A211716	001	Jul 19, 2023	Jul NEWA
	@		20MG	A211716	002	Jul 19, 2023	Aug DISC
AB			20MG	A211716	002	Jul 19, 2023	Jul NEWA
	@		30MG	A211716	003	Jul 19, 2023	Aug DISC
AB			30MG	A211716	003	Jul 19, 2023	Jul NEWA
>D>	AB	DR REDDYS	10MG	A211756	001	Jul 14, 2023	Oct DISC
>A>		@	10MG	A211756	001	Jul 14, 2023	Oct DISC
AB			10MG	A211756	001	Jul 14, 2023	Jul NEWA
>D>	AB		20MG	A211756	002	Jul 14, 2023	Oct DISC
>A>		@	20MG	A211756	002	Jul 14, 2023	Oct DISC
AB			20MG	A211756	002	Jul 14, 2023	Jul NEWA
>D>	AB		30MG	A211756	003	Jul 14, 2023	Oct DISC
>A>		@	30MG	A211756	003	Jul 14, 2023	Oct DISC
AB			30MG	A211756	003	Jul 14, 2023	Jul NEWA
>A>	AB	GLENMARK PHARMS LTD	10MG	A211674	001	Oct 16, 2023	Oct NEWA
>A>	AB		20MG	A211674	002	Oct 16, 2023	Oct NEWA
>A>	AB		30MG	A211674	003	Oct 16, 2023	Oct NEWA
AB		SHILPA	10MG	A211774	001	Apr 07, 2023	Mar NEWA
AB			20MG	A211774	002	Apr 07, 2023	Mar NEWA
AB			30MG	A211774	003	Apr 07, 2023	Mar NEWA
	@	TEVA PHARMS USA INC	10MG	A211897	001	Aug 18, 2022	Feb DISC
	@		20MG	A211897	002	Aug 18, 2022	Feb DISC
	@		30MG	A211897	003	Aug 18, 2022	Feb DISC

ARFORMOTEROL TARTRATESOLUTION;INHALATION
ARFORMOTEROL TARTRATE

AN		RITEDOSE CORP	EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Feb CMFD
----	--	---------------	---------------------	---------	-----	--------------	----------

ARGATROBANINJECTABLE;INJECTION
ARGATROBAN

AP		GLAND PHARMA LTD	50MG/50ML (1MG/ML)	A217848	001	Jul 31, 2023	Jul NEWA
AP	!	HOSPIRA	250MG/2.5ML (100MG/ML)	A204120	001	Sep 21, 2016	Sep CHRS
	+	@ SANDOZ	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	Sep DISC
AP	+	!	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	May CAHN

ARIPIPIRAZOLESOLUTION;ORAL
ARIPIPIRAZOLE

AA		CHARTWELL RX	1MG/ML	A215595	001	Oct 25, 2022	May CAHN
>A>	AA	HETERO LABS LTD III	1MG/ML	A216150	001	Nov 01, 2023	Oct NEWA

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ABILIFY ASIMTUFII

+	OTSUKA	720MG/2.4ML (300MG/ML)	N217006	001	Apr 27, 2023	Apr NEWA
+	!	960MG/3.2ML (300MG/ML)	N217006	002	Apr 27, 2023	Apr NEWA

TABLET;ORAL

ARIPIPIRAZOLE

AB		BRECKENRIDGE	2MG	A091279	001	Jan 09, 2017	Sep CAHN
AB			5MG	A091279	002	Jan 09, 2017	Sep CAHN
AB			10MG	A091279	003	Jan 09, 2017	Sep CAHN
AB			15MG	A091279	004	Jan 09, 2017	Sep CAHN
AB			20MG	A091279	005	Jan 09, 2017	Sep CAHN
AB			30MG	A091279	006	Jan 09, 2017	Sep CAHN
AB		SUNSHINE	2MG	A213037	001	Oct 02, 2023	Sep NEWA
AB			5MG	A213037	002	Oct 02, 2023	Sep NEWA
AB			10MG	A213037	003	Oct 02, 2023	Sep NEWA

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

@ COREPHARMA

50MG

A201514 001 Mar 25, 2019 Feb CAHN

@

150MG

A201514 002 Mar 25, 2019 Feb CAHN

@

250MG

A201514 003 Mar 25, 2019 Feb CAHN

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE

AP ORBICULAR

1MG/ML

A217413 001 Apr 20, 2023 Apr NEWA

AP

2MG/ML

A217413 002 Apr 20, 2023 Apr NEWA

AP

PENN LIFE

1MG/ML

A209873 001 May 06, 2019 May CAHN

ASPIRIN

CAPSULE, EXTENDED RELEASE;ORAL

DURLAZA

>D> + @ ESPERO

162.5MG

N200671 001 Sep 04, 2015 Oct CAHN

+ @

162.5MG

N200671 001 Sep 04, 2015 Aug DISC

>A>

+ @ HESP

162.5MG

N200671 001 Sep 04, 2015 Oct CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

@ CHARTWELL RX

325MG;200MG

A089594 001 Mar 31, 1989 Mar CAHN

ASPIRIN; METHOCARBAMOL

TABLET;ORAL

ROBAXISAL

+ @ ROBINS AH

325MG;400MG

N012281 001 Mar CRLD

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

@ CIPLA

EQ 100MG BASE

A200626 001 Aug 09, 2018 Aug DISC

@

EQ 150MG BASE

A200626 002 Aug 09, 2018 Aug DISC

@

EQ 200MG BASE

A200626 003 Aug 09, 2018 Aug DISC

@

EQ 300MG BASE

A200626 004 Aug 09, 2018 Aug DISC

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

@ AUROBINDO PHARMA USA

50MG;25MG

A074203 001 Oct 31, 1993 Apr CAHN

@

100MG;25MG

A074203 002 Oct 31, 1993 Apr CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB ZYDUS PHARMS USA INC

10MG

A079017 007 Apr 05, 2023 Mar NEWA

ATORVASTATIN CALCIUM

SUSPENSION;ORAL

ATORVALIQ

+! CMP DEV LLC

20MG/5ML

N213260 001 Feb 01, 2023 Feb NEWA

TABLET;ORAL

ATORVASTATIN CALCIUM

AB BIOCON PHARMA

EQ 10MG BASE

A216436 001 Nov 23, 2022 Sep CMFD

@

EQ 10MG BASE

A216436 001 Nov 23, 2022 May DISC

AB

EQ 20MG BASE

A216436 002 Nov 23, 2022 Sep CMFD

@

EQ 20MG BASE

A216436 002 Nov 23, 2022 May DISC

AB

EQ 40MG BASE

A216436 003 Nov 23, 2022 Sep CMFD

@

EQ 40MG BASE

A216436 003 Nov 23, 2022 May DISC

AB

EQ 80MG BASE

A216436 004 Nov 23, 2022 Sep CMFD

@

EQ 80MG BASE

A216436 004 Nov 23, 2022 May DISC

>A>

AB CADILA PHARMS LTD

EQ 10MG BASE

A212103 001 Oct 16, 2023 Oct NEWA

>A>

AB

EQ 20MG BASE

A212103 002 Oct 16, 2023 Oct NEWA

>A>

AB

EQ 40MG BASE

A212103 003 Oct 16, 2023 Oct NEWA

>A>

AB

EQ 80MG BASE

A212103 004 Oct 16, 2023 Oct NEWA

AB HETERO LABS LTD V

EQ 10MG BASE

A214344 001 Sep 12, 2023 Sep NEWA

AB

EQ 20MG BASE

A214344 002 Sep 12, 2023 Sep NEWA

AB

EQ 40MG BASE

A214344 003 Sep 12, 2023 Sep NEWA

TABLET;ORAL
ATORVASTATIN CALCIUM

AB		EQ 80MG BASE	A214344	004	Sep 12, 2023	Sep NEWA
	@ LEPU PHARM	EQ 10MG BASE	A216848	001	Nov 03, 2022	Apr DISC
	@	EQ 20MG BASE	A216848	002	Nov 03, 2022	Apr DISC
	@	EQ 40MG BASE	A216848	003	Nov 03, 2022	Apr DISC
	@	EQ 80MG BASE	A216848	004	Nov 03, 2022	Apr DISC

ATROPINE

SOLUTION;INTRAMUSCULAR
ATROPEN

	+ @ MMT	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004	May DISC
	+ @	EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003	May DISC
	+ @	EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003	May DISC
	+ @	EQ 2MG SULFATE/0.7ML	N017106	001		May DISC

ATROPINE SULFATE

SOLUTION;INTRAVENOUS
ATROPINE SULFATE

>A>	AP	AMNEAL	1MG/10ML (0.1MG/ML)	A215342	002	Oct 25, 2023	Oct NEWA
		SOLUTION/DROPS;OPHTHALMIC					
		ATROPINE SULFATE					
AT	+	AKORN	1%	N206289	001	Jul 18, 2014	Jul CHRS
AT	!	AMNEAL	1%	A214752	001	Jul 14, 2022	Jul CHRS
AT	+	RISING	1%	N206289	001	Jul 18, 2014	Sep CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
@ UPSHER SMITH LABS 0.025MG;2.5MG

A210571 001 Aug 31, 2018 Jun DISC

AVACINCAPTAD PEGOL SODIUM

SOLUTION;INTRAVITREAL
IZERVAY

	+!	IVERIC BIO	EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML)	N217225	001	Aug 04, 2023	Aug NEWA
--	----	------------	---------------------------------------	---------	-----	--------------	----------

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS
AZACITIDINE

AP		JIANGSU HANSO PHARM	100MG/VIAL	A215905	001	Jun 28, 2023	Jun NEWA
----	--	---------------------	------------	---------	-----	--------------	----------

AZELAIC ACID

AEROSOL, FOAM;TOPICAL
FINACEA

	+!	LEO PHARMA AS	15%	N207071	001	Jul 29, 2015	Feb CTEC
--	----	---------------	-----	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL
AZELASTINE HYDROCHLORIDE

AB		BIONPHARMA	0.137MG/SPRAY	A090176	001	Jul 28, 2015	Jun CAHN
----	--	------------	---------------	---------	-----	--------------	----------

AZITHROMYCIN

FOR SUSPENSION;ORAL
AZITHROMYCIN

AB		HAINAN POLY	EQ 100MG BASE/5ML	A217036	001	Jul 27, 2023	Jul NEWA
AB			EQ 200MG BASE/5ML	A217036	002	Jul 27, 2023	Jul NEWA

INJECTABLE;INJECTION
AZITHROMYCIN

AP		SLATE RUN PHARMA	EQ 500MG BASE/VIAL	A203412	001	Oct 09, 2018	Sep CAHN
----	--	------------------	--------------------	---------	-----	--------------	----------

TABLET;ORAL

AZITHROMYCIN

	@	ACI	EQ 250MG BASE	A215772	001	Jul 15, 2022	Jan DISC
	@		EQ 500MG BASE	A215773	001	Jul 12, 2022	Jan DISC
	@	AUROBINDO PHARMA USA	EQ 600MG BASE	A065360	001	Jan 08, 2007	May CAHN
	@	ZYDUS PHARMS	EQ 250MG BASE	A213275	001	Apr 11, 2023	Aug DISC
AB			EQ 250MG BASE	A213275	001	Apr 11, 2023	Mar NEWA
	@		EQ 500MG BASE	A213056	001	Apr 07, 2023	Aug DISC
AB			EQ 500MG BASE	A213056	001	Apr 07, 2023	Mar NEWA

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

@ AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213	001	Jul 25, 2012	Jan DISC
! BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068	001	Oct 30, 1995	Jan CTEC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

@ AKORN	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065088	001	Feb 06, 2004	Jan DISC
---------	--	---------	-----	--------------	----------

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP	ACIC PHARMS	0.5MG/ML	A216309	001	Aug 10, 2023	Aug NEWA
AP		2MG/ML	A216309	002	Aug 10, 2023	Aug NEWA
AP	RUBICON	0.5MG/ML	A217324	001	Feb 22, 2023	Feb NEWA
AP		1MG/ML	A217324	002	Feb 22, 2023	Feb NEWA
AP		2MG/ML	A217324	003	Feb 22, 2023	Feb NEWA

SUSPENSION;ORAL

BACLOFEN

AB	ANI PHARMS	25MG/5ML	A217252	001	Jun 08, 2023	Aug CAHN
AB	SLAYBACK PHARMA LLC	25MG/5ML	A217252	001	Jun 08, 2023	Jun NFTG
	FLEQSUVY					
AB	+! AZURITY	25MG/5ML	N215602	001	Feb 04, 2022	Jun CFTG

TABLET;ORAL

BACLOFEN

AB	BEXIMCO PHARMS USA	5MG	A214114	003	Sep 19, 2023	Sep NEWA
>D> AB	KARTHA	5MG	A214374	001	Mar 05, 2021	Oct CAHN
>D> AB		10MG	A214374	002	Mar 05, 2021	Oct CAHN
>D> AB		20MG	A214374	003	Mar 05, 2021	Oct CAHN
>A> AB	RISING	5MG	A214374	001	Mar 05, 2021	Oct CAHN
>A> AB		10MG	A214374	002	Mar 05, 2021	Oct CAHN
>A> AB		20MG	A214374	003	Mar 05, 2021	Oct CAHN
AB	UNICHEM	5MG	A212067	003	Mar 09, 2023	Mar NEWA
	@ UPSHER SMITH LABS	10MG	A090334	001	Feb 18, 2010	Sep CAHN
	@	20MG	A090334	002	Feb 18, 2010	Sep CAHN

BALOXAVIR MARBOXIL

TABLET;ORAL

XOFLUZA

+ @ GENENTECH INC	20MG	N210854	001	Oct 24, 2018	Jun DISC
+	40MG	N210854	002	Oct 24, 2018	Jun CHRS
+!	80MG	N210854	003	Mar 18, 2021	Jun CHRS

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

@ DASH PHARMS NATCO	750MG	A077807	001	Dec 28, 2007	Feb CAHN
AB ZYDUS	750MG	A217592	001	Jun 08, 2023	Jun NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB	COREPHARMA	5MG	A077128	001	Mar 08, 2006	Mar CAHN
AB		10MG	A077128	002	Mar 08, 2006	Mar CAHN
AB		20MG	A077128	003	Mar 08, 2006	Mar CAHN
AB		40MG	A077128	004	Mar 08, 2006	Mar CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX	5MG;6.25MG	A078794	001	Aug 21, 2014	May CMFD
AB		10MG;12.5MG	A078794	002	Aug 21, 2014	May CMFD
AB		20MG;12.5MG	A078794	003	Aug 21, 2014	May CMFD
AB		20MG;25MG	A078794	004	Aug 21, 2014	May CMFD

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP	APOTEX	25MG/VIAL	A204230	001	Jun 05, 2023	May NEWA
AP		100MG/VIAL	A204230	002	Jun 05, 2023	May NEWA
AP	BRECKENRIDGE	25MG/VIAL	A205447	001	Feb 14, 2023	Feb NEWA
AP		100MG/VIAL	A205447	002	Feb 14, 2023	Feb NEWA
AP	EUGIA PHARMA	25MG/VIAL	A214739	001	Jun 05, 2023	May NEWA
AP		100MG/VIAL	A214739	002	Jun 05, 2023	May NEWA
AP	KINDOS	25MG/VIAL	A211001	001	Jun 05, 2023	May NEWA
AP		100MG/VIAL	A211001	002	Jun 05, 2023	May NEWA
	@ MYLAN LABS LTD	25MG/VIAL	A204104	001	Apr 28, 2023	May DISC
AP		25MG/VIAL	A204104	001	Apr 28, 2023	Apr NEWA
	@	100MG/VIAL	A204104	002	Apr 28, 2023	May DISC
AP		100MG/VIAL	A204104	002	Apr 28, 2023	Apr NEWA
AP	NANG KUANG PHARM CO	25MG/VIAL	A206554	001	Jun 07, 2023	May NEWA
AP		100MG/VIAL	A206554	002	Jun 07, 2023	May NEWA

SOLUTION; INTRAVENOUS

BELRAPZO

AP	+! EAGLE PHARMS	100MG/4ML (25MG/ML)	N205580	001	May 15, 2018	Aug CDFR
	BENDAMUSTINE HYDROCHLORIDE					
AP	+! APOTEX	100MG/4ML (25MG/ML)	N215033	001	Dec 07, 2022	Aug CTEC
AP	+! BAXTER HLTHCARE CORP	100MG/4ML (25MG/ML)	N216078	001	Dec 15, 2022	Sep CTEC
	+ @ HOSPIRA	25MG/ML (25MG/ML)	N211530	001	Dec 15, 2022	Jan DISC
	+ @	100MG/4ML (25MG/ML)	N211530	002	Dec 15, 2022	Jan DISC
	+ @	200MG/8ML (25MG/ML)	N211530	003	Dec 15, 2022	Jan DISC

SOLUTION; IV (INFUSION)

BELRAPZO

AP	+! EAGLE PHARMS	100MG/4ML (25MG/ML)	N205580	001	May 15, 2018	Aug CTEC
----	-----------------	---------------------	---------	-----	--------------	----------

BENZONATATE

CAPSULE; ORAL

BENZONATATE

>D>	AA	ASCENT PHARMS INC	150MG	A211518	002	Feb 22, 2019	Oct CTEC
>A>			150MG	A211518	002	Feb 22, 2019	Oct CTEC
	AA	CHARTWELL RX	100MG	A040682	001	Jul 30, 2007	Feb CAHN
>D>	AA		100MG	A210562	001	Nov 09, 2018	Oct DISC
>A>	@		100MG	A210562	001	Nov 09, 2018	Oct DISC
>D>	AA		150MG	A210562	002	Nov 09, 2018	Oct DISC
>A>	@		150MG	A210562	002	Nov 09, 2018	Oct DISC
	AA		200MG	A040682	002	Jul 30, 2007	Feb CAHN
>D>	AA		200MG	A210562	003	Nov 09, 2018	Oct DISC
>A>	@		200MG	A210562	003	Nov 09, 2018	Oct DISC
	AA	HERITAGE PHARMS LABS	100MG	A040682	001	Jul 30, 2007	Aug CAHN
	AA		200MG	A040682	002	Jul 30, 2007	Aug CAHN
	AA	! PURACAP PHARM LLC	100MG	A206948	001	Dec 19, 2018	Aug CHRS
	AA	!	200MG	A206948	002	Dec 19, 2018	Aug CHRS
	@	THEPHARMANETWORK LLC	100MG	A040627	001	Mar 30, 2007	Aug DISC
	@		150MG	A040627	003	Sep 24, 2014	Aug DISC
	@		200MG	A040627	002	Jul 25, 2007	Aug DISC

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

	+ @ BAUSCH	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Feb DISC
	CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE					
AB	! GLENMARK PHARMS	5%;EQ 1% BASE	A209252	001	Mar 14, 2019	Feb CHRS
AB	TARO	3.75%;EQ 1.2% BASE	A208683	001	Jun 05, 2018	Aug CMFD
	ONEXTON					
AB	+! BAUSCH	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	Aug CTEC

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPOTASTINE BESILATE

AT	ALEMBIC	1.5%	A214588	001	Apr 05, 2023	Mar NEWA
----	---------	------	---------	-----	--------------	----------

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

AB	HIKMA	3MG/ML;EQ 3MG BASE/ML	A077838	001	Jan 17, 2023	Jan NEWA
----	-------	-----------------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

@ SHREE HARI INTL EQ 0.05% BASE

A070274 001 Aug 12, 1985 Sep CAHN

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

@ PAI HOLDINGS PHARM EQ 0.05% BASE

A206389 001 Feb 13, 2018 May DISC

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

@ PAI HOLDINGS PHARM EQ 0.05% BASE

A206118 001 Nov 09, 2017 May DISC

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	GLENMARK PHARMS LTD	0.064%;0.005%	A214688	001	Mar 21, 2023	Mar NFTG
----	---------------------	---------------	---------	-----	--------------	----------

ENSTILAR

AB	+! LEO PHARMA AS	0.064%;0.005%	N207589	001	Oct 16, 2015	Mar CFTG
----	------------------	---------------	---------	-----	--------------	----------

OINTMENT;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

>A>	@ CHARTWELL RX	0.064%;0.005%	A201615	001	Jan 14, 2013	Oct CAHN
-----	----------------	---------------	---------	-----	--------------	----------

>D>	@ TOLMAR	0.064%;0.005%	A201615	001	Jan 14, 2013	Oct CAHN
-----	----------	---------------	---------	-----	--------------	----------

@ 0.064%;0.005%

A201615 001 Jan 14, 2013 Feb DISC

SUSPENSION;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	COSETTE	0.064%;0.005%	A210765	001	May 11, 2020	Feb CAHN
----	---------	---------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	! TARO	EQ 0.05% BASE;1%	A075673	001	May 29, 2001	May CHRS
----	--------	------------------	---------	-----	--------------	----------

LOTRISONE

	+ @ ORGANON	EQ 0.05% BASE;1%	N018827	001	Jul 10, 1984	May DISC
--	-------------	------------------	---------	-----	--------------	----------

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

AB	! TARO	0.12%	A208204	001	May 24, 2017	Aug CHRS
----	--------	-------	---------	-----	--------------	----------

AB	XIROMED	0.12%	A210639	001	Apr 18, 2023	Apr NEWA
----	---------	-------	---------	-----	--------------	----------

LUXIQ

	+ @ MYLAN	0.12%	N020934	001	Feb 28, 1999	Aug DISC
--	-----------	-------	---------	-----	--------------	----------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

@ AKORN EQ 0.5% BASE

A075386 001 Jun 30, 2000 Feb DISC

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA	CHARTWELL RX	5MG	A040728	002	Oct 26, 2007	May CAHN
----	--------------	-----	---------	-----	--------------	----------

AA		10MG	A040728	003	Oct 26, 2007	May CAHN
----	--	------	---------	-----	--------------	----------

AA		25MG	A040728	004	Oct 26, 2007	May CAHN
----	--	------	---------	-----	--------------	----------

AA		50MG	A040728	001	Oct 26, 2007	May CAHN
----	--	------	---------	-----	--------------	----------

BEXAGLIFLOZIN

TABLET;ORAL

BRENZAVVY

	+! THERACOSBIO	20MG	N214373	001	Jan 20, 2023	Jan NEWA
--	----------------	------	---------	-----	--------------	----------

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB	ADAPTIS	50MG	A079089	001	Jul 06, 2009	Sep CAHN
----	---------	------	---------	-----	--------------	----------

AB	BRECKENRIDGE	50MG	A091011	001	Jun 10, 2015	Sep CAHN
----	--------------	------	---------	-----	--------------	----------

AB	PINNACLE LIFE SCI	50MG	A079089	001	Jul 06, 2009	Jan CAHN
----	-------------------	------	---------	-----	--------------	----------

BIMATOPROST

IMPLANT;OPHTHALMIC
DURYSTA

+! ABBVIE 10MCG N211911 001 Mar 04, 2020 Jan CAHN

SOLUTION/DROPS;OPHTHALMIC
LUMIGAN

+! ABBVIE 0.01% N022184 001 Aug 31, 2010 Jul CAHN

+ @ 0.03% N021275 001 Mar 16, 2001 Jul CAHN

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

AB PAR PHARM 140MG;125MG;125MG A205770 001 Mar 06, 2023 Feb NFTG

AB RICONPHARMA LLC 140MG;125MG;125MG A217511 001 Jul 03, 2023 Jun NEWA

PYLERA

AB +! ABBVIE 140MG;125MG;125MG N050786 001 Sep 28, 2006 Mar CAHN

AB +! ALLERGAN 140MG;125MG;125MG N050786 001 Sep 28, 2006 Feb CFTG

AB +! LABS JUVISE 140MG;125MG;125MG N050786 001 Sep 28, 2006 Sep CAHN

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

! NOSTRUM LABS INC 262.4MG, N/A, N/A;N/A, 250MG, A202584 001 Nov 30, 2018 Aug CAHN
N/A;N/A, N/A, 500MG

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB ALEMBIC 5MG A204891 001 Jan 11, 2017 Feb CAHN

AB 10MG A204891 002 Jan 11, 2017 Feb CAHN

@ DASH PHARMS NATCO 5MG A075831 001 Dec 14, 2005 Feb CAHN

@ 10MG A075831 002 Dec 14, 2005 Feb CAHN

AB PRINSTON INC 5MG A217368 001 Jul 14, 2023 Jul NEWA

AB 10MG A217368 002 Jul 14, 2023 Jul NEWA

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

AP SLATE RUN PHARMA 250MG/VIAL A213078 001 May 28, 2021 Sep CAHN

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

@ ACCORD HLTHCARE 3.5MG/VIAL A204405 001 Jul 26, 2022 Feb DISC

POWDER;INTRAVENOUS

BORTEZOMIB

@ DR REDDYS 3.5MG/VIAL N206927 001 Oct 04, 2019 May DISC

@ FRESENIUS KABI USA 3.5MG/VIAL N205004 001 Nov 06, 2017 May DISC

>D> SOLUTION;INTRAVENOUS

>D> BORTEZOMIB

>D> +! MAIA PHARMS INC 3.5MG/1.4ML (2.5MG/ML) N215331 002 Jul 27, 2022 Oct DISC

>A> + @ 3.5MG/1.4ML (2.5MG/ML) N215331 002 Jul 27, 2022 Oct DISC

BOSENTAN

TABLET;ORAL

BOSENTAN

>D> AB HIKMA 62.5MG A208695 001 Apr 26, 2019 Oct DISC

>A> @ 62.5MG A208695 001 Apr 26, 2019 Oct DISC

>D> AB 125MG A208695 002 Apr 26, 2019 Oct DISC

>A> @ 125MG A208695 002 Apr 26, 2019 Oct DISC

@ PAR PHARM INC 62.5MG A205699 001 Apr 26, 2019 Apr DISC

@ 125MG A205699 002 Apr 26, 2019 Apr DISC

BOSUTINIB MONOHYDRATE

CAPSULE;ORAL

BOSULIF

>D> +! PF PRISM CV EQ 50MG BASE N217729 001 Sep 26, 2023 Oct CHRS

>A> + EQ 50MG BASE N217729 001 Sep 26, 2023 Oct CHRS

+! EQ 50MG BASE N217729 001 Sep 26, 2023 Sep NEWA

>D> + EQ 100MG BASE N217729 002 Sep 26, 2023 Oct CHRS

>A> +! EQ 100MG BASE N217729 002 Sep 26, 2023 Oct CHRS

CAPSULE; ORAL
BOSULIF

+ EQ 100MG BASE N217729 002 Sep 26, 2023 Sep NEWA

BRETYLIUM TOSYLATEINJECTABLE; INJECTION
BRETYLIUM TOSYLATE
@ BRECKENRIDGE

50MG/ML

A204386 001 Dec 21, 2018 Feb DISC

BREXPIRAZOLE

TABLET; ORAL

BREXPIRAZOLE

@ AJANTA PHARMA LTD

0.25MG

A213718 001 Feb 03, 2023 Aug DISC

AB 0.25MG A213718 001 Feb 03, 2023 Jan NEWA

@ 0.5MG A213718 002 Feb 03, 2023 Aug DISC

AB 0.5MG A213718 002 Feb 03, 2023 Jan NEWA

@ 1MG A213718 003 Feb 03, 2023 Aug DISC

AB 1MG A213718 003 Feb 03, 2023 Jan NEWA

@ 2MG A213718 004 Feb 03, 2023 Aug DISC

AB 2MG A213718 004 Feb 03, 2023 Jan NEWA

@ 3MG A213718 005 Feb 03, 2023 Aug DISC

AB 3MG A213718 005 Feb 03, 2023 Jan NEWA

@ 4MG A213718 006 Feb 03, 2023 Aug DISC

AB 4MG A213718 006 Feb 03, 2023 Jan NEWA

@ AMNEAL 0.25MG A213562 001 Jan 31, 2023 Mar DISC

AB 0.25MG A213562 001 Jan 31, 2023 Jan NEWA

@ 0.5MG A213562 002 Jan 31, 2023 Mar DISC

AB 0.5MG A213562 002 Jan 31, 2023 Jan NEWA

@ 1MG A213562 003 Jan 31, 2023 Mar DISC

AB 1MG A213562 003 Jan 31, 2023 Jan NEWA

@ 2MG A213562 004 Jan 31, 2023 Mar DISC

AB 2MG A213562 004 Jan 31, 2023 Jan NEWA

@ 3MG A213562 005 Jan 31, 2023 Mar DISC

AB 3MG A213562 005 Jan 31, 2023 Jan NEWA

@ 4MG A213562 006 Jan 31, 2023 Mar DISC

AB 4MG A213562 006 Jan 31, 2023 Jan NEWA

>A> AB AUROBINDO PHARMA LTD 0.25MG A213659 001 Nov 02, 2023 Oct NEWA

>A> AB 0.5MG A213659 002 Nov 02, 2023 Oct NEWA

>A> AB 1MG A213659 003 Nov 02, 2023 Oct NEWA

>A> AB 2MG A213659 004 Nov 02, 2023 Oct NEWA

>A> AB 3MG A213659 005 Nov 02, 2023 Oct NEWA

>A> AB 4MG A213659 006 Nov 02, 2023 Oct NEWA

@ LUPIN LTD 0.25MG A213512 001 Mar 17, 2023 May DISC

AB 0.25MG A213512 001 Mar 17, 2023 Mar NEWA

@ 0.5MG A213512 002 Mar 17, 2023 May DISC

AB 0.5MG A213512 002 Mar 17, 2023 Mar NEWA

@ 1MG A213512 003 Mar 17, 2023 May DISC

AB 1MG A213512 003 Mar 17, 2023 Mar NEWA

@ 2MG A213512 004 Mar 17, 2023 May DISC

AB 2MG A213512 004 Mar 17, 2023 Mar NEWA

@ 3MG A213512 005 Mar 17, 2023 May DISC

AB 3MG A213512 005 Mar 17, 2023 Mar NEWA

@ 4MG A213512 006 Mar 17, 2023 May DISC

AB 4MG A213512 006 Mar 17, 2023 Mar NEWA

>A> AB OPTIMUS 0.25MG A213758 001 Oct 25, 2023 Oct NEWA

>A> AB 0.5MG A213758 002 Oct 25, 2023 Oct NEWA

>A> AB 1MG A213758 003 Oct 25, 2023 Oct NEWA

>A> AB 2MG A213758 004 Oct 25, 2023 Oct NEWA

>A> AB 3MG A213758 005 Oct 25, 2023 Oct NEWA

>A> AB 4MG A213758 006 Oct 25, 2023 Oct NEWA

@ TEVA PHARMS USA INC 0.25MG A213692 001 Aug 11, 2022 Feb DISC

@ 0.5MG A213692 002 Aug 11, 2022 Feb DISC

@ 1MG A213692 003 Aug 11, 2022 Feb DISC

@ 2MG A213692 004 Aug 11, 2022 Feb DISC

@ 3MG A213692 005 Aug 11, 2022 Feb DISC

@ 4MG A213692 006 Aug 11, 2022 Feb DISC

@ ZYDUS PHARMS 0.25MG A213660 001 Jan 10, 2023 Jun DISC

@ 0.5MG A213660 002 Jan 10, 2023 Jun DISC

@ 1MG A213660 003 Jan 10, 2023 Jun DISC

@ 2MG A213660 004 Jan 10, 2023 Jun DISC

@ 3MG A213660 005 Jan 10, 2023 Jun DISC

@ 4MG A213660 006 Jan 10, 2023 Jun DISC

TABLET; ORAL
REXULTI

>D>	+	OTSUKA	0.25MG	N205422	001	Jul 10, 2015	Oct CTEC
>A>	AB	+	0.25MG	N205422	001	Jul 10, 2015	Oct CTEC
		+	0.25MG	N205422	001	Jul 10, 2015	Aug CTEC
>D>		+	0.5MG	N205422	002	Jul 10, 2015	Oct CTEC
>A>	AB	+	0.5MG	N205422	002	Jul 10, 2015	Oct CTEC
		+	0.5MG	N205422	002	Jul 10, 2015	Aug CTEC
>D>		+	1MG	N205422	003	Jul 10, 2015	Oct CTEC
>A>	AB	+	1MG	N205422	003	Jul 10, 2015	Oct CTEC
		+	1MG	N205422	003	Jul 10, 2015	Aug CTEC
>D>		+	2MG	N205422	004	Jul 10, 2015	Oct CTEC
>A>	AB	+	2MG	N205422	004	Jul 10, 2015	Oct CTEC
		+	2MG	N205422	004	Jul 10, 2015	Aug CTEC
>D>		+	3MG	N205422	005	Jul 10, 2015	Oct CTEC
>A>	AB	+	3MG	N205422	005	Jul 10, 2015	Oct CTEC
		+	3MG	N205422	005	Jul 10, 2015	Aug CTEC
>D>		+	4MG	N205422	006	Jul 10, 2015	Oct CTEC
>A>	AB	+	4MG	N205422	006	Jul 10, 2015	Oct CTEC
		+	4MG	N205422	006	Jul 10, 2015	Aug CTEC

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
BRIMONIDINE TARTRATE

AB	ALEMBIC	0.1%	A216909	001	Aug 01, 2023	Jul NEWA
AT		0.15%	A215225	001	Mar 29, 2023	Mar NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

AB	ALEMBIC	0.2%;EQ 0.5% BASE	A215230	001	Aug 25, 2023	Aug NEWA
AB	SENTISS	0.2%;EQ 0.5% BASE	A091086	001	Oct 31, 2022	Jul CAHN

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC
AZOPT

AB	+	SANDOZ	1%	N020816	001	Apr 01, 1998	Sep CAHN
		BRINZOLAMIDE					
AB		PADAGIS US	1%	A211914	001	Jul 28, 2023	Jul NEWA

BRIVARACETAM

TABLET; ORAL
BRIVARACETAM

@ AUROBINDO PHARMA LTD 50MG
@ 100MG
@ LUPIN LTD 10MG
@ 25MG
@ 50MG
@ 75MG
@ 100MG

A214848 001 Jan 06, 2023 Mar DISC
A214848 002 Jan 06, 2023 Mar DISC
A214918 001 Dec 20, 2022 Mar DISC
A214918 002 Dec 20, 2022 Mar DISC
A214918 003 Dec 20, 2022 Mar DISC
A214918 004 Dec 20, 2022 Mar DISC
A214918 005 Dec 20, 2022 Mar DISC

BRIVIACT

+ UCB INC 10MG
+ 25MG
+ 50MG
+ 75MG
+! 100MG

N205836 001 May 12, 2016 Mar CTEC
N205836 002 May 12, 2016 Mar CTEC
N205836 003 May 12, 2016 Mar CTEC
N205836 004 May 12, 2016 Mar CTEC
N205836 005 May 12, 2016 Mar CTEC

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
BROMFENAC SODIUM

AT2	AKORN	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Jun CHRS
AT2	!	ALEMBIC	A210560	001	Jun 21, 2019	Jun CHRS
AT2		LUPIN LTD	A202903	001	Aug 15, 2023	Aug NEWA
AT2		SENTISS	A203395	001	Jan 22, 2014	Jul CAHN

BROMOCRIPTINE MESYLATE

TABLET; ORAL
BROMOCRIPTINE MESYLATE

@ AUROBINDO PHARMA USA EQ 2.5MG BASE

A076962 001 Sep 24, 2004 Apr CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMFED-DM

AA	+	WOCKHARDT BIO AG	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Jun CHRS
AA	+	!	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Jun CRLD
		BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE					
		@ BIONPHARMA	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	Jun CAHN
		@ BRECKENRIDGE	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	Jan DISC
AA	!	PADAGIS US	2MG/5ML;10MG/5ML;30MG/5ML	A205292	001	Jul 15, 2014	Jun CHRS

BUDESONIDE

AEROSOL, FOAM; RECTAL

BUDESONIDE

AB		PADAGIS ISRAEL	2MG/ACTUATION	A215328	001	Apr 12, 2023	Mar NFTG
		UCERIS					
AB	+	!	2MG/ACTUATION	N205613	001	Oct 07, 2014	Mar CFTG

CAPSULE, DELAYED RELEASE; ORAL

ORTIKOS

>D>	+	SUN PHARM INDS INC	6MG	N211929	001	Jun 13, 2019	Oct DISC
>A>	+	@	6MG	N211929	001	Jun 13, 2019	Oct DISC
>D>	+	!	9MG	N211929	002	Jun 13, 2019	Oct DISC
>A>	+	@	9MG	N211929	002	Jun 13, 2019	Oct DISC

BUDESONIDE; FORMOTEROL FUMARATE

AEROSOL, METERED; INHALATION

SYMBICORT AEROSPHERE

+	!	ASTRAZENECA	0.16MG/INH;0.0048MG/INH	N216579	001	Apr 28, 2023	Apr NEWA
---	---	-------------	-------------------------	---------	-----	--------------	----------

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP		SAGENT	0.25MG/ML	A074441	001	Jan 27, 1995	Aug CAHN
		TABLET; ORAL					
		BUMETANIDE					
AB		TARO	0.5MG	A213458	001	Jul 24, 2023	Jul NEWA
AB			1MG	A213458	002	Jul 24, 2023	Jul NEWA
AB			2MG	A213458	003	Jul 24, 2023	Jul NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

AP		KINDOS	0.25%	A216039	001	Jun 23, 2023	Jun NEWA
AP			0.5%	A216039	002	Jun 23, 2023	Jun NEWA
AP		STERISCIENCE	0.25%	A091503	001	Oct 18, 2011	Jun CMFD
AP			0.5%	A091503	002	Oct 18, 2011	Jun CMFD

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

AP		STERISCIENCE	0.25%	A091487	002	Oct 18, 2011	Jun CMFD
AP			0.5%	A091487	001	Oct 18, 2011	Jun CMFD
AP			0.75%	A091487	003	Oct 18, 2011	Jun CMFD

INJECTABLE; SPINAL

BUPIVACAINE HYDROCHLORIDE

@	BAXTER HLTHCARE CORP	0.75%	A207266	001	Jul 25, 2016	Aug DISC
---	----------------------	-------	---------	-----	--------------	----------

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUPRENORPHINE

	@	ALVOGEN	7.5MCG/HR	A207490	005	Mar 21, 2023	Sep DISC
AB			7.5MCG/HR	A207490	005	Mar 21, 2023	Mar NEWA

SOLUTION, EXTENDED RELEASE; SUBCUTANEOUS

BRIXADI

+	BRAEBURN	8MG/0.16ML (50MG/ML)	N210136	001	May 23, 2023	May NEWA
+		16MG/0.32ML (50MG/ML)	N210136	002	May 23, 2023	May NEWA
+		24MG/0.48ML (50MG/ML)	N210136	003	May 23, 2023	May NEWA
+		32MG/0.64ML (50MG/ML)	N210136	004	May 23, 2023	May NEWA
+		64MG/0.18ML (356MG/ML)	N210136	005	May 23, 2023	May NEWA
+		96MG/0.27ML (356MG/ML)	N210136	006	May 23, 2023	May NEWA
+	!	128MG/0.36ML (356MG/ML)	N210136	007	May 23, 2023	May NEWA

BUPRENORPHINE HYDROCHLORIDE

	INJECTABLE; INJECTION					
	BUPRENEX					
	+ @ INDIVIOR	EQ 0.3MG BASE/ML	N018401	001		Jul DISC
	BUPRENORPHINE HYDROCHLORIDE					
AP	! PAR STERILE PRODUCTS	EQ 0.3MG BASE/ML	A206586	001	Jul 28, 2015	Jul CHRS

BUPROPION HYDROCHLORIDE

	TABLET, EXTENDED RELEASE; ORAL					
	BUPROPION HYDROCHLORIDE					
	@ ANCHEN PHARMS	150MG	A077284	001	Dec 14, 2006	Sep DISC
AB1	ANNORA PHARMA	100MG	A216800	001	May 31, 2023	May NEWA
AB1		150MG	A216800	002	May 31, 2023	May NEWA
AB1		200MG	A216800	003	May 31, 2023	May NEWA
AB3	SCINOPHARM TAIWAN	150MG	A210081	001	Nov 03, 2017	Sep CAHN
AB3		300MG	A210081	002	Nov 03, 2017	Sep CAHN

BUSPIRONE HYDROCHLORIDE

	TABLET; ORAL					
	BUSPIRONE HYDROCHLORIDE					
	@ GRAVITI PHARMS	5MG	A075413	001	Mar 19, 2002	Feb CAHN
	@	10MG	A075413	002	Mar 19, 2002	Feb CAHN
	@	15MG	A075413	003	Mar 19, 2002	Feb CAHN
	@ RISING	5MG	A075413	001	Mar 19, 2002	Aug CAHN
	@	10MG	A075413	002	Mar 19, 2002	Aug CAHN
	@	15MG	A075413	003	Mar 19, 2002	Aug CAHN
AB	ZYDUS PHARMS	7.5MG	A078888	005	Mar 21, 2023	Mar NEWA

BUSULFAN

	INJECTABLE; INJECTION					
	BUSULFAN					
	@ AM REGENT	6MG/ML	A202259	001	Dec 22, 2015	Jan DISC
	@ ARTHUR GRP	6MG/ML	A205106	001	Sep 21, 2018	Mar DISC
	TABLET; ORAL					
	MYLERAN					
	+! WAYLIS THERAP	2MG	N009386	001		Sep CAHN

BUTENAFINE HYDROCHLORIDE

	CREAM; TOPICAL					
	MENTAX					
	+ @ MYLAN	1%	N020524	001	Oct 18, 1996	Jul DISC

CABAZITAXEL

	SOLUTION; INTRAVENOUS					
	CABAZITAXEL					
	+! ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021	Feb CMFD
	@ APOTEX	60MG/1.5ML (40MG/ML)	A207736	001	Feb 10, 2023	Aug DISC
AP		60MG/1.5ML (40MG/ML)	A207736	001	Feb 10, 2023	Feb NEWA
AP	DR REDDYS	60MG/1.5ML (40MG/ML)	A207718	001	Feb 10, 2023	Feb NEWA
	@ MYLAN LABS LTD	60MG/1.5ML (40MG/ML)	A207381	001	Jul 05, 2023	Jul DISC
AP		60MG/1.5ML (40MG/ML)	A207381	001	Jul 05, 2023	Jun NEWA

CABOZANTINIB S-MALATE

	CAPSULE; ORAL					
	COMETRIQ					
	+ EXELIXIS	EQ 20MG BASE	N203756	001	Nov 29, 2012	Jun CHRS
	+!	EQ 80MG BASE	N203756	002	Nov 29, 2012	Jun CHRS

CALCIPOTRIENE

	CREAM; TOPICAL					
	CALCIPOTRIENE					
>A>	@ CHARTWELL RX	0.005%	A200935	001	May 30, 2012	Oct CAHN
>D>	@ TOLMAR	0.005%	A200935	001	May 30, 2012	Oct CAHN
	@	0.005%	A200935	001	May 30, 2012	Feb DISC
	SOLUTION; TOPICAL					
	CALCIPOTRIENE					
AT	CHARTWELL RX	0.005%	A207163	001	Dec 26, 2017	Jul CAHN
AT	! COSETTE	0.005%	A078468	001	Mar 24, 2011	Feb CHRS

CALCITRIOL

CAPSULE;ORAL						
CALCITRIOL						
AB	! STRIDES PHARMA	0.5MCG	A091356	002	Dec 12, 2014	May CHRS
ROCALTROL						
AB	+ VALIDUS PHARMS	0.5MCG	N018044	002		May CHRS
INJECTABLE;INJECTION						
CALCITRIOL						
AP	! LONG GROVE PHARMS	0.001MG/ML	A078066	001	Jan 29, 2008	Aug CAHN
	@	0.002MG/ML	A078066	002	Jan 29, 2008	Aug CAHN
SOLUTION;ORAL						
CALCITRIOL						
AA	PATRIN	1MCG/ML	A203973	001	Jul 28, 2023	Jul NEWA
AA	RISING	1MCG/ML	A209798	001	Nov 21, 2018	Jul CAHN

CALCIUM ACETATE

CAPSULE;ORAL						
CALCIUM ACETATE						
	@ SQUARE PHARMS	667MG	A217205	001	Mar 13, 2023	Sep DISC
AB		667MG	A217205	001	Mar 13, 2023	Mar NEWA
SOLUTION;ORAL						
PHOSLYRA						
	+ @ FRESENIUS MEDCL	667MG/5ML	N022581	001	Apr 18, 2011	Jun DISC

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS						
CALCIUM GLUCONATE						
AP	B BRAUN MEDICAL INC	10GM/100ML (100MG/ML)	A216541	001	Aug 21, 2023	Aug NFTG
>D>	+! FRESENIUS KABI USA	5GM/50ML (100MG/ML)	N208418	002	Jun 15, 2017	Oct CFTG
>A>	AP +!	5GM/50ML (100MG/ML)	N208418	002	Jun 15, 2017	Oct CFTG
AP	+!	10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017	Aug CFTG
>A>	AP NIVAGEN PHARMS INC	5GM/50ML (100MG/ML)	A213071	002	Oct 19, 2023	Oct NFTG
>A>	AP SOMERSET	5GM/50ML (100MG/ML)	A217689	001	Oct 19, 2023	Oct NFTG
>A>	AP	10GM/100ML (100MG/ML)	A217689	002	Oct 19, 2023	Oct NEWA
CALCIUM GLUCONATE IN SODIUM CHLORIDE						
AP	AMNEAL	1GM/50ML (20MG/ML)	A217174	001	Sep 05, 2023	Aug NFTG
AP		2GM/100ML (20MG/ML)	A217174	002	Sep 05, 2023	Aug NFTG
AP	+! FRESENIUS KABI USA	1GM/50ML (20MG/ML)	N208418	004	Jun 17, 2021	Aug CFTG
AP	+!	2GM/100ML (20MG/ML)	N208418	005	Jun 17, 2021	Aug CFTG

CANDESARTAN CILEXETIL

TABLET;ORAL						
CANDESARTAN CILEXETIL						
AB	PRINSTON INC	8MG	A206233	001	Aug 21, 2023	Aug NEWA
AB		16MG	A206233	002	Aug 21, 2023	Aug NEWA
AB		32MG	A206233	003	Aug 21, 2023	Aug NEWA
AB	ZYDUS LIFESCIENCES	4MG	A091390	001	Aug 23, 2017	May CAHN
AB		8MG	A091390	002	Aug 23, 2017	May CAHN
AB		16MG	A091390	003	Aug 23, 2017	May CAHN
AB		32MG	A091390	004	Aug 23, 2017	May CAHN

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL						
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE						
AB	ZYDUS LIFESCIENCES	16MG;12.5MG	A203466	001	Nov 27, 2017	May CAHN
AB		32MG;12.5MG	A203466	002	Nov 27, 2017	May CAHN
AB		32MG;25MG	A203466	003	Nov 27, 2017	May CAHN

CANTHARIDIN

SOLUTION;TOPICAL						
YCANTH						
	+! VERRICA PHARMS	0.7%	N212905	001	Jul 21, 2023	Jul NEWA

CAPECITABINE

TABLET;ORAL						
CAPECITABINE						
>A>	AB TEYRO LABS	150MG	A217237	001	Oct 23, 2023	Oct NEWA
>A>	AB	500MG	A217237	002	Oct 23, 2023	Oct NEWA
XELODA						
AB	+ CHEPLAPHARM	150MG	N020896	001	Apr 30, 1998	Apr CAHN
AB	+!	500MG	N020896	002	Apr 30, 1998	Apr CAHN

CAPTOPRIL

TABLET; ORAL					
CAPTOPRIL					
	@ AUROBINDO PHARMA USA	12.5MG	A 074434	001	Feb 13, 1996 May CAHN
	@	25MG	A 074434	002	Feb 13, 1996 May CAHN
	@	50MG	A 074434	003	Feb 13, 1996 May CAHN
	@	100MG	A 074434	004	Feb 13, 1996 May CAHN
AB	CHANGZHOU PHARM	12.5MG	A 214442	001	Jan 27, 2023 Jan NEWA
AB		25MG	A 214442	002	Jan 27, 2023 Jan NEWA
AB		50MG	A 214442	003	Jan 27, 2023 Jan NEWA
AB		100MG	A 214442	004	Jan 27, 2023 Jan NEWA
AB	COREPHARMA	12.5MG	A 074737	001	Oct 28, 1998 Mar CAHN
AB		25MG	A 074737	002	Oct 28, 1998 Mar CAHN
AB		50MG	A 074737	003	Oct 28, 1998 Mar CAHN
AB		100MG	A 074737	004	Oct 28, 1998 Mar CAHN
AB	KENTON	12.5MG	A 074677	004	May 30, 1997 Sep CAHN
AB		25MG	A 074677	002	May 30, 1997 Sep CAHN
AB		50MG	A 074677	001	May 30, 1997 Sep CAHN
AB		100MG	A 074677	003	May 30, 1997 Sep CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL					
CAPTOPRIL AND HYDROCHLOROTHIAZIDE					
	RISING	25MG; 15MG	A 074896	001	Dec 29, 1997 May CMFD
!		25MG; 25MG	A 074896	002	Dec 29, 1997 May CMFD
!		50MG; 15MG	A 074896	004	Dec 29, 1997 May CMFD
		50MG; 25MG	A 074896	003	Dec 29, 1997 May CMFD

CARBAMAZEPINE

SUSPENSION; ORAL					
CARBAMAZEPINE					
AB	CHARTWELL RX	100MG/5ML	A 075714	001	Jun 05, 2002 Jan CAHN
TABLET; ORAL					
CARBAMAZEPINE					
	@ RK PHARMA	200MG	A 214328	001	Aug 16, 2021 Jun CAHN
TABLET, EXTENDED RELEASE; ORAL					
CARBAMAZEPINE					
	@ AJANTA PHARMA LTD	100MG	A 216193	001	Mar 24, 2023 Sep DISC
AB		100MG	A 216193	001	Mar 24, 2023 Mar NEWA
	@	200MG	A 216193	002	Mar 24, 2023 Sep DISC
AB		200MG	A 216193	002	Mar 24, 2023 Mar NEWA
	@	400MG	A 216193	003	Mar 24, 2023 Sep DISC
AB		400MG	A 216193	003	Mar 24, 2023 Mar NEWA
AB	AMNEAL PHARMS	100MG	A 212704	001	Sep 22, 2023 Sep NEWA
AB		200MG	A 212704	002	Sep 22, 2023 Sep NEWA
AB		400MG	A 212704	003	Sep 22, 2023 Sep NEWA
AB	RICONPHARMA LLC	100MG	A 216404	001	Dec 02, 2022 Jun CMFD
AB		200MG	A 216404	002	Dec 02, 2022 Jun CMFD
AB		400MG	A 216404	003	Dec 02, 2022 Jun CMFD
AB	SCIECURE PHARMA INC	100MG	A 216235	001	Mar 02, 2023 Feb NEWA
AB		200MG	A 216235	002	Mar 02, 2023 Feb NEWA
AB		400MG	A 216235	003	Mar 02, 2023 Feb NEWA

CARBIDOPA; LEVODOPA

TABLET; ORAL					
CARBIDOPA AND LEVODOPA					
	@ ZYDUS PHARMS	10MG; 100MG	A 215999	001	Apr 04, 2023 Aug DISC
AB		10MG; 100MG	A 215999	001	Apr 04, 2023 Mar NEWA
	@	25MG; 100MG	A 215999	002	Apr 04, 2023 Aug DISC
AB		25MG; 100MG	A 215999	002	Apr 04, 2023 Mar NEWA
	@	25MG; 250MG	A 215999	003	Apr 04, 2023 Aug DISC
AB		25MG; 250MG	A 215999	003	Apr 04, 2023 Mar NEWA
TABLET, EXTENDED RELEASE; ORAL					
CARBIDOPA AND LEVODOPA					
AB	! SCIEGEN PHARMS INC	50MG; 200MG	A 214091	002	Oct 05, 2021 May CHRS
AB	SUN PHARM INDS	50MG; 200MG	A 077828	002	Aug 23, 2007 May CHRS
TABLET, ORALLY DISINTEGRATING; ORAL					
CARBIDOPA AND LEVODOPA					
	SUN PHARM	10MG; 100MG	A 078690	001	Jul 31, 2009 Apr CTEC
		25MG; 100MG	A 078690	002	Jul 31, 2009 Apr CTEC

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

! GENUS 4MG/5ML

A040458 001 Apr 25, 2003 Sep CAHN

TABLET; ORAL

CARBINOXAMINE MALEATE

AA ! GENUS 4MG

A040442 001 Mar 19, 2003 Sep CAHN

CARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

>D> AP AKORN 600MG/60ML (10MG/ML)

A091268 002 Jul 28, 2010 Oct CAHN

>A> AP EPIC PHARMA LLC 600MG/60ML (10MG/ML)

A091268 002 Jul 28, 2010 Oct CAHN

AP NOVAST LABS 450MG/45ML (10MG/ML)

A208487 003 Apr 26, 2017 May CMFD

AP 600MG/60ML (10MG/ML)

A208487 004 Apr 26, 2017 May CMFD

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

CARBOPROST TROMETHAMINE

AP ALEMBIC EQ 0.25MG BASE/ML

A217198 001 Jun 15, 2023 Jun NEWA

AP CAPLIN EQ 0.25MG BASE/ML

A216882 001 Feb 13, 2023 Feb NEWA

AP EUGIA PHARMA EQ 0.25MG BASE/ML

A216939 001 May 25, 2023 May NEWA

AP GLAND PHARMA LTD EQ 0.25MG BASE/ML

A217657 001 Aug 07, 2023 Jul NEWA

AP SOLA PHARMS EQ 0.25MG BASE/ML

A216824 001 May 19, 2023 Jun CAHN

AP STERISCIENCE EQ 0.25MG BASE/ML

A216897 001 Jul 25, 2023 Jul NEWA

AP WELDING EQ 0.25MG BASE/ML

A216824 001 May 19, 2023 May NEWA

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

+ ONYX PHARMS AMGEN 10MG/VIAL

N202714 003 Jun 07, 2018 Jun CAHN

+ 30MG/VIAL

N202714 002 Jun 03, 2016 Jun CAHN

AP +! 60MG/VIAL

N202714 001 Jul 20, 2012 Jun CAHN

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL

CARIPRAZINE HYDROCHLORIDE

@ ZYDUS EQ 1.5MG BASE

A213984 001 Sep 09, 2022 May CAHN

@ EQ 3MG BASE

A213984 002 Sep 09, 2022 May CAHN

@ EQ 4.5MG BASE

A213984 003 Sep 09, 2022 May CAHN

@ EQ 6MG BASE

A213984 004 Sep 09, 2022 May CAHN

VRAYLAR

+! ABBVIE EQ 1.5MG BASE

N204370 001 Sep 17, 2015 Jan CAHN

+ EQ 3MG BASE

N204370 002 Sep 17, 2015 Jan CAHN

+ EQ 4.5MG BASE

N204370 003 Sep 17, 2015 Jan CAHN

+ EQ 6MG BASE

N204370 004 Sep 17, 2015 Jan CAHN

CARMUSTINE

INJECTABLE; INJECTION

CARMUSTINE

@ ACCORD HLTHCARE 100MG/VIAL

A214117 001 Dec 27, 2022 Jul DISC

AP 100MG/VIAL

A214117 001 Dec 27, 2022 Mar CTNA

>A> AP ALEMBIC 100MG/VIAL

A215730 001 Oct 20, 2023 Oct NEWA

AP MSN 100MG/VIAL

A214814 001 May 11, 2023 May NEWA

@ MYLAN LABS LTD 100MG/VIAL

A215368 001 Mar 03, 2023 Mar DISC

AP 100MG/VIAL

A215368 001 Mar 03, 2023 Feb NEWA

AP PENN LIFE 100MG/VIAL

A209278 001 Apr 02, 2019 May CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF IN PLASTIC CONTAINER

>D> ! BAXTER HLTHCARE EQ 20MG BASE/ML

A063002 002 Mar 28, 1991 Oct DISC

>A> @ EQ 20MG BASE/ML

A063002 002 Mar 28, 1991 Oct DISC

POWDER; INTRAVENOUS

CEFAZOLIN SODIUM

+! HQ SPCLT PHARMA EQ 2GM BASE/VIAL

N211413 001 May 08, 2023 May NEWA

CEFDINIR

CAPSULE;ORAL						
CEFDINIR						
AB	ANDA REPOSITORY	300MG	A065418	001	Jul 18, 2007	Sep CAHN
FOR SUSPENSION;ORAL						
CEFDINIR						
AB	ANDA REPOSITORY	125MG/5ML	A065429	001	Jul 18, 2007	Sep CAHN
AB		250MG/5ML	A065429	002	Jul 18, 2007	Sep CAHN

CEFOTAXIME SODIUM

INJECTABLE;INJECTION
CEFOTAXIME

@	HIKMA	EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002	Mar DISC
@		EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002	Mar DISC
@		EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002	Mar DISC
@		EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002	Mar DISC

CEFOTETAN DISODIUM

INJECTABLE;INJECTION
CEFOTAN

+	@ PAI HOLDINGS PHARM	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	May DISC
+	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	May DISC
CEFOTETAN						
!	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065374	001	Aug 09, 2007	May CTEC
!		EQ 2GM BASE/VIAL	A065374	002	Aug 09, 2007	May CTEC

CEFPODOXIME PROXETIL

TABLET;ORAL

CEFPODOXIME PROXETIL						
AB	ANDA REPOSITORY	EQ 100MG BASE	A065388	001	Nov 14, 2007	Sep CAHN
AB		EQ 200MG BASE	A065388	002	Nov 14, 2007	Sep CAHN

CEFTAROLINE FOSAMIL

POWDER;INTRAVENOUS
TEFLARO

+	!	ABBVIE	400MG/VIAL	N200327	001	Oct 29, 2010	May CAHN
+	!		600MG/VIAL	N200327	002	Oct 29, 2010	May CAHN

CEFTAZIDIME

INJECTABLE;INJECTION
CEFTAZIDIME

AP	!	ACS DOBFAR	1GM/VIAL	A062640	002	Nov 20, 1985	May CHRS
AP	!		2GM/VIAL	A062640	003	Nov 20, 1985	May CHRS
AP	!		6GM/VIAL	A062640	004	Feb 03, 1992	May CHRS
FORTAZ							
+	@	PAI HOLDINGS PHARM	500MG/VIAL	N050578	001	Jul 19, 1985	May DISC
+	@		1GM/VIAL	N050578	002	Jul 19, 1985	May DISC
+	@		2GM/VIAL	N050578	003	Jul 19, 1985	May DISC
+	@		6GM/VIAL	N050578	004	Jul 19, 1985	May DISC
TAZICEF							
@	HOSPIRA	500MG/VIAL	A062662	001	Mar 06, 1986	May DISC	
		500MG/VIAL	A062662	001	Mar 06, 1986	May CTEC	

CEFTRIAZONE SODIUM

INJECTABLE;INJECTION
CEFTRIAZONE SODIUM

AP		ANDA REPOSITORY	EQ 10GM BASE/VIAL	A091117	001	Jan 20, 2017	Sep CAHN
----	--	-----------------	-------------------	---------	-----	--------------	----------

CEFUROXIME AXETIL

TABLET;ORAL

CEFUROXIME AXETIL						
AB	ANDA REPOSITORY	EQ 125MG BASE	A065359	001	Feb 15, 2008	Sep CAHN
AB		EQ 250MG BASE	A065359	002	Feb 15, 2008	Sep CAHN
AB		EQ 500MG BASE	A065359	003	Feb 15, 2008	Sep CAHN

CEFUROXIME SODIUM

INJECTABLE; INJECTION							
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER							
	+ @ B BRAUN	EQ 750MG BASE/VIAL	N050780	001	Feb 21, 2001	Jun	DISC
	+!	EQ 750MG BASE/VIAL	N050780	001	Feb 21, 2001	May	CTEC
	+ @	EQ 1.5GM BASE/VIAL	N050780	002	Feb 21, 2001	Jun	DISC
CEFUROXIME SODIUM							
	@ ACS DOBFAR SPA	EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jun	DISC
AP	! HIKMA	EQ 1.5GM BASE/VIAL	A065048	002	Jan 09, 2004	Jun	CHRS
	@	EQ 7.5GM BASE/VIAL	A065046	001	Jan 09, 2004	Jun	DISC
ZINACEF							
	+ @ PAI HOLDINGS PHARM	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jun	DISC
	+ @	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jun	DISC
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS							
CEFUROXIME SODIUM							
AB	! HIKMA	EQ 750MG BASE/VIAL	A065048	001	Jan 09, 2004	Jun	CHRS
ZINACEF							
	+ @ PAI HOLDINGS PHARM	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jun	DISC

CELECOXIB

CAPSULE; ORAL							
CELECOXIB							
	@ MYLAN	50MG	A078857	001	May 30, 2014	Jun	DISC
	@	100MG	A078857	002	Feb 11, 2015	Mar	DISC
	@	200MG	A078857	003	Feb 11, 2015	Jun	DISC
	@	400MG	A078857	004	Feb 11, 2015	Jun	DISC
	@ YABAO PHARM	100MG	A212564	001	Apr 10, 2023	Sep	DISC
AB		100MG	A212564	001	Apr 10, 2023	Mar	NEWA
	@	200MG	A212564	002	Apr 10, 2023	Sep	DISC
AB		200MG	A212564	002	Apr 10, 2023	Mar	NEWA
	@	400MG	A212564	003	Apr 10, 2023	Sep	DISC
AB		400MG	A212564	003	Apr 10, 2023	Mar	NEWA
SOLUTION; ORAL							
ELYXYB							
	+ @ SCILEX HLDG	25MG/ML	N212157	001	May 05, 2020	Feb	CAHN

CEPHALEXIN

CAPSULE; ORAL							
CEPHALEXIN							
AB	ANDA REPOSITORY	EQ 250MG BASE	A065248	001	Jun 28, 2005	Sep	CAHN
AB		EQ 500MG BASE	A065248	002	Jun 28, 2005	Sep	CAHN

CETIRIZINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC							
ZERVIAE							
>D>	+! EYEVANCE	EQ 0.24% BASE	N208694	001	May 30, 2017	Oct	CAHN
>A>	+! HARROW EYE	EQ 0.24% BASE	N208694	001	May 30, 2017	Oct	CAHN
SYRUP; ORAL							
CETIRIZINE HYDROCHLORIDE							
AA	BIONPHARMA	5MG/5ML	A078488	001	Oct 06, 2008	Jun	CAHN

CETRORELIX ACETATE

POWDER; SUBCUTANEOUS							
CETRORELIX ACETATE							
AP	TEVA PHARMS INC	EQ 0.25MG BASE/VIAL	A215737	001	Aug 12, 2022	Jul	CAHN

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL							
CEVIMELINE HYDROCHLORIDE							
AB	AUROBINDO PHARMA	30MG	A215056	001	Apr 18, 2023	Apr	NEWA
AB	RUBICON	30MG	A216682	001	Apr 06, 2023	Mar	NEWA

CHLORAMBUCIL

TABLET; ORAL							
LEUKERAN							
	+! WAYLIS THERAP	2MG	N010669	002		Sep	CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB	ALEMBIC	5MG; 2.5MG	A216969	001	Sep 15, 2023	Sep NEWA
AB	AUROBINDO PHARMA LTD	5MG; 2.5MG	A216419	001	Sep 14, 2023	Sep NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT	CHARTWELL RX	0.12%	A075006	001	Mar 03, 2004	Jan CAHN
----	--------------	-------	---------	-----	--------------	----------

CHLOROPROCAINE HYDROCHLORIDE

SOLUTION; INTRATHECAL

CLOROTEKAL

	+ @ B BRAUN MEDICAL INC	50MG/5ML (10MG/ML)	N208791	001	Sep 26, 2017	Sep DISC
--	-------------------------	--------------------	---------	-----	--------------	----------

CHLOROTHIAZIDE

TABLET; ORAL

DIURIL

	+ @ RISING	250MG	N011145	004		Sep CAHN
	+ @	500MG	N011145	002		Sep CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

DIURIL

AP	+! RISING	EQ 500MG BASE/VIAL	N011145	005		Sep CAHN
----	-----------	--------------------	---------	-----	--	----------

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB	ALEMBIC	10MG	A217350	001	Jul 18, 2023	Jul NEWA
AB		25MG	A217350	002	Jul 18, 2023	Jul NEWA
AB		50MG	A217350	003	Jul 18, 2023	Jul NEWA
AB		100MG	A217350	004	Jul 18, 2023	Jul NEWA
AB		200MG	A217350	005	Jul 18, 2023	Jul NEWA
AB	AMNEAL PHARMS CO	10MG	A209755	001	Sep 10, 2018	Apr CTEC
AB		25MG	A209755	002	Sep 10, 2018	Apr CTEC
AB		50MG	A209755	003	Sep 10, 2018	Apr CTEC
AB		100MG	A209755	004	Sep 10, 2018	Apr CTEC
AB		200MG	A209755	005	Sep 10, 2018	Apr CTEC
AB	APPCO	10MG	A213590	001	Aug 31, 2020	Jul CMFD
AB		25MG	A213590	002	Aug 31, 2020	Jul CMFD
AB		50MG	A213590	003	Aug 31, 2020	Jul CMFD
AB		100MG	A213590	004	Aug 31, 2020	Jul CMFD
AB		200MG	A213590	005	Aug 31, 2020	Jul CMFD
AB	CHARTWELL RX	10MG	A212630	001	Nov 29, 2021	Sep CAHN
AB		25MG	A212630	002	Nov 29, 2021	Sep CAHN
AB		50MG	A212630	003	Nov 29, 2021	Sep CAHN
AB		100MG	A212630	004	Nov 29, 2021	Sep CAHN
AB		200MG	A212630	005	Nov 29, 2021	Sep CAHN
AB	LUPIN	10MG	A213327	001	Jul 13, 2023	Jul NEWA
AB		25MG	A213327	002	Jul 13, 2023	Jul NEWA
AB		50MG	A213327	003	Jul 13, 2023	Jul NEWA
AB		100MG	A213327	004	Jul 13, 2023	Jul NEWA
AB		200MG	A213327	005	Jul 13, 2023	Jul NEWA

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AB	APPCO	375MG	A212047	001	Jan 27, 2023	Jan NEWA
AB		750MG	A212047	002	Jan 27, 2023	Jan NEWA
AB	APTAPHARMA INC	375MG	A212053	001	Sep 14, 2020	Sep CAHN
AB		750MG	A212053	002	Sep 14, 2020	Sep CAHN
AB	AUROBINDO PHARMA LTD	375MG	A089853	002	Aug 17, 2023	Aug NEWA
AB		750MG	A089853	003	Aug 17, 2023	Aug NEWA
AA	BELCHER	250MG	A215540	001	Jan 24, 2023	Jan NEWA
AA	COREPHARMA	250MG	A214702	001	Apr 10, 2023	Mar NEWA
AA	GRAVITI PHARMS	250MG	A216925	001	Aug 09, 2023	Jul NEWA
AA	RISE PHARMA	250MG	A215158	001	Jul 29, 2021	Sep CAHN
AB	UPSHER SMITH LABS	375MG	A212047	001	Jan 27, 2023	Sep CAHN
AB		750MG	A212047	002	Jan 27, 2023	Sep CAHN

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

@ ANI PHARMS

EQ 4GM RESIN/PACKET

A074554 001 Oct 02, 1996 Aug DISC

@

EQ 4GM RESIN/SCOOPFUL

A074554 002 Oct 02, 1996 Aug DISC

CHOLIC ACID

CAPSULE;ORAL

CHOLBAM

+ MIRUM

50MG

N205750 001 Mar 17, 2015 Sep CAHN

+!

250MG

N205750 002 Mar 17, 2015 Sep CAHN

CHOLINE C-11

INJECTABLE;INTRAVENOUS

CHOLINE C-11

@ WA UNIV SCH MED

4-33.1mCi/ML

A208413 001 Jan 10, 2017 Jul DISC

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

AB SCINOPHARM TAIWAN

EQ 45MG FENOFIBRIC ACID

A210469 001 Jul 05, 2019 Sep CAHN

AB

EQ 135MG FENOFIBRIC ACID

A210469 002 Jul 05, 2019 Sep CAHN

CICLOPIROX

SHAMPOO;TOPICAL

CICLOPIROX

@ PAI HOLDINGS PHARM

1%

A209975 001 Apr 05, 2018 May DISC

SOLUTION;TOPICAL

CICLOPIROX

>D> @ ENCUBE

8%

A077687 001 Sep 18, 2007 Oct CMFD

>A> AT

8%

A077687 001 Sep 18, 2007 Oct CMFD

AT

! PADAGIS US

8%

A077623 001 Sep 18, 2007 Jan CHRS

PENLAC

+ @ VALEANT BERMUDA

8%

N021022 001 Dec 17, 1999 Jan DISC

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

@ AUROBINDO PHARMA USA

50MG

A077019 001 Nov 23, 2004 Apr CAHN

@

100MG

A077019 002 Nov 23, 2004 Apr CAHN

AB EPIC PHARMA LLC

50MG

A077022 002 Mar 11, 2005 Jun CMFD

AB

100MG

A077022 001 Nov 23, 2004 Jun CMFD

CIMETIDINE

TABLET;ORAL

CIMETIDINE

@ PLIVA

800MG

A074566 001 Feb 27, 1997 Sep DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

>D> AA ! AKORN

EQ 300MG BASE/5ML

A074664 001 Oct 28, 1997 Oct CAHN

>A> AA

! PAI HOLDINGS PHARM

EQ 300MG BASE/5ML

A074664 001 Oct 28, 1997 Oct CAHN

@ PHARMOBEDIANT CNSLTG

EQ 300MG BASE/5ML

A074757 001 Oct 17, 1997 Sep CAHN

@ XTTRIUM LABS INC

EQ 300MG BASE/5ML

A074757 001 Oct 17, 1997 Jul DISC

AA

EQ 300MG BASE/5ML

A074757 001 Oct 17, 1997 Mar CAHN

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

AB CHARTWELL RX

EQ 30MG BASE

A213325 001 May 18, 2020 Jun CAHN

AB

EQ 60MG BASE

A213325 002 May 18, 2020 Jun CAHN

AB

EQ 90MG BASE

A213325 003 May 18, 2020 Jun CAHN

AB SLATE RUN PHARMA

EQ 30MG BASE

A210207 001 Aug 01, 2018 Sep CAHN

AB

EQ 60MG BASE

A210207 002 Aug 01, 2018 Sep CAHN

AB

EQ 90MG BASE

A210207 003 Aug 01, 2018 Sep CAHN

CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPRO

AB	+	BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997	May CTEC
AB	+	!	500MG/5ML	N020780	002	Sep 26, 1997	May CTEC
CIPROFLOXACIN							
AB		CHARTWELL	250MG/5ML	A200563	001	Mar 05, 2014	May CMFD
AB			500MG/5ML	A200563	002	Mar 05, 2014	May CMFD
INJECTABLE, SUSPENSION; OTIC							
OTIPRIO							
	+	@ ALK ABELLO	6% (60MG/ML)	N207986	001	Dec 10, 2015	Jan DISC

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

CILOXAN

	+	!	SANDOZ	EQ 0.3% BASE	N020369	001	Mar 30, 1998	Sep CAHN
SOLUTION/DROPS;OPHTHALMIC								
CILOXAN								
AT	+	!	SANDOZ	EQ 0.3% BASE	N019992	001	Dec 31, 1990	Sep CAHN
CIPROFLOXACIN HYDROCHLORIDE								
	@		AKORN	EQ 0.3% BASE	A076555	001	Dec 11, 2008	Feb DISC
	@		PAI HOLDINGS PHARM	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Aug DISC
AT			RUBICON	EQ 0.3% BASE	A075928	001	Jun 09, 2004	Aug CMFD
TABLET;ORAL								
CIPROFLOXACIN HYDROCHLORIDE								
AB			AMNEAL	EQ 100MG BASE	A075939	001	Mar 03, 2005	Jun CMFD
AB				EQ 250MG BASE	A075939	002	Jun 09, 2004	Jun CMFD
AB				EQ 500MG BASE	A075939	003	Jun 09, 2004	Jun CMFD
AB				EQ 750MG BASE	A075939	004	Jun 09, 2004	Jun CMFD
	@		TARO	EQ 100MG BASE	A076912	001	Feb 18, 2005	Aug DISC
	@			EQ 250MG BASE	A076912	002	Oct 06, 2004	Aug DISC
	@			EQ 500MG BASE	A076912	003	Oct 06, 2004	Aug DISC
	@			EQ 750MG BASE	A076912	004	Oct 06, 2004	Aug DISC

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC

CIPRO HC

	+	!	SANDOZ	EQ 0.2% BASE; 1%	N020805	001	Feb 10, 1998	Sep CAHN
--	---	---	--------	------------------	---------	-----	--------------	----------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

	@		RISING	212.6MG; EQ 287.5MG BASE	A078183	001	Mar 22, 2007	Jun CAHN
	@			425.2MG; EQ 574.9MG BASE	A078183	002	Mar 22, 2007	Jun CAHN

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS; OTIC

CIPRODEX

AB	+	!	SANDOZ	0.3%;0.1%	N021537	001	Jul 18, 2003	Sep CAHN
CIPROFLOXACIN AND DEXAMETHASONE								
AB			AKORN	0.3%;0.1%	A215768	001	Jun 09, 2023	Jun NEWA
AB			SENTISS	0.3%;0.1%	A215768	001	Jun 09, 2023	Aug CAHN

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP			CAPLIN	EQ 2MG BASE/ML	A217725	001	Jun 09, 2023	Jun NEWA
AP				EQ 10MG BASE/ML	A217725	002	Jun 09, 2023	Jun NEWA
AP			HIKMA	EQ 2MG BASE/ML	A203079	001	Apr 19, 2023	Apr NEWA

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CELEXA

AB	+		ABBVIE	EQ 10MG BASE	N020822	001	Apr 27, 2000	Feb CAHN
AB	+			EQ 20MG BASE	N020822	002	Jul 17, 1998	Feb CAHN
AB	+	!		EQ 40MG BASE	N020822	003	Jul 17, 1998	Feb CAHN
	@			EQ 60MG BASE	N020822	004	Jul 17, 1998	Feb CAHN

CLARITHROMYCIN

FOR SUSPENSION;ORAL

CLARITHROMYCIN

SANDOZ

125MG/5ML

A065283 002 Sep 04, 2007 May CTEC

!

250MG/5ML

A065283 003 Sep 04, 2007 May CTEC

TABLET;ORAL

CLARITHROMYCIN

@ TEVA

250MG

A065155 001 May 31, 2005 Sep DISC

@

500MG

A065155 002 May 31, 2005 Sep DISC

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

AB

NOSTRUM LABS INC

500MG

A203243 001 Feb 29, 2016 Sep CMFD

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB

GLENMARK PHARMS LTD

EQ 75MG BASE

A216957 001 Mar 10, 2023 Mar NEWA

AB

EQ 150MG BASE

A216957 002 Mar 10, 2023 Mar NEWA

AB

EQ 300MG BASE

A216957 003 Mar 10, 2023 Mar NEWA

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA

CHARTWELL RX

EQ 75MG BASE/5ML

A206958 001 May 05, 2017 Feb CAHN

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

CLINDAMYCIN PHOSPHATE

AT

! PADAGIS ISRAEL

1%

A090785 001 Mar 31, 2010 Jun CHRS

EVOCLIN

+ @ MYLAN

1%

N050801 001 Oct 22, 2004 Jun DISC

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

AB1

ZYDUS LIFESCIENCES

EQ 1% BASE

A216587 001 Sep 19, 2023 Sep NEWA

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

AP

HIKMA

EQ 6MG BASE/ML

A214401 001 Apr 05, 2023 Mar NEWA

AP

EQ 12MG BASE/ML

A214401 002 Apr 05, 2023 Mar NEWA

AP

EQ 18MG BASE/ML

A214401 003 Apr 05, 2023 Mar NEWA

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AT

CHARTWELL RX

EQ 1% BASE

A209846 001 Feb 08, 2018 May CAHN

@ PAI HOLDINGS PHARM

EQ 1% BASE

A206945 001 Dec 30, 2016 Aug DISC

@ XTTRIUM LABS INC

EQ 1% BASE

A063304 001 Jul 15, 1997 Jan CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB2

ENCUBE

1.2%;0.025%

A216943 001 Sep 01, 2023 Aug NEWA

CLOBAZAM

SUSPENSION;ORAL

CLOBAZAM

@ ACCORD HLTHCARE

2.5MG/ML

A216008 001 Sep 06, 2022 Mar DISC

@ UPSHER SMITH LABS

2.5MG/ML

A210569 001 Oct 22, 2018 Mar DISC

>D> AB

VISTAPHARM

2.5MG/ML

A210746 001 Jul 10, 2019 Oct DISC

>A>

@

2.5MG/ML

A210746 001 Jul 10, 2019 Oct DISC

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

@ NOVAST LABS

0.05%

A206805 001 Jul 31, 2017 Sep CAHN

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1

! CHARTWELL RX

0.05%

A211207 001 Mar 26, 2021 May CAHN

@ ENCUBE

0.05%

A212982 001 Aug 28, 2020 Jun CHRS

@ PAI HOLDINGS PHARM

0.05%

A209974 001 Apr 17, 2018 Aug DISC

@ TORRENT

0.05%

A211836 001 Dec 30, 2019 Feb DISC

CLOBETASOL PROPIONATE (EMOLLIENT)

@ ANI PHARMS

0.05%

A075733 001 Aug 22, 2001 Apr DISC

CREAM;TOPICAL									
CLOBETASOL PROPIONATE (EMOLLIENT)									
@ PAI HOLDINGS PHARM	0.05%			A209411	001	Aug 21, 2017		Aug	DISC
GEL;TOPICAL									
CLOBETASOL PROPIONATE									
@ PAI HOLDINGS PHARM	0.05%			A208881	001	Mar 06, 2017		Aug	DISC
LOTION;TOPICAL									
CLOBETASOL PROPIONATE									
@ PAI HOLDINGS PHARM	0.05%			A208667	001	Nov 29, 2016		Aug	DISC
IMPEKLO									
+ @ MYLAN	0.05%			N213691	001	May 19, 2020		Sep	DISC
OINTMENT;TOPICAL									
CLOBETASOL PROPIONATE									
@ PAI HOLDINGS PHARM	0.05%			A208589	001	Jan 23, 2019		Aug	DISC
SHAMPOO;TOPICAL									
CLOBETASOL PROPIONATE									
@ ACTAVIS MID ATLANTIC	0.05%			A078854	001	Jun 07, 2011		Sep	DISC
SOLUTION;TOPICAL									
CLOBETASOL PROPIONATE									
AT ! TARO	0.05%			A075224	001	Nov 16, 1998		Aug	CHRS

CLOFARABINE

SOLUTION;INTRAVENOUS
CLOFARABINE

@ EUGIA PHARMA	20MG/20ML (1MG/ML)			A212457	001	Oct 03, 2022		Mar	DISC
----------------	--------------------	--	--	---------	-----	--------------	--	-----	------

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL
CLOMIPRAMINE HYDROCHLORIDE

AB AUROBINDO PHARMA	25MG			A216440	001	Mar 20, 2023		Mar	NEWA
AB	50MG			A216440	002	Mar 20, 2023		Mar	NEWA
AB	75MG			A216440	003	Mar 20, 2023		Mar	NEWA
AB CHEMISTRY HLTH	25MG			A211364	001	Feb 07, 2020		Sep	CAHN
AB	50MG			A211364	002	Feb 07, 2020		Sep	CAHN
AB	75MG			A211364	003	Feb 07, 2020		Sep	CAHN
AB RK PHARMA	25MG			A213221	001	Jun 22, 2020		Jun	CAHN
AB	50MG			A213221	002	Jun 22, 2020		Jun	CAHN
AB	75MG			A213221	003	Jun 22, 2020		Jun	CAHN

CLONAZEPAM

TABLET;ORAL
CLONAZEPAM

AB AUROBINDO PHARMA USA	0.5MG			A075150	001	Oct 05, 1998		Jan	CMFD
AB	1MG			A075150	002	Oct 05, 1998		Jan	CMFD
AB	2MG			A075150	003	Oct 05, 1998		Jan	CMFD
@ CHARTWELL RX	0.5MG			A074925	001	Sep 30, 1997		Sep	CAHN
@	1MG			A074925	002	Sep 30, 1997		Sep	CAHN
@	2MG			A074925	003	Sep 30, 1997		Sep	CAHN

CLONIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
CLONIDINE HYDROCHLORIDE

>D> AB1 AMNEAL PHARMS NY	0.1MG			A210052	001	Nov 20, 2017		Oct	DISC
>A> @	0.1MG			A210052	001	Nov 20, 2017		Oct	DISC

CLOPIDOGREL BISULFATE

TABLET;ORAL
CLOPIDOGREL BISULFATE

@ CHARTWELL RX	EQ 75MG BASE			A202266	001	Aug 14, 2012		Jun	CAHN
@	EQ 300MG BASE			A202266	002	Nov 20, 2012		Jun	CAHN
AB HETERO LABS LTD V	EQ 75MG BASE			A205345	001	Aug 04, 2023		Aug	NEWA
AB	EQ 300MG BASE			A205345	002	Aug 04, 2023		Aug	NEWA
AB RISING	EQ 75MG BASE			A204359	001	Feb 02, 2017		Aug	CAHN
@ SUN PHARM	EQ 75MG BASE			A090494	001	May 17, 2012		Sep	DISC

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL
CLORAZEPATE DIPOTASSIUM

@ DASH PHARMS	3.75MG			A071509	001	Oct 19, 1987		Feb	CAHN
@	7.5MG			A071510	001	Oct 19, 1987		Feb	CAHN
@	15MG			A071511	001	Oct 19, 1987		Feb	CAHN

CLOTTRIMAZOLECREAM;TOPICAL
LOTTRIMIN

+ @ SCHERING PLOUGH 1%

N017619 001

Sep CRLD

SOLUTION;TOPICAL
CLOTTRIMAZOLE

>A> AT SCIEGEN PHARMS INC 1%

A216569 001 Oct 16, 2023 Oct NEWA

CLOZAPINETABLET;ORAL
CLOZAPINE

@ DR REDDYS LABS SA 25MG

A203807 001 Sep 17, 2015 Apr CAHN

@ 50MG

A203807 003 Aug 22, 2017 Apr CAHN

@ 100MG

A203807 002 Sep 17, 2015 Apr CAHN

@ 200MG

A203807 004 Aug 22, 2017 Apr CAHN

@ MAYNE PHARMA 25MG

A203807 001 Sep 17, 2015 Apr DISC

@ 50MG

A203807 003 Aug 22, 2017 Apr DISC

@ 100MG

A203807 002 Sep 17, 2015 Apr DISC

@ 200MG

A203807 004 Aug 22, 2017 Apr DISC

TABLET, ORALLY DISINTEGRATING;ORAL

CLOZAPINE

AB MYLAN 150MG

A201824 004 Aug 07, 2023 Jul NEWA

AB 200MG

A201824 005 Aug 07, 2023 Jul NEWA

AB TEVA PHARMS USA 150MG

A203039 001 Nov 25, 2015 Jul CTEC

AB 200MG

A203039 002 Nov 25, 2015 Jul CTEC

COCAINE HYDROCHLORIDESOLUTION;NASAL
NUMBRINO

+! OMNIVIVUM PHARMS 4%

N209575 001 Jan 10, 2020 Aug CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

+ @ ACTAVIS MID ATLANTIC 10MG/5ML;6.25MG/5ML

A088763 001 Oct 31, 1984 Sep DISC

AA ! TRIS PHARMA INC 10MG/5ML;6.25MG/5ML

A200386 001 Jun 29, 2012 Sep CHRS

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

TRIACIN-C

! ANIMA 10MG/5ML;30MG/5ML;1.25MG/5ML

A088704 001 Mar 22, 1985 Mar CAHN

COLCHICINECAPSULE;ORAL
COLCHICINE

AB PAR PHARM INC 0.6MG

A208678 001 Nov 29, 2018 Jun CMFD

MITIGARE

AB +! HIKMA INTL PHARMS 0.6MG

N204820 001 Sep 26, 2014 Jun CTEC

TABLET;ORAL

LODOCO

+! AGEPHA PHARMA FZ 0.5MG

N215727 001 Jun 16, 2023 Jun NEWA

COLCHICINE; PROBENECID

TABLET;ORAL

PROBENECID AND COLCHICINE

>A> AB RISING 0.5MG;500MG

A217030 001 Oct 24, 2023 Oct NEWA

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION;ORAL

COLESEVELAM HYDROCHLORIDE

AB IMPAX 3.75GM/PACKET

A212886 001 Jan 18, 2023 Jan NEWA

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

@ CHARTWELL RX 625MG

A201354 001 Dec 17, 2020 May CAHN

@ UNITED RES LABS 625MG

A213456 001 Jan 21, 2022 Sep DISC

AB 625MG

A213456 001 Jan 21, 2022 Sep CAHN

COLESTIPOL HYDROCHLORIDE

TABLET; ORAL

COLESTIPOL HYDROCHLORIDE

AB	ANI PHARMS	1GM	A216517	001	Mar 10, 2023	Apr CAHN
AB	PRAXGEN	1GM	A216517	001	Mar 10, 2023	Mar NEWA

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

@	HIKMA INTL PHARMS	25MG	A080776	002		Jul DISC
---	-------------------	------	---------	-----	--	----------

CRIZOTINIB

CAPSULE, PELLETS; ORAL

XALKORI

+	PF PRISM CV	20MG	N217581	001	Sep 07, 2023	Sep NEWA
+		50MG	N217581	002	Sep 07, 2023	Sep NEWA
+	!	150MG	N217581	003	Sep 07, 2023	Sep NEWA

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

@	EUGIA PHARMA	10MG/ML	A074209	001	Apr 26, 1994	May CAHN
AN	VIRTUS	10MG/ML	A075437	001	Apr 21, 2000	Apr CAHN

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

@	AKORN	4%	A074706	001	Apr 29, 1998	Feb DISC
!	SANDOZ	4%	A075282	001	Jun 16, 1999	Feb CTEC
AT	!	SANDOZ INC	A075282	001	Jun 16, 1999	Feb CHRS

CYANOCOBALAMIN

SPRAY, METERED; NASAL

CYANOCOBALAMIN

AB	LUPIN	0.5MG/SPRAY	A210629	001	Jun 30, 2023	Jun NEWA	
AB	NASCOBAL						
AB	+	ENDO PHARMS INC	0.5MG/SPRAY	N021642	001	Jan 31, 2005	Jun CTEC

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

@	APOTEX	15MG	A206703	001	Jul 24, 2018	Mar DISC
@		30MG	A206703	002	Jul 24, 2018	Mar DISC

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	CHARTWELL RX	5MG	A078218	002	Jun 19, 2015	Feb CAHN
AB		7.5MG	A078218	003	Nov 03, 2020	Feb CAHN
AB		10MG	A078218	001	Apr 18, 2008	Feb CAHN

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOGYL

+	ALCON LABS INC	0.5%	A084109	001		Feb CTEC
---	----------------	------	---------	-----	--	----------

CYCLOPENTOLATE HYDROCHLORIDE

@	AKORN	0.5%	A205937	001	Dec 09, 2015	Feb DISC
---	-------	------	---------	-----	--------------	----------

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

AP	SAGENT PHARMS INC	500MG/VIAL	A214529	001	Jul 17, 2023	Jul NEWA	
AP		1GM/VIAL	A214529	002	Jul 17, 2023	Jul NEWA	
AP		2GM/VIAL	A214529	003	Jul 17, 2023	Jul NEWA	
>A>	AP	SUNNY	500MG/VIAL	A215089	001	Oct 26, 2023	Oct NEWA
>A>	AP		1GM/VIAL	A215089	002	Oct 26, 2023	Oct NEWA
>A>	AP		2GM/VIAL	A215089	003	Oct 26, 2023	Oct NEWA
AP	XGEN PHARMS	500MG/VIAL	A211757	001	Oct 18, 2022	May CAHN	
AP		1GM/VIAL	A211757	002	Oct 18, 2022	May CAHN	
AP		2GM/VIAL	A211757	003	Oct 18, 2022	May CAHN	

SOLUTION; INTRAVENOUS

CYCLOPHOSPHAMIDE

+	DR REDDYS	500MG/ML (500MG/ML)	N210852	001	Jun 07, 2023	Jun NEWA
+		1GM/2ML (500MG/ML)	N210852	002	Jun 07, 2023	Jun NEWA
+		2GM/4ML (500MG/ML)	N210852	003	Jun 07, 2023	Jun NEWA

SOLUTION; INTRAVENOUS
CYCLOPHOSPHAMIDE

+ @ NEVAKAR INJECTABLES	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Aug DISC
+!	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Jun NEWA
+ @	1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Aug DISC
+!	1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Jun NEWA
+! SANDOZ	500MG/5ML (100MG/ML)	N217150	001	Sep 12, 2023	Sep NEWA
+!	1GM/10ML (100MG/ML)	N217150	002	Sep 12, 2023	Sep NEWA
+!	2GM/20ML (100MG/ML)	N217150	003	Sep 12, 2023	Sep NEWA

CYCLOSPORINE

EMULSION; OPHTHALMIC
CYCLOSPORINE

AB	APOTEX	0.05%	A207606	001	Jan 12, 2023	Jan NEWA
	VERKAZIA					
>A>	+! HARROW EYE	0.1%	N214965	001	Jun 23, 2021	Oct CAHN
>D>	+! SANTEN	0.1%	N214965	001	Jun 23, 2021	Oct CAHN

SOLUTION; OPHTHALMIC
VEVYE

+! HARROW EYE	0.1%	N217469	001	May 30, 2023	Sep CAHN
+! NOVALIQ GMBH	0.1%	N217469	001	May 30, 2023	May NEWA

SOLUTION; ORAL

CYCLOSPORINE

@ PHARMOBEDIENT CNSLTG	100MG/ML	A065133	001	Sep 17, 2004	Sep CAHN
@ XTTRIUM LABS INC	100MG/ML	A065133	001	Sep 17, 2004	Jul DISC
AB2	100MG/ML	A065133	001	Sep 17, 2004	Jan CAHN
	SANDIMMUNE				
+! NOVARTIS	100MG/ML	N050574	001	Nov 14, 1983	Jul CTEC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	PATRIN	2MG/5ML	A204823	001	Dec 27, 2016	Sep CAHN
----	--------	---------	---------	-----	--------------	----------

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	CHARTWELL RX	4MG	A088212	001	May 26, 1983	Mar CMFD
AA	KENTON	4MG	A040644	001	May 30, 2006	Sep CAHN
AA	RISING	4MG	A207555	001	Jan 31, 2017	Aug CAHN
	@	4MG	A207783	001	Dec 29, 2016	May DISC

DABRAFENIB MESYLATE

TABLET, FOR SUSPENSION; ORAL
TAFINLAR

+! NOVARTIS	EQ 10MG BASE	N217514	001	Mar 16, 2023	Mar NEWA
-------------	--------------	---------	-----	--------------	----------

DALBAVANCIN HYDROCHLORIDE

POWDER; INTRAVENOUS

DALVANCE

+! ABBVIE	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Jun CAHN
-----------	--------------------	---------	-----	--------------	----------

DAPRODUSTAT

TABLET; ORAL

JESDUVROQ

+ GLAXOSMITHKLINE	1MG	N216951	001	Feb 01, 2023	Feb NEWA
+	2MG	N216951	002	Feb 01, 2023	Feb NEWA
+	4MG	N216951	003	Feb 01, 2023	Feb NEWA
+	6MG	N216951	004	Feb 01, 2023	Feb NEWA
+!	8MG	N216951	005	Feb 01, 2023	Feb NEWA

DAPSONE

GEL; TOPICAL

ACZONE

	AB	+! ABBVIE	5%	N021794	001	Jul 07, 2005	Jun CAHN
		DAPSONE					
	AB	ACRUX DDS	5%	A213907	001	Jun 06, 2023	May NEWA
>A>	AB	ALEMBIC	7.5%	A215718	001	Oct 27, 2023	Oct NEWA
>A>	AB	AMNEAL	5%	A209890	001	Oct 19, 2023	Oct NEWA
	AB		7.5%	A212701	001	May 31, 2023	May NEWA
	AB	BELOTECA	5%	A213907	001	Jun 06, 2023	Sep CAHN
>A>	AB	ENCUBE	5%	A212383	001	Oct 13, 2023	Oct NEWA
>A>	AB	PADAGIS ISRAEL	5%	A215087	001	Oct 31, 2023	Oct NEWA
>A>	AB		7.5%	A212657	001	Nov 01, 2023	Oct NEWA

TABLET; ORAL

DAPSONE

		@ CHARTWELL RX	25MG	A204074	001	May 10, 2016	Sep CAHN
		@	100MG	A204074	002	May 10, 2016	Sep CAHN
AB	+	EVEREST LIFE SCI	100MG	A086842	001		Jun CHRS
AB	!	NOVITIUM PHARMA	100MG	A206505	002	Dec 01, 2016	Jun CHRS
AB		RISING	25MG	A207165	002	Jul 20, 2023	Jul NEWA
		@ VIRTUS	25MG	A204074	001	May 10, 2016	Sep CAHN
		@	100MG	A204074	002	May 10, 2016	Sep CAHN

DAPTOMYCIN

POWDER; INTRAVENOUS

DAPTOMYCIN

AP		HAINAN POLY PHARM	500MG/VIAL	A215890	001	Aug 18, 2022	Sep CMFD
		@	500MG/VIAL	A215890	001	Aug 18, 2022	Feb DISC
AP		MYLAN	500MG/VIAL	A213966	001	Aug 07, 2023	Jul NEWA
AP	!	QILU PHARM HAINAN	500MG/VIAL	A215316	001	Aug 24, 2021	May CHRS
	+	XELLIA PHARMS APS	350MG/VIAL	N217415	001	Jan 30, 2023	Jan NEWA
	+		500MG/VIAL	N217415	002	Jan 30, 2023	Jan NEWA

SOLUTION; INTRAVENOUS

DAPTOMYCIN IN 0.9% SODIUM CHLORIDE

	+	BAXTER HLTHCARE CORP	350MG/50ML (7MG/ML)	N213645	002	Feb 27, 2023	Mar NEWA
	+		500MG/50ML (10MG/ML)	N213645	003	Feb 27, 2023	Mar NEWA
	+		700MG/100ML (7MG/ML)	N213645	004	Feb 27, 2023	Mar NEWA
	+		1GM/100ML (10MG/ML)	N213645	005	Feb 27, 2023	Mar NEWA

DARUNAVIR

TABLET; ORAL

DARUNAVIR

		HETERO LABS LTD III	400MG	A202083	001	Sep 14, 2023	Sep NEWA
AB			600MG	A202083	002	Sep 14, 2023	Sep NEWA

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DAUNORUBICIN HYDROCHLORIDE

>A>	AP	HONG KONG	EQ 5MG BASE/ML	A065035	001	Jan 24, 2000	Oct CAHN
>D>	AP	TEVA PHARMS USA	EQ 5MG BASE/ML	A065035	001	Jan 24, 2000	Oct CAHN

DEFERASIROX

GRANULE; ORAL

DEFERASIROX

AB		ANNORA PHARMA	90MG	A216229	003	Mar 16, 2023	Mar NEWA
----	--	---------------	------	---------	-----	--------------	----------

TABLET; ORAL

DEFERASIROX

>A>	AB	AUROBINDO PHARMA LTD	90MG	A214474	001	Oct 16, 2023	Oct NEWA
>A>	AB		180MG	A214474	002	Oct 16, 2023	Oct NEWA
>A>	AB		360MG	A214474	003	Oct 16, 2023	Oct NEWA
	AB	CHARTWELL RX	90MG	A212669	001	May 27, 2021	Mar CAHN
	AB		180MG	A212669	002	May 27, 2021	Mar CAHN
	AB		360MG	A212669	003	May 27, 2021	Mar CAHN
		@ CIPLA	90MG	A211852	001	Feb 11, 2020	Mar DISC
		@	180MG	A211852	003	Jun 15, 2020	Mar DISC
		@	360MG	A211852	002	Feb 11, 2020	Mar DISC

TABLET, FOR SUSPENSION; ORAL

DEFERASIROX

		@ TEVA PHARMS USA	125MG	A207124	001	Sep 23, 2022	Mar DISC
		@	250MG	A207124	002	Sep 23, 2022	Mar DISC
		@	500MG	A207124	003	Sep 23, 2022	Mar DISC

DEFERIPRONE

TABLET; ORAL

DEFERIPRONE

AB	!	HIKMA	1GM	A213239	002	Feb 08, 2022	May CHRS
		FERRIPROX					
AB	+	CHIESI	1GM	N021825	002	Jul 25, 2019	May CHRS

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

>A>	AB	SANDOZ	10MG	A072103	002	May 24, 1988	Oct CMS1
>A>	AB		25MG	A072103	003	May 24, 1988	Oct CMS1
>A>	AB		50MG	A072103	004	May 24, 1988	Oct CMS1

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

>A>	AB	75MG	A072103	005	Jun 20, 1988	Oct CMS1
>A>	AB	150MG	A072103	006	Jun 20, 1988	Oct CMS1

DESLORATADINE

TABLET;ORAL

DESLORATADINE

@	DASH PHARMS	5MG	A078351	001	Feb 10, 2012	Feb CAHN
---	-------------	-----	---------	-----	--------------	----------

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION

DESMOPRESSIN ACETATE

>D>	AP	AM REGENT	0.004MG/ML	A091374	001	Feb 14, 2019	Oct DISC
>A>	@		0.004MG/ML	A091374	001	Feb 14, 2019	Oct DISC
	AP	GLAND	0.004MG/ML	A216904	001	Mar 20, 2023	Mar NEWA
	AP	HONG KONG	0.004MG/ML	A074888	001	Oct 15, 1997	Sep CAHN

SPRAY, METERED;NASAL

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

	AB	! APOTEX	0.01MG/SPRAY	A076703	001	Jan 27, 2005	Aug CHRS
		@ SUN PHARM	0.01MG/SPRAY	A078271	001	Dec 23, 2013	Aug DISC

>D> TABLET;SUBLINGUAL

>D> NOCDURNA

>D>	+	FERRING PHARMS INC	0.0277MG	N022517	001	Jun 21, 2018	Oct DISC
>A>	+	@	0.0277MG	N022517	001	Jun 21, 2018	Oct DISC
>D>	+	!	0.0553MG	N022517	002	Jun 21, 2018	Oct DISC
>A>	+	@	0.0553MG	N022517	002	Jun 21, 2018	Oct DISC

DESONIDE

AEROSOL, FOAM;TOPICAL

VERDESO

+	@	ALMIRALL	0.05%	N021978	001	Sep 19, 2006	Sep DISC
---	---	----------	-------	---------	-----	--------------	----------

LOTION;TOPICAL

DESONIDE

@	PAI HOLDINGS PHARM	0.05%	A207855	001	Sep 28, 2017	May DISC
---	--------------------	-------	---------	-----	--------------	----------

OINTMENT;TOPICAL

DESONIDE

@	PAI HOLDINGS PHARM	0.05%	A212002	001	Mar 12, 2019	Aug DISC
---	--------------------	-------	---------	-----	--------------	----------

DESOXIMETASONE

OINTMENT;TOPICAL

DESOXIMETASONE

@	PAI HOLDINGS PHARM	0.25%	A208101	001	Feb 25, 2016	Aug DISC
---	--------------------	-------	---------	-----	--------------	----------

DEUTETRABENAZINE

TABLET, EXTENDED RELEASE;ORAL

AUSTEDO XR

+	TEVA	6MG	N216354	001	Feb 17, 2023	Feb NEWA
+		12MG	N216354	002	Feb 17, 2023	Feb NEWA
+	!	24MG	N216354	003	Feb 17, 2023	Feb NEWA

DEXAMETHASONE

ELIXIR;ORAL

DEXAMETHASONE

+	@	PHARMOBEDIANT CNSLTG	0.5MG/5ML	A088254	001	Jul 27, 1983	Sep CAHN
+	@	XTTRIUM LABS INC	0.5MG/5ML	A088254	001	Jul 27, 1983	Jan CAHN

SUSPENSION/DROPS;OPHTHALMIC

MAXIDEX

+	!	HARROW EYE	0.1%	N013422	001		May CAHN
---	---	------------	------	---------	-----	--	----------

TABLET;ORAL

DEXAMETHASONE

AB	ALVOGEN	4MG	A088481	004	Apr 28, 1983	Apr CTEC
AB		6MG	A088481	001	Nov 28, 1983	Apr CTEC
BP	APOTEX	0.5MG	A217695	001	Aug 23, 2023	Aug NEWA
BP		0.75MG	A217695	002	Aug 23, 2023	Aug NEWA
BP		1MG	A217695	003	Aug 23, 2023	Aug NEWA
AB		1.5MG	A217695	004	Aug 23, 2023	Aug NEWA
AB		2MG	A217695	005	Aug 23, 2023	Aug NEWA
AB		4MG	A217695	006	Aug 23, 2023	Aug NEWA
AB		6MG	A217695	007	Aug 23, 2023	Aug NEWA
AB	BIONPHARMA	2MG	A217538	001	Apr 26, 2023	Apr NEWA

TABLET; ORAL

DEXAMETHASONE

AB		4MG	A217001	001	Apr 19, 2023	Apr NEWA
AB		6MG	A217001	002	Apr 19, 2023	Apr NEWA
AB	NOVITIUM PHARMA	2MG	A217696	001	May 09, 2023	Apr NEWA
AB	PRASCO	4MG	A080399	002	Apr 20, 2022	Apr CMFD
	@	4MG	A080399	002	Apr 20, 2022	Feb DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	GENEYORK PHARMS	EQ 10MG PHOSPHATE/ML	A214890	001	Jul 07, 2023	Jun NEWA
AP	GLAND PHARMA LTD	EQ 10MG PHOSPHATE/ML	A215654	002	Sep 25, 2023	Sep NEWA
AP	HIKMA	EQ 4MG PHOSPHATE/ML	A211451	001	Aug 01, 2023	Jul NEWA

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

MAXITROL

AT	+! SANDOZ	0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N050065	002		Sep CAHN
----	-----------	---	---------	-----	--	----------

SUSPENSION/DROPS; OPHTHALMIC

MAXITROL

AT	+! HARROW EYE	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N050023	002		May CAHN
----	---------------	---	---------	-----	--	----------

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRADEX

AB	+! SANDOZ	0.1%; 0.3%	N050592	001	Aug 18, 1988	Sep CAHN
----	-----------	------------	---------	-----	--------------	----------

TOBRADEX ST

>D>	+! EYEVANCE	0.05%; 0.3%	N050818	001	Feb 13, 2009	Oct CAHN
-----	-------------	-------------	---------	-----	--------------	----------

>A>	+! HARROW EYE	0.05%; 0.3%	N050818	001	Feb 13, 2009	Oct CAHN
-----	---------------	-------------	---------	-----	--------------	----------

TOBRAMYCIN AND DEXAMETHASONE

@ AMNEAL 0.1%; 0.3%

A212991	001	Jul 15, 2021	Jun DISC
---------	-----	--------------	----------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	AMNEAL	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A216604	001	May 15, 2023	May NEWA
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A216604	002	May 15, 2023	May NEWA
AP	MILLA PHARMS	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A217308	001	Jun 07, 2023	May NEWA
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A217308	002	Jun 07, 2023	May NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FOCALIN XR

AB	+ SANDOZ	5MG	N021802	001	May 26, 2005	Sep CAHN
AB	+	10MG	N021802	002	May 26, 2005	Sep CAHN
AB	+	15MG	N021802	004	Aug 01, 2006	Sep CAHN
AB	+	20MG	N021802	003	May 26, 2005	Sep CAHN
AB	+	25MG	N021802	008	Apr 21, 2011	Sep CAHN
AB	+	30MG	N021802	005	Oct 23, 2009	Sep CAHN
AB	+	35MG	N021802	007	Apr 21, 2011	Sep CAHN
AB	+!	40MG	N021802	006	Aug 11, 2010	Sep CAHN

TABLET; ORAL

FOCALIN

AB	+ SANDOZ	2.5MG	N021278	001	Nov 13, 2001	Sep CAHN
AB	+	5MG	N021278	002	Nov 13, 2001	Sep CAHN
AB	+!	10MG	N021278	003	Nov 13, 2001	Sep CAHN

DEXTROAMPHETAMINE SULFATE

SOLUTION; ORAL

DEXTROAMPHETAMINE SULFATE

AA	! PRASCO	5MG/5ML	A040776	001	Jan 29, 2008	Mar CAHN
----	----------	---------	---------	-----	--------------	----------

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	Jan CTEC
AA		7.5MG	A090533	003	Oct 25, 2011	Jan CTEC
AA		15MG	A090533	005	Oct 25, 2011	Jan CTEC

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA		20MG	A090533	006	Oct 25, 2011	Jan CTEC
AA		30MG	A090533	007	Oct 25, 2011	Jan CTEC
AA	WINDER LABS LLC	2.5MG	A212160	001	Jun 07, 2021	Jan CMFD
AA		5MG	A212160	002	Jun 07, 2021	Jan CMFD
AA		7.5MG	A212160	003	Jun 07, 2021	Jan CMFD
AA		10MG	A212160	004	Jun 07, 2021	Jan CMFD
AA		15MG	A212160	005	Jun 07, 2021	Jan CMFD
AA		20MG	A212160	006	Jun 07, 2021	Jan CMFD
AA		30MG	A212160	007	Jun 07, 2021	Jan CMFD

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
AP	FRESENIUS KABI USA 5GM/100ML;149MG/100ML;225MG/100ML	A212348	001	Jul 30, 2021	Mar CMFD	
	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP	FRESENIUS KABI USA 5GM/100ML;74.5MG/100ML;450MG/100ML	A213523	001	Mar 09, 2021	Mar CMFD	
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
AP	FRESENIUS KABI USA 5GM/100ML;149MG/100ML;225MG/100ML	A212348	002	Jul 30, 2021	Mar CMFD	
AP	+! ICU MEDICAL INC 5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Mar CHRS	
AP	+ 5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Mar CTEC	
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP	FRESENIUS KABI USA 5GM/100ML;149MG/100ML;450MG/100ML	A213523	002	Mar 09, 2021	Mar CMFD	
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
AP	FRESENIUS KABI USA 5GM/100ML;149MG/100ML;900MG/100ML	A213445	001	Mar 09, 2021	Mar CMFD	
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP	FRESENIUS KABI USA 5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Mar CMFD	
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP	FRESENIUS KABI USA 5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Mar CMFD	
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
AP	FRESENIUS KABI USA 5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Mar CMFD	

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

SOLUTION;ORAL, RECTAL

DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM

AA	ANDA REPOSITORY 66%;10%	A214201	001	Jun 27, 2022	Sep CAHN	
----	-------------------------	---------	-----	--------------	----------	--

DIAZEPAM

GEL;RECTAL

DIASTAT ACUDIAL

AB	+! BAUSCH 10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	May CFTG	
AB	+! 20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005	May CFTG	
	DIAZEPAM					
AB	NOVEL LABS INC 10MG/2ML (5MG/ML)	A091076	001	May 30, 2023	May NFTG	
AB	20MG/4ML (5MG/ML)	A091076	002	May 30, 2023	May NFTG	

INJECTABLE;INJECTION

DIAZEPAM

AP	HIKMA 5MG/ML	A070311	001	Dec 16, 1985	Sep CMFD	
----	--------------	---------	-----	--------------	----------	--

TABLET;ORAL

DIAZEPAM

>A>	@ AIPING PHARM INC 2MG	A070302	001	Dec 20, 1985	Oct CAHN	
>A>	@ 5MG	A070303	001	Dec 20, 1985	Oct CAHN	
>A>	@ 10MG	A070304	001	Dec 20, 1985	Oct CAHN	
>D>	@ UPSHER SMITH LABS 2MG	A070302	001	Dec 20, 1985	Oct CAHN	
>D>	@ 5MG	A070303	001	Dec 20, 1985	Oct CAHN	
>D>	@ 10MG	A070304	001	Dec 20, 1985	Oct CAHN	

DICLOFENAC EPOLAMINE

SYSTEM;TOPICAL

FLECTOR

+!	IBSA 1.3%	N021234	001	Jan 31, 2007	Aug CAHN	
----	-----------	---------	-----	--------------	----------	--

DICLOFENAC POTASSIUM

TABLET;ORAL

DICLOFENAC POTASSIUM

	@ CHARTWELL RX 50MG	A075582	001	Feb 23, 2001	May CAHN	
AB	SENORES PHARMS 50MG	A215787	001	Mar 15, 2023	Mar NEWA	

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION

DIHYDROERGOTAMINE MESYLATE

AP	GLAND PHARMA LTD	1MG/ML	A215623	001	Aug 18, 2023	Aug NEWA
	SPRAY, METERED;NASAL					
	DIHYDROERGOTAMINE MESYLATE					
AB	AMNEAL	0.5MG/SPRAY	A214105	001	Jan 04, 2022	Apr CMFD
AB	RUBICON	0.5MG/SPRAY	A216881	001	Jun 22, 2023	Jun NEWA

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB1	TWI PHARMS	60MG	A217377	001	Mar 01, 2023	Feb NEWA
AB1		90MG	A217377	002	Mar 01, 2023	Feb NEWA
AB1		120MG	A217377	003	Mar 01, 2023	Feb NEWA

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP	EUGIA PHARMA	5MG/ML	A216552	001	Mar 29, 2023	Mar NEWA
AP	! SAGENT	5MG/ML	A074617	001	Feb 28, 1996	Aug CAHN

TABLET;ORAL

DILTIAZEM HYDROCHLORIDE

	@ EDENBRIDGE PHARMS	30MG	A211596	001	Nov 18, 2019	Aug DISC
	@	60MG	A211596	002	Nov 18, 2019	Aug DISC
	@	90MG	A211596	003	Nov 18, 2019	Aug DISC
	@	120MG	A211596	004	Nov 18, 2019	Aug DISC

TABLET, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB	AMTA	120MG	A216439	001	Mar 07, 2023	Feb NEWA
AB		180MG	A216439	002	Mar 07, 2023	Feb NEWA
AB		240MG	A216439	003	Mar 07, 2023	Feb NEWA
AB		300MG	A216439	004	Mar 07, 2023	Feb NEWA
AB		360MG	A216439	005	Mar 07, 2023	Feb NEWA
AB		420MG	A216439	006	Mar 07, 2023	Feb NEWA
AB	SCIEGEN PHARMS INC	120MG	A216327	001	Apr 06, 2023	Mar NEWA
AB		180MG	A216327	002	Apr 06, 2023	Mar NEWA
AB		240MG	A216327	003	Apr 06, 2023	Mar NEWA
AB		300MG	A216327	004	Apr 06, 2023	Mar NEWA
AB		360MG	A216327	005	Apr 06, 2023	Mar NEWA
AB		420MG	A216327	006	Apr 06, 2023	Mar NEWA

DIMERCAPROL

INJECTABLE;INJECTION

BAL

+!	PROVEPHARM SAS	10%	N005939	001		Aug CAHN
----	----------------	-----	---------	-----	--	----------

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIMETHYL FUMARATE

AB	SOLA PHARMS	120MG	A210436	001	Mar 26, 2021	Feb CMFD
AB		240MG	A210436	002	Mar 26, 2021	Feb CMFD

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+!	PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982	Apr CRLD
----	-------------	------------	---------	-----	--------------	----------

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

	@ FRESENIUS KABI USA	5MG/ML	A074956	001	Sep 30, 1998	Jun DISC
--	----------------------	--------	---------	-----	--------------	----------

TABLET;ORAL

DIPYRIDAMOLE

	@ ANI PHARMS	25MG	A086944	002	Apr 16, 1991	Apr DISC
	@	50MG	A086944	001	Feb 25, 1992	Apr DISC
	@	75MG	A086944	003	Feb 25, 1992	Apr DISC
AB	RISING	25MG	A040733	001	Feb 13, 2007	Sep CAHN
AB		50MG	A040733	002	Feb 13, 2007	Sep CAHN
AB		75MG	A040733	003	Feb 13, 2007	Sep CAHN

DISULFIRAMTABLET; ORAL
DISULFIRAM

AB	!	CHARTWELL MOLECULES	500MG	A091563	002	Dec 31, 2012	Aug CHRS
	@	DASH PHARMS	250MG	A203916	001	Mar 04, 2015	Feb CAHN
	@		500MG	A203916	002	Mar 04, 2015	Feb CAHN
AB		HIKMA	500MG	A202652	002	Feb 05, 2014	Aug CHRS

DIVALPROEX SODIUMTABLET, DELAYED RELEASE; ORAL
DIVALPROEX SODIUM

	@	ACTAVIS LABS FL INC	EQ 500MG VALPROIC ACID	A079080	001	Feb 25, 2011	Sep DISC
AB		CHARTWELL RX	EQ 125MG VALPROIC ACID	A077296	001	Jul 31, 2008	Jun CAHN
AB			EQ 250MG VALPROIC ACID	A077296	002	Jul 31, 2008	Jun CAHN
AB			EQ 500MG VALPROIC ACID	A077296	003	Jul 31, 2008	Jun CAHN

TABLET, EXTENDED RELEASE; ORAL
DEPAKOTE ER

AB	+	ABBVIE	EQ 500MG VALPROIC ACID	N021168	001	Aug 04, 2000	Aug CHRS
		DIVALPROEX SODIUM					
AB	!	AMNEAL PHARMS	EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015	Aug CHRS
AB		ANNORA PHARMA	EQ 250MG VALPROIC ACID	A215527	001	Sep 26, 2023	Sep NEWA
AB			EQ 500MG VALPROIC ACID	A215527	002	Sep 26, 2023	Sep NEWA

DOCETAXELINJECTABLE; INJECTION
DOCETAXEL

AP		ALEMBIC	20MG/2ML (10MG/ML)	A215744	001	Feb 28, 2023	Feb NEWA
AP			80MG/8ML (10MG/ML)	A215744	002	Feb 28, 2023	Feb NEWA
AP			160MG/16ML (10MG/ML)	A215744	003	Feb 28, 2023	Feb NEWA
	@	MYLAN LABS LTD	20MG/ML (20MG/ML)	A203892	001	May 11, 2023	Sep DISC
AP			20MG/ML (20MG/ML)	A203892	001	May 11, 2023	Apr NEWA
	@		80MG/4ML (20MG/ML)	A203892	002	May 11, 2023	Sep DISC
AP			80MG/4ML (20MG/ML)	A203892	002	May 11, 2023	Apr NEWA
	@	NOVAST LABS	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Sep CAHN
AP			80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Sep CAHN
AP			160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Sep CAHN
		SOLUTION; INTRAVENOUS					
		DOCETAXEL					
	+	@ INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Jul CAHN
	+	@	80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Jul CAHN
	+	@	160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Jul CAHN
	+	@ MERIDIAN LABS	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	May DISC
	+	@	80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	May DISC
	+	@	160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	May DISC

DOFETILIDECAPSULE; ORAL
DOFETILIDE

	@	RK PHARMA	0.125MG	A215323	001	Apr 14, 2022	Jun CAHN
	@		0.25MG	A215323	002	Apr 14, 2022	Jun CAHN
	@		0.5MG	A215323	003	Apr 14, 2022	Jun CAHN

DONEPEZIL HYDROCHLORIDESOLUTION; ORAL
ARICEPT

	+	@ EISAI INC	5MG/5ML	N021719	001	Oct 18, 2004	Jun CRLD
--	---	-------------	---------	---------	-----	--------------	----------

DORZOLAMIDE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

AT		RUBICON	EQ 2% BASE	A078395	001	Oct 28, 2008	Aug CMFD
----	--	---------	------------	---------	-----	--------------	----------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATESOLUTION/DROPS; OPHTHALMIC
COSOPT

AT1	+	THEA PHARMA	EQ 2% BASE; EQ 0.5% BASE	N020869	001	Apr 07, 1998	May CTEC
		COSOPT PF					
AT2	+	THEA PHARMA	EQ 2% BASE; EQ 0.5% BASE	N202667	001	Feb 01, 2012	May CTEC
		DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE					
AT1		AKORN	EQ 2% BASE; EQ 0.5% BASE	A077847	001	Oct 28, 2008	May CTEC
>D> AT1			EQ 2% BASE; EQ 0.5% BASE	A203058	001	Sep 22, 2014	Oct CAHN

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT1		EQ 2% BASE;EQ 0.5% BASE	A203058	001	Sep 22, 2014	May CTEC
AT1	ALEMBIC	EQ 2% BASE;EQ 0.5% BASE	A213099	001	May 04, 2021	May CTEC
AT1	BAUSCH AND LOMB	EQ 2% BASE;EQ 0.5% BASE	A090037	001	Jul 14, 2009	May CTEC
>A> AT1	EPIC PHARMA LLC	EQ 2% BASE;EQ 0.5% BASE	A203058	001	Sep 22, 2014	Oct CAHN
AT1	EUGIA PHARMA	EQ 2% BASE;EQ 0.5% BASE	A207629	001	May 14, 2021	May CTEC
AT2		EQ 2% BASE;EQ 0.5% BASE	A207630	001	Jul 24, 2018	May CTEC
AT1	FDC LTD	EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019	May CTEC
AT1	GLAND PHARMA LTD	EQ 2% BASE;EQ 0.5% BASE	A215520	001	Sep 19, 2022	May CTEC
AT1	HIKMA	EQ 2% BASE;EQ 0.5% BASE	A077847	001	Oct 28, 2008	Sep CAHN
AT1	INDOCO	EQ 2% BASE;EQ 0.5% BASE	A202054	001	Sep 03, 2014	May CTEC
AT2	INGENUS PHARMS LLC	EQ 2% BASE;EQ 0.5% BASE	A217260	001	May 01, 2023	May CTEC
AT		EQ 2% BASE;EQ 0.5% BASE	A217260	001	May 01, 2023	Apr NEWA
AT1	MICRO LABS	EQ 2% BASE;EQ 0.5% BASE	A204777	001	May 28, 2020	May CTEC
AT2		EQ 2% BASE;EQ 0.5% BASE	A215936	001	Jan 25, 2022	May CTEC
AT1	SANDOZ	EQ 2% BASE;EQ 0.5% BASE	A078749	001	Nov 06, 2008	May CTEC
AT1		EQ 2% BASE;EQ 0.5% BASE	A090604	001	Nov 18, 2009	May CTEC
AT1	SOMERSET	EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	May CTEC
@	TEVA PHARMS	EQ 2% BASE;EQ 0.5% BASE	A078704	001	Sep 28, 2009	Sep DISC
AT1		EQ 2% BASE;EQ 0.5% BASE	A078704	001	Sep 28, 2009	May CTEC

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

AB	HERITAGE PHARMA	EQ 1MG BASE	A205210	001	Feb 13, 2018	Sep CTEC
AB		EQ 2MG BASE	A205210	002	Feb 13, 2018	Sep CTEC
AB		EQ 4MG BASE	A205210	003	Feb 13, 2018	Sep CTEC
AB		EQ 8MG BASE	A205210	004	Feb 13, 2018	Sep CTEC
AB	MLV	EQ 1MG BASE	A212727	001	Mar 15, 2022	Aug CAHN
AB		EQ 2MG BASE	A212727	002	Mar 15, 2022	Aug CAHN
AB		EQ 4MG BASE	A212727	003	Mar 15, 2022	Aug CAHN
AB		EQ 8MG BASE	A212727	004	Mar 15, 2022	Aug CAHN
@	PLIVA	EQ 1MG BASE	A075750	001	Jun 08, 2001	Sep DISC
@		EQ 2MG BASE	A075750	002	Jun 08, 2001	Sep DISC
@		EQ 4MG BASE	A075750	003	Jun 08, 2001	Sep DISC
@		EQ 8MG BASE	A075750	004	Jun 08, 2001	Sep DISC
AB	RISING	EQ 1MG BASE	A212727	001	Mar 15, 2022	Sep CAHN
AB		EQ 2MG BASE	A212727	002	Mar 15, 2022	Sep CAHN
AB		EQ 4MG BASE	A212727	003	Mar 15, 2022	Sep CAHN
AB		EQ 8MG BASE	A212727	004	Mar 15, 2022	Sep CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

>A> AB	CHEMISTRY HLTH	EQ 10MG BASE	A211619	001	Mar 09, 2021	Oct CAHN
>A> AB		EQ 25MG BASE	A211619	002	Mar 09, 2021	Oct CAHN
>A> AB		EQ 50MG BASE	A211619	003	Mar 09, 2021	Oct CAHN
>A> AB		EQ 75MG BASE	A211619	004	Mar 09, 2021	Oct CAHN
>A> AB		EQ 100MG BASE	A211619	005	Mar 09, 2021	Oct CAHN
>D> AB	LEADING	EQ 10MG BASE	A211619	001	Mar 09, 2021	Oct CAHN
>D> AB		EQ 25MG BASE	A211619	002	Mar 09, 2021	Oct CAHN
>D> AB		EQ 50MG BASE	A211619	003	Mar 09, 2021	Oct CAHN
>D> AB		EQ 75MG BASE	A211619	004	Mar 09, 2021	Oct CAHN
>D> AB		EQ 100MG BASE	A211619	005	Mar 09, 2021	Oct CAHN
AB	MICRO LABS	EQ 10MG BASE	A217688	001	Jun 27, 2023	Jun NEWA
AB		EQ 25MG BASE	A217688	002	Jun 27, 2023	Jun NEWA
AB		EQ 50MG BASE	A217688	003	Jun 27, 2023	Jun NEWA
AB		EQ 75MG BASE	A217688	004	Jun 27, 2023	Jun NEWA
AB		EQ 100MG BASE	A217688	005	Jun 27, 2023	Jun NEWA
AB	UNIQUE PHARM	EQ 10MG BASE	A217975	001	Aug 21, 2023	Aug NEWA
AB		EQ 25MG BASE	A217975	002	Aug 21, 2023	Aug NEWA
AB		EQ 50MG BASE	A217975	003	Aug 21, 2023	Aug NEWA
AB		EQ 75MG BASE	A217975	004	Aug 21, 2023	Aug NEWA
AB		EQ 100MG BASE	A217975	005	Aug 21, 2023	Aug NEWA
AB	ZYDUS LIFESCIENCES	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar CAHN
AB		EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar CAHN
AB		EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar CAHN
AB		EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar CAHN
AB		EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar CAHN
AB		EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar CAHN
AB	ZYDUS PHARMS	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar NEWA
AB		EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar NEWA

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB		EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar NEWA
AB		EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar NEWA
AB		EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar NEWA
AB		EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar NEWA

CONCENTRATE;ORAL

DOXEPIN HYDROCHLORIDE

!	LANNETT CO INC	EQ 10MG BASE/ML	A074721	001	Dec 29, 1998	Jul CTEC
@	PHARMOBEDIENT CNSLTG	EQ 10MG BASE/ML	A071918	001	Jul 20, 1988	Sep CAHN
@	XTTRIUM LABS INC	EQ 10MG BASE/ML	A071918	001	Jul 20, 1988	Jul DISC

CREAM;TOPICAL

DOXEPIN HYDROCHLORIDE

AB	AMNEAL	5%	A212357	001	Aug 16, 2023	Aug NEWA
AB	TEVA PHARMS	5%	A215408	001	Feb 17, 2023	Feb NFTG
AB	ZONALON					
AB	+! MYLAN	5%	N020126	001	Apr 01, 1994	Feb CFTG

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB	MSN	EQ 3MG BASE	A214823	001	Apr 03, 2023	Mar NEWA
AB		EQ 6MG BASE	A214823	002	Apr 03, 2023	Mar NEWA
AB	ZYDUS PHARMS	EQ 3MG BASE	A202761	001	Aug 16, 2023	Aug NEWA
AB		EQ 6MG BASE	A202761	002	Aug 16, 2023	Aug NEWA

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

>D>	@ AKORN	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016	Oct CAHN
>D>	@	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Oct CAHN
AP	ALEMBIC	4MCG/2ML (2MCG/ML)	A215810	001	Jun 15, 2023	Jun NEWA
>A>	@ EPIC PHARMA LLC	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016	Oct CAHN
>A>	@	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Oct CAHN

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

!	HIKMA	10MG/VIAL	A062921	001	Mar 17, 1989	Sep CTEC
@	PHARMACHEMIE BV	2MG/ML	A063336	001	Feb 28, 1995	Sep DISC
@		10MG/VIAL	A063097	001	May 21, 1990	Sep DISC
@		20MG/VIAL	A063097	002	May 21, 1990	Sep DISC
@		50MG/VIAL	A063097	003	May 21, 1990	Sep DISC
@		200MG/100ML	A063336	004	Feb 28, 1995	Sep DISC

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB	BAXTER HLTHCARE CORP	20MG/10ML (2MG/ML)	A212219	001	Oct 19, 2022	Sep CAHN
AB		50MG/25ML (2MG/ML)	A212219	002	Oct 19, 2022	Sep CAHN

DOXYCYCLINE

TABLET;ORAL

DOXYCYCLINE

@	UPSHER SMITH LABS	EQ 50MG BASE	A065377	001	Nov 07, 2006	Sep CAHN
@		EQ 75MG BASE	A065377	002	Nov 07, 2006	Sep CAHN
@		EQ 100MG BASE	A065377	003	Nov 07, 2006	Sep CAHN
@		EQ 150MG BASE	A065427	001	Jun 07, 2007	Sep CAHN

DOXYCYCLINE HYCLATE

INJECTABLE;INJECTION

DOXYCYCLINE

@	HIKMA	EQ 100MG BASE/VIAL	A062569	001	Mar 09, 1988	Aug DISC
AP	! ZYDUS PHARMS	EQ 100MG BASE/VIAL	A207757	001	Sep 28, 2017	Aug CHRS

DOXYCYCLINE HYCLATE

AP	GLAND PHARMA LTD	EQ 100MG BASE/VIAL	A215583	001	Apr 12, 2023	Mar NEWA
@	PAR STERILE PRODUCTS	EQ 100MG BASE/VIAL	A216690	001	Dec 07, 2022	Jun DISC

TABLET;ORAL

DOXYCYCLINE HYCLATE

AB	MYLAN	EQ 100MG BASE	A062432	001	Feb 15, 1983	Sep CMFD
@	ORYZA PHARMS SHENZHN	EQ 100MG BASE	A213475	001	Mar 10, 2021	Feb CAHN
@	PHARMOBEDIENT	EQ 100MG BASE	A213475	001	Mar 10, 2021	Aug CAHN

TABLET, DELAYED RELEASE;ORAL

DORYX

+	@ MAYNE PHARMA	EQ 50MG BASE	N050795	006	Dec 19, 2014	Jun DISC
+		EQ 80MG BASE	N050795	004	Apr 11, 2013	Aug CTEC

TABLET, DELAYED RELEASE;ORAL							
DORYX							
AB	+	EQ 80MG BASE	N050795	004	Apr 11, 2013	Aug	CFTG
	+ @	EQ 100MG BASE	N050795	002	May 06, 2005	Jun	DISC
AB	+	EQ 200MG BASE	N050795	005	Apr 11, 2013	Jul	CHRS
DORYX MPC							
	+ MAYNE PHARMA	EQ 60MG BASE	N050795	007	May 20, 2016	Aug	CTEC
AB	+	EQ 60MG BASE	N050795	007	May 20, 2016	Aug	CFTG
	+ @	EQ 120MG BASE	N050795	008	May 20, 2016	Jun	DISC
DOXYCYCLINE HYCLATE							
	@ AUROBINDO PHARMA USA	EQ 150MG BASE	A091052	001	Feb 08, 2012	May	CAHN
AB	!	HERITAGE PHARMS	A200856	004	Nov 13, 2018	Jul	CHRS
	@ LUPIN	EQ 50MG BASE	A208741	001	Aug 11, 2023	Aug	DISC
AB		EQ 50MG BASE	A208741	001	Aug 11, 2023	Aug	NEWA
	@	EQ 60MG BASE	A208741	002	Aug 11, 2023	Aug	DISC
AB		EQ 60MG BASE	A208741	002	Aug 11, 2023	Aug	NFTG
	@	EQ 75MG BASE	A208741	003	Aug 11, 2023	Aug	DISC
AB		EQ 75MG BASE	A208741	003	Aug 11, 2023	Aug	NEWA
	@	EQ 80MG BASE	A208741	004	Aug 11, 2023	Aug	DISC
AB		EQ 80MG BASE	A208741	004	Aug 11, 2023	Aug	NEWA
	@	EQ 100MG BASE	A208741	005	Aug 11, 2023	Aug	DISC
AB		EQ 100MG BASE	A208741	005	Aug 11, 2023	Aug	NEWA
	@	EQ 120MG BASE	A208741	006	Aug 11, 2023	Aug	DISC
		EQ 120MG BASE	A208741	006	Aug 11, 2023	Aug	NEWA
	@	EQ 150MG BASE	A208741	007	Aug 11, 2023	Aug	DISC
AB		EQ 150MG BASE	A208741	007	Aug 11, 2023	Aug	NEWA
	@	EQ 200MG BASE	A208741	008	Aug 11, 2023	Aug	DISC
AB		EQ 200MG BASE	A208741	008	Aug 11, 2023	Aug	NEWA
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE</u>							
TABLET, DELAYED RELEASE;ORAL							
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE							
AB	BIONPHARMA	10MG;10MG	A217000	001	Aug 04, 2023	Jul	NEWA
<u>DROPERIDOL</u>							
INJECTABLE;INJECTION							
DROPERIDOL							
	! AM REGENT	2.5MG/ML	A072123	001	Oct 24, 1988	Jul	CTEC
AP	!	2.5MG/ML	A072123	001	Oct 24, 1988	Jul	CHRS
	@ HIKMA	2.5MG/ML	A208197	001	Dec 14, 2017	Jul	DISC
AP		2.5MG/ML	A208197	001	Dec 14, 2017	May	CAHN
	@ HOSPIRA	2.5MG/ML	A071981	001	Feb 29, 1988	Jul	DISC
INAPSINE							
	+ @ AKORN	2.5MG/ML	N016796	001		Jul	DISC
	+ @ RISING	2.5MG/ML	N016796	001		Sep	CAHN
<u>DROSPIRENONE</u>							
TABLET, CHEWABLE;ORAL							
DROSPIRENONE							
	+ @ EXELTIS USA INC	3.5MG	N216285	001	Jun 29, 2022	Jun	DISC
<u>DROSPIRENONE; ETHINYL ESTRADIOL</u>							
TABLET;ORAL							
DROSPIRENONE AND ETHINYL ESTRADIOL							
	@ BARR	3MG;0.02MG	A078515	001	Mar 30, 2009	Sep	DISC
TABLET;ORAL-28							
DROSPIRENONE AND ETHINYL ESTRADIOL							
	@ BARR	3MG;0.03MG	A077527	001	May 09, 2008	Sep	DISC
<u>DROXIDOPA</u>							
CAPSULE;ORAL							
DROXIDOPA							
	@ CHARTWELL RX	100MG	A214217	001	May 05, 2022	May	CAHN
	@	200MG	A214217	002	May 05, 2022	May	CAHN
	@	300MG	A214217	003	May 05, 2022	May	CAHN
<u>DULOXETINE HYDROCHLORIDE</u>							
CAPSULE, DELAYED REL PELLETS;ORAL							
DRIZALMA SPRINKLE							
	+ @ SUN PHARM	EQ 30MG BASE	N212516	002	Jul 19, 2019	Mar	DISC
	+ @	EQ 40MG BASE	N212516	003	Jul 19, 2019	Jan	DISC
	+ @	EQ 60MG BASE	N212516	004	Jul 19, 2019	Mar	DISC

CAPSULE, DELAYED REL PELLETS; ORAL							
DULOXETINE HYDROCHLORIDE							
AB	ZYDUS HLTHCARE	EQ 40MG BASE	A090739	004	Apr 18, 2023	Apr	NEWA
<u>DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM</u>							
POWDER; INTRAVENOUS							
XACDURO (COPACKAGED)							
+	ENTASIS THERAP	EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL	N216974	001	May 23, 2023	Jun	CMS1
+	!	EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL	N216974	001	May 24, 2023	May	NEWA
<u>DUTASTERIDE</u>							
CAPSULE; ORAL							
DUTASTERIDE							
AB	ADAPTIS	0.5MG	A204376	001	Apr 07, 2017	Sep	CAHN
<u>DYCLONINE HYDROCHLORIDE</u>							
SOLUTION; TOPICAL							
DYCLOPRO							
!	SEPTODONT	0.5%	A200480	001	Nov 20, 2018	May	CAHN
!		1%	A200480	002	Nov 20, 2018	May	CAHN
<u>ECONAZOLE NITRATE</u>							
CREAM; TOPICAL							
ECONAZOLE NITRATE							
@	AUROBINDO PHARMA USA	1%	A210364	001	Apr 18, 2018	Apr	CAHN
@	PAI HOLDINGS PHARM	1%	A076574	001	Dec 17, 2004	May	DISC
<u>EDETATE CALCIUM DISODIUM</u>							
INJECTABLE; INJECTION							
EDETATE CALCIUM DISODIUM							
!	CASPER PHARMA LLC	200MG/ML	A216435	001	May 03, 2023	Apr	NFTG
		200MG/ML	A216435	001	May 03, 2023	Apr	NFTG
<u>EFAVIRENZ</u>							
CAPSULE; ORAL							
EFAVIRENZ							
	AUROBINDO PHARMA	50MG	A078064	001	Dec 15, 2017	Mar	CTEC
!		200MG	A078064	003	Dec 15, 2017	Mar	CHRS
		200MG	A078064	003	Dec 15, 2017	Mar	CTEC
SUSTIVA							
+	@ BRISTOL MYERS SQUIBB	50MG	N020972	001	Sep 17, 1998	Mar	DISC
+	@	200MG	N020972	003	Sep 17, 1998	Mar	DISC
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE</u>							
TABLET; ORAL							
EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE							
AB	STRIDES PHARMA	600MG; 200MG; 300MG	A201802	001	Oct 03, 2023	Sep	NEWA
<u>ELACESTRANT DIHYDROCHLORIDE</u>							
TABLET; ORAL							
ORSERDU							
+	STEMLINE THERAP	EQ 86MG BASE	N217639	001	Jan 27, 2023	Jan	NEWA
+	!	EQ 345MG BASE	N217639	002	Jan 27, 2023	Jan	NEWA
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR</u>							
GRANULES; ORAL							
TRIKAFTA (COPACKAGED)							
+	VERTEX PHARMS INC	80MG, 60MG, 40MG; 59.5MG	N217660	001	Apr 26, 2023	Apr	NEWA
+	!	100MG, 75MG, 50MG; 75MG	N217660	002	Apr 26, 2023	Apr	NEWA
<u>ELIGLUSTAT TARTRATE</u>							
CAPSULE; ORAL							
ELIGLUSTAT TARTRATE							
AB	UPSHER SMITH LABS	EQ 84MG BASE	A212420	001	May 02, 2023	Sep	CAHN
AB	ZENARA	EQ 84MG BASE	A212420	001	May 02, 2023	Apr	NEWA

EMPAGLIFLOZIN

TABLET; ORAL

EMPAGLIFLOZIN

@ ZYDUS PHARMS

10MG

A212138 001 Aug 03, 2022 Jan DISC

@

25MG

A212138 002 Aug 03, 2022 Jan DISC

JARDIANCE

+ BOEHRINGER INGELHEIM

10MG

N204629 001 Aug 01, 2014 Jan CTEC

+!

25MG

N204629 002 Aug 01, 2014 Jan CTEC

EMTRICITABINE

CAPSULE; ORAL

EMTRICITABINE

AB AUROBINDO PHARMA LTD 200MG

A079188 001 Mar 15, 2023 Mar NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

@ APOTEX

200MG; 300MG

A208740 001 Jun 16, 2021 Apr DISC

@ AUROBINDO PHARMA LTD

100MG; 150MG

A211640 001 Mar 09, 2023 Sep DISC

AB 100MG; 150MG

A211640 001 Mar 09, 2023 Mar NEWA

@

133MG; 200MG

A211640 002 Mar 09, 2023 Sep DISC

AB 133MG; 200MG

A211640 002 Mar 09, 2023 Mar NEWA

@

167MG; 250MG

A211640 003 Mar 09, 2023 Sep DISC

AB 167MG; 250MG

A211640 003 Mar 09, 2023 Mar NEWA

@ CIPLA

200MG; 300MG

A090958 001 Apr 02, 2021 Sep DISC

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

@ CHARTWELL RX

2.5MG

A075048 001 Aug 22, 2000 May CAHN

@

5MG

A075048 002 Aug 22, 2000 May CAHN

@

10MG

A075048 003 Aug 22, 2000 May CAHN

@

20MG

A075048 004 Aug 22, 2000 May CAHN

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP DR REDDYS 1.25MG/ML

A075578 001 Aug 22, 2000 Apr CMFD

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP BE PHARMS 30MG/0.3ML (100MG/ML)

A214646 001 Jun 06, 2023 May NEWA

AP 40MG/0.4ML (100MG/ML)

A214646 002 Jun 06, 2023 May NEWA

AP 60MG/0.6ML (100MG/ML)

A214646 003 Jun 06, 2023 May NEWA

AP 80MG/0.8ML (100MG/ML)

A214646 004 Jun 06, 2023 May NEWA

AP 100MG/ML (100MG/ML)

A214646 005 Jun 06, 2023 May NEWA

AP 120MG/0.8ML (150MG/ML)

A214646 006 Jun 06, 2023 May NEWA

AP 150MG/ML (150MG/ML)

A214646 007 Jun 06, 2023 May NEWA

AP GLAND 30MG/0.3ML (100MG/ML)

A078990 001 Sep 28, 2018 Jun CAHN

AP 40MG/0.4ML (100MG/ML)

A078990 002 Sep 28, 2018 Jun CAHN

AP 60MG/0.6ML (100MG/ML)

A078990 003 Sep 28, 2018 Jun CAHN

AP 80MG/0.8ML (100MG/ML)

A078990 004 Sep 28, 2018 Jun CAHN

AP 100MG/ML (100MG/ML)

A078990 005 Sep 28, 2018 Jun CAHN

AP 120MG/0.8ML (150MG/ML)

A078990 006 Sep 28, 2018 Jun CAHN

AP 150MG/ML (150MG/ML)

A078990 007 Sep 28, 2018 Jun CAHN

AP SHENZHEN TECHDOW 30MG/0.3ML (100MG/ML)

A205660 001 Mar 15, 2023 Mar NEWA

AP 40MG/0.4ML (100MG/ML)

A205660 002 Mar 15, 2023 Mar NEWA

AP 60MG/0.6ML (100MG/ML)

A205660 003 Mar 15, 2023 Mar NEWA

AP 80MG/0.8ML (100MG/ML)

A205660 004 Mar 15, 2023 Mar NEWA

AP 100MG/ML (100MG/ML)

A205660 005 Mar 15, 2023 Mar NEWA

AP 120MG/0.8ML (150MG/ML)

A205660 006 Mar 15, 2023 Mar NEWA

AP 150MG/ML (150MG/ML)

A205660 007 Mar 15, 2023 Mar NEWA

ENTECAVIR

TABLET; ORAL

ENTECAVIR

AB VITRUVIAS 0.5MG

A212106 001 Aug 10, 2020 Sep CAHN

AB 1MG

A212106 002 Aug 10, 2020 Sep CAHN

ENTRECTINIB

>A>	PELLETS;ORAL						
>A>	ROZLYTREK						
>A>	+! GENENTECH INC	50MG/PACKET	N218550	001	Oct 20, 2023	Oct	NEWA

EPHEDRINE SULFATE

	SOLUTION;INTRAVENOUS						
	EPHEDRINE SULFATE						
AP	OAK TREE PHARMA	50MG/ML (50MG/ML)	N208609	001	Mar 01, 2017	Aug	CAHN
	+! OPERAND PHARMS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Jun	CAHN
	+!	50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Jun	CAHN
AP	RENEW PHARMS	50MG/ML (50MG/ML)	N208609	001	Mar 01, 2017	Aug	CAHN
AP	SAGENT PHARMS INC	50MG/ML (50MG/ML)	A214528	001	Mar 09, 2023	Feb	NEWA
	@ ZYDUS PHARMS	50MG/ML (50MG/ML)	A217276	001	May 16, 2023	Sep	DISC
AP		50MG/ML (50MG/ML)	A217276	001	May 16, 2023	May	NEWA

EPINASTINE HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC						
	EPINASTINE HYDROCHLORIDE						
>D>	@ AKORN	0.05%	A204055	001	May 05, 2017	Oct	CAHN
>A>	@ EPIC PHARMA LLC	0.05%	A204055	001	May 05, 2017	Oct	CAHN

EPINEPHRINE

	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS						
	ADRENALIN						
	+! PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Sep	CTEC
	EPINEPHRINE						
	@ AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018	Sep	DISC
	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS						
	SYMJEPI						
>D>	+! ADAMIS PHARMS CORP	0.15MG/0.3ML (0.15MG/0.3ML)	N207534	002	Sep 27, 2018	Oct	DISC
>A>	+ @	0.15MG/0.3ML (0.15MG/0.3ML)	N207534	002	Sep 27, 2018	Oct	DISC
	SOLUTION;INTRAVENOUS						
>A>	ADRENALIN						
>A>	+! PAR STERILE PRODUCTS	2MG/250ML (8MCG/ML)	N215875	001	Apr 21, 2023	Oct	CTNA
>A>	+!	4MG/250ML (16MCG/ML)	N215875	002	Apr 21, 2023	Oct	CTNA
>A>	+!	5MG/250ML (20MCG/ML)	N215875	003	Apr 21, 2023	Oct	CTNA
>A>	+!	8MG/250ML (32MCG/ML)	N215875	004	Apr 21, 2023	Oct	CTNA
>A>	+!	10MG/250ML (40MCG/ML)	N215875	005	Apr 21, 2023	Oct	CTNA
	EPINEPHRINE						
	+! BPI LABS	1MG/ML (1MG/ML)	N205029	003	May 12, 2023	Jun	NEWA
>D>	EPINEPHRINE IN 0.9% SODIUM CHLORIDE						
>D>	+! PAR STERILE PRODUCTS	2MG/250ML (8MCG/ML)	N215875	001	Apr 21, 2023	Oct	CTNA
	+!	2MG/250ML (8MCG/ML)	N215875	001	Apr 21, 2023	Apr	NEWA
>D>	+!	4MG/250ML (16MCG/ML)	N215875	002	Apr 21, 2023	Oct	CTNA
	+!	4MG/250ML (16MCG/ML)	N215875	002	Apr 21, 2023	Apr	NEWA
>D>	+!	5MG/250ML (20MCG/ML)	N215875	003	Apr 21, 2023	Oct	CTNA
	+!	5MG/250ML (20MCG/ML)	N215875	003	Apr 21, 2023	Apr	NEWA
>D>	+!	8MG/250ML (32MCG/ML)	N215875	004	Apr 21, 2023	Oct	CTNA
	+!	8MG/250ML (32MCG/ML)	N215875	004	Apr 21, 2023	Apr	NEWA
>D>	+!	10MG/250ML (40MCG/ML)	N215875	005	Apr 21, 2023	Oct	CTNA
	+!	10MG/250ML (40MCG/ML)	N215875	005	Apr 21, 2023	Apr	NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

	INJECTABLE;INJECTION						
	LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE						
	! HOSPIRA	0.01MG/ML;2%	A089646	001	Jun 21, 1988	Apr	CTEC
	XYLOCAINE W/ EPINEPHRINE						
	+! FRESENIUS KABI USA	0.02MG/ML;2%	N006488	005		May	CTEC

EPLERENONE

	TABLET;ORAL						
	EPLERENONE						
AB	ANNORA PHARMA	25MG	A213812	001	Jun 02, 2023	May	NEWA
AB		50MG	A213812	002	Jun 02, 2023	May	NEWA
>D> AB	KARTHA	25MG	A214663	001	Mar 23, 2022	Oct	CAHN
>D> AB		50MG	A214663	002	Mar 23, 2022	Oct	CAHN
>A> AB	RISING	25MG	A214663	001	Mar 23, 2022	Oct	CAHN
>A> AB		50MG	A214663	002	Mar 23, 2022	Oct	CAHN

EPOPROSTENOL SODIUMINJECTABLE;INJECTION
EPOPROSTENOL SODIUM

AP1	HONG KONG	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Sep CAHN
AP1		EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Sep CAHN
AP2	! SUN PHARM	EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Feb CHRS
	VELETRI					
AP2	+ ACTELION	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb CHRS

EPTIFIBATIDEINJECTABLE;INJECTION
EPTIFIBATIDE

AP	SLATE RUN PHARMA	2MG/ML	A209864	001	Jan 25, 2019	Sep CAHN
AP		75MG/100ML	A209864	002	Jan 25, 2019	Sep CAHN

ERGOCALCIFEROLCAPSULE;ORAL
DRISDOL

AA	+ VALIDUS PHARMS	50,000 IU	N003444	001		Feb CHRS
	ERGOCALCIFEROL					
AA	CHARTWELL RX	50,000 IU	A040833	001	May 20, 2009	Feb CAHN
AA	! STRIDES PHARMA	50,000 IU	A090455	001	Aug 03, 2010	Feb CHRS

ERLOTINIB HYDROCHLORIDETABLET;ORAL
ERLOTINIB HYDROCHLORIDE

AB	! ZYDUS PHARMS	EQ 150MG BASE	A213065	003	Apr 16, 2020	Apr CHRS
	TARCEVA					
	+ @ OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	Apr DISC
	+ @	EQ 100MG BASE	N021743	002	Nov 18, 2004	Apr DISC
	+ @	EQ 150MG BASE	N021743	003	Nov 18, 2004	Apr DISC

ERTAPENEM SODIUMINJECTABLE;INTRAMUSCULAR, INTRAVENOUS
ERTAPENEM SODIUM

AP	SUN PHARM	EQ 1GM BASE/VIAL	A209145	001	May 02, 2023	Apr NEWA
----	-----------	------------------	---------	-----	--------------	----------

ERTUGLIFLOZINTABLET;ORAL
ERTUGLIFLOZIN

	@ AUROBINDO PHARMA LTD	5MG	A216947	001	Jul 13, 2023	Jul DISC
AB		5MG	A216947	001	Jul 13, 2023	Jul NFTG
	@	15MG	A216947	002	Jul 13, 2023	Jul DISC
AB		15MG	A216947	002	Jul 13, 2023	Jul NFTG
	STEGLATRO					
	+ MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017	Jul CTEC
AB	+	5MG	N209803	001	Dec 19, 2017	Jul CFTG
	+!	15MG	N209803	002	Dec 19, 2017	Jul CTEC
AB	+	15MG	N209803	002	Dec 19, 2017	Jul CFTG

ERYTHROMYCINGEL;TOPICAL
ERYTHROMYCIN
@ PAI HOLDINGS PHARM

		2%	A208154	001	Jul 19, 2017	May DISC
--	--	----	---------	-----	--------------	----------

OINTMENT;OPHTHALMIC
ERYTHROMYCIN

AT	SENTISS	0.5%	A064030	001	Jul 18, 1996	Aug CAHN
----	---------	------	---------	-----	--------------	----------

SOLUTION;TOPICAL
ERYTHROMYCIN

	@ PAI HOLDINGS PHARM	2%	A208100	001	Nov 20, 2017	Aug DISC
	@ PHARMOBEDIANT CNSLTG	2%	A062825	001	Oct 23, 1987	Sep CAHN
	@ XTTRIUM LABS INC	2%	A062825	001	Oct 23, 1987	Jul DISC

TABLET;ORAL

ERYTHROMYCIN

AB	ALEMBIC	250MG	A215661	001	Aug 24, 2023	Aug NEWA
AB		500MG	A215661	002	Aug 24, 2023	Aug NEWA
AB	ARBOR PHARMS LLC	500MG	A061621	002		Jan CHRS
AB	! CADILA PHARMS LTD	500MG	A213628	002	Jun 28, 2021	Jan CHRS
AB	ZYDUS	250MG	A212693	001	Mar 07, 2023	Feb NEWA
AB		500MG	A212693	002	Mar 07, 2023	Feb NEWA
AB	ZYDUS PHARMS	250MG	A215440	001	Aug 31, 2023	Aug NEWA

TABLET;ORAL							
ERYTHROMYCIN							
AB		500MG	A215440	002	Aug 31, 2023	Aug	NEWA
<u>ERYTHROMYCIN ETHYLSUCCINATE</u>							
TABLET;ORAL							
ERYTHROMYCIN ETHYLSUCCINATE							
	@ AUROBINDO PHARMA USA	EQ 400MG BASE	A062847	001	Sep 14, 1988	Apr	CAHN
<u>ERYTHROMYCIN LACTOBIONATE</u>							
INJECTABLE;INJECTION							
ERYTHROMYCIN LACTOBIONATE							
	@ EXELA PHARMA	EQ 500MG BASE/VIAL	A211086	001	Sep 17, 2020	May	DISC
<u>ESCITALOPRAM OXALATE</u>							
SOLUTION;ORAL							
ESCITALOPRAM OXALATE							
AA	CHARTWELL MOLECULAR	EQ 5MG BASE/5ML	A090477	001	Jun 12, 2013	Jul	CAHN
	LEXAPRO						
	+ @ ABBVIE	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Jan	CAHN
TABLET;ORAL							
ESCITALOPRAM OXALATE							
	@ DASH PHARMS	EQ 5MG BASE	A077550	001	May 14, 2015	Feb	CAHN
	@	EQ 10MG BASE	A077550	002	May 14, 2015	Feb	CAHN
	@	EQ 20MG BASE	A077550	003	May 14, 2015	Feb	CAHN
AB	JUBILANT CADISTA	EQ 5MG BASE	A202280	001	Sep 12, 2012	May	CAHN
AB		EQ 10MG BASE	A202280	002	Sep 12, 2012	May	CAHN
AB		EQ 20MG BASE	A202280	003	Sep 12, 2012	May	CAHN
LEXAPRO							
AB	+ ABBVIE	EQ 5MG BASE	N021323	001	Aug 14, 2002	Jan	CAHN
AB	+	EQ 10MG BASE	N021323	002	Aug 14, 2002	Jan	CAHN
AB	+!	EQ 20MG BASE	N021323	003	Aug 14, 2002	Jan	CAHN
<u>ESLICARBAZEPINE ACETATE</u>							
TABLET;ORAL							
APTOM							
AB	+ SUMITOMO PHARMA AM	200MG	N022416	001	Nov 08, 2013	Jul	CAHN
AB	+	400MG	N022416	002	Nov 08, 2013	Jul	CAHN
AB	+	600MG	N022416	003	Nov 08, 2013	Jul	CAHN
AB	+!	800MG	N022416	004	Nov 08, 2013	Jul	CAHN
ESLICARBAZEPINE ACETATE							
AB	ALKEM LABS LTD	200MG	A211199	001	Oct 06, 2023	Sep	NEWA
AB		400MG	A211199	002	Oct 06, 2023	Sep	NEWA
AB		600MG	A211199	003	Oct 06, 2023	Sep	NEWA
AB		800MG	A211199	004	Oct 06, 2023	Sep	NEWA
AB	HETERO LABS LTD V	200MG	A211186	001	Aug 03, 2023	Jul	NEWA
AB		400MG	A211186	002	Aug 03, 2023	Jul	NEWA
AB		600MG	A211186	003	Aug 03, 2023	Jul	NEWA
AB		800MG	A211186	004	Aug 03, 2023	Jul	NEWA
<u>ESMOLOL HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER							
AP	+! BAXTER HLTHCARE	2GM/100ML	N019386	005	Jan 27, 2003	Jan	CTEC
BREVIBLOC IN PLASTIC CONTAINER							
AP	+! BAXTER HLTHCARE	1GM/100ML	N019386	004	Feb 16, 2001	Jan	CTEC
ESMOLOL HYDROCHLORIDE							
AP	AMNEAL	1GM/100ML	A216603	001	Dec 13, 2022	Jan	CPOT
AP		2GM/100ML	A216603	002	Dec 13, 2022	Jan	CPOT
AP	EUGIA PHARMA	1GM/100ML	A216244	001	Mar 21, 2022	Jan	CPOT
AP		2GM/100ML	A216244	002	Mar 21, 2022	Jan	CPOT
>D> AP	FRESENIUS KABI USA	10MG/ML	A076573	001	May 02, 2005	Oct	DISC
>A>	@	10MG/ML	A076573	001	May 02, 2005	Oct	DISC
>D>		20MG/ML	A076573	002	Aug 23, 2023	Oct	DISC
>A>	@	20MG/ML	A076573	002	Aug 23, 2023	Oct	DISC
		20MG/ML	A076573	002	Aug 23, 2023	Aug	NEWA
AP	HQ SPCLT PHARMA	1GM/100ML	A214172	001	Dec 02, 2022	Jan	CPOT
AP		2GM/100ML	A214172	002	Dec 02, 2022	Jan	CPOT
AP	MYLAN LABS LTD	1GM/100ML	A206608	001	Jun 08, 2018	Jan	CPOT
AP		2GM/100ML	A206608	002	Jun 08, 2018	Jan	CPOT
AP	SAGENT PHARMS INC	1GM/100ML	A207107	001	Jun 08, 2018	Jan	CPOT
AP		2GM/100ML	A207107	002	Jun 08, 2018	Jan	CPOT

ESOMEPRAZOLE MAGNESIUMCAPSULE, DELAYED REL PELLETS;ORAL
ESOMEPRAZOLE MAGNESIUM

>A>	AB	GRANULES	EQ 20MG BASE	A217427	001	Oct 18, 2023	Oct NEWA
>A>	AB		EQ 40MG BASE	A217427	002	Oct 18, 2023	Oct NEWA
	AB	GUANGZHOU NOVAKEN	EQ 20MG BASE	A213859	001	Nov 18, 2020	Aug CMFD
	AB		EQ 40MG BASE	A213859	002	Nov 18, 2020	Aug CMFD
		@ HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Aug DISC
		@	EQ 40MG BASE	A202784	002	Sep 21, 2015	Aug DISC
	AB	PRINSTON INC	EQ 20MG BASE	A214920	001	Mar 28, 2023	Mar NEWA
	AB		EQ 40MG BASE	A214920	002	Mar 28, 2023	Mar NEWA
		@ TORRENT	EQ 20MG BASE	A203636	001	Oct 19, 2015	Aug DISC
		@	EQ 40MG BASE	A203636	002	Oct 19, 2015	Aug DISC
FOR SUSPENSION, DELAYED RELEASE;ORAL							
ESOMEPRAZOLE MAGNESIUM							
	AB	ZYDUS PHARMS	EQ 20MG BASE/PACKET	A206055	001	Jun 07, 2023	May NEWA
	AB		EQ 40MG BASE/PACKET	A206055	002	Jun 07, 2023	May NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXENTABLET, DELAYED RELEASE;ORAL
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

		@ ACTAVIS LABS FL INC	EQ 20MG BASE;375MG	A204470	001	Aug 24, 2022	Feb DISC
		@	EQ 20MG BASE;500MG	A204470	002	Aug 24, 2022	Feb DISC
	AB	! DR REDDYS	EQ 20MG BASE;500MG	A204206	002	Feb 18, 2020	Aug CHRS
>D>	AB	MYLAN	EQ 20MG BASE;375MG	A204920	001	Jul 20, 2021	Oct DISC
>A>		@	EQ 20MG BASE;375MG	A204920	001	Jul 20, 2021	Oct DISC
>D>	AB		EQ 20MG BASE;500MG	A204920	002	Jul 20, 2021	Oct DISC
>A>		@	EQ 20MG BASE;500MG	A204920	002	Jul 20, 2021	Oct DISC
	AB	SCIEGEN PHARMS INC	EQ 20MG BASE;375MG	A217738	001	Oct 11, 2023	Sep NEWA
	AB		EQ 20MG BASE;500MG	A217738	002	Oct 11, 2023	Sep NEWA
VIMOVO							
	+	@ HORIZON	EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010	Aug DISC
	+	@	EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010	Aug DISC

ESOMEPRAZOLE SODIUMINJECTABLE;INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP		EUGIA PHARMA	EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jan CHRS
		GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020	Apr CTEC

ESTRADIOLCREAM;VAGINAL
ESTRADIOL

AB		PRASCO	0.01%	A212313	001	Jul 15, 2021	Jun CAHN
----	--	--------	-------	---------	-----	--------------	----------

FILM, EXTENDED RELEASE;TRANSDERMAL
ALORA

>A>		@ ABBVIE	0.025MG/24HR	N020655	004	Apr 05, 2002	Oct CAHN
>A>		@	0.05MG/24HR	N020655	001	Dec 20, 1996	Oct CAHN
>A>		@	0.075MG/24HR	N020655	002	Dec 20, 1996	Oct CAHN
>A>		@	0.1MG/24HR	N020655	003	Dec 20, 1996	Oct CAHN
>D>		@ ALLERGAN	0.025MG/24HR	N020655	004	Apr 05, 2002	Oct CAHN
>D>		@	0.05MG/24HR	N020655	001	Dec 20, 1996	Oct CAHN
>D>		@	0.075MG/24HR	N020655	002	Dec 20, 1996	Oct CAHN
>D>		@	0.1MG/24HR	N020655	003	Dec 20, 1996	Oct CAHN

ESTRADIOL

AB2		ZYDUS NOVELTECH INC	0.025MG/24HR	A202985	001	Mar 29, 2023	Mar NEWA
AB2			0.0375MG/24HR	A202985	002	Mar 29, 2023	Mar NEWA
AB2			0.05MG/24HR	A202985	003	Mar 29, 2023	Mar NEWA
AB			0.06MG/24HR	A202985	004	Mar 29, 2023	Mar NEWA
AB2			0.075MG/24HR	A202985	005	Mar 29, 2023	Mar NEWA
AB2			0.1MG/24HR	A202985	006	Mar 29, 2023	Mar NEWA
		@ ZYDUS PHARMS	0.025MG/24HR	A202985	001	Mar 29, 2023	Jul DISC
AB2			0.025MG/24HR	A202985	001	Mar 29, 2023	Apr CAHN
		@	0.0375MG/24HR	A202985	002	Mar 29, 2023	Jul DISC
AB2			0.0375MG/24HR	A202985	002	Mar 29, 2023	Apr CAHN
		@	0.05MG/24HR	A202985	003	Mar 29, 2023	Jul DISC
AB2			0.05MG/24HR	A202985	003	Mar 29, 2023	Apr CAHN
		@	0.06MG/24HR	A202985	004	Mar 29, 2023	Jul DISC
AB			0.06MG/24HR	A202985	004	Mar 29, 2023	Apr CAHN
		@	0.075MG/24HR	A202985	005	Mar 29, 2023	Jul DISC
AB2			0.075MG/24HR	A202985	005	Mar 29, 2023	Apr CAHN
		@	0.1MG/24HR	A202985	006	Mar 29, 2023	Jul DISC

FILM, EXTENDED RELEASE;TRANSDERMAL								
ESTRADIOL								
AB2		0.1MG/24HR	A202985	006	Mar 29, 2023	Apr	CAHN	
GEL;TRANSDERMAL								
ESTRADIOL								
AB	NOVITIUM PHARMA	0.1%	A217610	001	Aug 24, 2023	Aug	NEWA	
INSERT;VAGINAL								
IMVEXXY								
+	MAYNE PHARMA	0.004MG	N208564	001	May 29, 2018	Jan	CAHN	
+	!	0.01MG	N208564	002	May 29, 2018	Jan	CAHN	
SYSTEM;TRANSDERMAL								
ESTRADIOL								
AB	ZYDUS NOVELTECH INC	0.014MG/24HR	A204379	001	Apr 17, 2023	Apr	NFTG	
AB	ZYDUS PHARMS	0.014MG/24HR	A204379	001	Apr 17, 2023	May	CAHN	
AB1		0.025MG/24HR	A206241	001	Dec 01, 2022	May	CAHN	
AB1		0.0375MG/24HR	A206241	002	Dec 01, 2022	May	CAHN	
AB1		0.05MG/24HR	A206241	003	Dec 01, 2022	May	CAHN	
AB1		0.075MG/24HR	A206241	004	Dec 01, 2022	May	CAHN	
AB1		0.1MG/24HR	A206241	005	Dec 01, 2022	May	CAHN	
MENOSTAR								
AB	+	BAYER HLTHCARE	0.014MG/24HR	N021674	001	Jun 08, 2004	Apr	CFTG
VIVELLE								
	@	SANDOZ	0.025MG/24HR	N020323	005	Aug 16, 2000	May	CAHN
	@		0.0375MG/24HR	N020323	001	Oct 28, 1994	May	CAHN
	@		0.05MG/24HR	N020323	002	Oct 28, 1994	May	CAHN
	@		0.075MG/24HR	N020323	003	Oct 28, 1994	May	CAHN
	@		0.1MG/24HR	N020323	004	Oct 28, 1994	May	CAHN
VIVELLE-DOT								
AB1	+	SANDOZ	0.025MG/24HR	N020538	009	May 03, 2002	May	CAHN
AB1	+		0.0375MG/24HR	N020538	005	Jan 08, 1999	May	CAHN
AB1	+		0.05MG/24HR	N020538	006	Jan 08, 1999	May	CAHN
AB1	+		0.075MG/24HR	N020538	007	Jan 08, 1999	May	CAHN
AB1	+	!	0.1MG/24HR	N020538	008	Jan 08, 1999	May	CAHN
TABLET;ORAL								
ESTRADIOL								
AB	NOVITIUM PHARMA	0.5MG	A217334	001	Sep 06, 2023	Aug	NEWA	
AB		1MG	A217334	002	Sep 06, 2023	Aug	NEWA	
AB		2MG	A217334	003	Sep 06, 2023	Aug	NEWA	
ESTRADIOL VALERATE								
INJECTABLE;INJECTION								
ESTRADIOL VALERATE								
AO	XIROMED	10MG/ML	A216656	001	Apr 28, 2023	Apr	NEWA	
AO		20MG/ML	A216656	002	Apr 28, 2023	Apr	NEWA	
AO		40MG/ML	A216656	003	Apr 28, 2023	Apr	NEWA	
ESTRADIOL; NORETHINDRONE ACETATE								
TABLET;ORAL								
ESTRADIOL AND NORETHINDRONE ACETATE								
AB	AUROBINDO PHARMA LTD	0.5MG;0.1MG	A214729	001	Jun 30, 2023	Jun	NEWA	
AB		1MG;0.5MG	A214729	002	Jun 30, 2023	Jun	NEWA	
ETHINYL ESTRADIOL; ETONOGESTREL								
RING;VAGINAL								
ENILLORING								
AB	XIROMED	0.015MG/24HR;0.12MG/24HR	A211157	001	Jun 29, 2023	Jun	NEWA	
ETHINYL ESTRADIOL; LEVONORGESTREL								
TABLET;ORAL								
BALCOLTRA								
AB3	+	AVION PHARMS	0.02MG;0.1MG	N208612	001	Jan 09, 2018	Aug	CFTG
LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE								
AB3	XIROMED	0.02MG;0.1MG	A214640	001	Aug 16, 2023	Aug	NFTG	
TABLET;ORAL-28								
LEVONORGESTREL AND ETHINYL ESTRADIOL								
	@	AMNEAL PHARMS	0.02MG;0.1MG	A201108	001	Feb 05, 2014	Jan	DISC
	@		0.03MG;0.15MG	A201095	001	Dec 08, 2014	Jan	DISC
AB1	HETERO LABS	0.02MG;0.1MG	A212298	001	Feb 13, 2023	Feb	NEWA	
AB	LUPIN LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075M	A200248	001	Nov 19, 2015	Jan	CTEC	
		G.0.125MG						

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL
ETHINYL ESTRADIOL AND NORELGESTROMIN

AB ZYDUS NOVELTECH INC 0.035MG/24HR;0.15MG/24HR A214594 001 Sep 14, 2023 Sep NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

RHUZDAH

@ AUROBINDO PHARMA 0.035MG;0.4MG

A207585 001 Oct 11, 2022 Apr DISC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

HAILEY 24 FE

AB ! GLENMARK PHARMS LTD 0.02MG;1MG

A204847 001 Nov 17, 2017 Feb CTNA

MINASTRIN 24 FE

+ @ APIL 0.02MG;1MG

N203667 001 May 08, 2013 Apr DISC

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB ! GLENMARK PHARMS LTD 0.02MG;1MG

A210369 001 Dec 26, 2017 Apr CHRS

TABLET;ORAL-21

TRI-LEGEST 21

@ BARR

0.02MG,0.03MG,0.035MG;1MG,1MG,1MG

A076405 001 Oct 26, 2007 Sep DISC

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

@ AMNEAL PHARMS 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG

A203870 001 Nov 12, 2015 Jan DISC

@ 0.035MG;0.25MG

A203865 001 Oct 27, 2015 Jun DISC

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28

TURQOZ

AB LUPIN LTD 0.03MG;0.3MG

A202980 001 Jul 31, 2023 Jul NEWA

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

RING;VAGINAL

ANNOVERA

+! MAYNE PHARMA 0.013MG/24HR;0.15MG/24HR

N209627 001 Aug 10, 2018 Jan CAHN

ETODOLAC

TABLET;ORAL

ETODOLAC

@ EDENBRIDGE PHARMS 400MG

A209888 001 Nov 30, 2018 Aug DISC

@ 500MG

A209888 002 Nov 30, 2018 Aug DISC

@ SHREE HARI INTL 400MG

A074839 001 Jul 11, 1997 Sep CAHN

@ 400MG

A074846 001 Feb 28, 1997 Sep CAHN

ETOMIDATE

INJECTABLE;INJECTION

ETOMIDATE

@ AVET LIFESCIENCES 2MG/ML

A204618 001 Aug 13, 2014 Sep DISC

ETOPOSIDE

INJECTABLE;INJECTION

ETOPOSIDE

@ DASH PHARMS 20MG/ML

A204927 001 Oct 31, 2017 Mar CAHN

@ DASH PHARMS NATCO 20MG/ML

A203507 001 Nov 20, 2017 Feb CAHN

>A> AP HONG KONG 20MG/ML

A074529 001 Jul 24, 1996 Oct CAHN

>D> AP TEVA PHARMS USA 20MG/ML

A074529 001 Jul 24, 1996 Oct CAHN

ETRASIMOD ARGININE

>A> TABLET;ORAL

>A> VELSIPITY

>A> +! PFIZER EQ 2MG BASE

N216956 001 Oct 12, 2023 Oct NEWA

EVEROLIMUSTABLET; ORAL
EVEROLIMUS

AB	TEVA PHARMS USA	10MG	A210050	004	Dec 09, 2019	Apr	CMFD
----	-----------------	------	---------	-----	--------------	-----	------

EXEMESTANETABLET; ORAL
EXEMESTANE

@	ALVOGEN	25MG	A200898	001	Jul 28, 2014	Feb	DISC
---	---------	------	---------	-----	--------------	-----	------

EZETIMIBETABLET; ORAL
EZETIMIBE

@	ORIENT PHARMA	10MG	A215693	001	Sep 13, 2022	Mar	DISC
---	---------------	------	---------	-----	--------------	-----	------

FAMOTIDINEFOR SUSPENSION; ORAL
FAMOTIDINE

AB	AJANTA PHARMA LTD	40MG/5ML	A217529	001	Sep 18, 2023	Sep	NEWA
AB	ALKEM LABS LTD	40MG/5ML	A216400	001	May 15, 2023	May	NEWA
AB	ANNORA PHARMA	40MG/5ML	A217330	001	Aug 17, 2023	Aug	NEWA
AB	APPCO	40MG/5ML	A217655	001	Jun 16, 2023	Jun	NEWA
AB	CARNEGIE	40MG/5ML	A217137	001	Jul 07, 2023	Jun	NEWA
AB	LUPIN LTD	40MG/5ML	A090440	001	Jun 29, 2010	Jun	CHRS
AB	MICRO LABS	40MG/5ML	A217842	001	Sep 14, 2023	Sep	NEWA
AB	! NOVITIUM PHARMA	40MG/5ML	A215043	001	Apr 20, 2021	Jun	CHRS
AB	UPSHER SMITH LABS	40MG/5ML	A217655	001	Jun 16, 2023	Sep	CAHN

INJECTABLE; INJECTION
FAMOTIDINE

>D>	AP	ATHENEX INC	10MG/ML	A075684	001	Apr 16, 2001	Oct	CAHN
	AP	SAGENT	10MG/ML	A075651	001	Apr 16, 2001	Aug	CAHN
>A>	AP		10MG/ML	A075684	001	Apr 16, 2001	Oct	CAHN
	@	ZYDUS PHARMS	10MG/ML	A215828	001	Nov 22, 2022	Apr	DISC
		FAMOTIDINE PRESERVATIVE FREE						
	AP	SAGENT	10MG/ML	A075622	001	Apr 16, 2001	Aug	CAHN
	AP		10MG/ML	A075825	001	Apr 17, 2001	Aug	CAHN

TABLET; ORAL
FAMOTIDINE

AB	ALKEM LABS LTD	20MG	A215630	001	Jan 07, 2022	Sep	CAHN	
AB		20MG	A217375	001	Apr 24, 2023	Apr	NEWA	
AB		40MG	A215630	002	Jan 07, 2022	Sep	CAHN	
AB		40MG	A217375	002	Apr 24, 2023	Apr	NEWA	
AB	CHARTWELL RX	20MG	A215630	001	Jan 07, 2022	Aug	CAHN	
AB		40MG	A215630	002	Jan 07, 2022	Aug	CAHN	
>D>	@	MANKIND PHARMA	20MG	A075302	001	Apr 16, 2001	Oct	CMFD
>A>	AB		20MG	A075302	001	Apr 16, 2001	Oct	CMFD
>D>	@		40MG	A075302	002	Apr 16, 2001	Oct	CMFD
>A>	AB		40MG	A075302	002	Apr 16, 2001	Oct	CMFD
AB	VKT PHARMA	20MG	A215630	001	Jan 07, 2022	Jan	CAHN	
AB		40MG	A215630	002	Jan 07, 2022	Jan	CAHN	

FAMOTIDINE; IBUPROFENTABLET; ORAL
IBUPROFEN AND FAMOTIDINE

AB	ASCENT PHARMS INC	26.6MG; 800MG	A216814	001	Mar 15, 2023	Mar	NEWA
----	-------------------	---------------	---------	-----	--------------	-----	------

FEBUXOSTATTABLET; ORAL
FEBUXOSTAT

>A>	AB	AUROBINDO PHARMA LTD	40MG	A210741	001	Oct 25, 2023	Oct	NEWA
>A>	AB		80MG	A210741	002	Oct 25, 2023	Oct	NEWA
	AB	MACLEODS PHARMS LTD	40MG	A207293	001	Sep 28, 2023	Sep	NEWA
	AB		80MG	A207293	002	Sep 28, 2023	Sep	NEWA
>D>	AB	MYLAN	40MG	A205385	001	Jul 01, 2019	Oct	DISC
>A>	@		40MG	A205385	001	Jul 01, 2019	Oct	DISC
	@		80MG	A205385	002	Jul 01, 2019	Jun	DISC
	AB	ZYDUS LIFESCIENCES	40MG	A205443	001	Jan 09, 2023	Jan	CAHN
	AB		80MG	A205443	002	Jan 09, 2023	Jan	CAHN

FENFLURAMINE HYDROCHLORIDE

SOLUTION; ORAL

FINTEPLA

+! UCB INC

EQ 2.2MG BASE/ML

N212102 001 Jun 25, 2020 Jun CAHN

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

+ @ LUPIN

90MG

N021695 005 Oct 18, 2013 Jun DISC

TABLET; ORAL

FENOFIBRATE

AB CHARTWELL RX

54MG

A209660 001 Feb 11, 2019 Feb CAHN

AB

160MG

A209660 002 Feb 11, 2019 Feb CAHN

AB CREEKWOOD PHARMS

40MG

A217732 001 Sep 07, 2023 Sep NEWA

AB

120MG

A217732 002 Sep 07, 2023 Sep NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

AB MISEMER

EQ 200MG BASE

A215548 001 May 16, 2023 May NEWA

EQ 300MG BASE

A215548 002 May 16, 2023 May NEWA

AB

EQ 400MG BASE

A215548 003 May 16, 2023 May NEWA

NALFON

AB + XSPIRE PHARMA

EQ 200MG BASE

N017604 003 May CTEC

TABLET; ORAL

NALFON

>D> @ DISTA

EQ 600MG BASE

N017710 001 Oct CRLD

>A> + @

EQ 600MG BASE

N017710 001 Oct CRLD

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB AVEVA

100MCG/HR

A077449 004 Oct 20, 2008 Jul CMFD

AB ZYDUS NOVELTECH INC

100MCG/HR

A209655 008 Jan 24, 2023 Jan NEWA

@ ZYDUS PHARMS

100MCG/HR

A209655 008 Jan 24, 2023 Jun DISC

AB

100MCG/HR

A209655 008 Jan 24, 2023 May CAHN

FENTANYL-12

AB AVEVA

12.5MCG/HR

A077449 005 Sep 11, 2015 Jul CMFD

AB ZYDUS NOVELTECH INC

12.5MCG/HR

A209655 001 Jan 24, 2023 Jan NEWA

@ ZYDUS PHARMS

12.5MCG/HR

A209655 001 Jan 24, 2023 Jun DISC

AB

12.5MCG/HR

A209655 001 Jan 24, 2023 May CAHN

FENTANYL-25

AB AVEVA

25MCG/HR

A077449 001 Oct 20, 2008 Jul CMFD

AB ZYDUS NOVELTECH INC

25MCG/HR

A209655 002 Jan 24, 2023 Jan NEWA

@ ZYDUS PHARMS

25MCG/HR

A209655 002 Jan 24, 2023 Jun DISC

AB

25MCG/HR

A209655 002 Jan 24, 2023 May CAHN

FENTANYL-37

AB AVEVA

37.5MCG/HR

A077449 006 Dec 06, 2017 Jul CMFD

AB ZYDUS NOVELTECH INC

37.5MCG/HR

A209655 003 Jan 24, 2023 Jan NEWA

@ ZYDUS PHARMS

37.5MCG/HR

A209655 003 Jan 24, 2023 Jun DISC

AB

37.5MCG/HR

A209655 003 Jan 24, 2023 May CAHN

FENTANYL-50

AB AVEVA

50MCG/HR

A077449 002 Oct 20, 2008 Jul CMFD

AB ZYDUS NOVELTECH INC

50MCG/HR

A209655 004 Jan 24, 2023 Jan NEWA

@ ZYDUS PHARMS

50MCG/HR

A209655 004 Jan 24, 2023 Jun DISC

AB

50MCG/HR

A209655 004 Jan 24, 2023 May CAHN

FENTANYL-62

AB AVEVA

62.5MCG/HR

A077449 007 Dec 06, 2017 Jul CMFD

AB ZYDUS NOVELTECH INC

62.5MCG/HR

A209655 005 Jan 24, 2023 Jan NEWA

@ ZYDUS PHARMS

62.5MCG/HR

A209655 005 Jan 24, 2023 Jun DISC

AB

62.5MCG/HR

A209655 005 Jan 24, 2023 May CAHN

FENTANYL-75

AB AVEVA

75MCG/HR

A077449 003 Oct 20, 2008 Jul CMFD

AB ZYDUS NOVELTECH INC

75MCG/HR

A209655 006 Jan 24, 2023 Jan NEWA

@ ZYDUS PHARMS

75MCG/HR

A209655 006 Jan 24, 2023 Jun DISC

AB

75MCG/HR

A209655 006 Jan 24, 2023 May CAHN

FENTANYL-87

AB AVEVA

87.5MCG/HR

A077449 008 Dec 06, 2017 Jul CMFD

AB MYLAN TECHNOLOGIES

87.5MCG/HR

A076258 008 Dec 29, 2014 Jul CTEC

87.5MCG/HR

A076258 008 Dec 29, 2014 Jun CTEC

AB

87.5MCG/HR

A076258 008 Dec 29, 2014 Jan CTEC

FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-87

AB	ZYDUS NOVELTECH INC	87.5MCG/HR	A209655	007	Jan 24, 2023	Jan NEWA
	@ ZYDUS PHARMS	87.5MCG/HR	A209655	007	Jan 24, 2023	Jun DISC
AB		87.5MCG/HR	A209655	007	Jan 24, 2023	May CAHN

FENTANYL CITRATE

INJECTABLE;INJECTION
FENTANYL CITRATE

	+! HIKMA	EQ 0.025MG BASE/0.5ML	N019101	002	Jan 20, 2023	Jan NEWA
AP	+!	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Jan CTNA

SUBLIMAZE PRESERVATIVE FREE

AP	+! RISING	EQ 0.05MG BASE/ML	N016619	001		Sep CAHN
----	-----------	-------------------	---------	-----	--	----------

SOLUTION;INTRAVENOUS
FENTANYL CITRATE

	+ @ EXELA PHARMA	EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML)	N215870	001	Feb 08, 2023	May DISC
	+!	EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML)	N215870	001	Feb 08, 2023	Feb NEWA
	+ @	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N215870	002	Feb 08, 2023	May DISC
	+!	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N215870	002	Feb 08, 2023	Feb NEWA

TROCHE/LOZENGE;TRANSMUCOSAL
ACTIQ

>D>	+ CEPHALON	EQ 0.2MG BASE	N020747	001	Nov 04, 1998	Oct CAHN
>A>	+	EQ 0.2MG BASE	N020747	001	Nov 04, 1998	Oct CAHN
	+	EQ 0.2MG BASE	N020747	001	Nov 04, 1998	Sep CTEC
>D>	+!	EQ 0.4MG BASE	N020747	002	Nov 04, 1998	Oct CAHN
>A>	+!	EQ 0.4MG BASE	N020747	002	Nov 04, 1998	Oct CAHN
	+	EQ 0.4MG BASE	N020747	002	Nov 04, 1998	Sep CTEC
>D>	+	EQ 0.6MG BASE	N020747	003	Nov 04, 1998	Oct CAHN
>A>	+	EQ 0.6MG BASE	N020747	003	Nov 04, 1998	Oct CAHN
	+	EQ 0.6MG BASE	N020747	003	Nov 04, 1998	Sep CTEC
>D>	+	EQ 0.8MG BASE	N020747	004	Nov 04, 1998	Oct CAHN
>A>	+	EQ 0.8MG BASE	N020747	004	Nov 04, 1998	Oct CAHN
	+	EQ 0.8MG BASE	N020747	004	Nov 04, 1998	Sep CTEC
>D>	+	EQ 1.2MG BASE	N020747	005	Nov 04, 1998	Oct CAHN
>A>	+	EQ 1.2MG BASE	N020747	005	Nov 04, 1998	Oct CAHN
	+	EQ 1.2MG BASE	N020747	005	Nov 04, 1998	Sep CTEC
>D>	+	EQ 1.6MG BASE	N020747	006	Nov 04, 1998	Oct CAHN
>A>	+	EQ 1.6MG BASE	N020747	006	Nov 04, 1998	Oct CAHN
	+	EQ 1.6MG BASE	N020747	006	Nov 04, 1998	Sep CTEC

FENTANYL CITRATE

	@ SPECGX LLC	EQ 0.2MG BASE	A078907	001	Oct 30, 2009	Sep DISC
	@	EQ 0.4MG BASE	A078907	002	Oct 30, 2009	Sep DISC
	@	EQ 0.6MG BASE	A078907	003	Oct 30, 2009	Sep DISC
	@	EQ 0.8MG BASE	A078907	004	Oct 30, 2009	Sep DISC
	@	EQ 1.2MG BASE	A078907	005	Oct 30, 2009	Sep DISC
	@	EQ 1.6MG BASE	A078907	006	Oct 30, 2009	Sep DISC

FERRIC PYROPHOSPHATE CITRATE

>D>	FOR SOLUTION;INTRAVENOUS					
>D>	TRIFERIC					
>D>	+ @ ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016	Oct CDFR
>A>	POWDER;INTRAVENOUS					
>A>	TRIFERIC					
>A>	+ @ ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016	Oct CDFR

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

	@ ACCORD HLTHCARE	4MG	A205012	001	Jan 04, 2023	Jul DISC
	@	8MG	A205012	002	Jan 04, 2023	Jul DISC
	@ ACTAVIS LABS FL INC	4MG	A204868	001	Jan 04, 2023	Jul DISC
	@	8MG	A204868	002	Jan 04, 2023	Jul DISC
	@ LUPIN LTD	4MG	A204983	001	Jan 05, 2023	Feb DISC
	@	8MG	A204983	002	Jan 05, 2023	Feb DISC

FEZOLINETANTTABLET; ORAL
VEOZAH

+! ASTELLAS 45MG N216578 001 May 12, 2023 May NEWA

FINAFLOXACINSUSPENSION/DROPS; OTIC
XTORO

+ @ FONSECA BIOSCIENCES 0.3% N206307 001 Dec 17, 2014 Jan CAHN

FINASTERIDE; TADALAFILCAPSULE; ORAL
ENTADFI

+! BLUE WATER BIOTECH 5MG; 5MG N215423 001 Dec 09, 2021 Jul CAHN

FINGOLIMOD HYDROCHLORIDECAPSULE; ORAL
FINGOLIMOD HYDROCHLORIDE

	@ BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Sep DISC
AB		EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Jan CMFD
AB	BIONPHARMA	EQ 0.5MG BASE	A210252	001	May 24, 2023	May NEWA

FINGOLIMOD LAURYL SULFATETABLET, ORALLY DISINTEGRATING; ORAL
TASCENSO ODT

+	CYCLE	EQ 0.25MG BASE	N214962	001	Dec 23, 2021	Jan CAHN
+	!	EQ 0.5MG BASE	N214962	002	Dec 09, 2022	Jan CAHN

FLOTUFOLASTAT F-18 GALLIUMSOLUTION; INTRAVENOUS
POSUMA

+	BLUE EARTH	25ML (8-158mCi/ML)	N216023	001	May 25, 2023	Aug CPOT
+	!	50ML (8-158mCi/ML)	N216023	001	May 25, 2023	May NEWA

FLUCONAZOLEFOR SUSPENSION; ORAL
FLUCONAZOLE

AB	HAINAN POLY	200MG/5ML	A215738	001	Sep 21, 2023	Sep NEWA
----	-------------	-----------	---------	-----	--------------	----------

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

	@ BAXTER HLTHCARE CORP	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010	Aug DISC
	@	400MG/200ML (2MG/ML)	A077947	002	May 26, 2010	Aug DISC

TABLET; ORAL

FLUCONAZOLE

>A>	AB	LUPIN LTD	50MG	A209146	001	Oct 20, 2023	Oct NEWA
>A>	AB		100MG	A209146	002	Oct 20, 2023	Oct NEWA
>A>	AB		150MG	A209146	003	Oct 20, 2023	Oct NEWA
>A>	AB		200MG	A209146	004	Oct 20, 2023	Oct NEWA

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

	@ ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Jun DISC
AP2		50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Jan CTEC
AP1	AREVA PHARMS	50MG/2ML (25MG/ML)	A090724	001	Sep 27, 2010	Jan CTEC
AP1	FRESENIUS KABI USA	50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007	Jan CTEC
AP		50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007	Jan CHRS
AP1	SAGENT PHARMS INC	50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Jan CTEC
	+ @ SANDOZ	50MG/2ML (25MG/ML)	N022137	001	Sep 21, 2007	Jun DISC
AP2	+	50MG/2ML (25MG/ML)	N022137	001	Sep 21, 2007	Jan CTEC

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

	@ HIKMA	0.1MG	A216013	001	Oct 27, 2022	Apr DISC
--	---------	-------	---------	-----	--------------	----------

FLUOCINOLONE ACETONIDE

	CREAM; TOPICAL								
	FLUOCINOLONE ACETONIDE								
	@ INVATECH	0.025%		A088045	001	Dec 16, 1982	Mar	CAHN	
	IMPLANT; INTRAVITREAL								
	YUTIQ								
	+! ALIMERA SCIENCES INC	0.18MG		N210331	001	Oct 12, 2018	Jun	CAHN	
	OIL; TOPICAL								
	FLUOCINOLONE ACETONIDE								
AT	NOVEL LABS INC	0.01%		A207345	001	Jul 31, 2023	Jul	NEWA	
AT		0.01%		A207347	001	Aug 07, 2023	Jul	NEWA	
	OIL/DROPS; OTIC								
	FLAC								
AT	PATRIN	0.01%		A210736	001	Apr 11, 2018	Sep	CAHN	
	SOLUTION; TOPICAL								
	FLUOCINOLONE ACETONIDE								
AT	CHARTWELL RX	0.01%		A209596	001	Dec 26, 2017	May	CAHN	

FLUOCINONIDE

	CREAM; TOPICAL								
	FLUOCINONIDE								
AB1	! AMNEAL	0.05%		A210554	001	Aug 21, 2018	Feb	CHRS	
>D>	@ ENCUBE	0.05%		A211410	001	Oct 16, 2018	Oct	CAHN	
>A>	@	0.05%		A211410	001	Oct 16, 2018	Oct	CAHN	
	@ PAI HOLDINGS PHARM	0.1%		A211758	001	Apr 03, 2019	Aug	DISC	
	+ @ TARO	0.05%		N019117	001	Jun 26, 1984	Feb	DISC	
	GEL; TOPICAL								
	FLUOCINONIDE								
	@ PAI HOLDINGS PHARM	0.05%		A209030	001	Jun 19, 2018	May	DISC	
	OINTMENT; TOPICAL								
	FLUOCINONIDE								
AB	CHARTWELL RX	0.05%		A207538	001	Jul 31, 2017	Apr	CAHN	
	@ PAI HOLDINGS PHARM	0.05%		A207680	001	Sep 28, 2018	Aug	DISC	
	SOLUTION; TOPICAL								
	FLUOCINONIDE								
AT	CHARTWELL RX	0.05%		A209118	001	Apr 23, 2018	May	CAHN	
	@ PAI HOLDINGS PHARM	0.05%		A207554	001	Mar 18, 2019	May	DISC	

FLUORESCEIN SODIUM

	INJECTABLE; INTRAVENOUS								
	AK-FLUOR 10%								
AP	+ LONG GROVE PHARMS	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)		N022186	001	Aug 08, 2008	Aug	CAHN	
	AK-FLUOR 25%								
AP	+! LONG GROVE PHARMS	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)		N022186	002	Aug 08, 2008	Sep	CFTG	
	+!	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)		N022186	002	Aug 08, 2008	Aug	CAHN	
	FLUORESCEIN SODIUM								
AP	NEXUS PHARMS	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)		A215709	001	Sep 25, 2023	Sep	NEWA	
AP		EQ 500MG BASE/2ML (EQ 250MG BASE/ML)		A215709	002	Sep 25, 2023	Sep	NFTG	

FLUOROESTRADIOL F-18

	SOLUTION; INTRAVENOUS								
	CERIANNA								
	+! GE HEALTHCARE	50ML (4-100mCi/ML)		N212155	001	May 20, 2020	Aug	CAHN	

FLUOROMETHOLONE

	SUSPENSION/DROPS; OPHTHALMIC								
	FML								
	+! ABBVIE	0.1%		N016851	002	Jul 28, 1982	Jan	CAHN	
	FML FORTE								
	+! ABBVIE	0.25%		N019216	001	Apr 23, 1986	Jan	CAHN	

FLUOROMETHOLONE ACETATESUSPENSION/DROPS;OPHTHALMIC
FLAREX

>D>	+	!	EYEVANCE	0.1%	N019079	001	Feb 11, 1986	Oct CAHN
>A>	+	!	HARROW EYE	0.1%	N019079	001	Feb 11, 1986	Oct CAHN

FLUOROMETHOLONE ACETATE; TOBRAMYCINSUSPENSION/DROPS;OPHTHALMIC
TOBRASONE

>D>	@	EYEVANCE	0.1%;0.3%	N050628	001	Jul 21, 1989	Oct CAHN
>A>	@	HARROW EYE	0.1%;0.3%	N050628	001	Jul 21, 1989	Oct CAHN

FLUOROURACILINJECTABLE;INJECTION
FLUOROURACIL

AP		ALEMBIC	2.5GM/50ML (50MG/ML)	A217295	001	Mar 03, 2023	Feb NEWA
>A>	AP		5GM/100ML (50MG/ML)	A217676	001	Oct 18, 2023	Oct NEWA

SOLUTION;TOPICAL
FLUOROURACIL

>A>	AT		ENCUBE	5%	A215612	001	Nov 02, 2023	Oct NEWA
>D>		!	TARO	5%	A076526	002	Nov 05, 2003	Oct CTEC
>A>	AT		!	5%	A076526	002	Nov 05, 2003	Oct CTEC

FLUOXETINE HYDROCHLORIDESOLUTION;ORAL
FLUOXETINE HYDROCHLORIDE

	@	CHARTWELL MOLECULAR	EQ 20MG BASE/5ML	A076458	001	May 14, 2004	Jul CAHN
AA		NOSTRUM LABS INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	Mar CMFD
	@	PHARMOBEDIENT CNSLTG	EQ 20MG BASE/5ML	A075514	001	Aug 29, 2002	Sep CAHN
	@	XTTRIUM LABS INC	EQ 20MG BASE/5ML	A075514	001	Aug 29, 2002	Jul DISC
AA			EQ 20MG BASE/5ML	A075514	001	Aug 29, 2002	Jan CAHN

TABLET;ORAL
FLUOXETINE HYDROCHLORIDE

@	PIRAMAL HLTHCARE UK	EQ 10MG BASE	A211444	001	Sep 13, 2022	Mar DISC
@		EQ 20MG BASE	A211444	002	Sep 13, 2022	Mar DISC
@	SLATE RUN PHARMA	EQ 10MG BASE	A211444	001	Sep 13, 2022	Sep CAHN
@		EQ 20MG BASE	A211444	002	Sep 13, 2022	Sep CAHN

FLUPHENAZINE DECANOATEINJECTABLE;INJECTION
FLUPHENAZINE DECANOATE

AO		GLAND PHARMA LTD	25MG/ML	A215509	001	Mar 30, 2023	Mar NEWA
>A>	AO		MSN	A215365	001	Nov 02, 2023	Oct NEWA

FLUPHENAZINE HYDROCHLORIDETABLET;ORAL
FLUPHENAZINE HYDROCHLORIDE

AB		AJANTA PHARMA LTD	1MG	A217410	001	Jan 05, 2023	Sep CMFD
	@		1MG	A217410	001	Jan 05, 2023	Jun DISC
AB			2.5MG	A217410	002	Jan 05, 2023	Sep CMFD
	@		2.5MG	A217410	002	Jan 05, 2023	Jun DISC
AB			5MG	A217410	003	Jan 05, 2023	Sep CMFD
	@		5MG	A217410	003	Jan 05, 2023	Jun DISC
AB			10MG	A217410	004	Jan 05, 2023	Sep CMFD
	@		10MG	A217410	004	Jan 05, 2023	Jun DISC
AB		AUROBINDO PHARMA LTD	1MG	A218055	001	Aug 18, 2023	Aug NEWA
AB			2.5MG	A218055	002	Aug 18, 2023	Aug NEWA
AB			5MG	A218055	003	Aug 18, 2023	Aug NEWA
AB			10MG	A218055	004	Aug 18, 2023	Aug NEWA
AB		CHARTWELL RX	1MG	A215141	001	Oct 20, 2021	Sep CAHN
AB			2.5MG	A215141	002	Oct 20, 2021	Sep CAHN
AB			5MG	A215141	003	Oct 20, 2021	Sep CAHN
AB			10MG	A215141	004	Oct 20, 2021	Sep CAHN
AB		DR REDDYS	1MG	A214534	001	Jan 07, 2021	Sep CAHN
AB			2.5MG	A214534	002	Jan 07, 2021	Sep CAHN
AB			5MG	A214534	003	Jan 07, 2021	Sep CAHN
AB			10MG	A214534	004	Jan 07, 2021	Sep CAHN
>A>	AB		GLENMARK PHARMS LTD	A216350	001	Nov 06, 2023	Oct NEWA
>A>	AB			A216350	002	Nov 06, 2023	Oct NEWA
>A>	AB			A216350	003	Nov 06, 2023	Oct NEWA
>A>	AB			A216350	004	Nov 06, 2023	Oct NEWA

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	MSN	1MG	A217189	001	Sep 11, 2023	Sep NEWA
AB		2.5MG	A217189	002	Sep 11, 2023	Sep NEWA
AB		5MG	A217189	003	Sep 11, 2023	Sep NEWA
AB		10MG	A217189	004	Sep 11, 2023	Sep NEWA
	@ PRASCO	1MG	A089804	002	Aug 12, 1988	Apr DISC
	@	2.5MG	A089804	003	Aug 12, 1988	Apr DISC
	@	5MG	A089804	004	Aug 12, 1988	Apr DISC
	@	10MG	A089804	001	Aug 12, 1988	Apr DISC

FLURANDRENOLIDE

CREAM; TOPICAL

FLURANDRENOLIDE

	@ CHARTWELL RX	0.05%	A205342	001	Apr 13, 2016	Aug CAHN
	LOTION; TOPICAL					
	CORDRAN					
	+ @ ALMIRALL	0.05%	N013790	001		May DISC
	FLURANDRENOLIDE					
	@ CHARTWELL RX	0.05%	A205343	001	Dec 22, 2016	Aug CAHN
	! PADAGIS ISRAEL	0.05%	A207133	001	Aug 30, 2016	May CTEC
AT	!	0.05%	A207133	001	Aug 30, 2016	May CHRS
	OINTMENT; TOPICAL					
	CORDRAN					
	+ @ ALMIRALL	0.05%	N012806	001		May DISC
	FLURANDRENOLIDE					
	! TELIGENT	0.05%	A207851	001	Dec 30, 2016	May CTEC
AT	!	0.05%	A207851	001	Dec 30, 2016	May CHRS

FLURBIPROFEN

TABLET; ORAL

ANSAID

>D>	@ PHARMACIA AND UPJOHN	50MG	N018766	002	Oct 31, 1988	Oct CRLD
>A>	+ @	50MG	N018766	002	Oct 31, 1988	Oct CRLD
>D>	@	100MG	N018766	003	Oct 31, 1988	Oct CRLD
>A>	+ @	100MG	N018766	003	Oct 31, 1988	Oct CRLD

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREO ELLIPTA

	+ GLAXO GRP LTD	0.05MG/INH; EQ 0.025MG BASE/INH	N204275	003	May 12, 2023	May NEWA
--	-----------------	---------------------------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

FLUTICASONE PROPIONATE

AB	CHARTWELL RX	0.05MG/SPRAY	A078492	001	Jan 09, 2012	Sep CAHN
----	--------------	--------------	---------	-----	--------------	----------

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE; ORAL

LESCOL XL

AB	+! SANDOZ	EQ 80MG BASE	N021192	001	Oct 06, 2000	Sep CAHN
----	-----------	--------------	---------	-----	--------------	----------

FLUVOXAMINE MALEATE

TABLET; ORAL

LUVOX

AB	+ ANI PHARMS	25MG	N021519	001	Dec 20, 2007	Jan CRLD
AB	+	50MG	N021519	002	Dec 20, 2007	Jan CRLD
AB	+	100MG	N021519	003	Dec 20, 2007	Jan CRLD

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

AP	GLAND PHARMA LTD	1.5GM/1.5ML (1GM/ML)	A216791	001	Jul 06, 2023	Jun NEWA
----	------------------	----------------------	---------	-----	--------------	----------

FORMOTEROL FUMARATE

SOLUTION; INHALATION

FORMOTEROL FUMARATE

AN	MANKIND PHARMA	0.02MG/2ML	A215883	001	Mar 22, 2023	Mar NEWA
----	----------------	------------	---------	-----	--------------	----------

FOSAPREPITANT DIMEGLUMINEPOWDER; INTRAVENOUS
FOSAPREPITANT DIMEGLUMINE

AP	PIRAMAL CRITICAL	EQ 150MG BASE/VIAL	A214683	001	May 16, 2023	May NEWA
	SOLUTION; INTRAVENOUS					
	FOCINVEZ					
>D>	+! SPES PHARMS	EQ 150MG BASE/50ML (EQ 3MG BASE/ML)	N216686	001	Aug 22, 2023	Oct CAHN
	+!	EQ 150MG BASE/50ML (EQ 3MG BASE/ML)	N216686	001	Aug 22, 2023	Aug NEWA
>A>	+! STERISCIENCE	EQ 150MG BASE/50ML (EQ 3MG BASE/ML)	N216686	001	Aug 22, 2023	Oct CAHN

FOSCARNET SODIUMINJECTABLE; INJECTION
FOSCARNET SODIUM

AP	AVET LIFESCIENCES	2.4GM/100ML	A213807	001	Jun 05, 2023	May NEWA
----	-------------------	-------------	---------	-----	--------------	----------

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDEPOWDER; INTRAVENOUS
AKYNZEO

	+ @ HELSINN HLTHCARE	EQ 235MG BASE/VIAL; EQ 0.25MG BASE/VIAL	N210493	001	Apr 19, 2018	Sep DISC
--	----------------------	---	---------	-----	--------------	----------

FOSPHENYTOIN SODIUMINJECTABLE; INJECTION
FOSPHENYTOIN SODIUM

>A> AP	GLAND PHARMA LTD	EQ 50MG PHENYTOIN NA/ML	A214926	001	Oct 13, 2023	Oct NEWA
	@ MYLAN LABS LTD	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010	Apr DISC

FROVATRIPTAN SUCCINATETABLET; ORAL
FROVATRIPTAN SUCCINATE
@ MYLAN

	EQ 2.5MG BASE	A202931	001	Aug 28, 2014	Apr DISC
--	---------------	---------	-----	--------------	----------

FULVESTRANTSOLUTION; INTRAMUSCULAR
FULVESTRANT

AO	EUGIA PHARMA	250MG/5ML (50MG/ML)	A215169	001	Jun 30, 2023	Jun NEWA
----	--------------	---------------------	---------	-----	--------------	----------

FUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDE

AP	AMNEAL PHARMS CO	10MG/ML	A207552	001	Jul 20, 2016	Aug CMFD
AP	SAGENT	10MG/ML	A214766	001	Jan 27, 2021	Aug CAHN

SOLUTION; ORAL
FUROSEMIDE

	@ PHARMOBEDIANT CNSLTG	10MG/ML	A070655	001	Oct 02, 1987	Sep CAHN
	@ XTTRIUM LABS INC	10MG/ML	A070655	001	Oct 02, 1987	Jan CAHN

TABLET; ORAL
FUROSEMIDE

	@ CHARTWELL RX	20MG	N018413	001	Nov 30, 1983	Mar CAHN
	@	40MG	N018413	002	Nov 30, 1983	Mar CAHN

GABAPENTINCAPSULE; ORAL
GABAPENTIN

AB	LAURUS	100MG	A217546	001	May 12, 2023	May NEWA
AB		300MG	A217546	002	May 12, 2023	May NEWA
AB		400MG	A217546	003	May 12, 2023	May NEWA

SOLUTION; ORAL
GABAPENTIN

AA	MISSION PHARMACAL	250MG/5ML	A078974	001	Feb 18, 2011	Aug CAHN
AA	RUBICON	250MG/5ML	A216492	001	Jan 18, 2023	Jan NEWA

TABLET; ORAL
GABAPENTIN

	@ CHARTWELL RX	600MG	A076120	001	Jan 27, 2006	May CAHN
	@	800MG	A076120	002	Jan 27, 2006	May CAHN
AB	GRANULES	600MG	A217116	001	Mar 28, 2023	Mar NEWA
AB		800MG	A217116	002	Mar 28, 2023	Mar NEWA
AB	GRAVITI PHARMS	600MG	A217995	001	Jul 19, 2023	Jul NEWA

TABLET;ORAL							
GABAPENTIN							
AB		800MG		A217995	002	Jul 19, 2023	Jul NEWA
AB	RISING	600MG		A217995	001	Jul 19, 2023	Aug CAHN
AB		800MG		A217995	002	Jul 19, 2023	Aug CAHN
GRALISE							
+	ALMATICA	450MG		N022544	003	Apr 18, 2023	Aug NEWA
+		750MG		N022544	004	Apr 18, 2023	Aug NEWA
+		900MG		N022544	005	Apr 18, 2023	Aug NEWA
<u>GADOBUTROL</u>							
SOLUTION;INTRAVENOUS							
GADAVIST							
AP	+! BAYER HLTHCARE	18.1416GM/30ML (604.72MG/ML)		N201277	004	Mar 14, 2011	Sep CFTG
AP	+!	39.3068GM/65ML (604.72MG/ML)		N201277	005	Mar 14, 2011	Sep CFTG
GADOBUTROL							
	@ HAINAN POLY PHARM	4.5354GM/7.5ML (604.72MG/ML)		A217480	001	Mar 15, 2023	Sep DISC
AP		4.5354GM/7.5ML (604.72MG/ML)		A217480	001	Mar 15, 2023	Mar NEWA
	@	9.0708GM/15ML (604.72MG/ML)		A217480	002	Mar 15, 2023	Sep DISC
AP		9.0708GM/15ML (604.72MG/ML)		A217480	002	Mar 15, 2023	Mar NEWA
AP	HENGRUI PHARMA	18.1416GM/30ML (604.72MG/ML)		A216081	001	Sep 08, 2023	Sep NFTG
AP		39.3068GM/65ML (604.72MG/ML)		A216081	002	Sep 08, 2023	Sep NFTG
<u>GADOTERATE MEGLUMINE</u>							
SOLUTION;INTRAVENOUS							
GADOTERATE MEGLUMINE							
AP	HENGRUI PHARMA	37.69GM/100ML (376.9MG/ML)		A215304	005	Apr 15, 2022	Feb CMS1
<u>GALANTAMINE HYDROBROMIDE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
GALANTAMINE HYDROBROMIDE							
AB	! AUROBINDO PHARMA	EQ 8MG BASE		A204895	001	Aug 05, 2016	Jul CHRS
<u>GALLIUM CITRATE GA-67</u>							
INJECTABLE;INJECTION							
GALLIUM CITRATE GA 67							
	@ LANTHEUS MEDCL	2mCi/ML		N017478	001		Sep DISC
<u>GALLIUM GA-68 DOTATOC</u>							
SOLUTION;INTRAVENOUS							
GALLIUM GA 68 EDOTREOTIDE							
+	UIHC PET IMAGING	0.5-4mCi/ML		N210828	001	Aug 21, 2019	Aug CTNA
<u>GALLIUM GA-68 EDOTREOTIDE</u>							
SOLUTION;INTRAVENOUS							
GALLIUM GA 68 EDOTREOTIDE							
+	UIHC PET IMAGING	0.5-4mCi/ML		N210828	001	Aug 21, 2019	Aug CAIN
<u>GANCICLOVIR SODIUM</u>							
INJECTABLE;INJECTION							
GANCICLOVIR SODIUM							
AP	SLATE RUN PHARMA	EQ 500MG BASE/VIAL		A204204	001	Nov 08, 2018	Sep CAHN
<u>GANIRELIX ACETATE</u>							
INJECTABLE;INJECTION							
GANIRELIX ACETATE							
AP	GLAND PHARMA LTD	250MCG/0.5ML		A215658	001	Feb 28, 2023	Feb NEWA
AP	+! ORGANON USA ORGANON	250MCG/0.5ML		N021057	001	Jul 29, 1999	May CAHN
<u>GATIFLOXACIN</u>							
SOLUTION/DROPS;OPHTHALMIC							
ZYMAR							
+	@ ALLERGAN	0.3%		N021493	001	Mar 28, 2003	Mar DISC
ZYMAXID							
AT	+! ABBVIE	0.5%		N022548	001	May 18, 2010	Jan CAHN

GEFITINIBTABLET; ORAL
GEFITINIB

AB	ACTAVIS LABS FL INC	250MG	A208913	001	Apr 26, 2023	Apr NEWA
AB	NATCO	250MG	A212827	001	May 31, 2023	May NEWA
AB	QILU PHARM HAINAN	250MG	A211591	001	Feb 13, 2023	Feb NEWA

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP	HIKMA	200MG/5.26ML (38MG/ML)	A213175	001	Mar 07, 2023	Feb NEWA
AP		1GM/26.3ML (38MG/ML)	A213175	002	Mar 07, 2023	Feb NEWA
AP		2GM/52.6ML (38MG/ML)	A213175	003	Mar 07, 2023	Feb NEWA
AP	NOVAST LABS	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Jun CMFD
AP		1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Jun CMFD
AP		2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Jun CMFD

SOLUTION; INTRAVENOUS
INFUGEM

+	@ SUN PHARM	EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	N208313	001	Jul 16, 2018	Jul DISC
+	@	EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N208313	002	Jul 16, 2018	Jul DISC
+	@	EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N208313	003	Jul 16, 2018	Jul DISC
+	@	EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N208313	004	Jul 16, 2018	Jul DISC
+	@	EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N208313	005	Jul 16, 2018	Jul DISC
+	@	EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N208313	006	Jul 16, 2018	Jul DISC
+	@	EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N208313	007	Jul 16, 2018	Jul DISC
+	@	EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N208313	008	Jul 16, 2018	Jul DISC
+	@	EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N208313	009	Jul 16, 2018	Jul DISC
+	@	EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N208313	010	Jul 16, 2018	Jul DISC

GENTAMICIN SULFATEINJECTABLE; INJECTION
GENTAMICIN SULFATE

AP	HIKMA	EQ 10MG BASE/ML	A062251	002		Sep CMFD
AP		EQ 40MG BASE/ML	A062251	001		Sep CMFD

OINTMENT; OPHTHALMIC
GENTAMICIN SULFATE

	@ AKORN	EQ 0.3% BASE	A064093	001	Aug 31, 1995	Feb DISC
!	FERA PHARMS LLC	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb CTEC
AT	!	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb CHRS

OINTMENT; TOPICAL
GENTAMICIN SULFATE

	@ PAI HOLDINGS PHARM	EQ 0.1% BASE	A209233	001	Dec 31, 2018	May DISC
--	----------------------	--------------	---------	-----	--------------	----------

SOLUTION/DROPS; OPHTHALMIC
GENOPTIC

	@ ALLERGAN	EQ 0.3% BASE	A062452	001	Oct 10, 1984	Feb DISC
--	------------	--------------	---------	-----	--------------	----------

GENTAK

	@ AKORN	EQ 0.3% BASE	A064163	001	Oct 12, 2001	Feb DISC
--	---------	--------------	---------	-----	--------------	----------

GENTAMICIN SULFATE

AT	!	SANDOZ	EQ 0.3% BASE	A062196	001	Feb CHRS
----	---	--------	--------------	---------	-----	----------

GENTAMICIN SULFATE; PREDNISOLONE ACETATEOINTMENT; OPHTHALMIC
PRED-G

+	@ ALLERGAN	EQ 0.3% BASE; 0.6%	N050612	001	Dec 01, 1989	Jan DISC
---	------------	--------------------	---------	-----	--------------	----------

GEPIRONE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
EXXUA

+	FABRE KRAMER	EQ 18.2MG BASE	N021164	001	Sep 22, 2023	Sep NEWA
+		EQ 36.3MG BASE	N021164	002	Sep 22, 2023	Sep NEWA
+		EQ 54.5MG BASE	N021164	003	Sep 22, 2023	Sep NEWA
+	!	EQ 72.6MG BASE	N021164	004	Sep 22, 2023	Sep NEWA

GLATIRAMER ACETATEFOR SOLUTION;SUBCUTANEOUS
COPAXONE

+ @ TEVA PHARMS USA 20MG/VIAL N020622 001 Dec 20, 1996 Jun CRLD

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

	RUBICON	2.5MG	A214874	001	Oct 03, 2023	Sep NFTG
AB		5MG	A214874	002	Oct 03, 2023	Sep NEWA
AB		10MG	A214874	003	Oct 03, 2023	Sep NEWA
	GLUCOTROL					
	+ @ PFIZER	2.5MG	N017783	003	May 11, 1993	Sep CFTG
	+ @	5MG	N017783	001	May 08, 1984	Sep CFTG
	+ @	10MG	N017783	002	May 08, 1984	Sep CFTG

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

@ DASH PHARMS	2.5MG;250MG	A078083	001	Apr 12, 2007	Feb CAHN
@	2.5MG;500MG	A078083	002	Apr 12, 2007	Feb CAHN
@	5MG;500MG	A078083	003	Apr 12, 2007	Feb CAHN

GLUCAGON

INJECTABLE;INJECTION

GLUCAGON

>D> AP	AMPHASTAR PHARMS INC	1MG/VIAL	A208086	001	Dec 28, 2020	Oct CTEC
>A>	!	1MG/VIAL	A208086	001	Dec 28, 2020	Oct CTEC
>D> AP	+! LILLY	1MG/VIAL	N020928	001	Sep 11, 1998	Oct DISC
>A>	+ @	1MG/VIAL	N020928	001	Sep 11, 1998	Oct DISC
	POWDER;NASAL					
	BAQSIMI					
	+! AMPHASTAR PHARMS INC	3MG	N210134	001	Jul 24, 2019	Sep CAHN
	SOLUTION;SUBCUTANEOUS					
	GVOKE KIT					
	+! XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	005	Aug 20, 2021	May NEWA
	GVOKE PFS					
	+ @ XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	001	Sep 10, 2019	Jan DISC

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

RAVICTI

+! HORIZON THERAP US 1.1GM/ML N203284 001 Feb 01, 2013 Jan CAHN

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

@ LUPIN LTD	0.2MG/ML	A213655	001	Feb 07, 2023	Apr DISC
AP	0.2MG/ML	A213655	001	Feb 07, 2023	Jan NEWA
@ MANKIND PHARMA	0.2MG/ML	A217354	001	Feb 27, 2023	Aug DISC
AP	0.2MG/ML	A217354	001	Feb 27, 2023	Feb NEWA
AP	SAGENT	A210083	001	Feb 21, 2020	Aug CAHN
AP	UMEDICA	A212591	001	Oct 13, 2021	Sep CAHN

SOLUTION;INHALATION

LONHALA MAGNAIR KIT

+ @ SUMITOMO PHARMA AM	25MCG/ML	N208437	001	Dec 05, 2017	Jul CAHN
+ @ SUNOVION RESP	25MCG/ML	N208437	001	Dec 05, 2017	Jul DISC

TABLET;ORAL

GLYCOPYRROLATE

AA	ALEMBIC	1MG	A203657	001	Nov 30, 2018	Feb CAHN
AA		2MG	A203657	002	Nov 30, 2018	Feb CAHN
AA	AUROBINDO PHARMA	1MG	A202675	001	Apr 15, 2013	Jan CAHN
AA		2MG	A202675	002	Oct 30, 2018	Jan CAHN
AA	INDOCO	1MG	A091182	001	Feb 03, 2014	Sep CAHN
AA		2MG	A091182	002	Feb 03, 2014	Sep CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
DARTISLA ODT

+ @ EDENBRIDGE PHARMS 1.7MG N215019 001 Dec 16, 2021 Jun DISC

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATESOLUTION; INTRAVENOUS
PREVDUO

+!	SLAYBACK PHARMA LLC	0.6MG/3ML (0.2MG/ML); 3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023	Feb	NEWA
----	---------------------	--	---------	-----	--------------	-----	------

GRANISETRONFILM, EXTENDED RELEASE; TRANSDERMAL
SANCUSO

+!	CUMBERLAND	3.1MG/24HR	N022198	001	Sep 12, 2008	Sep	CAHN
----	------------	------------	---------	-----	--------------	-----	------

GRANISETRON HYDROCHLORIDE

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

@	AUROBINDO PHARMA USA	EQ 1MG BASE	A078725	001	Jan 30, 2008	May	CAHN
---	----------------------	-------------	---------	-----	--------------	-----	------

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB	AJANTA PHARMA LTD	EQ 1MG BASE	A217293	001	Apr 27, 2023	Apr	NEWA
AB		EQ 2MG BASE	A217293	002	Apr 27, 2023	Apr	NEWA
AB	AUROBINDO PHARMA USA	EQ 1MG BASE	A074796	001	Jan 27, 1997	Jul	CMFD
AB		EQ 2MG BASE	A074796	002	Jan 27, 1997	Jul	CMFD
AB	I 3 PHARMS	EQ 1MG BASE	A216828	001	Oct 05, 2023	Sep	NEWA
AB		EQ 2MG BASE	A216828	002	Oct 05, 2023	Sep	NEWA
>A>	RUBICON	EQ 1MG BASE	A216762	001	Oct 17, 2023	Oct	NEWA
>A>		EQ 2MG BASE	A216762	002	Oct 17, 2023	Oct	NEWA

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

AB	ALEMBIC	EQ 1MG BASE	A217269	001	Aug 07, 2023	Jul	NEWA
AB		EQ 2MG BASE	A217269	002	Aug 07, 2023	Jul	NEWA
AB		EQ 3MG BASE	A217269	003	Aug 07, 2023	Jul	NEWA
AB		EQ 4MG BASE	A217269	004	Aug 07, 2023	Jul	NEWA

HALCINONIDE

CREAM; TOPICAL

HALCINONIDE

AB	CHARTWELL RX	0.1%	A214723	001	Sep 08, 2021	May	CAHN
----	--------------	------	---------	-----	--------------	-----	------

HALOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

HALOBETASOL PROPIONATE

AB	PADAGIS ISRAEL	0.05%	A215266	001	Aug 11, 2023	Aug	NFTG
	LEXETTE						

AB	+!	MAYNE PHARMA	0.05%	N210566	001	May 24, 2018	Aug	CFTG
----	----	--------------	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

@	PAI HOLDINGS PHARM	0.05%	A209978	001	Mar 20, 2018	May	DISC
---	--------------------	-------	---------	-----	--------------	-----	------

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

	@	ACTAVIS GROUP	0.5MG	A200854	001	Jul 01, 2022	Jan	DISC
	@		1MG	A200854	002	Jul 01, 2022	Jan	DISC
	@		2MG	A200854	003	Jul 01, 2022	Jan	DISC
	@		5MG	A200854	004	Jul 01, 2022	Jan	DISC
	@		10MG	A200854	005	Jul 01, 2022	Jan	DISC
	@		20MG	A200854	006	Jul 01, 2022	Jan	DISC
	@	AIPING PHARM INC	0.5MG	A071128	001	Feb 17, 1987	Aug	CAHN
	@		1MG	A071129	001	Feb 17, 1987	Aug	CAHN
AB			2MG	A071130	001	Feb 17, 1987	Aug	CAHN
AB			5MG	A071131	001	Feb 17, 1987	Aug	CAHN
AB			10MG	A071132	001	May 12, 1987	Aug	CAHN
	@		20MG	A071133	001	May 12, 1987	Aug	CAHN
AB		SCIEGEN PHARMS INC	2MG	A071130	001	Feb 17, 1987	Sep	CAHN
AB			5MG	A071131	001	Feb 17, 1987	Sep	CAHN
AB			10MG	A071132	001	May 12, 1987	Sep	CAHN
AB		ZYDUS PHARMS USA	0.5MG	A077580	001	Jan 17, 2023	Jan	NEWA
AB			1MG	A077580	002	Jan 17, 2023	Jan	NEWA
AB			2MG	A077580	006	Jan 17, 2023	Jan	NEWA

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION
HALOPERIDOL DECANOATE

AO	MANKIND PHARMA	EQ 50MG BASE/ML	A216730	001	May 23, 2023	May NEWA
AO		EQ 100MG BASE/ML	A216730	002	May 23, 2023	May NEWA

HALOPERIDOL LACTATE

INJECTABLE;INJECTION
HALOPERIDOL

>D>	@ AKORN	EQ 5MG BASE/ML	A204849	001	Sep 06, 2017	Oct CAHN
>A>	@ EPIC PHARMA LLC	EQ 5MG BASE/ML	A204849	001	Sep 06, 2017	Oct CAHN

HEPARIN SODIUM

INJECTABLE;INJECTION
HEPARIN SODIUM

>D>	@ AKORN	1,000 UNITS/ML	N017486	001		Oct CAHN
>D>	@	5,000 UNITS/ML	N017486	002		Oct CAHN
>D>	@	10,000 UNITS/ML	N017486	003		Oct CAHN
>D>	@	20,000 UNITS/ML	N017486	004		Oct CAHN
>D>	@	40,000 UNITS/ML	N017486	005		Oct CAHN
>A>	@ EPIC PHARMA LLC	1,000 UNITS/ML	N017486	001		Oct CAHN
>A>	@	5,000 UNITS/ML	N017486	002		Oct CAHN
>A>	@	10,000 UNITS/ML	N017486	003		Oct CAHN
>A>	@	20,000 UNITS/ML	N017486	004		Oct CAHN
>A>	@	40,000 UNITS/ML	N017486	005		Oct CAHN
AP	NANJING KING-FRIEND	5,000 UNITS/ML	A212061	001	Jul 15, 2020	Feb CMFD
	HEPARIN SODIUM PRESERVATIVE FREE					
AP	NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020	Feb CMFD

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

>D>	AA	! AKORN	1.5MG/5ML;5MG/5ML	A040613	001	Feb 08, 2008	Oct CAHN
>A>	AA	! PAI HOLDINGS PHARM	1.5MG/5ML;5MG/5ML	A040613	001	Feb 08, 2008	Oct CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
HYDRALAZINE HYDROCHLORIDE

AP	EUGIA PHARMA	20MG/ML	A215147	001	Feb 13, 2023	Feb NEWA
	@ MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016	May DISC

TABLET;ORAL

	HYDRALAZINE HYDROCHLORIDE					
AA	HERITAGE PHARMS INC	10MG	A040858	001	Feb 26, 2010	May CMFD
AA		25MG	A040858	002	Feb 26, 2010	May CMFD
AA		50MG	A040858	003	Feb 26, 2010	May CMFD
AA		100MG	A040858	004	Feb 26, 2010	May CMFD

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL
HYDROCHLOROTHIAZIDE

@ SUN PHARM INDS INC	12.5MG	A090651	001	Apr 07, 2014	Sep DISC
----------------------	--------	---------	-----	--------------	----------

TABLET;ORAL

	HYDROCHLOROTHIAZIDE					
AB	HERITAGE PHARMS	12.5MG	A085182	003	May 02, 2023	Apr NEWA

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET;ORAL
LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB	! INVAGEN PHARMS	12.5MG;20MG	A204058	002	May 23, 2017	Jun CHRS
AB	!	25MG;20MG	A204058	003	May 23, 2017	Jun CHRS

ZESTORETIC

AB	+ ALMATICA	12.5MG;20MG	N019888	001	Sep 20, 1990	Jun CHRS
AB	+	25MG;20MG	N019888	002	Jul 20, 1989	Jun CHRS

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	GRANULES	12.5MG;50MG	A218015	001	Sep 29, 2023	Sep NEWA
AB		12.5MG;100MG	A218015	002	Sep 29, 2023	Sep NEWA
AB		25MG;100MG	A218015	003	Sep 29, 2023	Sep NEWA

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB	MACLEODS PHARMS LTD	12.5MG; 20MG	A204801	001	Jun 01, 2023	May NEWA
AB		12.5MG; 40MG	A204801	002	Jun 01, 2023	May NEWA
AB		25MG; 40MG	A204801	003	Jun 01, 2023	May NEWA
	@ TORRENT	12.5MG; 20MG	A206515	001	May 03, 2017	Aug DISC
	@	12.5MG; 40MG	A206515	002	May 03, 2017	Aug DISC
	@	25MG; 40MG	A206515	003	May 03, 2017	Aug DISC
	@ ZYDUS PHARMS	12.5MG; 20MG	A206377	001	Feb 24, 2023	Jul DISC
AB		12.5MG; 20MG	A206377	001	Feb 24, 2023	Feb NEWA
	@	12.5MG; 40MG	A206377	002	Feb 24, 2023	Jul DISC
AB		12.5MG; 40MG	A206377	002	Feb 24, 2023	Feb NEWA
	@	25MG; 40MG	A206377	003	Feb 24, 2023	Jul DISC
AB		25MG; 40MG	A206377	003	Feb 24, 2023	Feb NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX	12.5MG; EQ 10MG BASE	A091524	001	Mar 12, 2013	Jan CAHN
AB		12.5MG; EQ 20MG BASE	A091524	002	Mar 12, 2013	Jan CAHN
AB		25MG; EQ 20MG BASE	A091524	003	Mar 12, 2013	Jan CAHN
	@ CHARTWELL RX	12.5MG; EQ 10MG BASE	A076374	001	Mar 31, 2004	Apr CAHN
	@	12.5MG; EQ 20MG BASE	A076374	002	Mar 31, 2004	Apr CAHN
	@	25MG; EQ 20MG BASE	A076374	003	Mar 31, 2004	Apr CAHN

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

	+ @ PFIZER	50MG; 50MG	N012616	005	Dec 30, 1982	Sep DISC
--	------------	------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	AMNEAL PHARMS	12.5MG; 80MG	A204382	001	Aug 11, 2023	Aug NEWA
AB		12.5MG; 160MG	A204382	002	Aug 11, 2023	Aug NEWA
AB		12.5MG; 320MG	A204382	004	Aug 11, 2023	Aug NEWA
AB		25MG; 160MG	A204382	003	Aug 11, 2023	Aug NEWA
AB		25MG; 320MG	A204382	005	Aug 11, 2023	Aug NEWA

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

>D>	@ ENCUBE	2.5%	A203810	001	Jul 23, 2018	Oct CAHN
>A>	@	2.5%	A203810	001	Jul 23, 2018	Oct CAHN

TABLET; ORAL

HYDROCORTISONE

AB	AUROBINDO PHARMA LTD	5MG	A214649	001	Jul 17, 2023	Jul NEWA
AB		10MG	A214649	002	Jul 17, 2023	Jul NEWA
AB		20MG	A214649	003	Jul 17, 2023	Jul NEWA

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OPHTHALMIC

COR-OTICIN

>D>	@ AKORN	1.5%; EQ 3.5MG BASE/ML	A060188	001		Oct CAHN
>A>	@ EPIC PHARMA LLC	1.5%; EQ 3.5MG BASE/ML	A060188	001		Oct CAHN

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HYDROCHLORIDE

AP	HIKMA	2MG/ML	A202159	001	Apr 27, 2018	May CAHN
	HOSPIRA INC	0.25MG/0.5ML	N200403	005	Mar 03, 2023	Mar NEWA
		4MG/ML	N200403	003	Dec 01, 2011	Apr CTEC

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD

	+ @ AKORN	1%; 0.25%	N019261	001	Jan 30, 1992	Feb DISC
--	-----------	-----------	---------	-----	--------------	----------

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL					
HYDROXYCHLOROQUINE SULFATE					
AB	CHARTWELL RX	200MG	A210543	001	Jul 06, 2018 May CAHN
	@ TEVA PHARMS	200MG	A040081	001	Sep 30, 1994 Sep DISC
SOVUNA					
+	NOVITIUM PHARMA	200MG	N214581	001	Jan 14, 2022 Sep CTNA
+	!	300MG	N214581	002	Jan 14, 2022 Sep CTNA

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR					
HYDROXYPROGESTERONE CAPROATE					
	@ ASPEN GLOBAL INC	1250MG/5ML (250MG/ML)	A200271	001	Aug 24, 2015 Jul DISC

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC					
LACRISERT					
+	!	BAUSCH	5MG	N018771	001 Jan CAHN
+	!	BAUSCH AND LOMB INC	5MG	N018771	001 Jan CAHN

HYDROXYUREA

TABLET; ORAL					
SIKLOS					
+	THERAVIA	100MG	N208843	001	Dec 21, 2017 Sep CAHN
+	!	1GM	N208843	002	Dec 21, 2017 Sep CAHN

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION					
HYDROXYZINE HYDROCHLORIDE					
+	!	AM REGENT	25MG/ML	A087408	001 Feb CRLD
+	!		50MG/ML	A087408	002 Feb CRLD
SYRUP; ORAL					
HYDROXYZINE HYDROCHLORIDE					
AA	+	CHARTWELL RX	10MG/5ML	A087294	001 Apr 12, 1982 Aug CAHN
TABLET; ORAL					
HYDROXYZINE HYDROCHLORIDE					
AB		CHARTWELL RX	10MG	A040804	001 Jun 30, 2008 Jan CAHN
AB			25MG	A040804	002 Jun 30, 2008 Jan CAHN
AB			50MG	A040804	003 Jun 30, 2008 Jan CAHN
AB		GRAVITI PHARMS	10MG	A217652	001 Aug 17, 2023 Aug NEWA
AB			25MG	A217652	002 Aug 17, 2023 Aug NEWA
AB			50MG	A217652	003 Aug 17, 2023 Aug NEWA

HYDROXYZINE PAMOATE

CAPSULE; ORAL					
HYDROXYZINE PAMOATE					
AB		HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001 Jun 03, 2013 Mar CTEC
AB			EQ 50MG HYDROCHLORIDE	A201507	002 Jun 03, 2013 Mar CTEC

IBRUTINIB

CAPSULE; ORAL					
IMBRUVICA					
+		PHARMACYCLICS LLC	70MG	N205552	002 Dec 20, 2017 Jun CAHN
+	!		140MG	N205552	001 Nov 13, 2013 Jun CAHN
SUSPENSION; ORAL					
IMBRUVICA					
+	!	PHARMACYCLICS LLC	70MG/ML	N217003	001 Aug 24, 2022 Jun CAHN
TABLET; ORAL					
IMBRUVICA					
+		PHARMACYCLICS LLC	140MG	N210563	001 Feb 16, 2018 Jun CAHN
+			280MG	N210563	002 Feb 16, 2018 Jun CAHN
+			420MG	N210563	003 Feb 16, 2018 Jun CAHN
+	@		560MG	N210563	004 Feb 16, 2018 Jul DISC
+	!		560MG	N210563	004 Feb 16, 2018 Jun CAHN

IBUPROFENSUSPENSION;ORAL
IBUPROFEN

>D>	@ AKORN	100MG/5ML	A205647	001	Nov 03, 2016	Oct CAHN
>A>	@ PAI HOLDINGS PHARM	100MG/5ML	A205647	001	Nov 03, 2016	Oct CAHN
AB	STRIDES PHARMA	100MG/5ML	A215311	001	May 27, 2022	Aug CMFD

ICATIBANT ACETATEINJECTABLE;SUBCUTANEOUS
ICATIBANT ACETATE

AP	EUGIA PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213521	001	Aug 14, 2023	Aug NEWA
----	--------------	------------------------------------	---------	-----	--------------	----------

ICOSAPENT ETHYLCAPSULE;ORAL
ICOSAPENT ETHYL

AB	DR REDDYS	500MG	A209499	002	Mar 08, 2023	Feb NEWA
AB	HIKMA	500MG	A209457	002	Mar 08, 2023	Feb NEWA
AB	STRIDES PHARMA	500MG	A217844	001	Sep 22, 2023	Sep NEWA
AB		1GM	A217844	002	Sep 22, 2023	Sep NEWA
AB	ZYDUS	500MG	A217656	001	Apr 20, 2023	Apr NEWA
AB		1GM	A217656	002	Apr 20, 2023	Apr NEWA

IDARUBICIN HYDROCHLORIDEINJECTABLE;INJECTION
IDARUBICIN HYDROCHLORIDE PFS

AP	HONG KONG	1MG/ML	A065036	001	May 01, 2002	Sep CAHN
----	-----------	--------	---------	-----	--------------	----------

IFOSFAMIDEINJECTABLE;INJECTION
IFOSFAMIDE

AP	! HONG KONG	1GM/20ML (50MG/ML)	A076657	001	Apr 04, 2007	Sep CAHN
AP	!	3GM/60ML (50MG/ML)	A076657	002	Apr 04, 2007	Sep CAHN

IMATINIB MESYLATETABLET;ORAL
IMATINIB MESYLATE

	@ BRECKENRIDGE	EQ 100MG BASE	A205990	001	Feb 08, 2019	Mar DISC
	@	EQ 400MG BASE	A205990	002	Feb 08, 2019	Jun DISC
AB	CHARTWELL RX	EQ 100MG BASE	A208429	001	Jan 17, 2019	Jan CAHN
AB		EQ 400MG BASE	A208429	002	Jan 17, 2019	Jan CAHN

IMIQUIMODCREAM;TOPICAL
ALDARA

	+ @ BAUSCH	5%	N020723	001	Feb 27, 1997	Feb DISC
AB	! GLENMARK GENERICS	5%	A201994	001	Mar 06, 2012	Feb CHRS

INDAPAMIDETABLET;ORAL
INDAPAMIDE

	@ AUROBINDO PHARMA USA	1.25MG	A075105	001	Jul 23, 1998	Apr CAHN
	@	2.5MG	A075105	002	Jul 23, 1998	Apr CAHN
AB	RISING	1.25MG	A074461	002	Mar 26, 1997	Jul CMFD
AB		2.5MG	A074461	001	Mar 27, 1996	Jul CMFD

INDOCYANINE GREENINJECTABLE;INJECTION
IC-GREEN

	@ OAK TREE PHARMA	10MG/VIAL	N011525	003		Aug CAHN
AP	+!	25MG/VIAL	N011525	001		Aug CAHN
	@	40MG/VIAL	N011525	004		Aug CAHN
	@	50MG/VIAL	N011525	002		Aug CAHN
	@ RENEW PHARMS	10MG/VIAL	N011525	003		Aug CAHN
	+ @	25MG/VIAL	N011525	001		Sep DISC
AP	+!	25MG/VIAL	N011525	001		Aug CAHN
	@	40MG/VIAL	N011525	004		Aug CAHN
	@	50MG/VIAL	N011525	002		Aug CAHN
	INDOCYANINE GREEN					
	! RENEW PHARMS	25MG/VIAL	A040811	001	Nov 21, 2007	Sep CTEC
AP	!	25MG/VIAL	A040811	001	Nov 21, 2007	Sep CHRS

INDOMETHACIN

CAPSULE;ORAL							
INDOCIN							
	+ @ ZYLA LIFE SCIENCES	25MG	N016059	001		Sep	CAHN
	+ @	50MG	N016059	002		Sep	CAHN
INDOMETHACIN							
AB	CHARTWELL MOLECULES	25MG	N018829	002	Aug 06, 1984	Feb	CMFD
AB		50MG	N018829	001	Aug 06, 1984	Feb	CMFD
CAPSULE, EXTENDED RELEASE;ORAL							
INDOCIN SR							
	+ @ ZYLA	75MG	N018185	001	Feb 23, 1982	Sep	CAHN
SUPPOSITORY;RECTAL							
INDOCIN							
	+ @ ZYLA LIFE SCIENCES	50MG	N017814	001	Aug 13, 1984	Jul	CAHN
INDOMETHACIN							
AB	! COSETTE	50MG	A073314	001	Aug 31, 1992	Jul	CTEC
AB	ZYDUS	50MG	A216184	001	Aug 02, 2023	Jul	NEWA
SUSPENSION;ORAL							
INDOCIN							
	+! ZYLA	25MG/5ML	N018332	001	Oct 10, 1985	Jun	CAHN

INFIGRATINIB PHOSPHATE

CAPSULE;ORAL							
TRUSELTIQ							
	+ @ HELSINN HLTHCARE	25MG	N214622	001	May 28, 2021	Apr	DISC
	+ @	100MG	N214622	002	May 28, 2021	Apr	DISC

IOPAMIDOL

INJECTABLE;INJECTION							
IOPAMIDOL							
AP1	HAINAN POLY	41%	A215382	001	Feb 27, 2023	Sep	CTEC
AP		41%	A215382	001	Feb 27, 2023	Feb	NEWA
AP2		41%	A217134	001	Sep 27, 2023	Sep	NFTG
AP		61%	A215382	002	Feb 27, 2023	Feb	NEWA
ISOVUE-200							
AP2	+! BRACCO	41%	N018735	006	Jul 07, 1987	Sep	CFTG
ISOVUE-250							
	+ @ BRACCO	51%	N020327	002	Oct 12, 1994	Jun	DISC
ISOVUE-M 200							
AP1	+! BRACCO	41%	N018735	001	Dec 31, 1985	Sep	CTEC
AP	+!	41%	N018735	001	Dec 31, 1985	Feb	CTEC
ISOVUE-M 300							
AP	+! BRACCO	61%	N018735	004	Dec 31, 1985	Feb	CTEC

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL							
IPRATROPIUM BROMIDE							
	@ AUROBINDO PHARMA USA	0.021MG/SPRAY	A075552	001	Mar 31, 2003	Apr	CAHN
	@	0.042MG/SPRAY	A075553	001	Mar 31, 2003	Apr	CAHN

IRBESARTAN

TABLET;ORAL							
IRBESARTAN							
	@ ANDA REPOSITORY	75MG	A203161	001	Sep 27, 2012	Sep	CAHN
	@	150MG	A203161	002	Sep 27, 2012	Sep	CAHN
	@	300MG	A203161	003	Sep 27, 2012	Sep	CAHN
AB	UNICHEM	75MG	A203020	001	Dec 07, 2015	Jun	CMFD
AB		150MG	A203020	002	Dec 07, 2015	Jun	CMFD
AB		300MG	A203020	003	Dec 07, 2015	Jun	CMFD
	@ UPSHER SMITH LABS	75MG	A200461	001	Sep 27, 2012	Sep	CAHN
	@	150MG	A200461	002	Sep 27, 2012	Sep	CAHN
	@	300MG	A200461	003	Sep 27, 2012	Sep	CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION							
IRINOTECAN HYDROCHLORIDE							
	@ ANDA REPOSITORY	40MG/2ML (20MG/ML)	A078953	001	Apr 15, 2010	Sep	CAHN
	@	100MG/5ML (20MG/ML)	A078953	002	Apr 15, 2010	Sep	CAHN

ISONIAZID

TABLET; ORAL

ISONIAZID

AA	GENUS LIFESCIENCES	100MG	A040090	001	Jun 26, 1997	Sep CAHN
AA		300MG	A040090	002	Jun 26, 1997	Sep CAHN
	LANIAZID					
	@ CHARTWELL MOLECULAR	50MG	A080140	001		Feb CAHN
	@	100MG	A080140	002		Feb CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

	@ AM REGENT	0.2MG/ML	A214775	001	Oct 19, 2022	Apr DISC
AP	HIKMA	0.2MG/ML	A211703	001	Apr 26, 2023	Apr NEWA
	@ MYLAN LABS LTD	0.2MG/ML	A212573	001	Sep 06, 2022	Jul DISC
AP	PENN LIFE	0.2MG/ML	A215542	001	Sep 20, 2022	May CAHN
	@ ZYDUS PHARMS	0.2MG/ML	A215557	001	Apr 14, 2023	Aug DISC
AP		0.2MG/ML	A215557	001	Apr 14, 2023	Apr NEWA
	ISUPREL					
	+ @ BAUSCH	0.2MG/ML	N010515	001		Jun DISC

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

	@ SHANDONG	120MG	A214115	001	Apr 29, 2022	May DISC
--	------------	-------	---------	-----	--------------	----------

ISOSULFAN BLUE

INJECTABLE; INJECTION

ISOSULFAN BLUE

AP	AM REGENT	1%	A210294	001	May 17, 2023	May NEWA
----	-----------	----	---------	-----	--------------	----------

ISOTRETINOIN

CAPSULE; ORAL

ISOTRETINOIN

AB1	ZYDUS PHARMS	10MG	A211568	001	Aug 29, 2023	Aug NEWA
AB1		20MG	A211568	002	Aug 29, 2023	Aug NEWA
AB1		30MG	A211568	003	Aug 29, 2023	Aug NEWA
AB1		40MG	A211568	004	Aug 29, 2023	Aug NEWA

IVACAFTOR

GRANULE; ORAL

KALYDECO

	+ VERTEX PHARMS INC	5.8MG/PACKET	N207925	004	May 03, 2023	May NEWA
	+	13.4MG/PACKET	N207925	005	May 03, 2023	May NEWA

IVERMECTIN

CREAM; TOPICAL

IVERMECTIN

AB	ZYDUS	1%	A215210	001	Aug 02, 2022	Jul CMFD
	@	1%	A215210	001	Aug 02, 2022	Jan DISC

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HYDROCHLORIDE

	@ FRESENIUS KABI USA	EQ 10MG BASE/ML	A215808	001	Jan 13, 2023	Jul DISC
AP		EQ 10MG BASE/ML	A215808	001	Jan 13, 2023	Jan NEWA
	@	EQ 50MG BASE/ML	A215808	002	Jan 13, 2023	Jul DISC
AP		EQ 50MG BASE/ML	A215808	002	Jan 13, 2023	Jan NEWA
AP	GLAND PHARMA LTD	EQ 50MG BASE/ML	A216809	002	Jan 24, 2023	Jan NEWA
AP		EQ 100MG BASE/ML	A216809	003	Jan 24, 2023	Jan NEWA

KETOCONAZOLE

TABLET; ORAL

KETOCONAZOLE

	@ AUROBINDO PHARMA USA	200MG	A075597	001	Dec 23, 1999	May CAHN
AB	RISE PHARMA	200MG	A075912	001	Jan 10, 2002	Sep CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	ASPIRO	15MG/ML	A217166	001	Jun 20, 2023	Jun NEWA
AP		30MG/ML	A217166	002	Jun 20, 2023	Jun NEWA
AP	CAPLIN	15MG/ML	A217789	001	May 10, 2023	Apr NEWA
AP		30MG/ML	A217789	002	May 10, 2023	Apr NEWA

SOLUTION/DROPS; OPHTHALMIC

ACULAR

AT	+! ABBVIE	0.5%	N019700	001	Nov 09, 1992	Jan CAHN
	KETOROLAC TROMETHAMINE					
	@ AKORN	0.5%	A078434	001	Nov 05, 2009	Jan DISC
	@ CHARTWELL RX	0.5%	A078434	001	Nov 05, 2009	Sep CAHN

TABLET; ORAL

KETOROLAC TROMETHAMINE

	@ AIPING PHARM INC	10MG	A074790	001	Jun 26, 1997	Aug CAHN
AB		10MG	A210616	001	Aug 16, 2018	Aug CAHN
AB	BIONPHARMA	10MG	A216759	001	Feb 23, 2023	Feb NEWA
	@ CHARTWELL RX	10MG	A074790	001	Jun 26, 1997	Sep CAHN
AB		10MG	A210616	001	Aug 16, 2018	Sep CAHN
AB	LEADING	10MG	A215745	001	Feb 23, 2023	Feb NEWA

KETOTIFEN FUMARATE

DRUG-ELUTING CONTACT LENS; OPHTHALMIC

ACUVUE THERAVISION WITH KETOTIFEN

	+ @ JOHNSON JOHNSON VISN	EQ 19MCG BASE	N022388	001	Feb 25, 2022	May DISC
--	--------------------------	---------------	---------	-----	--------------	----------

LACOSAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

MOTPOLY XR

	+ AUCTA	100MG	N216185	001	May 04, 2023	May NEWA
	+	150MG	N216185	002	May 04, 2023	May NEWA
	+!	200MG	N216185	003	May 04, 2023	May NEWA

SOLUTION; INTRAVENOUS

LACOSAMIDE

AP	MSN	200MG/20ML (10MG/ML)	A215979	001	Feb 09, 2023	Feb NEWA
----	-----	----------------------	---------	-----	--------------	----------

SOLUTION; ORAL

LACOSAMIDE

AA	LEADING PHARMA	10MG/ML	A216461	001	Feb 06, 2023	Aug CAHN
AA	MEDLEY PHARMS	10MG/ML	A216461	001	Feb 06, 2023	Jan NEWA

TABLET; ORAL

LACOSAMIDE

	@ ACCORD HLTHCARE	50MG	A205011	001	Jul 12, 2022	Jan DISC
	@	100MG	A205011	002	Jul 12, 2022	Jan DISC
	@	150MG	A205011	003	Jul 12, 2022	Jan DISC
	@	200MG	A205011	004	Jul 12, 2022	Jan DISC
	@ ACTAVIS LABS FL INC	50MG	A204855	001	Jan 05, 2023	Jul DISC
	@	100MG	A204855	002	Jan 05, 2023	Jul DISC
	@	150MG	A204855	003	Jan 05, 2023	Jul DISC
	@	200MG	A204855	004	Jan 05, 2023	Jul DISC
	@ APOTEX	50MG	A214567	001	Sep 23, 2022	Mar DISC
	@	100MG	A214567	002	Sep 23, 2022	Mar DISC
	@	150MG	A214567	003	Sep 23, 2022	Mar DISC
	@	200MG	A214567	004	Sep 23, 2022	Mar DISC

LACTULOSE

SOLUTION; ORAL

LACTULOSE

AA	AUROBINDO PHARMA LTD	10GM/15ML	A074602	001	Nov 14, 1996	Sep CAHN
	@ VISTAPHARM	10GM/15ML	A074138	001	Sep 30, 1992	Sep DISC
AA	XTTRIUM LABS INC	10GM/15ML	A075911	001	Feb 21, 2002	Mar CMFD

SOLUTION; ORAL, RECTAL

LACTULOSE

>D>	AA	AKORN	10GM/15ML	A074077	001	Jul 03, 1995	Oct CAHN
	AA	BAJAJ	10GM/15ML	A076645	001	Jul 28, 2003	Feb CMFD
>A>	AA	PAI HOLDINGS PHARM	10GM/15ML	A074077	001	Jul 03, 1995	Oct CAHN

LAMIVUDINESOLUTION;ORAL
LAMIVUDINE

AA	CHARTWELL MOLECULAR	10MG/ML	A203564	001	Oct 31, 2014	Jul CAHN
AA	HETERO LABS LTD III	10MG/ML	A091475	001	Oct 06, 2023	Sep NEWA

TABLET;ORAL
LAMIVUDINE

@ AUROBINDO PHARMA USA	100MG	A204002	001	Dec 31, 2014	May CAHN
------------------------	-------	---------	-----	--------------	----------

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATETABLET;ORAL
TEMIXYS

+ @ CHARTWELL RX	300MG;300MG	N211284	001	Nov 16, 2018	Mar CAHN
------------------	-------------	---------	-----	--------------	----------

LAMOTRIGINETABLET;ORAL
LAMOTRIGINE

@ CHARTWELL MOLECULAR	25MG	A077783	001	Nov 01, 2010	Jan CAHN
@	100MG	A077783	002	Nov 01, 2010	Jan CAHN
@	150MG	A077783	003	Nov 01, 2010	Jan CAHN
@	200MG	A077783	004	Nov 01, 2010	Jan CAHN

LANSOPRAZOLETABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
LANSOPRAZOLE

AB AUROBINDO PHARMA LTD	15MG	A207167	001	Mar 28, 2023	Mar NEWA
AB	30MG	A207167	002	Mar 28, 2023	Mar NEWA

LATANOPROSTSOLUTION/DROPS;OPHTHALMIC
LATANOPROST

>D>	@ AKORN	0.005%	A090887	001	Jul 19, 2011	Oct CAHN
	@	0.005%	A090887	001	Jul 19, 2011	Jan DISC
>A>	@ EPIC PHARMA LLC	0.005%	A090887	001	Jul 19, 2011	Oct CAHN

LATANOPROST; NETARSUDIL DIMESYLATESOLUTION/DROPS;OPHTHALMIC
ROCKLATAN

+! ALCON LABS INC	0.005%;EQ 0.02% BASE	N208259	001	Mar 12, 2019	May CAHN
-------------------	----------------------	---------	-----	--------------	----------

LENALIDOMIDECAPSULE;ORAL
LENALIDOMIDE

AB APOTEX	2.5MG	A211022	005	Mar 07, 2023	Feb NEWA
AB	20MG	A211022	006	Mar 07, 2023	Feb NEWA
AB ARROW INTL	2.5MG	A201452	005	Mar 06, 2023	Feb NEWA
AB	20MG	A201452	006	Mar 06, 2023	Feb NEWA
AB CIPLA	2.5MG	A214618	001	Mar 06, 2023	Feb NEWA
AB	20MG	A210435	005	Mar 06, 2023	Feb NEWA
AB EUGIA PHARMA	2.5MG	A213885	001	Mar 06, 2023	Feb NEWA
AB	5MG	A213885	002	Mar 06, 2023	Feb NEWA
AB	10MG	A213885	003	Mar 06, 2023	Feb NEWA
AB	15MG	A213885	004	Mar 06, 2023	Feb NEWA
AB	20MG	A213885	005	Mar 06, 2023	Feb NEWA
AB	25MG	A213885	006	Mar 06, 2023	Feb NEWA
AB HETERO LABS LTD V	2.5MG	A212414	001	May 11, 2023	May NEWA
AB	5MG	A212414	002	May 11, 2023	May NEWA
AB	10MG	A212414	003	May 11, 2023	May NEWA
AB	15MG	A212414	004	May 11, 2023	May NEWA
AB	20MG	A212414	005	May 11, 2023	May NEWA
AB	25MG	A212414	006	May 11, 2023	May NEWA
AB LOTUS PHARM CO LTD	2.5MG	A210480	005	Mar 06, 2023	Feb NEWA
AB	20MG	A210480	006	Mar 06, 2023	Feb NEWA
AB MYLAN	2.5MG	A213912	005	Mar 06, 2023	Feb NEWA
AB	20MG	A213912	006	Mar 06, 2023	Feb NEWA
AB SUN PHARM	2.5MG	A211846	005	Mar 06, 2023	Feb NEWA
AB	5MG	A211846	001	Feb 08, 2023	Jan NEWA
AB	10MG	A211846	002	Feb 08, 2023	Jan NEWA
AB	15MG	A211846	003	Feb 08, 2023	Jan NEWA
AB	20MG	A211846	006	Mar 06, 2023	Feb NEWA
AB	25MG	A211846	004	Feb 08, 2023	Jan NEWA

CAPSULE;ORAL							
LENALIDOMIDE							
	@ TORRENT	10MG	A213405	001	Feb 17, 2023	Aug	DISC
AB		10MG	A213405	001	Feb 17, 2023	Feb	NEWA
	@	20MG	A213405	003	Aug 03, 2023	Aug	DISC
AB		20MG	A213405	003	Aug 03, 2023	Jul	NEWA
	@	25MG	A213405	002	Feb 17, 2023	Aug	DISC
AB		25MG	A213405	002	Feb 17, 2023	Feb	NEWA
AB	ZYDUS PHARMS	2.5MG	A210154	005	Mar 06, 2023	Feb	NEWA
AB		20MG	A210154	006	Mar 06, 2023	Feb	NEWA
REVLIMID							
AB	+ BRISTOL MYERS SQUIBB	2.5MG	N021880	005	Dec 21, 2011	Sep	CAHN
AB	+	5MG	N021880	001	Dec 27, 2005	Sep	CAHN
AB	+	10MG	N021880	002	Dec 27, 2005	Sep	CAHN
AB	+	15MG	N021880	003	Jun 29, 2006	Sep	CAHN
AB	+	20MG	N021880	006	Jun 05, 2013	Sep	CAHN
AB	+	25MG	N021880	004	Jun 29, 2006	Sep	CAHN
<u>LENIOLISIB PHOSPHATE</u>							
TABLET;ORAL							
JOENJA							
	+! PHARMING	EQ 70MG BASE	N217759	001	Mar 24, 2023	Mar	NEWA
<u>LETROZOLE</u>							
TABLET;ORAL							
LETROZOLE							
	@ CHARTWELL RX	2.5MG	A202716	001	May 16, 2013	Feb	CAHN
<u>LEUCOVORIN CALCIUM</u>							
INJECTABLE;INJECTION							
LEUCOVORIN CALCIUM							
	! FRESENIUS KABI USA	EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Apr	CHRS
		EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Apr	CTEC
	!	EQ 10MG BASE/ML	A207241	001	Mar 14, 2018	Apr	CHRS
AP	HAINAN POLY	EQ 50MG BASE/VIAL	A217021	001	Jul 10, 2023	Jun	NEWA
AP		EQ 100MG BASE/VIAL	A217021	002	Jul 10, 2023	Jun	NEWA
AP		EQ 200MG BASE/VIAL	A217021	003	Jul 10, 2023	Jun	NEWA
AP		EQ 500MG BASE/VIAL	A217021	004	Jul 10, 2023	Jun	NEWA
AP	KINDOS	EQ 50MG BASE/VIAL	A216590	001	Jul 19, 2023	Jul	NEWA
AP		EQ 100MG BASE/VIAL	A216590	002	Jul 19, 2023	Jul	NEWA
AP		EQ 200MG BASE/VIAL	A216590	003	Jul 19, 2023	Jul	NEWA
AP		EQ 350MG BASE/VIAL	A216590	004	Jul 19, 2023	Jul	NEWA
AP		EQ 500MG BASE/VIAL	A216590	005	Jul 19, 2023	Jul	NEWA
LEUCOVORIN CALCIUM PRESERVATIVE FREE							
	@ HIKMA	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Apr	DISC
<u>LEUPROLIDE ACETATE</u>							
INJECTABLE;INJECTION							
LEUPROLIDE ACETATE							
AP	HONG KONG	1MG/0.2ML	A075471	001	Oct 25, 2000	Sep	CAHN
AP	RK PHARMA	1MG/0.2ML	A213829	001	Aug 13, 2021	Jun	CAHN
LUPRON DEPOT							
	+! ABBVIE ENDOCRINE INC	7.5MG	N019732	001	Jan 26, 1989	Jul	CPOT
	+!	11.25MG	N020708	001	Mar 07, 1997	Jul	CPOT
	+	22.5MG	N020517	001	Dec 22, 1995	Jul	CPOT
	+!	30MG	N020517	002	May 30, 1997	Jul	CPOT
	+!	45MG	N020517	003	Jun 17, 2011	Jul	CPOT
POWDER;INTRAMUSCULAR							
LUPRON DEPOT-PED KIT							
	+! ABBVIE ENDOCRINE INC	45MG	N020263	009	Apr 14, 2023	Apr	NEWA
POWDER;SUBCUTANEOUS							
ELIGARD KIT							
	+! TOLMAR	7.5MG	N021343	001	Jan 23, 2002	Feb	CAHN
	+!	22.5MG	N021379	001	Jul 24, 2002	Feb	CAHN
	+!	30MG	N021488	001	Feb 13, 2003	Feb	CAHN
	+!	45MG	N021731	001	Dec 14, 2004	Feb	CAHN

LEVALBUTEROL HYDROCHLORIDESOLUTION; INHALATION
XOPENEX

AN	+	!	HIKMA	EQ 0.0103% BASE	N020837	003	Jan 30, 2002	Sep CAHN
AN	+	!		EQ 0.021% BASE	N020837	001	Mar 25, 1999	Sep CAHN
AN	+	!		EQ 0.042% BASE	N020837	002	Mar 25, 1999	Sep CAHN
AN	+	!		EQ 0.25% BASE	N020837	004	Jul 18, 2003	Sep CAHN

LEVAMLODIPINE MALEATETABLET; ORAL
CONJUPRI

	+	@	CSPC OUYI	EQ 2.5MG BASE	N212895	002	Dec 19, 2019	Sep DISC
	+	@		EQ 5MG BASE	N212895	003	Dec 19, 2019	Sep DISC

LEVETIRACETAMINJECTABLE; INTRAVENOUS
LEVETIRACETAM

AP			BAXTER HLTHCARE CORP	500MG/100ML (5MG/ML)	A217059	001	Oct 02, 2023	Sep NEWA
AP				1GM/100ML (10MG/ML)	A217059	002	Oct 02, 2023	Sep NEWA
AP				1.5GM/100ML (15MG/ML)	A217059	003	Oct 02, 2023	Sep NEWA
			LEVETIRACETAM IN SODIUM CHLORIDE					
AP			FRESENIUS KABI USA	500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Jan NEWA
AP				1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Jan NEWA

SOLUTION; ORAL

LEVETIRACETAM

AA			ALEMBIC	100MG/ML	A203067	001	May 09, 2013	Feb CAHN
AA			BIONPHARMA	100MG/ML	A079120	001	Jan 16, 2009	Jun CAHN
		@	PHARMOBEDIENT CNSLTG	100MG/ML	A090028	001	Mar 03, 2010	Sep CAHN
>A>	AA		QUAGEN	100MG/ML	A090079	001	Apr 11, 2012	Oct CAHN
	AA			100MG/ML	A090079	001	Apr 11, 2012	Feb CAHN
>D>	AA		SCIEGEN PHARMS INC	100MG/ML	A090079	001	Apr 11, 2012	Oct CAHN
	AA			100MG/ML	A090079	001	Apr 11, 2012	Sep CAHN
		@	XTTRIUM LABS INC	100MG/ML	A090028	001	Mar 03, 2010	Mar CAHN

TABLET; ORAL

LEVETIRACETAM

AB			GRANULES	250MG	A217878	001	Jun 13, 2023	Jun NEWA
AB				500MG	A217878	002	Jun 13, 2023	Jun NEWA
AB				750MG	A217878	003	Jun 13, 2023	Jun NEWA
AB				1GM	A217878	004	Jun 13, 2023	Jun NEWA
		@	MYLAN	250MG	A076919	001	Nov 04, 2008	Apr DISC

TABLET, EXTENDED RELEASE; ORAL

ELEPSIA XR

	+	@	TRIPOINT	1GM	N204417	001	Dec 20, 2018	Sep DISC
	+	@		1.5GM	N204417	002	Dec 20, 2018	Sep DISC

LEVETIRACETAM

		@	AUROBINDO PHARMA USA	500MG	A200475	001	Dec 19, 2011	Apr CAHN
		@		750MG	A200475	002	Dec 19, 2011	Apr CAHN
		@		1GM	A200475	003	Dec 07, 2015	Apr CAHN
		@	CHARTWELL RX	500MG	A091291	001	Sep 12, 2011	Sep CAHN
		@		750MG	A091291	002	Sep 12, 2011	Sep CAHN
AB			OVERSEAS	500MG	A212688	002	May 05, 2023	Apr NEWA
		@	SUN PHARM	500MG	A203059	001	Sep 09, 2013	Aug DISC
		@		750MG	A203059	002	Sep 09, 2013	Aug DISC

LEVOBUNOLOL HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
AKBETA

>D>		@	AKORN	0.25%	A074779	001	Oct 29, 1996	Oct CAHN
>A>		@	EPIC PHARMA LLC	0.25%	A074779	001	Oct 29, 1996	Oct CAHN

LEVOFLOXACINSOLUTION; ORAL
LEVOFLOXACIN

AA	!		NOVITIUM PHARMA	250MG/10ML	A091678	001	Jun 20, 2011	Aug CAHN
----	---	--	-----------------	------------	---------	-----	--------------	----------

SOLUTION/DROPS; OPHTHALMIC
LEVOFLOXACIN

	@		AKORN	0.5%	A090268	001	Dec 20, 2010	Jan DISC
	!		RISING	0.5%	A077700	001	Dec 20, 2010	Jan CTEC

LEVOLEUCOVORINPOWDER; INTRAVENOUS
KHAPZORY

	+	@ ACROTECH BIOPHARMA	300MG/VIAL	N211226	002	Oct 19, 2018	Aug DISC
--	---	----------------------	------------	---------	-----	--------------	----------

LEVOLEUCOVORIN CALCIUMSOLUTION; INTRAVENOUS
LEVOLEUCOVORIN CALCIUM

		@ AILEX PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A213797	001	Nov 02, 2021	Sep CAHN
AP	!	GLAND PHARMA LTD	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210892	002	Sep 14, 2018	May CTEC
AP		HAINAN POLY PHARM	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A217314	001	May 22, 2023	May NEWA
AP			EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A217314	002	May 22, 2023	May NEWA

LEVOMILNACIPRAN HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
FETZIMA

	+	ABBVIE	EQ 20MG BASE	N204168	001	Jul 25, 2013	Mar CTEC
AB	+		EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan CAHN
	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Mar CTEC
AB	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan CAHN
	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Mar CTEC
AB	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan CAHN
	+		EQ 120MG BASE	N204168	004	Jul 25, 2013	Mar CTEC
AB	+		EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan CAHN

LEVOMILNACIPRAN HYDROCHLORIDE

		@ AUROBINDO PHARMA LTD	EQ 20MG BASE	A210826	001	Jan 06, 2023	Mar DISC
		@	EQ 40MG BASE	A210826	002	Jan 06, 2023	Mar DISC
		@	EQ 80MG BASE	A210826	003	Jan 06, 2023	Mar DISC
		@	EQ 120MG BASE	A210826	004	Jan 06, 2023	Mar DISC
AB		PRINSTON INC	EQ 20MG BASE	A210771	001	Mar 20, 2023	Mar NEWA
AB			EQ 40MG BASE	A210771	002	Mar 20, 2023	Mar NEWA
AB			EQ 80MG BASE	A210771	003	Mar 20, 2023	Mar NEWA
AB			EQ 120MG BASE	A210771	004	Mar 20, 2023	Mar NEWA

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION
SCANDONEST L

		@ DEPROCO	0.05MG/ML; 2%	A088388	001	Oct 10, 1984	Sep DISC
--	--	-----------	---------------	---------	-----	--------------	----------

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

AB		HIKMA	2MG	A074278	001	Mar 31, 2000	Jan CMFD
AB	!	NOVITIUM PHARMA	3MG	A213479	002	Jan 12, 2021	Apr CTEC
AB		SUN PHARM INDS INC	3MG	A213906	002	Apr 25, 2023	Apr NEWA

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

LEVOTHYROXINE SODIUM

		@ TEVA PHARMS USA INC	0.137MG	A211369	005	May 02, 2023	May DISC
AB			0.137MG	A211369	005	May 02, 2023	Apr NFTG
		@	0.175MG	A211369	006	May 02, 2023	May DISC
AB			0.175MG	A211369	006	May 02, 2023	Apr NFTG
		@	0.2MG	A211369	004	Nov 09, 2022	May DISC
		TIROSINT					
	+	IBSA	0.013MG	N021924	013	Aug 01, 2007	Aug CAHN
	+		0.025MG	N021924	002	Oct 13, 2006	Aug CAHN
	+		0.0375MG	N021924	014	Jun 22, 2022	Aug CAHN
	+		0.044MG	N021924	015	Jun 22, 2022	Aug CAHN
	+		0.05MG	N021924	003	Oct 13, 2006	Aug CAHN
	+		0.0625MG	N021924	016	Jun 22, 2022	Aug CAHN
	+		0.075MG	N021924	004	Oct 13, 2006	Aug CAHN
	+		0.088MG	N021924	010	Oct 02, 2009	Aug CAHN
	+		0.1MG	N021924	005	Oct 13, 2006	Aug CAHN
	+		0.112MG	N021924	008	Oct 02, 2009	Aug CAHN
	+		0.125MG	N021924	006	Oct 13, 2006	Aug CAHN
	+		0.137MG	N021924	009	Oct 02, 2009	Aug CAHN
	+		0.15MG	N021924	007	Oct 13, 2006	Aug CAHN

CAPSULE;ORAL							
TIROSINT							
	+	0.175MG	N021924	011	Apr 25, 2017	Aug	CAHN
	+	0.2MG	N021924	012	Apr 25, 2017	Aug	CAHN
	+	INSTITUT BIOCHIMIQUE	N021924	009	Oct 02, 2009	May	CTEC
AB	+	0.137MG	N021924	009	Oct 02, 2009	Apr	CFTG
	+	0.175MG	N021924	011	Apr 25, 2017	May	CTEC
AB	+	0.175MG	N021924	011	Apr 25, 2017	Apr	CFTG
	+	0.2MG	N021924	012	Apr 25, 2017	May	CTEC
POWDER;INTRAVENOUS							
LEVOTHYROXINE SODIUM							
AP	ZYDUS PHARMS	100MCG/VIAL	A217066	001	Mar 24, 2023	Mar	NEWA
AP		200MCG/VIAL	A217066	002	Mar 24, 2023	Mar	NEWA
AP		500MCG/VIAL	A217066	003	Mar 24, 2023	Mar	NEWA
SOLUTION;ORAL							
TIROSINT-SOL							
	+	IBSA	N206977	001	Dec 15, 2016	Aug	CAHN
	+	25MCG/ML	N206977	002	Dec 15, 2016	Aug	CAHN
	+	37.5MCG/ML	N206977	013	Jan 13, 2021	Aug	CAHN
	+	44MCG/ML	N206977	014	Jan 13, 2021	Aug	CAHN
	+	50MCG/ML	N206977	003	Dec 15, 2016	Aug	CAHN
	+	62.5MCG/ML	N206977	015	Jan 13, 2021	Aug	CAHN
	+	75MCG/ML	N206977	004	Dec 15, 2016	Aug	CAHN
	+	88MCG/ML	N206977	005	Dec 15, 2016	Aug	CAHN
	+	100MCG/ML	N206977	006	Dec 15, 2016	Aug	CAHN
	+	112MCG/ML	N206977	007	Dec 15, 2016	Aug	CAHN
	+	125MCG/ML	N206977	008	Dec 15, 2016	Aug	CAHN
	+	137MCG/ML	N206977	009	Dec 15, 2016	Aug	CAHN
	+	150MCG/ML	N206977	010	Dec 15, 2016	Aug	CAHN
	+	175MCG/ML	N206977	011	Dec 15, 2016	Aug	CAHN
	+	200MCG/ML	N206977	012	Dec 15, 2016	Aug	CAHN

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL							
LEVOTHYROXINE SODIUM							
AB4	ASCENT PHARMS INC	0.025MG	A215259	001	Jan 18, 2023	Jan	NEWA
AB4		0.05MG	A215259	002	Jan 18, 2023	Jan	NEWA
AB4		0.075MG	A215259	003	Jan 18, 2023	Jan	NEWA
AB4		0.088MG	A215259	004	Jan 18, 2023	Jan	NEWA
AB4		0.1MG	A215259	005	Jan 18, 2023	Jan	NEWA
AB4		0.112MG	A215259	006	Jan 18, 2023	Jan	NEWA
AB4		0.125MG	A215259	007	Jan 18, 2023	Jan	NEWA
AB4		0.137MG	A215259	008	Jan 18, 2023	Jan	NEWA
AB4		0.15MG	A215259	009	Jan 18, 2023	Jan	NEWA
AB4		0.175MG	A215259	010	Jan 18, 2023	Jan	NEWA
AB4		0.2MG	A215259	011	Jan 18, 2023	Jan	NEWA
AB4		0.3MG	A215259	012	Jan 18, 2023	Jan	NEWA
AB2	MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Jan	CTEC
AB2		0.05MG	A211417	002	Dec 21, 2022	Jan	CTEC
AB2		0.075MG	A211417	003	Dec 21, 2022	Jan	CTEC
AB2		0.088MG	A211417	004	Dec 21, 2022	Jan	CTEC
AB2		0.1MG	A211417	005	Dec 21, 2022	Jan	CTEC
AB2		0.112MG	A211417	006	Dec 21, 2022	Jan	CTEC
AB2		0.125MG	A211417	007	Dec 21, 2022	Jan	CTEC
AB2		0.137MG	A211417	008	Dec 21, 2022	Jan	CTEC
AB2		0.15MG	A211417	009	Dec 21, 2022	Jan	CTEC
AB2		0.175MG	A211417	010	Dec 21, 2022	Jan	CTEC
AB2		0.2MG	A211417	011	Dec 21, 2022	Jan	CTEC
AB2		0.3MG	A211417	012	Dec 21, 2022	Jan	CTEC

LIDOCAINE

OINTMENT;TOPICAL							
LIDOCAINE							
	@ AILEX PHARMS LLC	5%	A212486	001	Oct 17, 2019	Sep	CAHN
	@ PAI HOLDINGS PHARM	5%	A205318	001	Feb 01, 2016	May	DISC
>D> AT	VITRUVIAS THERAP	5%	A208822	001	Sep 25, 2017	Oct	DISC
>A>	@	5%	A208822	001	Sep 25, 2017	Oct	DISC
PATCH;TOPICAL							
LIDOCAINE							
AB	IBSA	5%	A209190	001	Apr 30, 2020	Aug	CAHN
AB	INST BIOCHIMIQUE SA	5%	A209190	001	Apr 30, 2020	Apr	CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

AP	+	!	HOSPIRA	1%	A083158	001		Aug	CRLD
AP	+	!		2%	A083158	002		Aug	CRLD
AP			HUONS	2%	A212821	002	Jun 15, 2023	Jun	NEWA
AP			MANKIND PHARMA	1%	A217692	001	Jun 16, 2023	Jun	NEWA
AP				1%	A217693	001	Jul 11, 2023	Jun	NEWA
AP				2%	A217692	002	Jun 16, 2023	Jun	NEWA
AP				2%	A217693	002	Jul 11, 2023	Jun	NEWA

JELLY; TOPICAL

GLYDO

AT	!		SAGENT PHARMS INC	2%	A201094	001	Apr 28, 2014	Apr	CHRS
			LIDOCAINE HYDROCHLORIDE						
AT			AKORN	2%	A040433	001	Feb 12, 2003	Apr	CHRS
AT			SENTISS	2%	A040433	001	Feb 12, 2003	Aug	CAHN
			XYLOCAINE						
	+	@	EPIC PHARMA LLC	2%	N008816	001		Sep	CAHN
			SOLUTION; ORAL						
			LIDOCAINE HYDROCHLORIDE						
AT			RUBICON	2%	A216780	001	Mar 28, 2023	Mar	NEWA
			LIDOCAINE HYDROCHLORIDE VISCOUS						
AT			CHARTWELL MOLECULAR	2%	A040708	001	Feb 27, 2007	Jul	CAHN

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

>D>	AB		FOUGERA PHARMS	2.5%; 2.5%	A076453	001	Aug 18, 2003	Oct	CHRS
>A>	AB	!		2.5%; 2.5%	A076453	001	Aug 18, 2003	Oct	CHRS
>D>	AB	!	HIKMA	2.5%; 2.5%	A076290	001	Sep 25, 2003	Oct	CHRS
>A>	AB			2.5%; 2.5%	A076290	001	Sep 25, 2003	Oct	CHRS
			@ PAI HOLDINGS PHARM	2.5%; 2.5%	A205887	001	Jun 29, 2018	May	DISC

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

	+	@	TARO PHARMS	7%; 7%	N021717	001	Jun 29, 2006	Aug	DISC
--	---	---	-------------	--------	---------	-----	--------------	-----	------

LIFITEGRAST

SOLUTION/DROPS; OPHTHALMIC

LIFITEGRAST

>A>	AB		EUGIA PHARMA	5%	A215063	001	Nov 07, 2023	Oct	NEWA
-----	----	--	--------------	----	---------	-----	--------------	-----	------

LINACLOTIDE

CAPSULE; ORAL

LINACLOTIDE

			@ AUROBINDO PHARMA	145MCG	A209611	001	Feb 07, 2023	Mar	DISC
AB				145MCG	A209611	001	Feb 07, 2023	Jan	NEWA
			@	290MCG	A209611	002	Feb 07, 2023	Mar	DISC
AB				290MCG	A209611	002	Feb 07, 2023	Jan	NEWA
			LINZESS						
	+	!	ABBVIE	145MCG	N202811	001	Aug 30, 2012	Mar	CTEC
	+			290MCG	N202811	002	Aug 30, 2012	Mar	CTEC
AB	+	!	ALLERGAN	145MCG	N202811	001	Aug 30, 2012	Jan	CTEC
AB	+			290MCG	N202811	002	Aug 30, 2012	Jan	CTEC

LINAGLIPTIN

TABLET; ORAL

LINAGLIPTIN

			@ ZYDUS PHARMS	5MG	A208448	001	Mar 30, 2023	Jul	DISC
AB				5MG	A208448	001	Mar 30, 2023	Mar	NEWA

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

LINAGLIPTIN AND METFORMIN HYDROCHLORIDE

			@ ZYDUS PHARMS	2.5MG; 500MG	A208449	001	Mar 30, 2023	Jul	DISC
AB				2.5MG; 500MG	A208449	001	Mar 30, 2023	Mar	NEWA
			@	2.5MG; 850MG	A208449	002	Mar 30, 2023	Jul	DISC
AB				2.5MG; 850MG	A208449	002	Mar 30, 2023	Mar	NEWA
			@	2.5MG; 1GM	A208449	003	Mar 30, 2023	Jul	DISC
AB				2.5MG; 1GM	A208449	003	Mar 30, 2023	Mar	NEWA

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOMYCIN HYDROCHLORIDE

@ GENEYORK PHARMS	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Sep CAHN
@ HAINAN POLY	EQ 300MG BASE/ML	A216662	001	Dec 21, 2022	Jun DISC
@ PRAXGEN PHARMS	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Jul CAHN
@ SLATE RUN PHARMA	EQ 300MG BASE/ML	A216662	001	Dec 21, 2022	Sep CAHN

LINEZOLID

SOLUTION; INTRAVENOUS

LINEZOLID

AP	HIKMA	600MG/300ML (2MG/ML)	A206454	001	Aug 22, 2022	Sep CAHN
----	-------	----------------------	---------	-----	--------------	----------

TABLET; ORAL

LINEZOLID

AB	CHARTWELL RX	600MG	A210702	001	Apr 25, 2019	Mar CAHN
----	--------------	-------	---------	-----	--------------	----------

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

LIOTHYRONINE SODIUM

!	XGEN PHARMS	EQ 0.01MG BASE/ML	A076923	001	Aug 17, 2005	Jun CHRS
		EQ 0.01MG BASE/ML	A076923	001	Aug 17, 2005	Jun CTEC

TRIOSTAT

+	@ PAR STERILE PRODUCTS	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	Jun DISC
---	------------------------	-------------------	---------	-----	--------------	----------

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

LISDEXAMFETAMINE DIMESYLATE

AB	ACTAVIS ELIZABETH	10MG	A202802	001	Aug 25, 2023	Aug NFTG
AB		20MG	A202802	002	Aug 25, 2023	Aug NFTG
AB		30MG	A202802	003	Aug 25, 2023	Aug NFTG
AB		40MG	A202802	004	Aug 25, 2023	Aug NFTG
AB		50MG	A202802	005	Aug 25, 2023	Aug NFTG
AB		60MG	A202802	006	Aug 25, 2023	Aug NFTG
AB		70MG	A202802	007	Aug 25, 2023	Aug NFTG
AB	ALKEM LABS LTD	10MG	A217194	001	Aug 25, 2023	Aug NFTG
AB		20MG	A217194	002	Aug 25, 2023	Aug NFTG
AB		30MG	A217194	003	Aug 25, 2023	Aug NFTG
AB		40MG	A217194	004	Aug 25, 2023	Aug NFTG
AB		50MG	A217194	005	Aug 25, 2023	Aug NFTG
AB		60MG	A217194	006	Aug 25, 2023	Aug NFTG
AB		70MG	A217194	007	Aug 25, 2023	Aug NFTG
AB	AMNEAL	20MG	A202830	001	Aug 25, 2023	Aug NFTG
AB		30MG	A202830	002	Aug 25, 2023	Aug NFTG
AB		40MG	A202830	003	Aug 25, 2023	Aug NFTG
AB		50MG	A202830	004	Aug 25, 2023	Aug NFTG
AB		60MG	A202830	005	Aug 25, 2023	Aug NFTG
AB		70MG	A202830	006	Aug 25, 2023	Aug NFTG
AB	APOTEX	10MG	A216944	001	Aug 25, 2023	Aug NFTG
AB		20MG	A216944	002	Aug 25, 2023	Aug NFTG
AB		30MG	A216944	003	Aug 25, 2023	Aug NFTG
AB		40MG	A216944	004	Aug 25, 2023	Aug NFTG
AB		50MG	A216944	005	Aug 25, 2023	Aug NFTG
AB		60MG	A216944	006	Aug 25, 2023	Aug NFTG
AB		70MG	A216944	007	Aug 25, 2023	Aug NFTG
AB	ASCENT PHARMS INC	10MG	A217442	001	Aug 25, 2023	Aug NFTG
AB		20MG	A217442	002	Aug 25, 2023	Aug NFTG
AB		30MG	A217442	003	Aug 25, 2023	Aug NFTG
AB		40MG	A217442	004	Aug 25, 2023	Aug NFTG
AB		50MG	A217442	005	Aug 25, 2023	Aug NFTG
AB		60MG	A217442	006	Aug 25, 2023	Aug NFTG
AB		70MG	A217442	007	Aug 25, 2023	Aug NFTG
AB	HIKMA	20MG	A202827	001	Aug 25, 2023	Aug NFTG
AB		30MG	A202827	002	Aug 25, 2023	Aug NFTG
AB		40MG	A202827	003	Aug 25, 2023	Aug NFTG
AB		50MG	A202827	004	Aug 25, 2023	Aug NFTG
AB		60MG	A202827	005	Aug 25, 2023	Aug NFTG
AB		70MG	A202827	006	Aug 25, 2023	Aug NFTG
AB	LANNETT CO INC	10MG	A215802	001	Aug 25, 2023	Aug NFTG
AB		20MG	A215802	002	Aug 25, 2023	Aug NFTG
AB		30MG	A215802	003	Aug 25, 2023	Aug NFTG
AB		40MG	A215802	004	Aug 25, 2023	Aug NFTG
AB		50MG	A215802	005	Aug 25, 2023	Aug NFTG

CAPSULE;ORAL

LISDEXAMFETAMINE DIMESYLATE

AB		60MG	A215802	006	Aug 25, 2023	Aug NFTG
AB		70MG	A215802	007	Aug 25, 2023	Aug NFTG
AB	MYLAN	10MG	A202835	001	Aug 25, 2023	Aug NFTG
AB		20MG	A202835	002	Aug 25, 2023	Aug NFTG
AB		30MG	A202835	003	Aug 25, 2023	Aug NFTG
AB		40MG	A202835	004	Aug 25, 2023	Aug NFTG
AB		50MG	A202835	005	Aug 25, 2023	Aug NFTG
AB		60MG	A202835	006	Aug 25, 2023	Aug NFTG
AB		70MG	A202835	007	Aug 25, 2023	Aug NFTG
AB	NORWICH	10MG	A214547	001	Aug 25, 2023	Aug NFTG
AB		20MG	A214547	002	Aug 25, 2023	Aug NFTG
AB		30MG	A214547	003	Aug 25, 2023	Aug NFTG
AB		40MG	A214547	004	Aug 25, 2023	Aug NFTG
AB		50MG	A214547	005	Aug 25, 2023	Aug NFTG
AB		60MG	A214547	006	Aug 25, 2023	Aug NFTG
AB		70MG	A214547	007	Aug 25, 2023	Aug NFTG
AB	PRINSTON INC	10MG	A216266	001	Aug 25, 2023	Aug NFTG
AB		20MG	A216266	002	Aug 25, 2023	Aug NFTG
AB		30MG	A216266	003	Aug 25, 2023	Aug NFTG
AB		40MG	A216266	004	Aug 25, 2023	Aug NFTG
AB		50MG	A216266	005	Aug 25, 2023	Aug NFTG
AB		60MG	A216266	006	Aug 25, 2023	Aug NFTG
AB		70MG	A216266	007	Aug 25, 2023	Aug NFTG
AB	RHODES PHARMS	10MG	A215330	001	Aug 25, 2023	Aug NFTG
AB		20MG	A215330	002	Aug 25, 2023	Aug NFTG
AB		30MG	A215330	003	Aug 25, 2023	Aug NFTG
AB		40MG	A215330	004	Aug 25, 2023	Aug NFTG
AB		50MG	A215330	005	Aug 25, 2023	Aug NFTG
AB		60MG	A215330	006	Aug 25, 2023	Aug NFTG
AB		70MG	A215330	007	Aug 25, 2023	Aug NFTG
AB	SPECGX LLC	10MG	A211840	001	Aug 25, 2023	Aug NFTG
AB		20MG	A211840	002	Aug 25, 2023	Aug NFTG
AB		30MG	A211840	003	Aug 25, 2023	Aug NFTG
AB		40MG	A211840	004	Aug 25, 2023	Aug NFTG
AB		50MG	A211840	005	Aug 25, 2023	Aug NFTG
AB		60MG	A211840	006	Aug 25, 2023	Aug NFTG
AB		70MG	A211840	007	Aug 25, 2023	Aug NFTG
AB	SUN PHARM INDS INC	10MG	A214484	001	Aug 25, 2023	Aug NFTG
AB		20MG	A214484	002	Aug 25, 2023	Aug NFTG
AB		30MG	A214484	003	Aug 25, 2023	Aug NFTG
AB		40MG	A214484	004	Aug 25, 2023	Aug NFTG
AB		50MG	A214484	005	Aug 25, 2023	Aug NFTG
AB		60MG	A214484	006	Aug 25, 2023	Aug NFTG
AB		70MG	A214484	007	Aug 25, 2023	Aug NFTG
VYVANSE						
AB	+ TAKEDA PHARMS USA	10MG	N021977	007	Oct 30, 2014	Aug CFTG
AB	+	20MG	N021977	004	Dec 10, 2007	Aug CFTG
AB	+	30MG	N021977	001	Feb 23, 2007	Aug CFTG
AB	+	40MG	N021977	005	Dec 10, 2007	Aug CFTG
AB	+	50MG	N021977	002	Feb 23, 2007	Aug CFTG
AB	+	60MG	N021977	006	Dec 10, 2007	Aug CFTG
AB	+	70MG	N021977	003	Feb 23, 2007	Aug CFTG

TABLET, CHEWABLE;ORAL

LISDEXAMFETAMINE DIMESYLATE

AB	ASCENT PHARMS INC	10MG	A217068	001	Aug 25, 2023	Aug NFTG
AB		20MG	A217068	002	Aug 25, 2023	Aug NFTG
AB		30MG	A217068	003	Aug 25, 2023	Aug NFTG
AB		40MG	A217068	004	Aug 25, 2023	Aug NFTG
AB		50MG	A217068	005	Aug 25, 2023	Aug NFTG
AB		60MG	A217068	006	Aug 25, 2023	Aug NFTG
AB	SUN PHARM INDS INC	10MG	A214134	001	Aug 25, 2023	Aug NFTG
AB		20MG	A214134	002	Aug 25, 2023	Aug NFTG
AB		30MG	A214134	003	Aug 25, 2023	Aug NFTG
AB		40MG	A214134	004	Aug 25, 2023	Aug NFTG
AB		50MG	A214134	005	Aug 25, 2023	Aug NFTG
AB		60MG	A214134	006	Aug 25, 2023	Aug NFTG
AB	TEVA PHARMS	10MG	A215415	001	Aug 25, 2023	Aug NFTG
AB		20MG	A215415	002	Aug 25, 2023	Aug NFTG
AB		30MG	A215415	003	Aug 25, 2023	Aug NFTG
AB		40MG	A215415	004	Aug 25, 2023	Aug NFTG
AB		50MG	A215415	005	Aug 25, 2023	Aug NFTG
AB		60MG	A215415	006	Aug 25, 2023	Aug NFTG

TABLET, CHEWABLE;ORAL
VYVANSE

AB	+	TAKEDA PHARMS USA	10MG	N208510	001	Jan 28, 2017	Aug CFTG
AB	+		20MG	N208510	002	Jan 28, 2017	Aug CFTG
AB	+		30MG	N208510	003	Jan 28, 2017	Aug CFTG
AB	+		40MG	N208510	004	Jan 28, 2017	Aug CFTG
AB	+		50MG	N208510	005	Jan 28, 2017	Aug CFTG
AB	+		60MG	N208510	006	Jan 28, 2017	Aug CFTG

LISINOPRIL

TABLET;ORAL
LISINOPRIL

	@	HERITAGE PHARMA	2.5MG	A075752	001	Jul 01, 2002	Aug DISC
AB			2.5MG	A075752	001	Jul 01, 2002	Mar CMFD
	@		5MG	A075752	002	Jul 01, 2002	Aug DISC
AB			5MG	A075752	002	Jul 01, 2002	Mar CMFD
	@		10MG	A075752	003	Jul 01, 2002	Aug DISC
AB			10MG	A075752	003	Jul 01, 2002	Mar CMFD
	@		20MG	A075752	004	Jul 01, 2002	Aug DISC
AB			20MG	A075752	004	Jul 01, 2002	Mar CMFD
	@		30MG	A075752	005	Jul 01, 2002	Aug DISC
AB			30MG	A075752	005	Jul 01, 2002	Mar CMFD
	@		40MG	A075752	006	Jul 01, 2002	Aug DISC
AB			40MG	A075752	006	Jul 01, 2002	Mar CMFD
	@	RISEING	2.5MG	A075999	001	Jul 01, 2002	Aug CAHN
	@		5MG	A075999	002	Jul 01, 2002	Aug CAHN
	@		10MG	A075999	003	Jul 01, 2002	Aug CAHN
	@		20MG	A075999	004	Jul 01, 2002	Aug CAHN
	@		30MG	A075999	005	Jul 01, 2002	Aug CAHN
	@		40MG	A075999	006	Jul 01, 2002	Aug CAHN

LITHIUM CITRATE

SYRUP;ORAL
LITHIUM CITRATE

AA	!	PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Aug CTEC
AA		RUBICON	EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Aug NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL
LOPERAMIDE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	2MG	A218122	001	Sep 05, 2023	Aug NEWA
AB		JUBILANT CADISTA	2MG	A217840	001	Jul 05, 2023	Jun NEWA
AB		RUBICON	2MG	A216876	001	Jan 26, 2023	Jan NEWA
AB		ZYDUS LIFESCIENCES	2MG	A217471	001	Mar 23, 2023	Apr CAHN
AB		ZYDUS PHARMS	2MG	A217471	001	Mar 23, 2023	Mar NEWA

LORAZEPAM

TABLET;ORAL
LORAZEPAM

	@	AMNEAL PHARMS	0.5MG	A078826	001	Jun 23, 2010	May DISC
	@		1MG	A078826	002	Jun 23, 2010	May DISC
	@		2MG	A078826	003	Jun 23, 2010	May DISC
AB		SUN PHARM INDS LTD	0.5MG	A076045	001	Aug 29, 2001	Sep CMFD
AB			1MG	A076045	002	Aug 29, 2001	Sep CMFD
AB			2MG	A076045	003	Aug 29, 2001	Sep CMFD

LOSARTAN POTASSIUM

TABLET;ORAL
LOSARTAN POTASSIUM

AB		GRANULES	25MG	A215959	001	Feb 23, 2023	Feb NEWA
AB			50MG	A215959	002	Feb 23, 2023	Feb NEWA
AB			100MG	A215959	003	Feb 23, 2023	Feb NEWA
AB		MSN	25MG	A217396	001	Aug 14, 2023	Aug NEWA
AB			50MG	A217396	002	Aug 14, 2023	Aug NEWA
AB			100MG	A217396	003	Aug 14, 2023	Aug NEWA

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC
LOTEPREDNOL ETABONATE

AB		SENTISS	0.5%	A212080	001	Feb 10, 2021	Aug CAHN
AB		SUN PHARM	0.5%	A215384	001	Aug 09, 2023	Jul NEWA

SUSPENSION/DROPS;OPHTHALMIC							
ALREX							
AB	+!	BAUSCH AND LOMB	0.2%	N020803	001	Mar 09, 1998	Mar CFTG
LOTEPREDNOL ETABONATE							
AB		AKORN	0.2%	A215933	001	Apr 12, 2023	Mar NFTG
AB		SENTISS	0.2%	A215933	001	Apr 12, 2023	Aug CAHN
AB			0.5%	A207609	001	Apr 17, 2019	Jul CAHN
<u>LOTILANER</u>							
SOLUTION/DROPS;OPHTHALMIC							
XDEMY							
	+!	TARSUS	0.25%	N217603	001	Jul 24, 2023	Jul NEWA
<u>LOVASTATIN</u>							
TABLET;ORAL							
LOVASTATIN							
	@	AUROBINDO PHARMA USA	10MG	A075451	001	Dec 17, 2001	May CAHN
	@		10MG	A075935	001	Dec 17, 2001	Apr CAHN
	@		20MG	A075451	002	Dec 17, 2001	May CAHN
	@		20MG	A075935	002	Dec 17, 2001	Apr CAHN
	@		40MG	A075451	003	Dec 17, 2001	May CAHN
	@		40MG	A075935	003	Dec 17, 2001	Apr CAHN
<u>LUBIPROSTONE</u>							
CAPSULE;ORAL							
LUBIPROSTONE							
AB		AMNEAL	8MCG	A209450	001	Nov 30, 2021	Jan CMFD
AB			24MCG	A209450	002	Nov 30, 2021	Jan CMFD
AB		ZYDUS PHARMS	8MCG	A214131	001	Mar 23, 2023	Mar NEWA
AB			24MCG	A214131	002	Mar 23, 2023	Mar NEWA
<u>LUMASIRAN SODIUM</u>							
SOLUTION;SUBCUTANEOUS							
OXLUMO							
	+!	ALNYLAM PHARMS INC	EQ 94.5MG BASE/0.5ML (EQ 94.5MG BASE/0.5ML)	N214103	001	Nov 23, 2020	Aug CPOT
<u>LURASIDONE HYDROCHLORIDE</u>							
TABLET;ORAL							
LURASIDONE HYDROCHLORIDE							
AB		AMNEAL PHARMS CO	20MG	A208002	001	Jan 03, 2019	Feb CMFD
AB			40MG	A208002	002	Jan 03, 2019	Feb CMFD
AB			60MG	A208002	003	Jan 03, 2019	Feb CMFD
AB			80MG	A208002	004	Jan 03, 2019	Feb CMFD
AB			120MG	A208002	005	Jan 03, 2019	Feb CMFD
AB		AUROBINDO PHARMA LTD	20MG	A208045	001	Mar 10, 2023	Mar NEWA
AB			40MG	A208045	002	Mar 10, 2023	Mar NEWA
AB			60MG	A208045	003	Mar 10, 2023	Mar NEWA
AB			80MG	A208045	004	Mar 10, 2023	Mar NEWA
AB			120MG	A208045	005	Mar 10, 2023	Mar NEWA
AB		AVET LIFESCIENCES	20MG	A208058	001	Sep 04, 2019	Sep CMFD
AB			40MG	A208058	002	Sep 04, 2019	Sep CMFD
AB			60MG	A208058	003	Sep 04, 2019	Sep CMFD
AB			80MG	A208058	004	Sep 04, 2019	Sep CMFD
AB			120MG	A208058	005	Feb 28, 2023	Sep CMFD
	@		120MG	A208058	005	Feb 28, 2023	Mar DISC
AB			120MG	A208058	005	Feb 28, 2023	Feb NEWA
AB		LUPIN LTD	20MG	A208031	001	Jan 03, 2019	Feb CMFD
AB			40MG	A208031	002	Jan 03, 2019	Feb CMFD
AB			60MG	A208031	003	Jan 03, 2019	Feb CMFD
AB			80MG	A208031	004	Jan 03, 2019	Feb CMFD
AB			120MG	A208031	005	Jan 03, 2019	Feb CMFD
AB		MACLEODS PHARMS LTD	20MG	A212124	001	Jun 09, 2023	Jun NEWA
AB			40MG	A212124	002	Jun 09, 2023	Jun NEWA
AB			60MG	A212124	003	Jun 09, 2023	Jun NEWA
AB			80MG	A212124	004	Jun 09, 2023	Jun NEWA
AB			120MG	A212124	005	Jun 09, 2023	Jun NEWA
AB		PIRAMAL HLTHCARE UK	20MG	A212091	001	Dec 28, 2020	Feb CMFD
AB			40MG	A212091	002	Dec 28, 2020	Feb CMFD
AB			60MG	A212091	003	Dec 28, 2020	Feb CMFD
AB			80MG	A212091	004	Dec 28, 2020	Feb CMFD
AB			120MG	A212091	005	Dec 28, 2020	Feb CMFD
AB		TORRENT	20MG	A208055	001	Jan 03, 2019	Feb CMFD

TABLET;ORAL					
LURASIDONE HYDROCHLORIDE					
AB	40MG	A208055	002	Jan 03, 2019	Feb CMFD
AB	80MG	A208055	003	Jan 03, 2019	Feb CMFD
AB	120MG	A208055	004	Jan 03, 2019	Feb CMFD
<u>MACIMORELIN ACETATE</u>					
FOR SOLUTION;ORAL					
MACRILEN					
+ @	NOVO EQ 60MG BASE/POUCH	N205598	001	Dec 20, 2017	May DISC
<u>MACITENTAN</u>					
TABLET;ORAL					
MACITENTAN					
@ AUROBINDO PHARMA LTD 10MG		A211198	001	Apr 18, 2023	Apr DISC
AB	10MG	A211198	001	Apr 18, 2023	Apr NEWA
OPSUMIT					
+!	ACTELION 10MG	N204410	001	Oct 18, 2013	Apr CTEC
AB	10MG	N204410	001	Oct 18, 2013	Apr CFTG
<u>MAFENIDE ACETATE</u>					
FOR SOLUTION;TOPICAL					
MAFENIDE ACETATE					
@	NOVAST LABS 5%	A206716	001	Jul 31, 2017	May DISC
<u>MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE</u>					
INJECTABLE;INJECTION					
MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5					
AP	FRESENIUS KABI USA 30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215370	001	Jun 29, 2022	Mar CMFD
MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4					
AP	FRESENIUS KABI USA 30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215371	001	Jun 08, 2022	Mar CMFD
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER					
AP	+! BAXTER HLTHCARE 30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	001		Mar CTEC
PLASMA-LYTE A IN PLASTIC CONTAINER					
AP	+! BAXTER HLTHCARE 30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	002	Nov 22, 1982	Mar CTEC
<u>MAGNESIUM SULFATE</u>					
INJECTABLE;INJECTION					
MAGNESIUM SULFATE IN PLASTIC CONTAINER					
AP	AMNEAL 2GM/50ML (40MG/ML)	A216597	001	Feb 15, 2023	Feb NEWA
AP	4GM/100ML (40MG/ML)	A216597	002	Feb 15, 2023	Feb NEWA
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE</u>					
FOR SOLUTION;ORAL					
SUFLAVE					
+!	BRAINTREE LABS 0.9GM/BOT;178.7GM/BOT;1.12GM/BOT;0 .5GM/BOT;7.3GM/BOT	N215344	001	Jun 15, 2023	Jun NEWA
<u>MARAVIROC</u>					
TABLET;ORAL					
MARAVIROC					
AB	I 3 PHARMS 150MG	A217114	001	Aug 17, 2023	Aug NEWA
AB	300MG	A217114	002	Aug 17, 2023	Aug NEWA
<u>MAVACAMTEN</u>					
CAPSULE;ORAL					
CAMZYOS					
+!	BRISTOL 5MG	N214998	002	Apr 28, 2022	Sep CHRS
+	15MG	N214998	004	Apr 28, 2022	Sep CHRS
<u>MECLIZINE HYDROCHLORIDE</u>					
TABLET;ORAL					
MECLIZINE HYDROCHLORIDE					
@ ANI PHARMS 12.5MG		A084657	002		Aug DISC
@ 25MG		A084657	001		Aug DISC
AA	AUROBINDO PHARMA USA 12.5MG	A202640	001	Sep 17, 2012	Sep CMFD
AA	25MG	A202640	002	Sep 17, 2012	Sep CMFD
AA	50MG	A202640	003	Sep 17, 2012	Sep CMFD
AA	WILSHIRE PHARMS INC 12.5MG	A205136	001	Feb 22, 2019	May CAHN

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

AA		25MG	A205136	002	Feb 22, 2019	May CAHN
AA		50MG	A205136	003	Feb 22, 2019	May CAHN

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLOFENAMATE SODIUM

	@ CHARTWELL RX	EQ 50MG BASE	A072262	001	Nov 29, 1988	Jan CAHN
	@	EQ 100MG BASE	A072263	001	Nov 29, 1988	Jan CAHN

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

MEDROXYPROGESTERONE ACETATE

AB	AMNEAL	150MG/ML	A215397	001	Jun 07, 2023	May NEWA
	@ HIKMA	150MG/ML	A214309	001	Jan 05, 2023	Jul DISC
>A> AB	HONG KONG	150MG/ML	A076553	001	Jul 28, 2004	Oct CAHN
>D> AB	TEVA PHARMS USA	150MG/ML	A076553	001	Jul 28, 2004	Oct CAHN

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGESTROL ACETATE

	@ BIONPHARMA	125MG/ML	A204688	001	Dec 01, 2017	Jun CAHN
	@ BRECKENRIDGE	125MG/ML	A204688	001	Dec 01, 2017	Jan DISC
	@ XTTRIUM LABS INC	40MG/ML	A076721	001	Nov 01, 2004	Jul DISC
AB		40MG/ML	A076721	001	Nov 01, 2004	Jan CAHN

MELOXICAM

TABLET;ORAL

MELOXICAM

AB	ASCENT PHARMS INC	7.5MG	A217579	001	Jun 07, 2023	May NEWA
AB		15MG	A217579	002	Jun 07, 2023	May NEWA
AB	COREPHARMA	7.5MG	A077882	001	Jul 20, 2006	Feb CAHN
AB		15MG	A077882	002	Jul 20, 2006	Feb CAHN
	@ SCIEGEN PHARMS INC	7.5MG	A077920	001	Jul 19, 2006	Sep CAHN
	@	15MG	A077920	002	Jul 19, 2006	Sep CAHN

MELPHALAN HYDROCHLORIDE

POWDER;INTRA-ARTERIAL

HEPZATO

+	DEL CATH SYSTEMS INC	EQ 50MG BASE/VIAL	N201848	001	Aug 14, 2023	Aug NEWA
---	----------------------	-------------------	---------	-----	--------------	----------

SOLUTION;INTRAVENOUS

MELPHALAN HYDROCHLORIDE

+	APOTEX	EQ 90MG BASE/ML (EQ 90MG BASE/ML)	N217110	001	Aug 18, 2023	Aug NEWA
---	--------	-----------------------------------	---------	-----	--------------	----------

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

	@ ANI PHARMS	28MG	A205365	004	Feb 28, 2020	Feb DISC
	@ XIAMEN LP PHARM CO	7MG	A213985	001	Oct 11, 2022	Apr DISC
	@	14MG	A213985	002	Oct 11, 2022	Apr DISC
	@	28MG	A213985	003	Oct 11, 2022	Apr DISC
	NAMENDA XR					
	+ @ ABBVIE	7MG	N022525	001	Jun 21, 2010	Aug DISC
AB	+	7MG	N022525	001	Jun 21, 2010	Feb CAHN
AB	+	14MG	N022525	002	Jun 21, 2010	Feb CAHN
AB	+	21MG	N022525	003	Jun 21, 2010	Feb CAHN
AB	+	28MG	N022525	004	Jun 21, 2010	Feb CAHN

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

>D> AB	HIKMA	5MG	A208173	001	Feb 28, 2020	Oct DISC
>A>	@	5MG	A208173	001	Feb 28, 2020	Oct DISC
>D> AB		10MG	A208173	002	Feb 28, 2020	Oct DISC
>A>	@	10MG	A208173	002	Feb 28, 2020	Oct DISC
AB	WESTMINSTER PHARMS	5MG	A209527	001	May 07, 2018	Aug CAHN
AB		10MG	A209527	002	May 07, 2018	Aug CAHN
	@ YILING	5MG	A212947	001	Apr 03, 2020	Mar CAHN
	@	10MG	A212947	002	Apr 03, 2020	Mar CAHN
	NAMENDA					
AB	+ ABBVIE	5MG	N021487	001	Oct 16, 2003	Feb CAHN
AB	+	10MG	N021487	002	Oct 16, 2003	Feb CAHN

MEPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION
SCANDONEST PLAIN

! DEPROCO 3% A088387 001 Oct 10, 1984 May CTEC

MEROPENEMINJECTABLE; INJECTION
MEROPENEM

AP	BROOKS STERISCIENCE	500MG/VIAL	A216154	001	Aug 18, 2022	Jul CMFD
	@	500MG/VIAL	A216154	001	Aug 18, 2022	Mar DISC
AP		1GM/VIAL	A216154	002	Aug 18, 2022	Jul CMFD
	@	1GM/VIAL	A216154	002	Aug 18, 2022	Mar DISC

POWDER; INTRAVENOUS
MEROPENEM

+! HQ SPCLT PHARMA 2GM/VIAL N215212 001 Jul 26, 2023 Jul NEWA

MESALAMINECAPSULE, DELAYED RELEASE; ORAL
DELZICOL

AB +! ABBVIE 400MG N204412 001 Feb 01, 2013 Feb CAHN

CAPSULE, EXTENDED RELEASE; ORAL
APRISO

AB +! SALIX 375MG N022301 001 Oct 31, 2008 Sep CAHN

MESALAMINE

AB AMTA 375MG A217533 001 Jun 06, 2023 May NEWA

AB AUROBINDO PHARMA LTD 375MG A214477 001 Mar 31, 2023 Mar NEWA

ENEMA; RECTAL
MESALAMINE

AB ENCUBE 4GM/60ML A216941 001 May 30, 2023 May NEWA

SUPPOSITORY; RECTAL
CANASA

AB @ ABBVIE 500MG N021252 001 Jan 05, 2001 Feb CAHN

AB +! 1GM N021252 002 Nov 05, 2004 Feb CAHN

MESALAMINE

>A> AB PHARM SOURCING 1GM A207448 001 Apr 19, 2019 Oct CAHN

>D> AB RISING 1GM A207448 001 Apr 19, 2019 Oct CAHN

AB 1GM A207448 001 Apr 19, 2019 Sep CAHN

TABLET, DELAYED RELEASE; ORAL
MESALAMINE

AB SINOTHERAPEUTICS INC 1.2GM A217337 001 May 12, 2023 May NEWA

METAXALONETABLET; ORAL
METAXALONE

AB ! AMNEAL PHARMS 800MG A203399 001 Jun 21, 2013 Jul CHRS

+ @ PRIMUS PHARMS 640MG N022503 001 Jun 01, 2015 Jun DISC

+! 640MG N022503 001 Jun 01, 2015 Feb CMFD

SKELAXIN

+ @ KING PHARMS 800MG N013217 003 Aug 30, 2002 Jul DISC

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

@ SUN PHARM INDS INC 500MG A075967 001 Jan 29, 2002 Sep DISC

@ 850MG A075967 002 Jan 29, 2002 Sep DISC

@ 1GM A075967 003 Jan 29, 2002 Sep DISC

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

AB1 LAURUS 500MG A217631 001 Oct 05, 2023 Sep NEWA

AB 750MG A217631 002 Oct 05, 2023 Sep NEWA

AB3 RK PHARMA 500MG A215629 001 Jun 20, 2023 Jun CAHN

AB3 1GM A215629 002 Jun 20, 2023 Jun CAHN

AB3 VGYAAN 500MG A215629 001 Jun 20, 2023 Jun NEWA

AB3 1GM A215629 002 Jun 20, 2023 Jun NEWA

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL									
>D>	KOMBIGLYZE XR								
>D>	AB	+	ASTRAZENECA AB	500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010	Oct	DISC
>A>		+	@	500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010	Oct	DISC
	AB	+		500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010	Jul	CFTG
>D>	AB	+		1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010	Oct	DISC
>A>		+	@	1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010	Oct	DISC
	AB	+		1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010	Jul	CFTG
>D>	AB	+	!	1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Oct	DISC
>A>		+	@	1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Oct	DISC
	AB	+	!	1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Jul	CFTG
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE									
	AB		DR REDDYS LABS SA	500MG;EQ 5MG BASE	A207678	001	Aug 09, 2023	Jul	NEWA
	AB			1GM;EQ 2.5MG BASE	A207678	002	Aug 09, 2023	Jul	NEWA
>D>	AB			1GM;EQ 5MG BASE	A207678	003	Aug 09, 2023	Oct	CHRS
>A>	AB		!	1GM;EQ 5MG BASE	A207678	003	Aug 09, 2023	Oct	CHRS
	AB			1GM;EQ 5MG BASE	A207678	003	Aug 09, 2023	Jul	NEWA
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE									
	AB		MYLAN	500MG;EQ 5MG BASE	A205981	001	Jul 31, 2023	Jul	NFTG
	AB			1GM;EQ 2.5MG BASE	A205981	002	Jul 31, 2023	Jul	NFTG
	AB			1GM;EQ 5MG BASE	A205981	003	Jul 31, 2023	Jul	NFTG
	AB		SUN PHARM	500MG;EQ 5MG BASE	A206081	001	Jul 31, 2023	Jul	NFTG
	AB			1GM;EQ 2.5MG BASE	A206081	002	Jul 31, 2023	Jul	NFTG
	AB			1GM;EQ 5MG BASE	A206081	003	Jul 31, 2023	Jul	NFTG

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

JANUMET

+	MSD SUB MERCK	500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007	Mar CAHN
+	!	1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

JANUMET XR

+	MSD SUB MERCK	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	Sep CAHN
+		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	Sep CAHN
+	!	1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	Sep CAHN

METHADONE HYDROCHLORIDE

INJECTABLE;INJECTION

METHADONE HYDROCHLORIDE

AP		LONG GROVE PHARMS	10MG/ML	A208306	001	Oct 27, 2017	Aug CAHN
----	--	-------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

METHADONE HYDROCHLORIDE

@	SUN PHARM INDUSTRIES	5MG	A208305	001	Mar 30, 2018	Sep DISC
@		10MG	A208305	002	Mar 30, 2018	Sep DISC

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB		BIONPHARMA	5MG	A218149	001	Sep 25, 2023	Sep NEWA
AB			10MG	A218149	002	Sep 25, 2023	Sep NEWA
AB		MACLEODS PHARMS LTD	5MG	A209827	001	May 24, 2023	May NEWA
AB			10MG	A209827	002	May 24, 2023	May NEWA
AB		QINGDAO BAHEAL PHARM	5MG	A040547	001	Feb 18, 2005	Sep CAHN
AB			10MG	A040547	002	Feb 18, 2005	Sep CAHN
	@		20MG	A040547	004	Feb 18, 2005	Sep CAHN

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

@	BAXTER HLTHCARE CORP	1GM/10ML (100MG/ML)	A215065	001	Jul 14, 2022	Feb DISC
AP	SLATE RUN PHARMA	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Sep CAHN

TABLET;ORAL

METHOCARBAMOL

AA		ACME LABS	500MG	A203550	001	Feb 08, 2017	Sep CAHN
AA			750MG	A203550	002	Feb 08, 2017	Sep CAHN
AA		AUROBINDO PHARMA LTD	500MG	A213967	002	Feb 09, 2023	Feb NEWA
AA			750MG	A213967	001	Aug 12, 2020	Feb CMFD
AB	!	AUSTARPHARMA LLC	1GM	A200958	003	Dec 06, 2021	Jun CTEC
AA		DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Feb CAHN
AA			750MG	A203550	002	Feb 08, 2017	Feb CAHN

TABLET;ORAL							
METHOCARBAMOL							
AB	MIKART	1GM	A212707	001	Jun 12, 2023	Jun	NEWA
<u>METHOTREXATE</u>							
SOLUTION;ORAL							
JYLAMVO							
>A>	+! SHORLA	2MG/ML	N212479	001	Nov 29, 2022	Oct	CAHN
>D>	+ @ THERAKIND	2MG/ML	N212479	001	Nov 29, 2022	Oct	CAHN
	+ @	2MG/ML	N212479	001	Nov 29, 2022	May	DISC
SOLUTION;SUBCUTANEOUS							
REDITREX							
	+ @ NORDIC GRP	15MG/0.6ML (15MG/0.6ML)	N210737	004	Nov 27, 2019	Aug	DISC
	+ @	20MG/0.8ML (20MG/0.8ML)	N210737	006	Nov 27, 2019	Aug	DISC
	+ @	25MG/1ML (25MG/1ML)	N210737	008	Nov 27, 2019	Aug	DISC
<u>METHOTREXATE SODIUM</u>							
TABLET;ORAL							
METHOTREXATE SODIUM							
AB	DAITO	EQ 2.5MG BASE	A213362	001	Aug 07, 2023	Jul	NEWA
<u>METHSUXIMIDE</u>							
CAPSULE;ORAL							
CELONTIN							
AB	+! PARKE DAVIS	300MG	N010596	008		Apr	CFTG
METHSUXIMIDE							
AB	NOVITIUM PHARMA	300MG	A217213	001	May 01, 2023	Apr	NFTG
<u>METHYLDOPA</u>							
TABLET;ORAL							
METHYLDOPA							
	@ CHARTWELL RX	250MG	N018934	001	Jun 29, 1984	Jun	DISC
		250MG	N018934	001	Jun 29, 1984	May	CMFD
	@	500MG	N018934	002	Jun 29, 1984	Jun	DISC
	!	500MG	N018934	002	Jun 29, 1984	May	CMFD
<u>METHYLERGONOVINE MALEATE</u>							
TABLET;ORAL							
METHYLERGONOVINE MALEATE							
AB	! CHARTWELL RX	0.2MG	A091577	001	May 02, 2011	Jun	CAHN
<u>METHYLPHENIDATE HYDROCHLORIDE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
RITALIN LA							
AB1	+ SANDOZ	10MG	N021284	004	Apr 10, 2004	Sep	CAHN
AB1	+	20MG	N021284	001	Jun 05, 2002	Sep	CAHN
AB1	+	30MG	N021284	002	Jun 05, 2002	Sep	CAHN
AB1	+	40MG	N021284	003	Jun 05, 2002	Sep	CAHN
	+ @	60MG	N021284	005	Oct 27, 2014	Sep	CAHN
SOLUTION;ORAL							
METHYLPHENIDATE HYDROCHLORIDE							
AA	PATRIN	5MG/5ML	A210764	001	Apr 10, 2020	Sep	CAHN
AA		10MG/5ML	A210764	002	Apr 10, 2020	Sep	CAHN
TABLET;ORAL							
RITALIN							
AB	+ SANDOZ	5MG	N010187	003		Sep	CAHN
AB	+	10MG	N010187	006		Sep	CAHN
AB	+!	20MG	N010187	010		Sep	CAHN
TABLET, EXTENDED RELEASE;ORAL							
METHYLPHENIDATE HYDROCHLORIDE							
AB	ALKEM LABS LTD	18MG	A214447	001	May 23, 2023	May	NEWA
AB		27MG	A214447	002	May 23, 2023	May	NEWA
AB		36MG	A214447	003	May 23, 2023	May	NEWA
AB		54MG	A214447	004	May 23, 2023	May	NEWA
	@ AMNEAL PHARMS	18MG	A207515	001	Feb 01, 2018	Jun	DISC
	@	27MG	A207515	002	Feb 01, 2018	Jun	DISC
	@	36MG	A207515	003	Feb 01, 2018	Jun	DISC
	@	54MG	A207515	004	Feb 01, 2018	Jun	DISC
AB	SUN PHARM INDS INC	72MG	A217229	001	Aug 25, 2023	Aug	NEWA

METHYLPREDNISOLONE

TABLET; ORAL

MEDROL

+	PFIZER	2MG	N011153	002		Apr	CTEC
	METHYLPREDNISOLONE						
@	CHARTWELL RX	2MG	A209097	001	Feb 22, 2019	May	CAHN
@		4MG	A209097	002	Feb 22, 2019	May	CAHN
@		8MG	A209097	003	Feb 22, 2019	May	CAHN
@		16MG	A209097	004	Feb 22, 2019	May	CAHN
@		32MG	A209097	005	Feb 22, 2019	May	CAHN

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

>A>	AB	AMNEAL	40MG/ML	A216502	001	Nov 03, 2023	Oct	NEWA
>A>	AB		80MG/ML	A216502	002	Nov 03, 2023	Oct	NEWA
	AB	EUGIA PHARMA	40MG/ML	A211930	001	Apr 13, 2023	Apr	NEWA
	AB		80MG/ML	A211930	002	Apr 13, 2023	Apr	NEWA
	AB	HONG KONG	40MG/ML	A040557	001	Feb 23, 2005	Sep	CAHN
	AB		80MG/ML	A040557	002	Feb 23, 2005	Sep	CAHN
	AB	PAR STERILE PRODUCTS	40MG/ML	A214297	001	Jan 21, 2022	Jun	CMFD
	AB	SLAYBACK PHARMA LLC	40MG/ML	A214870	002	May 10, 2023	Apr	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA	!	PHARM ASSOC	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	Jul	CHRS
	@	PHARMOBEDIANT CNSLTG	EQ 5MG BASE/5ML	A074703	001	Oct 31, 1997	Sep	CAHN
	@	VISTAPHARM	EQ 5MG BASE/5ML	A075051	001	Jan 26, 2001	Sep	DISC
	@	XTTRIUM LABS INC	EQ 5MG BASE/5ML	A074703	001	Oct 31, 1997	Jul	DISC
AA	!		EQ 5MG BASE/5ML	A074703	001	Oct 31, 1997	Jan	CAHN

METOLAZONE

TABLET; ORAL

METOLAZONE

AB		AACE PHARMS	2.5MG	A216216	001	Oct 25, 2022	Aug	CMFD
	@		2.5MG	A216216	001	Oct 25, 2022	Apr	DISC
AB			5MG	A216216	002	Oct 25, 2022	Aug	CMFD
	@		5MG	A216216	002	Oct 25, 2022	Apr	DISC
AB			10MG	A216216	003	Oct 25, 2022	Aug	CMFD
	@		10MG	A216216	003	Oct 25, 2022	Apr	DISC
AB		NE RX PHARMA	2.5MG	A216216	001	Oct 25, 2022	Sep	CAHN
AB			5MG	A216216	002	Oct 25, 2022	Sep	CAHN
AB			10MG	A216216	003	Oct 25, 2022	Sep	CAHN
		MYKROX						
	@	CHARTWELL MOLECULAR	0.5MG	N019532	001	Oct 30, 1987	Jul	CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

	@	ACCORD HLTHCARE	EQ 25MG TARTRATE	A215637	001	Oct 18, 2022	Apr	DISC
	@		EQ 50MG TARTRATE	A215637	002	Oct 18, 2022	Apr	DISC
	@		EQ 100MG TARTRATE	A215637	003	Oct 18, 2022	Apr	DISC
	@		EQ 200MG TARTRATE	A215637	004	Oct 18, 2022	Apr	DISC
AB		GRANULES	EQ 25MG TARTRATE	A216509	001	Aug 07, 2023	Jul	NEWA
AB			EQ 25MG TARTRATE	A216916	001	Jun 12, 2023	Jun	NEWA
AB			EQ 50MG TARTRATE	A216509	002	Aug 07, 2023	Jul	NEWA
AB			EQ 50MG TARTRATE	A216916	002	Jun 12, 2023	Jun	NEWA
AB			EQ 100MG TARTRATE	A216509	003	Aug 07, 2023	Jul	NEWA
AB			EQ 100MG TARTRATE	A216916	003	Jun 12, 2023	Jun	NEWA
AB			EQ 200MG TARTRATE	A216509	004	Aug 07, 2023	Jul	NEWA
AB			EQ 200MG TARTRATE	A216916	004	Jun 12, 2023	Jun	NEWA
	@	LUPIN	EQ 25MG TARTRATE	A209272	001	Aug 15, 2023	Aug	DISC
AB			EQ 25MG TARTRATE	A209272	001	Aug 15, 2023	Aug	NEWA
	@		EQ 50MG TARTRATE	A209272	002	Aug 15, 2023	Aug	DISC
AB			EQ 50MG TARTRATE	A209272	002	Aug 15, 2023	Aug	NEWA
	@		EQ 100MG TARTRATE	A209272	003	Aug 15, 2023	Aug	DISC
AB			EQ 100MG TARTRATE	A209272	003	Aug 15, 2023	Aug	NEWA
	@		EQ 200MG TARTRATE	A209272	004	Aug 15, 2023	Aug	DISC
AB			EQ 200MG TARTRATE	A209272	004	Aug 15, 2023	Aug	NEWA

METOPROLOL TARTRATEINJECTABLE; INJECTION
METOPROLOL TARTRATE

@ HOSPIRA

1MG/ML

A075160 001 Jul 06, 1998 Jun DISC

TABLET; ORAL

METOPROLOL TARTRATE

>D>	AB	ZYDUS PHARMS	25MG	A212402	001	Apr 19, 2023	Oct DISC
>A>		@	25MG	A212402	001	Apr 19, 2023	Oct DISC
	AB		25MG	A212402	001	Apr 19, 2023	Apr NEWA
>D>	AB		50MG	A212402	002	Apr 19, 2023	Oct DISC
>A>		@	50MG	A212402	002	Apr 19, 2023	Oct DISC
	AB		50MG	A212402	002	Apr 19, 2023	Apr NEWA
>D>	AB		100MG	A212402	003	Apr 19, 2023	Oct DISC
>A>		@	100MG	A212402	003	Apr 19, 2023	Oct DISC
	AB		100MG	A212402	003	Apr 19, 2023	Apr NEWA

METRONIDAZOLE

CREAM; TOPICAL

METRONIDAZOLE

AB	ZYDUS LIFESCIENCES	0.75%	A217128	001	Apr 21, 2023	Apr NEWA
----	--------------------	-------	---------	-----	--------------	----------

GEL; TOPICAL

METRONIDAZOLE

>A>		@ CHARTWELL RX	1%	A090903	001	Jul 22, 2011	Oct CAHN
AB		COSETTE	1%	A216692	001	Jan 23, 2023	Jan NEWA
>D>		@ TOLMAR	1%	A090903	001	Jul 22, 2011	Oct CAHN
		@	1%	A090903	001	Jul 22, 2011	Feb DISC

GEL; VAGINAL

METRONIDAZOLE

AB	COSETTE	0.75%	A216323	001	Jul 12, 2023	Jun NEWA
	@ ENCUBE	0.75%	A077264	001	Oct 31, 2006	Mar CAHN
AB		0.75%	A215610	001	Jun 16, 2023	Jun NEWA

INJECTABLE; INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

AP	AMNEAL	500MG/100ML	A217665	001	May 24, 2023	Jun CMS1
----	--------	-------------	---------	-----	--------------	----------

SUSPENSION; ORAL

LIKMEZ

+! SAPTALIS PHARMS 500MG/5ML

N216755 001 Sep 22, 2023 Sep NEWA

TABLET; ORAL

FLAGYL

>D>	AB	+ PFIZER	250MG	N012623	001		Oct DISC
>A>		+ @	250MG	N012623	001		Oct DISC
>D>	AB	+!	500MG	N012623	003		Oct DISC
>A>		+ @	500MG	N012623	003		Oct DISC

METRONIDAZOLE

	AB	ALEMBIC	250MG	A208681	001	Jun 20, 2017	Feb CAHN
	AB		500MG	A208681	002	Jun 20, 2017	Feb CAHN
>D>	AB	AUROBINDO PHARMA LTD	500MG	A203974	002	May 29, 2015	Oct CHRS
>A>	AB	!	500MG	A203974	002	May 29, 2015	Oct CHRS

METRONIDAZOLE IN PLASTIC CONTAINER

INJECTABLE; INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

AP	AMNEAL	500MG/100ML	A217665	001	May 24, 2023	May NEWA
----	--------	-------------	---------	-----	--------------	----------

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

AB	CARNEGIE	150MG	A215315	001	Aug 26, 2022	Sep CAHN
AB		200MG	A215315	002	Aug 26, 2022	Sep CAHN
AB		250MG	A215315	003	Aug 26, 2022	Sep CAHN
AB	CHEMISTRY HLTH	150MG	A215876	001	Feb 27, 2023	Sep CAHN
AB		200MG	A215876	002	Feb 27, 2023	Sep CAHN
AB		250MG	A215876	003	Feb 27, 2023	Sep CAHN
AB	LEADING	150MG	A215876	001	Feb 27, 2023	Feb NEWA
AB		200MG	A215876	002	Feb 27, 2023	Feb NEWA
AB		250MG	A215876	003	Feb 27, 2023	Feb NEWA
AB	ZENARA	150MG	A215315	001	Aug 26, 2022	Feb CAHN
AB		200MG	A215315	002	Aug 26, 2022	Feb CAHN
AB		250MG	A215315	003	Aug 26, 2022	Feb CAHN

MICAFUNGIN SODIUMINJECTABLE; INTRAVENOUS
MICAFUNGIN SODIUM

AP	ZYDUS PHARMS	EQ 50MG BASE/VIAL	A215241	001	Oct 24, 2022	Aug CMFD
	@	EQ 50MG BASE/VIAL	A215241	001	Oct 24, 2022	Mar DISC
AP		EQ 100MG BASE/VIAL	A215241	002	Oct 24, 2022	Aug CMFD
	@	EQ 100MG BASE/VIAL	A215241	002	Oct 24, 2022	Mar DISC

SOLUTION; INTRAVENOUS

MICAFUNGIN IN SODIUM CHLORIDE 0.9%

+	BAXTER HLTHCARE CORP	EQ 50MG BASE/50ML (EQ 1MG BASE/ML)	N216142	001	Sep 29, 2023	Sep NEWA
+		EQ 100MG BASE/100ML (EQ 1MG BASE/ML)	N216142	002	Sep 29, 2023	Sep NEWA
+		EQ 150MG BASE/150ML (EQ 1MG BASE/ML)	N216142	003	Sep 29, 2023	Sep NEWA

MIDAZOLAM

SOLUTION; INTRAVENOUS

MIDAZOLAM IN 0.9% SODIUM CHLORIDE

AP	HIKMA	50MG/50ML (1MG/ML)	A216159	001	Apr 17, 2023	Apr NFTG	
AP		100MG/100ML (1MG/ML)	A216159	002	Apr 17, 2023	Apr NFTG	
AP	+	INFORLIFE	50MG/50ML (1MG/ML)	N211844	001	Mar 22, 2021	Apr CFTG
AP	+		100MG/100ML (1MG/ML)	N211844	002	Mar 22, 2021	Apr CFTG

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	MICRO LABS	EQ 1MG BASE/ML	A217504	001	Aug 21, 2023	Aug NEWA
AP		EQ 5MG BASE/ML	A217504	002	Aug 21, 2023	Aug NEWA
	@ RISING	EQ 5MG BASE/ML	A075481	001	Jun 30, 2000	Sep CAHN

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

>A>	AB	MANKIND PHARMA	2.5MG	A217271	001	Nov 01, 2023	Oct NEWA
>A>	AB		5MG	A217271	002	Nov 01, 2023	Oct NEWA
>A>	AB		10MG	A217271	003	Nov 01, 2023	Oct NEWA
>A>	AB	NOVUGEN	2.5MG	A211973	001	Oct 17, 2023	Oct NEWA
>A>	AB		5MG	A211973	002	Oct 17, 2023	Oct NEWA
>A>	AB		10MG	A211973	003	Oct 17, 2023	Oct NEWA

MIGLUSTAT

CAPSULE; ORAL

OPFOLDA

	+	AMICUS THERAP US	65MG	N215211	001	Sep 28, 2023	Sep NEWA
		YARGESA					
AB		EDENBRIDGE PHARMS	100MG	A209821	001	Aug 06, 2020	Jul CTNA

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

	+	ABBVIE	12.5MG	N022256	001	Jan 14, 2009	Jan CAHN
	+		25MG	N022256	002	Jan 14, 2009	Jan CAHN
	+		50MG	N022256	003	Jan 14, 2009	Jan CAHN
	+		100MG	N022256	004	Jan 14, 2009	Jan CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP	SHANDONG	EQ 1MG BASE/ML	A216373	001	Jan 23, 2023	Jan NEWA	
		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
>D>	AP	HOSPIRA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075885	001	May 28, 2002	Oct DISC
>A>		@	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075885	001	May 28, 2002	Oct DISC
>D>	AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A075885	002	May 28, 2002	Oct DISC
>A>		@	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A075885	002	May 28, 2002	Oct DISC

>D>	<u>MINOCYCLINE HYDROCHLORIDE</u>									
>D>	CAPSULE, EXTENDED RELEASE;ORAL									
>D>	XIMINO									
>D>	JOURNEY	EQ 45MG BASE	N201922	001	Jul 11, 2012	Oct	DISC			
>A>	@	EQ 45MG BASE	N201922	001	Jul 11, 2012	Oct	DISC			
>D>		EQ 90MG BASE	N201922	003	Jul 11, 2012	Oct	DISC			
>A>	@	EQ 90MG BASE	N201922	003	Jul 11, 2012	Oct	DISC			
>D>		EQ 135MG BASE	N201922	005	Jul 11, 2012	Oct	DISC			
>A>	@	EQ 135MG BASE	N201922	005	Jul 11, 2012	Oct	DISC			
	INJECTABLE;INJECTION									
	MINOCIN									
	+!	REMPEX	EQ 100MG BASE/VIAL	N050444	001			May	CTEC	
	TABLET, EXTENDED RELEASE;ORAL									
	MINOCYCLINE HYDROCHLORIDE									
AB	ZYDUS PHARMS	EQ 55MG BASE	A203553	002	Jun 16, 2023	Jun	NEWA			
AB		EQ 65MG BASE	A203553	003	Jun 16, 2023	Jun	NEWA			
AB		EQ 115MG BASE	A203553	007	Jun 16, 2023	Jun	NEWA			
	<u>MIRABEGRON</u>									
	TABLET, EXTENDED RELEASE;ORAL									
	MIRABEGRON									
	@	ZYDUS PHARMS	25MG	A209488	001	Sep 29, 2022	Mar	DISC		
	@		50MG	A209488	002	Sep 29, 2022	Mar	DISC		
	<u>MIRTAZAPINE</u>									
	TABLET;ORAL									
	MIRTAZAPINE									
AB	PRASCO	7.5MG	A216751	001	Jan 18, 2023	Jan	NEWA			
AB		15MG	A216751	002	Jan 18, 2023	Jan	NEWA			
AB		30MG	A216751	003	Jan 18, 2023	Jan	NEWA			
AB		45MG	A216751	004	Jan 18, 2023	Jan	NEWA			
>D> AB	SUN PHARM INDS INC	7.5MG	A076541	004	Apr 22, 2004	Oct	CHRS			
>A> AB	!	7.5MG	A076541	004	Apr 22, 2004	Oct	CHRS			
	REMERON									
AB	+!	ORGANON	15MG	N020415	001	Jun 14, 1996	Apr	CAHN		
AB	+		30MG	N020415	002	Jun 14, 1996	Apr	CAHN		
AB	+		30MG	N020415	002	Jun 14, 1996	May	CAHN		
	+	@	45MG	N020415	003	Mar 17, 1997	Apr	CAHN		
	+	@	45MG	N020415	003	Mar 17, 1997	May	CAHN		
	TABLET, ORALLY DISINTEGRATING;ORAL									
	REMERON SOLTAB									
AB	+!	ORGANON USA ORGANON	15MG	N021208	001	Jan 12, 2001	May	CAHN		
AB	+		30MG	N021208	002	Jan 12, 2001	May	CAHN		
AB	+		45MG	N021208	003	Jan 12, 2001	May	CAHN		
	<u>MISOPROSTOL</u>									
	TABLET;ORAL									
	MISOPROSTOL									
	@	NOVEL LABS INC	0.1MG	A091667	001	Jul 25, 2012	Feb	DISC		
	@		0.2MG	A091667	002	Jul 25, 2012	Feb	DISC		
	<u>MITOMYCIN</u>									
	INJECTABLE;INJECTION									
	MITOMYCIN									
>A> AP	EUGIA PHARMA	5MG/VIAL	A216732	001	Oct 30, 2023	Oct	NEWA			
>A> AP		20MG/VIAL	A216732	002	Oct 30, 2023	Oct	NEWA			
>A> AP		40MG/VIAL	A216732	003	Oct 30, 2023	Oct	NEWA			
	<u>MITOXANTRONE HYDROCHLORIDE</u>									
	INJECTABLE;INJECTION									
	MITOXANTRONE HYDROCHLORIDE									
AP	HONG KONG	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A077356	001	Apr 11, 2006	Sep	CAHN			
AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A077356	002	Apr 11, 2006	Sep	CAHN			
AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A077356	003	Apr 11, 2006	Sep	CAHN			

MODAFINILTABLET; ORAL
PROVIGIL

AB	+	CEPHALON	100MG	N020717	001	Dec 24, 1998	Jul CAHN
AB	+	!	200MG	N020717	002	Dec 24, 1998	Jul CAHN

MOMELOTINIB DIHYDROCHLORIDETABLET; ORAL
OJJAARA

+	GLAXOSMITHKLINE	EQ 100MG BASE	N216873	001	Sep 15, 2023	Sep NEWA
+		EQ 150MG BASE	N216873	002	Sep 15, 2023	Sep NEWA
+	!	EQ 200MG BASE	N216873	003	Sep 15, 2023	Sep NEWA

MOMETASONE FUROATELOTION; TOPICAL
ELOCON

+	@ ORGANON	0.1%	N019796	001	Mar 30, 1989	Mar DISC	
AB	!	PADAGIS ISRAEL	0.1%	A077180	001	Apr 06, 2005	Mar CHRS

MONTELUKAST SODIUMTABLET, CHEWABLE; ORAL
MONTELUKAST SODIUM

AB		CHARTWELL MOLECULAR	EQ 4MG BASE	A207464	001	Dec 06, 2018	Jan CAHN
AB			EQ 5MG BASE	A207464	002	Dec 06, 2018	Jan CAHN
AB		RISING	EQ 4MG BASE	A209011	001	Apr 18, 2017	Aug CAHN
AB			EQ 5MG BASE	A209011	002	Apr 18, 2017	Aug CAHN
	@	UNICHEM	EQ 4MG BASE	A208621	001	Jul 02, 2018	Aug DISC
	@		EQ 5MG BASE	A208621	002	Jul 02, 2018	Aug DISC

MORPHINE SULFATEINJECTABLE; INJECTION
MORPHINE SULFATE

AP		HIKMA	2MG/ML	A211452	001	Jan 12, 2023	Sep CAHN
AP			2MG/ML	A211452	001	Jan 12, 2023	Jan NFTG
AP			4MG/ML	A211452	002	Jan 12, 2023	Sep CAHN
AP			4MG/ML	A211452	002	Jan 12, 2023	Jan NEWA
AP			8MG/ML	A211452	003	Jan 12, 2023	Sep CAHN
AP			8MG/ML	A211452	003	Jan 12, 2023	Jan NEWA
AP			10MG/ML	A211452	004	Jan 12, 2023	Sep CAHN
AP			10MG/ML	A211452	004	Jan 12, 2023	Jan NEWA
			15MG/ML	A211452	005	Jan 12, 2023	Sep CAHN
			15MG/ML	A211452	005	Jan 12, 2023	Jan NFTG
AP	+	! HOSPIRA INC	2MG/ML	N202515	001	Nov 14, 2011	Jan CFTG
		SOLUTION; ORAL					
		MORPHINE SULFATE					
AA		PHARM ASSOC	10MG/5ML	A206573	002	Sep 12, 2023	Sep NEWA
		TABLET; ORAL					
		MORPHINE SULFATE					
AB		SPECGX LLC	15MG	A215194	001	Aug 21, 2023	Aug NEWA
AB			30MG	A215194	002	Aug 21, 2023	Aug NEWA
		TABLET, EXTENDED RELEASE; ORAL					
		MORPHABOND ER					
	+	@ OHOMO LIFE	15MG	N206544	001	Oct 02, 2015	Jun CAHN
	+	@	30MG	N206544	002	Oct 02, 2015	Jun CAHN
	+	@	60MG	N206544	003	Oct 02, 2015	Jun CAHN
	+	@	100MG	N206544	004	Oct 02, 2015	Jun CAHN

MOTIXAFORTIDE ACETATEPOWDER; SUBCUTANEOUS
APHEXDA

+	!	BIOLINERX LTD	EQ 62MG BASE/VIAL	N217159	001	Sep 08, 2023	Sep NEWA
---	---	---------------	-------------------	---------	-----	--------------	----------

MOXIFLOXACIN HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
MOXEZA

+	@	HARROW EYE	EQ 0.5% BASE	N022428	001	Nov 19, 2010	Jun DISC
AT2	+	!	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May CAHN
		MOXIFLOXACIN HYDROCHLORIDE					
	@	AKORN	EQ 0.5% BASE	A202916	001	Nov 09, 2017	Jan DISC
	!	LUPIN LTD	EQ 0.5% BASE	A204079	001	May 28, 2015	Jun CHRS

SOLUTION/DROPS;OPHTHALMIC
MOXIFLOXACIN HYDROCHLORIDE

		EQ 0.5% BASE	A204079	001	May 28, 2015	Jun CTEC
	TABLET;ORAL					
	MOXIFLOXACIN HYDROCHLORIDE					
AB	CHARTWELL RX	EQ 400MG BASE	A207285	001	Feb 13, 2017	Apr CAHN
AB	HETERO LABS LTD V	EQ 400MG BASE	A204836	001	Mar 02, 2023	Feb NEWA
	@ TORRENT	EQ 400MG BASE	A200160	001	Apr 03, 2014	Feb DISC

MUPIROCIN CALCIUM

CREAM;TOPICAL
MUPIROCIN

>D>	AB	PADAGIS ISRAEL	EQ 2% BASE	A212465	001	Aug 03, 2022	Oct DISC
>A>		@	EQ 2% BASE	A212465	001	Aug 03, 2022	Oct DISC

MYCOPHENOLATE MOFETIL

FOR SUSPENSION;ORAL
MYCOPHENOLATE MOFETIL

AB	AIRIS PHARMA PVT LTD	200MG/ML	A213955	001	Sep 11, 2023	Sep NEWA
AB	HETERO LABS LTD V	200MG/ML	A213955	001	Sep 11, 2023	Sep CAHN
AB	STRIDES PHARMA	200MG/ML	A212634	001	Aug 29, 2023	Aug NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION
MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP	BPI LABS	500MG/VIAL	A214283	001	Jun 01, 2023	May NEWA
----	----------	------------	---------	-----	--------------	----------

NABUMETONE

TABLET;ORAL
NABUMETONE

	@ AUROBINDO PHARMA USA	500MG	A090516	001	Jul 12, 2010	Apr CAHN
	@	750MG	A090516	002	Jul 12, 2010	Apr CAHN

NADOLOL

TABLET;ORAL
NADOLOL

AB	ALEMBIC	20MG	A211763	001	Jun 02, 2023	May NEWA	
AB		40MG	A211763	002	Jun 02, 2023	May NEWA	
AB		80MG	A211763	003	Jun 02, 2023	May NEWA	
>D>	AB	HERITAGE PHARMA	20MG	A074229	001	Aug 30, 1996	Oct DISC
>A>	@	20MG	A074229	001	Aug 30, 1996	Oct DISC	
>D>	AB	40MG	A074229	002	Aug 30, 1996	Oct DISC	
>A>	@	40MG	A074229	002	Aug 30, 1996	Oct DISC	
>D>	AB	80MG	A074255	001	Jan 24, 1996	Oct DISC	
>A>	@	80MG	A074255	001	Jan 24, 1996	Oct DISC	
AB	RK PHARMA	20MG	A212856	001	Sep 13, 2019	Jun CAHN	
AB		40MG	A212856	002	Sep 13, 2019	Jun CAHN	
AB		80MG	A212856	003	Sep 13, 2019	Jun CAHN	

NAFCILLIN SODIUM

INJECTABLE;INJECTION
NAFCILLIN SODIUM

AP	!	EUGIA PHARMA SPECCLTS	EQ 1GM BASE/VIAL	A091613	001	Dec 26, 2012	Jan CHRS
AP	!		EQ 2GM BASE/VIAL	A091613	002	Dec 26, 2012	Jan CHRS
AP	!		EQ 10GM BASE/VIAL	A091614	001	Dec 26, 2012	Jan CHRS
		@ SANDOZ	EQ 1GM BASE/VIAL	A062527	002	Aug 02, 1984	Jan DISC
		@	EQ 1GM BASE/VIAL	A062732	001	Dec 23, 1986	Jan DISC
		@	EQ 2GM BASE/VIAL	A062527	003	Aug 02, 1984	Jan DISC
		@	EQ 2GM BASE/VIAL	A062732	002	Dec 23, 1986	Jan DISC
		@	EQ 10GM BASE/VIAL	A062527	004	Aug 02, 1984	Jan DISC
>D>		@ STERISCIENCE	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Oct CMFD
>A>	AP		EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Oct CMFD
>D>		@	EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Oct CMFD
>A>	AP		EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Oct CMFD

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL
NAFTIFINE HYDROCHLORIDE

AB	AMNEAL	2%	A206960	001	Apr 10, 2017	Feb CAHN
	GEL;TOPICAL					
	NAFTIFINE HYDROCHLORIDE					
AB	AMNEAL	1%	A206165	001	Mar 20, 2019	Feb CAHN

GEL;TOPICAL									
NAFTIFINE HYDROCHLORIDE									
AB	TARO	2%		A208201	001	Apr 10, 2019	Mar	CMFD	
NAFTIN									
AB	SEBELA IRELAND LTD	2%		N204286	001	Jun 27, 2013	May	CTEC	
	+	2%		N204286	001	Jun 27, 2013	Feb	CTEC	
<u>NALMEFENE HYDROCHLORIDE</u>									
SPRAY;NASAL									
OPVEE									
	INDIVIOR	EQ 2.7MG BASE/SPRAY		N217470	001	May 22, 2023	Jun	CAHN	
	OPIANT PHARMS	EQ 2.7MG BASE/SPRAY		N217470	001	May 22, 2023	May	NEWA	
<u>NALOXEGOL OXALATE</u>									
TABLET;ORAL									
MOVANTIK									
	VALINOR	EQ 12.5MG BASE		N204760	001	Sep 16, 2014	Feb	CAHN	
	+	EQ 25MG BASE		N204760	002	Sep 16, 2014	Feb	CAHN	
<u>NALOXONE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
NALOXONE HYDROCHLORIDE									
AP	BPI LABS	1MG/ML		A216977	001	Oct 06, 2023	Sep	NEWA	
	@ CHARTWELL RX	0.4MG/ML		A207846	001	Dec 17, 2018	Sep	CAHN	
AP	HIKMA	1MG/ML		A212300	001	Jun 10, 2022	Sep	CAHN	
	@ PAR STERILE PRODUCTS	1MG/ML		A215964	001	Jul 29, 2022	Jan	DISC	
SPRAY, METERED;NASAL									
NALOXONE HYDROCHLORIDE									
	TEVA PHARMS USA	4MG/SPRAY		A209522	001	Apr 19, 2019	Jul	CTEC	
>D>	REXTOVY								
>D>	AMPHASTAR PHARMS INC	4MG/SPRAY		N208969	001	Mar 07, 2023	Oct	DISC	
>A>	@	4MG/SPRAY		N208969	001	Mar 07, 2023	Oct	DISC	
	+	4MG/SPRAY		N208969	001	Mar 07, 2023	Jun	CTNA	
	+	4MG/SPRAY		N208969	001	Mar 07, 2023	Mar	NEWA	
<u>NALTREXONE</u>									
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR									
NALTREXONE									
AP	TEVA PHARMS USA INC	380MG/VIAL		A213195	001	Jul 06, 2023	Jun	NFTG	
	VIVITROL								
AP	ALKERMES	380MG/VIAL		N021897	001	Apr 13, 2006	Jun	CFTG	
<u>NAPHAZOLINE HYDROCHLORIDE</u>									
SOLUTION/DROPS;OPHTHALMIC									
NAPHAZOLINE HYDROCHLORIDE									
	@ RISING	0.1%		A083590	001		Sep	CAHN	
<u>NAPROXEN</u>									
TABLET, DELAYED RELEASE;ORAL									
NAPROXEN									
	@ AUROBINDO PHARMA USA	375MG		A075390	001	Apr 19, 2001	Apr	CAHN	
	@	500MG		A075390	002	Apr 19, 2001	Apr	CAHN	
AB	TULEX PHARMS INC	375MG		A216908	001	May 31, 2023	May	NEWA	
AB		500MG		A216908	002	May 31, 2023	May	NEWA	
<u>NARATRIPTAN HYDROCHLORIDE</u>									
TABLET;ORAL									
NARATRIPTAN									
	@ AUROBINDO PHARMA USA	EQ 1MG BASE		A202431	001	May 31, 2012	Apr	CAHN	
	@	EQ 2.5MG BASE		A202431	002	May 31, 2012	Apr	CAHN	
<u>NATAMYCIN</u>									
SUSPENSION;OPHTHALMIC									
NATACYN									
>D>	EYEVANCE	5%		N050514	001		Oct	CAHN	
>A>	HARROW EYE	5%		N050514	001		Oct	CAHN	

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

AB	BEXIMCO PHARMS USA	EQ 2.5MG BASE	A216568	001	Mar 30, 2023	Mar NEWA
AB		EQ 5MG BASE	A216568	002	Mar 30, 2023	Mar NEWA
AB		EQ 10MG BASE	A216568	003	Mar 30, 2023	Mar NEWA
AB		EQ 20MG BASE	A216568	004	Mar 30, 2023	Mar NEWA

NEDOSIRAN SODIUM

SOLUTION; INJECTION

RIVFLOZA

+	NOVO	EQ 80MG BASE/0.5ML (EQ 160MG BASE/ML)	N215842	001	Sep 29, 2023	Sep NEWA
+		EQ 128MG BASE/0.8ML (EQ 160MG BASE/ML)	N215842	002	Sep 29, 2023	Sep NEWA
+		EQ 160MG BASE/ML (EQ 160MG BASE/ML)	N215842	003	Sep 29, 2023	Sep NEWA

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

@	AUROBINDO PHARMA USA	100MG	A076129	002	Sep 16, 2003	Apr CAHN
@		150MG	A076129	003	Sep 16, 2003	Apr CAHN
@		200MG	A076129	004	Sep 16, 2003	Apr CAHN
@		250MG	A076129	005	Sep 16, 2003	Apr CAHN

NELARABINE

INJECTABLE; INTRAVENOUS

ARRANON

AP	+	SANDOZ	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	May CAHN
		NELARABINE					
AP		AMNEAL	250MG/50ML (5MG/ML)	A216346	001	Apr 04, 2023	Mar NEWA
AP		SHORLA	250MG/50ML (5MG/ML)	A214809	001	Mar 03, 2023	Feb NEWA

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

>A>	AP	EUGIA PHARMA	5MG/10ML (0.5MG/ML)	A213244	001	Nov 02, 2023	Oct NEWA
>A>	AP		10MG/10ML (1MG/ML)	A213244	002	Nov 02, 2023	Oct NEWA
	AP	HIKMA	5MG/10ML (0.5MG/ML)	A207042	001	Dec 28, 2015	May CAHN
	AP		10MG/10ML (1MG/ML)	A207042	002	Dec 28, 2015	May CAHN
	AP	SAGENT PHARMS INC	5MG/10ML (0.5MG/ML)	A216542	001	Feb 17, 2023	Feb NEWA
	AP		10MG/10ML (1MG/ML)	A216542	002	Feb 17, 2023	Feb NEWA
	AP	UMEDICA	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Sep CAHN
	AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Sep CAHN

NEPAFENAC

SUSPENSION/DROPS; OPHTHALMIC

ILEVRO

+	HARROW EYE	0.3%	N203491	001	Oct 16, 2012	May CAHN
	NEVANAC					
+	HARROW EYE	0.1%	N021862	001	Aug 19, 2005	May CAHN

NETARSUDIL MESYLATE

SOLUTION/DROPS; OPHTHALMIC

RHOPRESSA

+	ALCON LABS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017	May CAHN
---	----------------	---------------	---------	-----	--------------	----------

NEVIRAPINE

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

@	AUROBINDO PHARMA	100MG	A208616	001	Nov 23, 2016	Sep DISC
@		400MG	A207698	001	Feb 28, 2017	Sep DISC
	VIRAMUNE XR					
+	BOEHRINGER INGELHEIM	100MG	N201152	002	Nov 08, 2012	Sep CTEC

NIACIN

TABLET, EXTENDED RELEASE;ORAL
NIACIN

AB	EYWA	500MG	A213090	001	Aug 25, 2023	Aug NEWA
AB		750MG	A213090	002	Aug 25, 2023	Aug NEWA
AB		1GM	A213090	003	Aug 25, 2023	Aug NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

AB	BIONPHARMA	20MG	A217555	001	May 03, 2023	Sep CAHN
AB		30MG	A217555	002	May 03, 2023	Sep CAHN
AB	SENORES PHARMS	20MG	A215377	001	Jul 17, 2023	Jul NEWA
AB		30MG	A215377	002	Jul 17, 2023	Jul NEWA
AB	SQUARE PHARMS	20MG	A217555	001	May 03, 2023	Apr NEWA
AB		30MG	A217555	002	May 03, 2023	Apr NEWA

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

AP	+! HIKMA INTL PHARMS	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008	Jun CTEC
AP	MICRO LABS	25MG/10ML (2.5MG/ML)	A216420	001	Jul 07, 2023	Jun NEWA
	@ SUN PHARM	25MG/10ML (2.5MG/ML)	N078405	001	Nov 17, 2009	Sep DISC

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

@	PHARMADAX INC	30MG	A216019	001	Nov 18, 2022	Apr DISC
@		60MG	A216019	002	Nov 18, 2022	Apr DISC
@	VITRUVIAS	30MG	A216019	001	Nov 18, 2022	Sep CAHN
@		60MG	A216019	002	Nov 18, 2022	Sep CAHN

NIRAPARIB TOSYLATE

TABLET;ORAL

ZEJULA

+	GLAXOSMITHKLINE	EQ 100MG BASE	N214876	001	Apr 26, 2023	Apr NEWA
+		EQ 200MG BASE	N214876	002	Apr 26, 2023	Apr NEWA
+		EQ 300MG BASE	N214876	003	Apr 26, 2023	Apr NEWA

NIRMATRELVIR; RITONAVIR

TABLET;ORAL

PAXLOVID (COPACKAGED)

+	PFIZER	150MG;100MG	N217188	001	May 25, 2023	May NEWA
+		300MG;100MG	N217188	002	May 25, 2023	May NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

@	AMTA	8.5MG	A216606	001	Apr 10, 2023	Sep DISC
AB		8.5MG	A216606	001	Apr 10, 2023	Mar NEWA

NITISINONE

CAPSULE;ORAL

NITISINONE

>A>	AB	ETON	2MG	A216201	001	May 25, 2023	Oct CAHN
>A>	AB		5MG	A216201	002	May 25, 2023	Oct CAHN
>A>	AB		10MG	A216201	003	May 25, 2023	Oct CAHN
>A>	AB		20MG	A216201	004	May 25, 2023	Oct CAHN
	AB	MEDUNIK	20MG	A212390	004	Apr 27, 2023	Apr NEWA
>D>	AB	ZENARA	2MG	A216201	001	May 25, 2023	Oct CAHN
	AB		2MG	A216201	001	May 25, 2023	May NEWA
>D>	AB		5MG	A216201	002	May 25, 2023	Oct CAHN
	AB		5MG	A216201	002	May 25, 2023	May NEWA
>D>	AB		10MG	A216201	003	May 25, 2023	Oct CAHN
	AB		10MG	A216201	003	May 25, 2023	May NEWA
>D>	AB		20MG	A216201	004	May 25, 2023	Oct CAHN
	AB		20MG	A216201	004	May 25, 2023	May NEWA

NITRIC OXIDE

GAS; INHALATION

GENOSYL

	+!	VERO BIOTECH INC	800PPM	N202860	001	Dec 20, 2019	Jan CAHN
		ULSPIRA					
AA		AIRGAS THERAP	800PPM	A203144	001	Jul 27, 2023	Jul NEWA

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

AB	+	CASPER PHARMA LLC	25MG/5ML	N009175	001		Jun CHRS
	+!		50MG/5ML	N009175	002	Jun 09, 2023	Jun NEWA

NITROFURANTOIN

AB		AUROBINDO PHARMA	25MG/5ML	A212607	001	May 11, 2023	May NEWA
AB		NOVITIUM PHARMA	25MG/5ML	A216385	001	Apr 14, 2023	Apr NEWA

TABLET; ORAL

FURALAN

@ CHARTWELL MOLECULAR

50MG

A080017 001

Jul CAHN

@

100MG

A080017 002

Jul CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

AB		AUROBINDO PHARMA USA	50MG	A074967	001	Jul 09, 1997	Apr CMFD
AB			100MG	A074967	002	Jul 09, 1997	Apr CMFD
AB			100MG	A077025	001	Aug 18, 2004	May CMFD
AB		MANKIND PHARMA	25MG	A217272	001	Mar 21, 2023	Mar NEWA
AB			50MG	A217272	002	Mar 21, 2023	Mar NEWA
AB			100MG	A217272	003	Mar 21, 2023	Mar NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

@ ALVOGEN

75MG; 25MG

A215002 001 Jul 20, 2022 Jan DISC

AB		AUROBINDO PHARMA	75MG; 25MG	A209225	001	Mar 30, 2023	Mar NEWA
----	--	------------------	------------	---------	-----	--------------	----------

AB		MANKIND PHARMA	75MG; 25MG	A217357	001	Jul 11, 2023	Jun NEWA
----	--	----------------	------------	---------	-----	--------------	----------

>A> AB		OMSAV PHARMA	75MG; 25MG	A217073	001	Nov 03, 2023	Oct NEWA
--------	--	--------------	------------	---------	-----	--------------	----------

NITROGLYCERIN

INJECTABLE; INJECTION

NITROGLYCERIN IN DEXTROSE 5%

+! BAXTER HLTHCARE 10MG/100ML

N019970 001 Dec 29, 1989 May CTEC

+! 20MG/100ML

N019970 002 Dec 29, 1989 May CTEC

+! 40MG/100ML

N019970 003 Dec 29, 1989 May CTEC

OINTMENT; TRANSDERMAL

NITROGLYCERIN

+! FOUGERA PHARMS INC 2%

A087355 001 Jul 08, 1988 May CRLD

TABLET; SUBLINGUAL

NITROGLYCERIN

>A> AB		AUROBINDO PHARMA	0.3MG	A217879	001	Oct 26, 2023	Oct NEWA
--------	--	------------------	-------	---------	-----	--------------	----------

>A> AB			0.4MG	A217879	002	Oct 26, 2023	Oct NEWA
--------	--	--	-------	---------	-----	--------------	----------

>A> AB			0.6MG	A217879	003	Oct 26, 2023	Oct NEWA
--------	--	--	-------	---------	-----	--------------	----------

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP		CAPLIN	EQ 1MG BASE/ML	A217575	001	Sep 15, 2023	Sep NEWA
----	--	--------	----------------	---------	-----	--------------	----------

>A> AP		HONG KONG	EQ 1MG BASE/ML	A040455	001	Mar 03, 2003	Oct CAHN
--------	--	-----------	----------------	---------	-----	--------------	----------

>D> AP		TEVA PHARMS USA	EQ 1MG BASE/ML	A040455	001	Mar 03, 2003	Oct CAHN
--------	--	-----------------	----------------	---------	-----	--------------	----------

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION; ORAL

NORTRIPTYLINE HYDROCHLORIDE

AA	!	PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 23, 2000	Aug CTEC
----	---	-------------	------------------	---------	-----	--------------	----------

AA		RUBICON	EQ 10MG BASE/5ML	A217731	001	Aug 15, 2023	Aug NEWA
----	--	---------	------------------	---------	-----	--------------	----------

NYSTATIN

		OINTMENT; TOPICAL							
		NYSTATIN							
		@ TORRENT	100,000 UNITS/GM	A211838	001	Jan 28, 2019	Mar	DISC	
		POWDER; TOPICAL							
		NYSTATIN							
AT		BEOWULF ASSET	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Sep	CAHN	
		SUSPENSION; ORAL							
		NILSTAT							
		+ @ CHARTWELL MOLECULES	100,000 UNITS/ML	N050299	001		Apr	CAHN	
		NYSTATIN							
>D>	AA	DASTECH GENERICS	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Oct	CAHN	
>A>	AA	MLV	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Oct	CAHN	
>D>	AA	VISTAPHARM	100,000 UNITS/ML	A064142	001	Jun 25, 1998	Oct	DISC	
>A>		@	100,000 UNITS/ML	A064142	001	Jun 25, 1998	Oct	DISC	
>D>	AA		100,000 UNITS/ML	A064142	002	Mar 07, 2011	Oct	DISC	
>A>		@	100,000 UNITS/ML	A064142	002	Mar 07, 2011	Oct	DISC	

NYSTATIN; TRIAMCINOLONE ACETONIDE

		CREAM; TOPICAL							
		NYSTATIN AND TRIAMCINOLONE ACETONIDE							
		@ TORRENT	100,000 UNITS/GM; 0.1%	A213142	001	Jul 14, 2020	Aug	DISC	
		OINTMENT; TOPICAL							
		NYSTATIN AND TRIAMCINOLONE ACETONIDE							
>D>	AT	AKORN	100,000 UNITS/GM; 0.1%	A207217	001	Aug 04, 2017	Oct	CAHN	
>A>	AT	EPIC PHARMA LLC	100,000 UNITS/GM; 0.1%	A207217	001	Aug 04, 2017	Oct	CAHN	
		@ PAI HOLDINGS PHARM	100,000 UNITS/GM; 0.1%	A208287	001	Dec 30, 2016	Aug	DISC	

OBETICHOLIC ACID

		TABLET; ORAL							
		OBETICHOLIC ACID							
		@ APOTEX	5MG	A214862	001	May 30, 2023	Sep	DISC	
AB			5MG	A214862	001	May 30, 2023	May	NFTG	
		@	10MG	A214862	002	May 30, 2023	Sep	DISC	
AB			10MG	A214862	002	May 30, 2023	May	NFTG	
>D>	AB	LUPIN LTD	5MG	A214980	001	May 30, 2023	Oct	DISC	
>A>		@	5MG	A214980	001	May 30, 2023	Oct	DISC	
AB			5MG	A214980	001	May 30, 2023	May	NFTG	
>D>	AB		10MG	A214980	002	May 30, 2023	Oct	DISC	
>A>		@	10MG	A214980	002	May 30, 2023	Oct	DISC	
AB			10MG	A214980	002	May 30, 2023	May	NFTG	
		@ MSN	5MG	A215017	001	May 30, 2023	Jun	DISC	
AB			5MG	A215017	001	May 30, 2023	May	NFTG	
		@	10MG	A215017	002	May 30, 2023	Jun	DISC	
AB			10MG	A215017	002	May 30, 2023	May	NFTG	
		OICALIVA							
>D>	AB	+ INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016	Oct	CTEC	
>A>		+	5MG	N207999	001	May 27, 2016	Oct	CTEC	
AB		+	5MG	N207999	001	May 27, 2016	May	CFTG	
>D>	AB	+!	10MG	N207999	002	May 27, 2016	Oct	CTEC	
>A>		+!	10MG	N207999	002	May 27, 2016	Oct	CTEC	
AB		+	10MG	N207999	002	May 27, 2016	May	CFTG	

OCTREOTIDE ACETATE

		INJECTABLE; INJECTION							
		OCTREOTIDE ACETATE							
AP		GLAND PHARMA LTD	EQ 0.1MG BASE/ML	A216839	002	Jun 22, 2023	Jun	NEWA	
AP			EQ 0.2MG BASE/ML	A216807	001	Jun 13, 2023	Jun	NEWA	
AP			EQ 0.5MG BASE/ML	A216839	001	Jun 22, 2023	Jun	NEWA	
AP			EQ 1MG BASE/ML	A216807	002	Jun 13, 2023	Jun	NEWA	
>A>	AP	HONG KONG	EQ 0.05MG BASE/ML	A075957	001	Oct 03, 2005	Oct	CAHN	
>A>	AP		EQ 0.1MG BASE/ML	A075957	002	Oct 03, 2005	Oct	CAHN	
>A>	AP		EQ 0.2MG BASE/ML	A075959	001	Nov 21, 2005	Oct	CAHN	
>A>	AP		EQ 0.5MG BASE/ML	A075957	003	Oct 03, 2005	Oct	CAHN	
>A>	AP		EQ 1MG BASE/ML	A075959	002	Nov 21, 2005	Oct	CAHN	
>D>	AP	TEVA PHARMS USA	EQ 0.05MG BASE/ML	A075957	001	Oct 03, 2005	Oct	CAHN	
>D>	AP		EQ 0.1MG BASE/ML	A075957	002	Oct 03, 2005	Oct	CAHN	
>D>	AP		EQ 0.2MG BASE/ML	A075959	001	Nov 21, 2005	Oct	CAHN	
>D>	AP		EQ 0.5MG BASE/ML	A075957	003	Oct 03, 2005	Oct	CAHN	
>D>	AP		EQ 1MG BASE/ML	A075959	002	Nov 21, 2005	Oct	CAHN	

OFLOXACINSOLUTION/DROPS;OPHTHALMIC
OFLOXACIN

AT	SENTISS	0.3%	A076407	001	Apr 15, 2008	Aug CAHN
----	---------	------	---------	-----	--------------	----------

OLANZAPINEINJECTABLE; INTRAMUSCULAR
OLANZAPINE

AP	ASPIRO	10MG/VIAL	A217466	001	Mar 22, 2023	Mar NEWA
----	--------	-----------	---------	-----	--------------	----------

TABLET; ORAL
OLANZAPINE

AB	CADILA PHARMS LTD	2.5MG	A210022	001	Feb 24, 2023	Feb NEWA
AB		5MG	A210022	002	Feb 24, 2023	Feb NEWA
AB		7.5MG	A210022	003	Feb 24, 2023	Feb NEWA
AB		10MG	A210022	004	Feb 24, 2023	Feb NEWA
AB		15MG	A210022	005	Feb 24, 2023	Feb NEWA
AB		20MG	A210022	006	Feb 24, 2023	Feb NEWA

ZYPREXA

AB	+ CHEPLAPHARM	2.5MG	N020592	001	Sep 30, 1996	Sep CAHN
AB	+!	5MG	N020592	002	Sep 30, 1996	Sep CAHN
AB	+	7.5MG	N020592	003	Sep 30, 1996	Sep CAHN
AB	+	10MG	N020592	004	Sep 30, 1996	Sep CAHN
AB	+	15MG	N020592	005	Sep 09, 1997	Sep CAHN
AB	+	20MG	N020592	006	Sep 09, 1997	Sep CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
OLANZAPINE

AB	HISUN PHARM HANGZHOU	5MG	A206892	001	Dec 31, 2020	Apr CMFD
AB		10MG	A206892	002	Dec 31, 2020	Apr CMFD
AB		15MG	A206892	003	Dec 31, 2020	Apr CMFD
AB		20MG	A206892	004	Dec 31, 2020	Apr CMFD
	@ ZYDUS PHARMS	5MG	A202889	001	Mar 09, 2023	Jul DISC
AB		5MG	A202889	001	Mar 09, 2023	Mar NEWA
	@	10MG	A202889	002	Mar 09, 2023	Jul DISC
AB		10MG	A202889	002	Mar 09, 2023	Mar NEWA
	@	15MG	A202889	003	Mar 09, 2023	Jul DISC
AB		15MG	A202889	003	Mar 09, 2023	Mar NEWA
	@	20MG	A202889	004	Mar 09, 2023	Jul DISC
AB		20MG	A202889	004	Mar 09, 2023	Mar NEWA

ZYPREXA ZYDIS

AB	+! CHEPLAPHARM	5MG	N021086	001	Apr 06, 2000	Sep CAHN
AB	+	10MG	N021086	002	Apr 06, 2000	Sep CAHN
AB	+	15MG	N021086	003	Apr 06, 2000	Sep CAHN
AB	+	20MG	N021086	004	Apr 06, 2000	Sep CAHN

OLANZAPINE PAMOATESUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
ZYPREXA RELPREVV

+	CHEPLAPHARM	EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009	Sep CAHN
+		EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009	Aug CAHN
+		EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009	Sep CAHN
+		EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009	Aug CAHN
+!		EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009	Sep CAHN
+!		EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009	Aug CAHN

OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL

>D>	AB	AMNEAL	5MG	A207480	001	Jul 11, 2023	Oct DISC
>A>		@	5MG	A207480	001	Jul 11, 2023	Oct DISC
	AB		5MG	A207480	001	Jul 11, 2023	Jun NEWA
>D>	AB		20MG	A207480	002	Jul 11, 2023	Oct DISC
>A>		@	20MG	A207480	002	Jul 11, 2023	Oct DISC
	AB		20MG	A207480	002	Jul 11, 2023	Jun NEWA
>D>	AB		40MG	A207480	003	Jul 11, 2023	Oct DISC
>A>		@	40MG	A207480	003	Jul 11, 2023	Oct DISC
	AB		40MG	A207480	003	Jul 11, 2023	Jun NEWA
	AB	MSN	5MG	A217399	001	Jan 18, 2023	Jan NEWA
	AB		20MG	A217399	002	Jan 18, 2023	Jan NEWA
	AB		40MG	A217399	003	Jan 18, 2023	Jan NEWA
		@ TORRENT	5MG	A202375	001	Apr 24, 2017	Aug DISC
		@	20MG	A202375	002	Apr 24, 2017	Aug DISC
		@	40MG	A202375	003	Apr 24, 2017	Aug DISC

OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL
OLOPATADINE HYDROCHLORIDE

AB	!	AMNEAL	0.665MG/SPRAY	A210901	001	Jan 28, 2020	May CHRS
		PATANASE					
	+	@ NOVARTIS	0.665MG/SPRAY	N021861	001	Apr 15, 2008	May DISC

OMAVELOXOLONE

CAPSULE;ORAL
SKYCLARYS

	+	! REATA PHARMS	50MG	N216718	001	Feb 28, 2023	Feb NEWA
--	---	----------------	------	---------	-----	--------------	----------

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

AB		ANDA REPOSITORY	20MG;1.1GM	A212587	001	Apr 30, 2020	Sep CAHN
AB			40MG;1.1GM	A212587	002	Apr 30, 2020	Sep CAHN

OMIDENEPAG ISOPROPYL

SOLUTION;OPHTHALMIC
OMLONTI

	+	@ SANTEN	0.002%	N215092	001	Sep 22, 2022	May DISC
--	---	----------	--------	---------	-----	--------------	----------

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

	!	CHARTWELL MOLECULES	16MG	A077406	001	Dec 26, 2006	Mar CHRS
	!		24MG	A077406	002	Dec 26, 2006	Mar CHRS
>A> AB		IPCA LABS LTD	4MG	A209389	001	Oct 30, 2023	Oct NEWA
>A> AB			8MG	A209389	002	Oct 30, 2023	Oct NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION
ZOFTRAN

	+	@ SANDOZ	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	May CAHN
		ZOFTRAN PRESERVATIVE FREE					
	+	@ SANDOZ	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	May CAHN
		SOLUTION;ORAL					
		ONDANSETRON HYDROCHLORIDE					
AA		CHARTWELL MOLECULAR	EQ 4MG BASE/5ML	A091342	001	Jan 27, 2011	Jul CAHN
		ZOFTRAN					
	+	@ SANDOZ	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	May CAHN
		TABLET;ORAL					
		ONDANSETRON HYDROCHLORIDE					
	!	CHARTWELL MOLECULES	EQ 24MG BASE	A077303	004	Jun 25, 2007	Feb CTEC
		ZOFTRAN					
	+	@ SANDOZ	EQ 4MG BASE	N020103	001	Dec 31, 1992	May CAHN
	+	@	EQ 8MG BASE	N020103	002	Dec 31, 1992	May CAHN
	+	@	EQ 24MG BASE	N020103	003	Aug 27, 1999	May CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL
ORPHENADRINE CITRATE

AB		RISING	100MG	A040249	001	Jan 29, 1999	Jan CAHN
----	--	--------	-------	---------	-----	--------------	----------

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL
OSELTAMIVIR PHOSPHATE

	@	ACCORD HLTHCARE	EQ 30MG BASE	A214726	001	Jul 25, 2022	Feb DISC
	@		EQ 45MG BASE	A214726	002	Jul 25, 2022	Feb DISC
	@		EQ 75MG BASE	A214726	003	Jul 25, 2022	Feb DISC
AB		INVAGEN PHARMS	EQ 30MG BASE	A217467	001	Oct 03, 2023	Sep NEWA
AB			EQ 45MG BASE	A217467	002	Oct 03, 2023	Sep NEWA
AB			EQ 75MG BASE	A217467	003	Oct 03, 2023	Sep NEWA
AB		SUNSHINE	EQ 30MG BASE	A212739	001	Mar 04, 2020	Jun CMFD
AB			EQ 45MG BASE	A212739	002	Mar 04, 2020	Jun CMFD
AB			EQ 75MG BASE	A212739	003	Mar 04, 2020	Jun CMFD

FOR SUSPENSION;ORAL
OSELTAMIVIR PHOSPHATE

	@	CHEMISTRY HLTH	EQ 6MG BASE/ML	A214949	001	Feb 28, 2022	Sep CAHN
--	---	----------------	----------------	---------	-----	--------------	----------

FOR SUSPENSION;ORAL							
OSELTAMIVIR PHOSPHATE							
AB	EPIC PHARMA LLC	EQ 6MG BASE/ML	A215538	001	Feb 14, 2023	Feb	NEWA
<u>OSILODROSTAT PHOSPHATE</u>							
TABLET;ORAL							
ISTURISA							
	+ @ RECORDATI RARE	EQ 10MG BASE	N212801	003	Mar 06, 2020	Jul	DISC
<u>OXACILLIN SODIUM</u>							
INJECTABLE;INJECTION							
OXACILLIN SODIUM							
	@ PIRAMAL CRITICAL	EQ 10GM BASE/VIAL	A206760	001	Oct 26, 2017	Sep	DISC
<u>OXAPROZIN</u>							
>A> CAPSULE;ORAL							
>A> COXANTO							
>A>	+! SOLUBIOMIX	300MG	N217927	001	Oct 20, 2023	Oct	NEWA
<u>OXCARBAZEPINE</u>							
SUSPENSION;ORAL							
OXCARBAZEPINE							
AB	CHARTWELL RX	300MG/5ML	A212428	001	Jun 21, 2021	May	CAHN
>A> AB	HETERO LABS LTD III	300MG/5ML	A216749	001	Oct 20, 2023	Oct	NEWA
AB	OAK TREE PHARMA	300MG/5ML	A211420	001	Jul 09, 2021	Aug	CAHN
	@ RENEW PHARMS	300MG/5ML	A211420	001	Jul 09, 2021	Sep	DISC
AB		300MG/5ML	A211420	001	Jul 09, 2021	Aug	CAHN
TABLET;ORAL							
OXCARBAZEPINE							
AB	ZYDUS	150MG	A211747	001	Jul 03, 2023	Jun	NEWA
AB		300MG	A211747	002	Jul 03, 2023	Jun	NEWA
AB		600MG	A211747	003	Jul 03, 2023	Jun	NEWA
TABLET, EXTENDED RELEASE;ORAL							
OXCARBAZEPINE							
	@ APOTEX	150MG	A213369	001	Jul 13, 2023	Sep	DISC
AB		150MG	A213369	001	Jul 13, 2023	Jul	NFTG
	@	300MG	A213369	002	Jul 13, 2023	Sep	DISC
AB		300MG	A213369	002	Jul 13, 2023	Jul	NFTG
	@	600MG	A213369	003	Jul 13, 2023	Sep	DISC
AB		600MG	A213369	003	Jul 13, 2023	Jul	NFTG
OXTELLAR XR							
	+ SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012	Sep	CTEC
AB	+	150MG	N202810	001	Oct 19, 2012	Jul	CFTG
	+	300MG	N202810	002	Oct 19, 2012	Sep	CTEC
AB	+	300MG	N202810	002	Oct 19, 2012	Jul	CFTG
	+!	600MG	N202810	003	Oct 19, 2012	Sep	CTEC
AB	+!	600MG	N202810	003	Oct 19, 2012	Jul	CFTG
<u>OXYBUTYNIN CHLORIDE</u>							
GEL;TRANSDERMAL							
GELNIQUE							
	+ @ ABBVIE	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	Sep	DISC
	+!	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	Apr	CAHN
SYRUP;ORAL							
OXYBUTYNIN CHLORIDE							
AA	CHARTWELL RX	5MG/5ML	A075039	001	Jan 29, 1999	Mar	CMFD
	@ PHARMOBEDIANT CNSLTG	5MG/5ML	A074868	001	Feb 12, 1997	Sep	CAHN
	@ XTTRIUM LABS INC	5MG/5ML	A074868	001	Feb 12, 1997	Mar	CAHN
TABLET;ORAL							
OXYBUTYNIN CHLORIDE							
	! APPCO	2.5MG	A209025	002	Feb 07, 2023	Jan	NFTG
AB	AVET LIFESCIENCES	5MG	A211682	001	May 10, 2019	Jun	CTEC
	! RISING	2.5MG	A209025	002	Feb 07, 2023	Sep	CAHN
AB		5MG	A209025	001	Dec 21, 2017	Sep	CAHN
TABLET, EXTENDED RELEASE;ORAL							
DITROPAN XL							
	+ @ JANSSEN PHARMS	5MG	N020897	001	Dec 16, 1998	Sep	DISC
	+ @	10MG	N020897	002	Dec 16, 1998	Sep	DISC

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

@ PHARMOBEDIANT CNSLTG 5MG/5ML
 @ VISTAPHARM 100MG/5ML

A206456 001 Jun 16, 2015 Sep CAHN
 A202537 001 Jul 30, 2012 Sep DISC

TABLET; ORAL

OXAYDO

+ @ ZYLA 5MG
 + @ 7.5MG

N202080 001 Jun 17, 2011 Sep DISC
 N202080 002 Jun 17, 2011 Sep DISC

OXYMETAZOLINE HYDROCHLORIDE

CREAM; TOPICAL

RHOFADÉ

+! MAYNE PHARMA 1%

N208552 001 Jan 18, 2017 Sep CAHN

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

@ DASH PHARMS 6MG/ML

A091540 001 Sep 29, 2011 Feb CAHN

POWDER; INTRAVENOUS

PACLITAXEL

+! AM REGENT 100MG/VIAL

N211875 001 Jul 27, 2022 Apr CAHN

PALBOCICLIB

TABLET; ORAL

IBRANCE

AB + PFIZER 75MG
 AB + 100MG
 AB +! 125MG

N212436 001 Nov 01, 2019 Aug CFTG
 N212436 002 Nov 01, 2019 Aug CFTG
 N212436 003 Nov 01, 2019 Aug CFTG

PALBOCICLIB

AB SYNTHON PHARMS INC 75MG
 AB 100MG
 AB 125MG

A215570 001 Aug 28, 2023 Aug NFTG
 A215570 002 Aug 28, 2023 Aug NFTG
 A215570 003 Aug 28, 2023 Aug NFTG

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

PALIPERIDONE

AB ASCENT PHARMS INC 1.5MG
 AB 3MG
 AB 6MG
 AB 9MG

A216174 001 Aug 23, 2023 Aug NEWA
 A216174 002 Aug 23, 2023 Aug NEWA
 A216174 003 Aug 23, 2023 Aug NEWA
 A216174 004 Aug 23, 2023 Aug NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP CHARTWELL RX EQ 0.25MG BASE/5ML (EQ 0.05MG
 BASE/ML)
 @ CIPLA EQ 0.25MG BASE/5ML (EQ 0.05MG
 BASE/ML)
 @ INGENUS PHARMS LLC EQ 0.25MG BASE/5ML (EQ 0.05MG
 BASE/ML)
 AP NANJING KING-FRIEND EQ 0.25MG BASE/5ML (EQ 0.05MG
 BASE/ML)
 @ NOVAST LABS EQ 0.25MG BASE/5ML (EQ 0.05MG
 BASE/ML)

A209287 001 Sep 19, 2018 Sep CAHN
 A206396 001 Sep 19, 2018 Feb DISC
 A208789 001 May 22, 2020 Feb DISC
 A215861 001 Aug 14, 2023 Aug NEWA
 A208789 001 May 22, 2020 Sep CAHN

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

@ HIKMA EQ 0.25MG BASE/2ML (EQ 0.125MG
 BASE/ML)

N207963 001 Aug 22, 2016 Sep DISC

PALOVAROTENE

CAPSULE; ORAL

SOHONOS

+ IPSEN INC 1MG
 + 1.5MG
 + 2.5MG
 + 5MG
 +! 10MG

N215559 001 Aug 16, 2023 Aug NEWA
 N215559 002 Aug 16, 2023 Aug NEWA
 N215559 003 Aug 16, 2023 Aug NEWA
 N215559 004 Aug 16, 2023 Aug NEWA
 N215559 005 Aug 16, 2023 Aug NEWA

PAMIDRONATE DISODIUMINJECTABLE; INJECTION
PAMIDRONATE DISODIUM

AP2	DR REDDYS	30MG/10ML (3MG/ML)	A078156	001	Aug 19, 2008	May CTEC
AP2		90MG/10ML (9MG/ML)	A078156	003	Aug 19, 2008	May CTEC
AP1	HIKMA	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	May CTEC
AP1	+	90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	May CTEC
AP2	HOSPIRA	30MG/10ML (3MG/ML)	A075841	001	Jun 27, 2002	May CTEC
AP		30MG/10ML (3MG/ML)	A075841	001	Jun 27, 2002	Apr CHRS
AP2		90MG/10ML (9MG/ML)	A075841	003	Jun 27, 2002	May CTEC
AP		90MG/10ML (9MG/ML)	A075841	003	Jun 27, 2002	Apr CHRS
AP2	MYLAN LABS LTD	30MG/10ML (3MG/ML)	A078520	001	Oct 31, 2008	May CTEC
AP2		90MG/10ML (9MG/ML)	A078520	002	Oct 31, 2008	May CTEC
AP1	SAGENT PHARMS INC	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	May CTEC
AP1		90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	May CTEC

PANTOPRAZOLE SODIUMFOR SUSPENSION, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

AB	AJANTA PHARMA LTD	EQ 40MG BASE	A217416	001	Feb 09, 2023	Feb NEWA
>A> AB	ANNORA PHARMA	EQ 40MG BASE	A216139	001	Oct 27, 2023	Oct NEWA
AB	DEXCEL	EQ 40MG BASE	A216247	001	Jun 16, 2023	Jun NEWA

INJECTABLE; INTRAVENOUS
PANTOPRAZOLE SODIUM

AP	KNACK	EQ 40MG BASE/VIAL	A214680	001	May 19, 2022	Sep CMFD
----	-------	-------------------	---------	-----	--------------	----------

PAROXETINE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
PAROXETINE HYDROCHLORIDE

@	EPIC PHARMA LLC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jan CAHN
@		EQ 25MG BASE	A213612	002	Aug 11, 2021	Jan CAHN
@		EQ 37.5MG BASE	A213612	003	May 26, 2022	Jan CAHN

PAROXETINE MESYLATETABLET; ORAL
PEXEVA

+	@ SEBELA IRELAND LTD	EQ 10MG BASE	N021299	001	Jul 03, 2003	May DISC
+	@	EQ 20MG BASE	N021299	002	Jul 03, 2003	May DISC
+	@	EQ 30MG BASE	N021299	003	Jul 03, 2003	May DISC

PATRIOMER SORBITE X CALCIUMPOWDER; ORAL
VELTASSA

>A>	+	VIFOR PHARMA	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Oct NEWA
-----	---	--------------	--------------------	---------	-----	--------------	----------

PAZOPANIB HYDROCHLORIDETABLET; ORAL
PAZOPANIB HYDROCHLORIDE

>A>	AB	APOTEX	EQ 200MG BASE	A217713	001	Oct 19, 2023	Oct NEWA
>A>	AB	SUN PHARM	EQ 200MG BASE	A215837	001	Oct 19, 2023	Oct NFTG
>A>	AB	TEVA PHARMS INC	EQ 200MG BASE	A217517	001	Oct 19, 2023	Oct NEWA
		VOTRIENT					
>D>	+	NOVARTIS	EQ 200MG BASE	N022465	001	Oct 19, 2009	Oct CFTG
>A>	AB	+	EQ 200MG BASE	N022465	001	Oct 19, 2009	Oct CFTG

PEGCETACOPLANSOLUTION; INTRAVITREAL
SYFOVRE

+	APELLIS PHARMS	15MG/0.1ML (15MG/0.1ML)	N217171	001	Feb 17, 2023	Feb NEWA
---	----------------	-------------------------	---------	-----	--------------	----------

PEMETREXED DISODIUMPOWDER; INTRAVENOUS
PEMETREXED DISODIUM

	@ AMNEAL	EQ 100MG BASE/VIAL	A210047	002	May 08, 2023	Jun DISC
AP		EQ 100MG BASE/VIAL	A210047	002	May 08, 2023	Apr NEWA
	@	EQ 500MG BASE/VIAL	A210047	001	Aug 04, 2022	Jun DISC
AP	MEITHEAL	EQ 100MG BASE/VIAL	A215479	001	Dec 13, 2022	Jan CAHN
AP		EQ 500MG BASE/VIAL	A215479	002	Dec 13, 2022	Jan CAHN
AP		EQ 750MG BASE/VIAL	A215479	003	Dec 13, 2022	Jan CAHN
AP		EQ 1GM BASE/VIAL	A215479	004	Dec 13, 2022	Jan CAHN
	@ MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203628	001	Mar 10, 2023	Mar DISC

POWDER; INTRAVENOUS							
PEMETREXED DISODIUM							
AP		EQ 500MG BASE/VIAL	A203628	001	Mar 10, 2023	Mar	NEWA
SOLUTION; INTRAVENOUS							
PEMETREXED							
+	SHILPA	EQ 100MG/10ML BASE (10MG/ML)	N215179	001	May 22, 2023	May	NEWA
+		EQ 500MG/50ML BASE (10MG/ML)	N215179	002	May 22, 2023	May	NEWA
+		EQ 1GM/100ML BASE (10MG/ML)	N215179	003	May 22, 2023	May	NEWA
PEMETREXED DISODIUM							
+	SANDOZ	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214657	001	May 26, 2022	Jan	CMS1
<u>PENCICLOVIR</u>							
CREAM; TOPICAL							
PENCICLOVIR							
AB	TORRENT	1%	A216981	001	Aug 07, 2023	Jul	NEWA
<u>PENTAMIDINE ISETHIONATE</u>							
FOR SOLUTION; INHALATION							
PENTAMIDINE ISETHIONATE							
AN	X-GEN PHARMS INC	300MG/VIAL	A206983	001	Jan 20, 2023	Jan	NEWA
<u>PENTOBARBITAL SODIUM</u>							
INJECTABLE; INJECTION							
PENTOBARBITAL SODIUM							
AP	PRAXGEN PHARMS	50MG/ML	A206677	001	Nov 27, 2017	Jul	CAHN
<u>PERAMPANEL</u>							
SUSPENSION; ORAL							
FYCOMPA							
+	CATALYST PHARMS	0.5MG/ML	N208277	001	Apr 29, 2016	Feb	CAHN
TABLET; ORAL							
FYCOMPA							
+	CATALYST PHARMS	2MG	N202834	001	Oct 22, 2012	Feb	CAHN
+		4MG	N202834	002	Oct 22, 2012	Feb	CAHN
+		6MG	N202834	003	Oct 22, 2012	Feb	CAHN
+		8MG	N202834	004	Oct 22, 2012	Feb	CAHN
+		10MG	N202834	005	Oct 22, 2012	Feb	CAHN
+		12MG	N202834	006	Oct 22, 2012	Feb	CAHN
<u>PERFLUOROHEXYLOCTANE</u>							
SOLUTION/DROPS; OPHTHALMIC							
MIEBO							
+	BAUSCH AND LOMB INC	1.338GM/ML	N216675	001	May 18, 2023	May	NEWA
<u>PERMETHRIN</u>							
CREAM; TOPICAL							
ELIMITE							
>D>	+ @ AUROBINDO PHARMA USA	5%	N019855	001	Aug 25, 1989	Oct	CMFD
>A>	AB +	5%	N019855	001	Aug 25, 1989	Oct	CMFD
PERMETHRIN							
AB	DR REDDYS LABS EU	5%	A209732	001	Aug 01, 2023	Jul	NEWA
<u>PEXIDARTINIB HYDROCHLORIDE</u>							
CAPSULE; ORAL							
TURALIO							
+	@ DAIICHI SANKYO INC	EQ 200MG BASE	N211810	001	Aug 02, 2019	Jun	DISC
<u>PHENOXYBENZAMINE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
PHENOXYBENZAMINE HYDROCHLORIDE							
AB	AUROBINDO PHARMA	10MG	A215600	001	May 08, 2023	Apr	NEWA
AB	RISING	10MG	A204551	001	Jun 20, 2023	Jun	NEWA
<u>PHENTERMINE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
PHENTERMINE HYDROCHLORIDE							
	@ LANNETT	15MG	A087022	002	Jan 20, 2012	Feb	DISC
	@	30MG	A087022	001	Feb 03, 1983	Feb	DISC

PHENTOLAMINE MESYLATESOLUTION;OPHTHALMIC
RYZUMVI

+!	OCUPHIRE	EQ 0.75% BASE	N217064	001	Sep 25, 2023	Sep NEWA
----	----------	---------------	---------	-----	--------------	----------

PHENYLEPHRINE HYDROCHLORIDESOLUTION;INTRAVENOUS
IMMPHENTIV

+	HIKMA	0.5MG/5ML (0.1MG/ML)	N203826	004	Mar 09, 2023	May CAHN
+		0.5MG/5ML (0.1MG/ML)	N203826	004	Mar 09, 2023	Mar NEWA
+		1MG/10ML (0.1MG/ML)	N203826	005	Mar 09, 2023	May CAHN
+		1MG/10ML (0.1MG/ML)	N203826	005	Mar 09, 2023	Mar NEWA

PHENYLEPHRINE HYDROCHLORIDE

AP2	AVET LIFESCIENCES	10MG/ML (10MG/ML)	A209968	001	Feb 28, 2023	Feb NEWA	
AP2	BE PHARMS	10MG/ML (10MG/ML)	A217521	001	Jun 26, 2023	Jun NEWA	
AP2		50MG/5ML (10MG/ML)	A217521	002	Jun 26, 2023	Jun NEWA	
AP2		100MG/10ML (10MG/ML)	A217521	003	Jun 26, 2023	Jun NEWA	
AP2	+	HIKMA	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	May CAHN
	+		50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	Jun CTEC
AP2	+		50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	May CAHN
	+		100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	Jun CTEC
AP2	+		100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	May CAHN

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT	+	AKORN	2.5%	N207926	001	Jan 15, 2015	Jul CHRS
AT	+		10%	N207926	002	Jan 15, 2015	Jul CHRS
AT	+	ALCON	2.5%	N207926	001	Jan 15, 2015	Jul CAHN
AT	+		10%	N207926	002	Jan 15, 2015	Jul CAHN
AT	!	MANKIND PHARMA	2.5%	A216859	001	Sep 29, 2022	Jul CHRS
AT	!		10%	A216496	001	Jan 11, 2023	Jul CHRS

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE VC PLAIN

@	XTTRIUM LABS INC	5MG/5ML;6.25MG/5ML	A088897	001	Jan 04, 1985	Jan CAHN
---	------------------	--------------------	---------	-----	--------------	----------

PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDESPRAY, METERED;OPHTHALMIC
MYDCOMBI

+	EYENOVIA	2.5%;1%	N215352	001	May 05, 2023	May NEWA
---	----------	---------	---------	-----	--------------	----------

PHENYTOIN SODIUM

CAPSULE;ORAL

DIPHENYLAN SODIUM

@	CHARTWELL MOLECULAR	30MG PROMPT	A080857	001		Jul CAHN
---	---------------------	-------------	---------	-----	--	----------

@		100MG PROMPT	A080857	002		Jul CAHN
---	--	--------------	---------	-----	--	----------

EXTENDED PHENYTOIN SODIUM

@	MYLAN	100MG EXTENDED	A040298	001	Dec 28, 1998	Mar DISC
---	-------	----------------	---------	-----	--------------	----------

@	UNICHEM	100MG EXTENDED	A213834	001	Oct 13, 2022	Apr DISC
---	---------	----------------	---------	-----	--------------	----------

PHYTONADIONE

TABLET;ORAL

MEPHYTON

+	@ BAUSCH	5MG	N010104	003		Feb DISC
---	----------	-----	---------	-----	--	----------

PHYTONADIONE

>A>	AB	AGNITIO	5MG	A213336	001	Oct 12, 2023	Oct NEWA
-----	----	---------	-----	---------	-----	--------------	----------

AB		SCIEGEN PHARMS INC	5MG	A213329	001	Jul 28, 2023	Jul NEWA
----	--	--------------------	-----	---------	-----	--------------	----------

AB	!	ZYDUS	5MG	A210189	001	Feb 20, 2019	Feb CHRS
----	---	-------	-----	---------	-----	--------------	----------

PILOCARPINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

ISOPTO CARPINE

AT	+	SANDOZ	1%	N200890	001	Jun 22, 2010	Sep CAHN
----	---	--------	----	---------	-----	--------------	----------

AT	+		2%	N200890	002	Jun 22, 2010	Sep CAHN
----	---	--	----	---------	-----	--------------	----------

AT	+		4%	N200890	003	Jun 22, 2010	Sep CAHN
----	---	--	----	---------	-----	--------------	----------

>A>		QLOSI					
-----	--	-------	--	--	--	--	--

>A>	+	ORASIS PHARMS	0.4%	N217836	001	Oct 17, 2023	Oct NEWA
-----	---	---------------	------	---------	-----	--------------	----------

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

@	ANDA REPOSITORY	EQ 15MG BASE	A078383	001	Mar 12, 2013	Sep CAHN
@		EQ 30MG BASE	A078383	002	Mar 12, 2013	Sep CAHN
@		EQ 45MG BASE	A078383	003	Mar 12, 2013	Sep CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

>A>	!	EUGIA PHARMA	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A217409	002	Oct 12, 2023	Oct NFTG
>A>	AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A217409	001	Oct 12, 2023	Oct NEWA
	AP	SHANDONG	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A204959	001	Aug 10, 2018	Apr CAHN
	AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A204959	002	Aug 10, 2018	Apr CAHN
	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A204959	003	Aug 10, 2018	Apr CAHN
	AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A217243	001	Apr 14, 2023	Apr NEWA
		ZOSYN IN PLASTIC CONTAINER					
	+	BAXTER HLTHCARE CORP	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998	Mar CAHN
	+		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998	Mar CAHN
	+		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998	Mar CAHN

PIRFENIDONE

CAPSULE; ORAL

PIRFENIDONE

	@	APOTEX	267MG	A212687	001	Jun 09, 2023	Sep DISC
AB			267MG	A212687	001	Jun 09, 2023	Jun NEWA
AB		LUPIN LTD	267MG	A212404	001	Aug 28, 2023	Aug NEWA
		TABLET; ORAL					
		PIRFENIDONE					
AB		APOTEX	267MG	A212709	001	May 31, 2023	May NEWA
AB			801MG	A212709	002	May 31, 2023	May NEWA
AB		LUPIN LTD	267MG	A212403	001	Aug 23, 2023	Aug NEWA
AB			801MG	A212403	002	Aug 23, 2023	Aug NEWA

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB		UNICHEM	10MG	A208340	001	Apr 13, 2017	Aug CTEC
AB			20MG	A208340	002	Apr 13, 2017	Aug CTEC

PIRTOBRUTINIB

TABLET; ORAL

JAYPIRCA

+	LOXO ONCOL	50MG	N216059	001	Jan 27, 2023	Jan NEWA
+	!	100MG	N216059	002	Jan 27, 2023	Jan NEWA

PITAVASTATIN CALCIUM

TABLET; ORAL

PITAVASTATIN CALCIUM

AB		MYLAN	EQ 1MG BASE	A206070	001	Apr 04, 2019	Sep CMFD
AB			EQ 2MG BASE	A206070	002	Apr 04, 2019	Sep CMFD
AB			EQ 4MG BASE	A206070	003	Apr 04, 2019	Sep CMFD
AB		ZYDUS PHARMS	EQ 1MG BASE	A206047	001	Feb 22, 2023	Feb NEWA
AB			EQ 2MG BASE	A206047	002	Feb 22, 2023	Feb NEWA
AB			EQ 4MG BASE	A206047	003	Feb 22, 2023	Feb NEWA

PLERIXAFOR

SOLUTION; SUBCUTANEOUS

MOZOBIL

AP	+	GENZYME	24MG/1.2ML (20MG/ML)	N022311	001	Dec 15, 2008	Jul CFTG
		PLERIXAFOR					
AP		AMNEAL	24MG/1.2ML (20MG/ML)	A215334	001	Jul 24, 2023	Jul NFTG
AP		DR REDDYS	24MG/1.2ML (20MG/ML)	A205182	001	Jul 24, 2023	Jul NFTG
AP		EUGIA PHARMA	24MG/1.2ML (20MG/ML)	A213672	001	Jul 24, 2023	Jul NFTG
AP		KINDOS	24MG/1.2ML (20MG/ML)	A215698	001	Jul 24, 2023	Jul NFTG
AP		MSN	24MG/1.2ML (20MG/ML)	A211901	001	Jul 24, 2023	Jul NFTG

SOLUTION;SUBCUTANEOUS							
PLERIXAFOR							
AP	TEVA PHARMS USA INC	24MG/1.2ML (20MG/ML)	A205197	001	Jul 24, 2023	Jul	NFTG
AP	ZYDUS PHARMS	24MG/1.2ML (20MG/ML)	A208980	001	Jul 26, 2023	Jul	NEWA
<u>POLYMYXIN B SULFATE</u>							
INJECTABLE;INJECTION							
POLYMYXIN B SULFATE							
AP	BEOWULF ASSET	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Sep	CAHN
<u>POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE</u>							
SOLUTION/DROPS;OPHTHALMIC							
POLYTRIM							
	+ @ ALLERGAN	10,000 UNITS/ML;EQ 1MG BASE/ML	N050567	001	Oct 20, 1988	Feb	DISC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE							
AT	! SANDOZ	10,000 UNITS/ML;EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Feb	CHRS
<u>POMALIDOMIDE</u>							
CAPSULE;ORAL							
POMALYST							
	+ BRISTOL	1MG	N204026	001	Feb 08, 2013	Jan	CAHN
	+	2MG	N204026	002	Feb 08, 2013	Jan	CAHN
	+	3MG	N204026	003	Feb 08, 2013	Jan	CAHN
	+!	4MG	N204026	004	Feb 08, 2013	Jan	CAHN
<u>PONATINIB HYDROCHLORIDE</u>							
TABLET;ORAL							
ICLUSIG							
	+ TAKEDA PHARMS USA	EQ 15MG BASE	N203469	001	Dec 14, 2012	Sep	CTEC
AB	+	EQ 15MG BASE	N203469	001	Dec 14, 2012	Jul	CFTG
	+!	EQ 45MG BASE	N203469	002	Dec 14, 2012	Sep	CTEC
AB	+!	EQ 45MG BASE	N203469	002	Dec 14, 2012	Jul	CFTG
PONATINIB HYDROCHLORIDE							
	@ APOTEX	EQ 15MG BASE	A215893	001	Jul 14, 2023	Sep	DISC
AB		EQ 15MG BASE	A215893	001	Jul 14, 2023	Jul	NFTG
	@	EQ 45MG BASE	A215893	002	Jul 14, 2023	Sep	DISC
AB		EQ 45MG BASE	A215893	002	Jul 14, 2023	Jul	NFTG
<u>POSACONAZOLE</u>							
TABLET, DELAYED RELEASE;ORAL							
POSACONAZOLE							
	@ ACTAVIS LABS FL INC	100MG	A207355	001	Nov 30, 2022	May	DISC
AB	I 3 PHARMS	100MG	A216488	001	Aug 28, 2023	Aug	NEWA
AB	WELDING	100MG	A216326	001	Jun 20, 2023	Jun	NEWA
AB	WESTMINSTER PHARMS	100MG	A216326	001	Jun 20, 2023	Jul	CAHN
<u>POTASSIUM ACETATE</u>							
INJECTABLE;INJECTION							
POTASSIUM ACETATE							
AP	EXELA PHARMA	2MEQ/ML	A212692	001	Oct 20, 2021	Feb	CMFD
<u>POTASSIUM CHLORIDE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
POTASSIUM CHLORIDE							
	@ CHARTWELL MOLECULAR	8MEQ	A204210	001	Mar 28, 2016	Jul	CAHN
	@	10MEQ	A204210	002	Mar 28, 2016	Jul	CAHN
FOR SOLUTION;ORAL							
POKONZA							
	+ PHARMA RES SOFTWARE	10MEQ	N208019	002	Aug 25, 2023	Sep	NEWA
POTASSIUM CHLORIDE							
AA	GRANULES	20MEQ	A213467	001	Jan 27, 2022	Jul	CMFD
AA	NOVITIUM PHARMA	20MEQ	A212816	001	Jul 12, 2023	Jun	NEWA
AA	+ PHARMA RES SOFTWARE	20MEQ	N208019	001	Aug 19, 2015	Sep	CHRS
	+!	40MEQ	N208019	003	Aug 25, 2023	Sep	NEWA
INJECTABLE;INJECTION							
POTASSIUM CHLORIDE							
AP	NEXUS PHARMS	2MEQ/ML	A217704	001	Aug 14, 2023	Aug	NEWA
SOLUTION;ORAL							
POTASSIUM CHLORIDE							
AA	ANDA REPOSITORY	20MEQ/15ML	A214892	001	Dec 30, 2022	Sep	CAHN
AA		40MEQ/15ML	A214892	002	Dec 30, 2022	Sep	CAHN
AA	BELCHER	20MEQ/15ML	A216156	001	Mar 07, 2023	Feb	NEWA

SOLUTION; ORAL							
POTASSIUM CHLORIDE							
AA		40MEQ/15ML	A216156	002	Mar 07, 2023	Feb	NEWA
	@ STRIDES PHARMA	40MEQ/15ML	A211665	001	Nov 17, 2022	May	DISC
TABLET, EXTENDED RELEASE; ORAL							
POTASSIUM CHLORIDE							
>A>	@ CHARTWELL RX	20MEQ	A210098	001	Apr 26, 2019	Oct	CAHN
AB1	RUBICON	10MEQ	A216321	001	Jun 16, 2023	Jun	NEWA
AB1		15MEQ	A216321	002	Jun 16, 2023	Jun	NEWA
AB1		20MEQ	A216321	003	Jun 16, 2023	Jun	NEWA
>D>	@ STRIDES PHARMA	20MEQ	A210098	001	Apr 26, 2019	Oct	CAHN
AB3	TWI PHARMS	10MEQ	A209688	001	Jan 12, 2018	Apr	CAHN
AB3	!	20MEQ	A209688	002	Jan 12, 2018	Apr	CAHN
AB3	! VITRUVIAS THERAP	20MEQ	A209688	002	Jan 12, 2018	Feb	CHRS

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION; INTRAVENOUS							
POTASSIUM PHOSPHATES							
AP	AM REGENT	1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML)	A216274	001	Oct 02, 2023	Sep	NFTG
AP		3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML)	A216274	002	Oct 02, 2023	Sep	NFTG
AP		11.8GM/50ML (236MG/ML); 11.2GM/50ML (224MG/ML)	A216274	003	Oct 02, 2023	Sep	NFTG
AP	AMNEAL	1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML)	A216344	001	Oct 10, 2023	Sep	NEWA
AP		3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML)	A216344	002	Oct 10, 2023	Sep	NEWA
AP		11.8GM/50ML (236MG/ML); 11.2GM/50ML (224MG/ML)	A216344	003	Oct 10, 2023	Sep	NEWA
AP	+! FRESENIUS KABI USA	1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML)	N212832	001	Nov 26, 2019	Sep	CFTG
AP	+!	3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML)	N212832	002	Nov 26, 2019	Sep	CFTG
AP	+!	11.8GM/50ML (236MG/ML); 11.2GM/50ML (224MG/ML)	N212832	003	Nov 26, 2019	Sep	CFTG

PRASUGREL HYDROCHLORIDE

TABLET; ORAL							
PRASUGREL							
AB	AMNEAL PHARMS	EQ 5MG BASE	A205913	001	Jun 19, 2018	Mar	CTEC
AB		EQ 10MG BASE	A205913	002	Jun 19, 2018	Mar	CTEC
	@ LUPIN LTD	EQ 5MG BASE	A205930	001	Jan 09, 2023	Feb	DISC
	@	EQ 10MG BASE	A205930	002	Jan 09, 2023	Feb	DISC
PRASUGREL HYDROCHLORIDE							
AB	UNICHEM	EQ 5MG BASE	A213315	001	Aug 28, 2023	Aug	NEWA
AB		EQ 10MG BASE	A213315	002	Aug 28, 2023	Aug	NEWA

PRAVASTATIN SODIUM

TABLET; ORAL							
PRAVASTATIN SODIUM							
AB	CHARTWELL RX	10MG	A077917	001	Jan 08, 2008	May	CAHN
AB		20MG	A077917	002	Jan 08, 2008	May	CAHN
AB		40MG	A077917	003	Jan 08, 2008	May	CAHN
AB		80MG	A077917	004	Jan 08, 2008	May	CAHN

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL							
PRAZOSIN HYDROCHLORIDE							
AB	ALEMBIC	EQ 1MG BASE	A217268	001	Mar 06, 2023	Feb	NEWA
AB		EQ 2MG BASE	A217268	002	Mar 06, 2023	Feb	NEWA
AB		EQ 5MG BASE	A217268	003	Mar 06, 2023	Feb	NEWA
AB	AUROBINDO PHARMA LTD	EQ 1MG BASE	A213052	001	Mar 31, 2023	Mar	NEWA
AB		EQ 2MG BASE	A213052	002	Mar 31, 2023	Mar	NEWA
AB		EQ 5MG BASE	A213052	003	Mar 31, 2023	Mar	NEWA

PREDNISOLONE

SYRUP; ORAL							
PREDNISOLONE							
AA	! CHARTWELL RX	15MG/5ML	A040323	001	May 13, 1999	Jun	CHRS
AA	PHARM ASSOC	15MG/5ML	A040571	001	Aug 25, 2005	Sep	CMFD
	@ PHARMOBEDIANT CNSLTG	15MG/5ML	A040313	001	Sep 10, 2003	Sep	CAHN
	@ XTTRIUM LABS INC	15MG/5ML	A040313	001	Sep 10, 2003	Jul	DISC
AA		15MG/5ML	A040313	001	Sep 10, 2003	Jan	CAHN

TABLET;ORAL

PREDNISOLONE

AB	AUROBINDO PHARMA LTD	5MG	A215673	001	Mar 17, 2023	Mar NEWA
BX	CHARTWELL MOLECULAR	5MG	A080531	002		May CMFD
AB	+! WATSON LABS	5MG	A080354	001		Mar CTEC

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

ECONOPRED

>D>	@ EYEVANCE	0.125%	N017468	001		Oct CAHN
>A>	@ HARROW EYE	0.125%	N017468	001		Oct CAHN
	OMNIPRED					
AB	+! SANDOZ	1%	N017469	001		Sep CAHN
	PRED FORTE					
AB	+! ABBVIE	1%	N017011	001		Jan CAHN
	PRED MILD					
	+! ABBVIE	0.12%	N017100	001		Feb CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA	EDENBRIDGE PHARMS	EQ 15MG BASE/5ML	A203559	003	Feb 06, 2023	Jan NEWA
AA		EQ 15MG BASE/5ML	A203559	003	Feb 06, 2023	Jan NEWA
AA		EQ 25MG BASE/5ML	A203559	004	Feb 06, 2023	Jan NEWA
AA		EQ 25MG BASE/5ML	A203559	004	Feb 06, 2023	Jan NEWA
AA	! MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010	Jan CTEC
AA	! PHARM ASSOC	EQ 15MG BASE/5ML	A076913	001	Apr 25, 2005	Jul CHRS
	@ PHARMOBEDIANT CNSLTG	EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002	Sep CAHN
	@ XTTRIUM LABS INC	EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002	Jul DISC
AA		EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002	Jan CAHN
	@	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Jul DISC
AA	!	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Jan CAHN

PREDNISONE

SOLUTION;ORAL

PREDNISONE

@ XTTRIUM LABS INC

5MG/5ML

A089726 001 Aug 02, 1988 Jan CAHN

TABLET;ORAL

PREDNISONE

AB	GENEYORK PHARMS	2.5MG	A210525	004	Dec 07, 2018	Sep CMS1
AB		5MG	A210525	005	Dec 07, 2018	Sep CMS1
AB	+! HIKMA	2.5MG	A087801	001	Apr 22, 1982	Jan CRLD
AB	+!	5MG	A080352	001		Jan CRLD
AB	+!	50MG	A084283	001		Jan CRLD
AB	JUBILANT CADISTA	2.5MG	A040362	004	Apr 17, 2023	Apr NEWA
AB		50MG	A040362	005	Apr 17, 2023	Apr NEWA

PREGABALIN

CAPSULE;ORAL

PREGABALIN

>D>	AB	ACI	25MG	A215755	001	Apr 26, 2023	Oct DISC
>A>		@	25MG	A215755	001	Apr 26, 2023	Oct DISC
	AB		25MG	A215755	001	Apr 26, 2023	Apr NEWA
>D>	AB		50MG	A215755	002	Apr 26, 2023	Oct DISC
>A>		@	50MG	A215755	002	Apr 26, 2023	Oct DISC
	AB		50MG	A215755	002	Apr 26, 2023	Apr NEWA
>D>	AB		75MG	A215755	003	Apr 26, 2023	Oct DISC
>A>		@	75MG	A215755	003	Apr 26, 2023	Oct DISC
	AB		75MG	A215755	003	Apr 26, 2023	Apr NEWA
>D>	AB		100MG	A215755	004	Apr 26, 2023	Oct DISC
>A>		@	100MG	A215755	004	Apr 26, 2023	Oct DISC
	AB		100MG	A215755	004	Apr 26, 2023	Apr NEWA
>D>	AB		150MG	A215755	005	Apr 26, 2023	Oct DISC
>A>		@	150MG	A215755	005	Apr 26, 2023	Oct DISC
	AB		150MG	A215755	005	Apr 26, 2023	Apr NEWA
>D>	AB		200MG	A215755	006	Apr 26, 2023	Oct DISC
>A>		@	200MG	A215755	006	Apr 26, 2023	Oct DISC
	AB		200MG	A215755	006	Apr 26, 2023	Apr NEWA
>D>	AB		225MG	A215755	007	Apr 26, 2023	Oct DISC
>A>		@	225MG	A215755	007	Apr 26, 2023	Oct DISC
	AB		225MG	A215755	007	Apr 26, 2023	Apr NEWA
>D>	AB		300MG	A215755	008	Apr 26, 2023	Oct DISC
>A>		@	300MG	A215755	008	Apr 26, 2023	Oct DISC

CAPSULE;ORAL						
PREGABALIN						
AB		300MG	A215755	008	Apr 26, 2023	Apr NEWA
AB	ADAPTIS	25MG	A216197	001	Jul 18, 2022	Sep CAHN
AB		50MG	A216197	002	Jul 18, 2022	Sep CAHN
AB		75MG	A216197	003	Jul 18, 2022	Sep CAHN
AB		100MG	A216197	004	Jul 18, 2022	Sep CAHN
AB		150MG	A216197	005	Jul 18, 2022	Sep CAHN
AB		200MG	A216197	006	Jul 18, 2022	Sep CAHN
AB		225MG	A216197	007	Jul 18, 2022	Sep CAHN
AB		300MG	A216197	008	Jul 18, 2022	Sep CAHN
AB	AUROBINDO PHARMA	25MG	A205321	001	Mar 29, 2023	Mar NEWA
AB		50MG	A205321	002	Mar 29, 2023	Mar NEWA
AB		75MG	A205321	003	Mar 29, 2023	Mar NEWA
AB		100MG	A205321	004	Mar 29, 2023	Mar NEWA
AB		150MG	A205321	005	Mar 29, 2023	Mar NEWA
AB		200MG	A205321	006	Mar 29, 2023	Mar NEWA
AB		225MG	A205321	007	Mar 29, 2023	Mar NEWA
AB		300MG	A205321	008	Mar 29, 2023	Mar NEWA
AB	CADILA PHARMS LTD	25MG	A206452	001	Jul 12, 2023	Jun NEWA
AB		50MG	A206452	002	Jul 12, 2023	Jun NEWA
AB		75MG	A206452	003	Jul 12, 2023	Jun NEWA
AB		100MG	A206452	004	Jul 12, 2023	Jun NEWA
AB		150MG	A206452	005	Jul 12, 2023	Jun NEWA
AB		200MG	A206452	006	Jul 12, 2023	Jun NEWA
AB		225MG	A206452	007	Jul 12, 2023	Jun NEWA
AB		300MG	A206452	008	Jul 12, 2023	Jun NEWA
AB	CHARTWELL RX	50MG	A212865	001	Mar 20, 2020	Mar CAHN
AB		75MG	A212865	002	Mar 20, 2020	Mar CAHN
AB		100MG	A212865	003	Mar 20, 2020	Mar CAHN
AB		150MG	A212865	004	Mar 20, 2020	Mar CAHN
AB	CREEKWOOD PHARMS	25MG	A213423	001	Mar 23, 2020	Aug CAHN
AB		50MG	A213423	002	Mar 23, 2020	Aug CAHN
AB		75MG	A213423	003	Mar 23, 2020	Aug CAHN
AB		100MG	A213423	004	Mar 23, 2020	Aug CAHN
AB		150MG	A213423	005	Mar 23, 2020	Aug CAHN
AB		200MG	A213423	006	Mar 23, 2020	Aug CAHN
AB		225MG	A213423	007	Mar 23, 2020	Aug CAHN
AB		300MG	A213423	008	Mar 23, 2020	Aug CAHN
AB	YILING	75MG	A210891	001	Sep 30, 2019	Mar CAHN
AB		300MG	A210891	002	Sep 30, 2019	Mar CAHN
	@ ZYDUS PHARMS	25MG	A206752	001	Dec 09, 2022	May DISC
	@	50MG	A206752	002	Dec 09, 2022	May DISC
	@	75MG	A206752	003	Dec 09, 2022	May DISC
	@	100MG	A206752	004	Dec 09, 2022	May DISC
	@	150MG	A206752	005	Dec 09, 2022	May DISC
	@	200MG	A206752	006	Dec 09, 2022	May DISC
	@	225MG	A206752	007	Dec 09, 2022	May DISC
	@	300MG	A206752	008	Dec 09, 2022	May DISC
SOLUTION;ORAL						
PREGABALIN						
AA	PATRIN	20MG/ML	A212604	001	Feb 18, 2022	Jan CAHN
TABLET, EXTENDED RELEASE;ORAL						
PREGABALIN						
AB	EPIC PHARMA LLC	82.5MG	A214496	001	Jun 01, 2023	Aug CAHN
AB		165MG	A214496	002	Jun 01, 2023	Aug CAHN
AB		330MG	A214496	003	Jun 01, 2023	Aug CAHN
	@ SCIEGEN PHARMS INC	82.5MG	A215675	001	Sep 14, 2022	May DISC
	@	165MG	A215675	002	Sep 14, 2022	May DISC
	@	330MG	A215675	003	Sep 14, 2022	May DISC
AB	SINOTHERAPEUTICS INC	82.5MG	A214496	001	Jun 01, 2023	May NEWA
AB		165MG	A214496	002	Jun 01, 2023	May NEWA
AB		330MG	A214496	003	Jun 01, 2023	May NEWA
	@ ZYDUS PHARMS	82.5MG	A215577	001	Aug 26, 2022	Jan DISC
	@	165MG	A215577	002	Aug 26, 2022	Jan DISC
	@	330MG	A215577	003	Aug 26, 2022	Jan DISC
<u>PROCAINAMIDE HYDROCHLORIDE</u>						
INJECTABLE;INJECTION						
PROCAINAMIDE HYDROCHLORIDE						
AP	! HOSPIRA	500MG/ML	A089070	001	Feb 12, 1986	Feb CTEC

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

AP	HIKMA	EQ 5MG BASE/ML	A213630	001	Nov 22, 2022	Sep CAHN
AP	SAGENT	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Jul CAHN

PROCHLORPERAZINE MALEATE

TABLET;ORAL

PROCHLORPERAZINE MALEATE

AB	AMNEAL	EQ 5MG BASE	A216598	001	Apr 17, 2023	Apr NEWA
AB		EQ 10MG BASE	A216598	002	Apr 17, 2023	Apr NEWA
AB	BIONPHARMA	EQ 5MG BASE	A217478	001	Apr 04, 2023	Mar NEWA
AB		EQ 10MG BASE	A217478	002	Apr 04, 2023	Mar NEWA
AB	GLENMARK PHARMS LTD	EQ 5MG BASE	A216595	001	Mar 17, 2023	Mar NEWA
AB		EQ 10MG BASE	A216595	002	Mar 17, 2023	Mar NEWA

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

	@ AMNEAL PHARMS	6.25MG/5ML	A040882	001	Dec 30, 2009	Jun DISC
AA	CHARTWELL RX	6.25MG/5ML	A040026	001	Sep 25, 1998	Sep CAHN
	@ PHARM ASSOC	6.25MG/5ML	A040643	001	Apr 26, 2006	Sep DISC

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

	@ AUROBINDO PHARMA USA	12.5MG	A091054	001	Aug 30, 2011	Apr CAHN
	@	25MG	A091054	002	Aug 30, 2011	Apr CAHN
	@	50MG	A091054	003	Aug 30, 2011	Apr CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPAFENONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	225MG	A213096	001	Feb 21, 2023	Feb NEWA
AB		325MG	A213096	002	Feb 21, 2023	Feb NEWA
AB		425MG	A213096	003	Feb 21, 2023	Feb NEWA
AB	SCINOPHARM TAIWAN	225MG	A212928	001	Jun 18, 2020	Sep CAHN
AB		325MG	A212928	002	Jun 18, 2020	Sep CAHN
AB		425MG	A212928	003	Jun 18, 2020	Sep CAHN

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PROPARACAINE HYDROCHLORIDE

AT	! BAUSCH AND LOMB	0.5%	A040074	001	Sep 29, 1995	Jul CHRS
----	-------------------	------	---------	-----	--------------	----------

PROPOFOL

INJECTABLE;INJECTION

PROPOFOL

AB	AVET LIFESCIENCES	10MG/ML	A206408	001	Oct 12, 2021	Jan CAHN
>D>	AB WATSON LABS INC	10MG/ML	A205307	001	Dec 22, 2015	Oct DISC
>A>	@	10MG/ML	A205307	001	Dec 22, 2015	Oct DISC

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

AB	AMICI	10MG	A070322	002	Oct 22, 1985	Sep CAHN
AB		20MG	A070322	003	Oct 22, 1985	Sep CAHN
AB		40MG	A070322	004	Oct 22, 1985	Sep CAHN
AB		60MG	A070322	005	Sep 24, 1986	Sep CAHN
AB		80MG	A070322	001	Aug 04, 1986	Sep CAHN
AB	! IMPAX LABS INC	80MG	A071976	001	Apr 06, 1988	Jun CHRS
AB	WATSON LABS	80MG	A070178	001	May 13, 1986	Jun CHRS

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

AB	+! DAVA PHARMS INC	50MG	N006188	001		Apr CTEC
AB	MACLEODS PHARMS LTD	50MG	A208867	001	May 10, 2023	Apr NEWA

PYRIDOSTIGMINE BROMIDE

SYRUP;ORAL

PYRIDOSTIGMINE BROMIDE

AA MSN 60MG/5ML
 AA RISING 60MG/5ML

A216512 001 Sep 21, 2023 Sep NEWA
 A208797 001 Jan 09, 2020 Sep CAHN

PYRIMETHAMINE

TABLET;ORAL

DARAPRIM

>A> AB +! TILDE SCIENCES 25MG
 >D> AB +! VYERA PHARMS LLC 25MG

N008578 001 Oct CAHN
 N008578 001 Oct CAHN

QUININE SULFATE

CAPSULE;ORAL

QUININE SULFATE

@ AUROBINDO PHARMA USA 324MG

A202581 001 Dec 14, 2012 May CAHN

QUIZARTINIB DIHYDROCHLORIDE

TABLET;ORAL

VANFLYTA

+ DAIICHI SANKYO INC EQ 17.7MG BASE
 +! EQ 26.5MG BASE

N216993 001 Jul 20, 2023 Jul NEWA
 N216993 002 Jul 20, 2023 Jul NEWA

RAMELTEON

TABLET;ORAL

RAMELTEON

AB AUROBINDO PHARMA LTD 8MG
 AB INNOGENIX 8MG
 @ 8MG
 AB 8MG
 AB MICRO LABS 8MG

A215972 001 Jul 10, 2023 Jun NEWA
 A215435 001 Aug 24, 2022 May CMFD
 A215435 001 Aug 24, 2022 Mar DISC
 A215435 001 Aug 24, 2022 Jan CAHN
 A215243 001 Feb 09, 2023 Feb NEWA

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

AB COREPHARMA 1.25MG
 AB 2.5MG
 AB 5MG
 AB 10MG

A079116 001 Jun 20, 2008 Feb CAHN
 A079116 002 Jun 20, 2008 Feb CAHN
 A079116 003 Jun 20, 2008 Feb CAHN
 A079116 004 Jun 20, 2008 Feb CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

@ HIKMA EQ 25MG BASE/ML
 @ EQ 25MG BASE/ML
 @ ZYDUS PHARMS USA INC EQ 25MG BASE/ML
 ZANTAC

A074777 001 Mar 02, 2005 May DISC
 A077458 001 Feb 16, 2006 May DISC
 A091534 001 Feb 22, 2013 May DISC

+ @ PAI HOLDINGS PHARM EQ 25MG BASE/ML

N019090 001 Oct 19, 1984 May DISC

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

>D> @ AKORN EQ 15MG BASE/ML
 >A> @ EPIC PHARMA LLC EQ 15MG BASE/ML

A091078 001 Mar 22, 2011 Oct CAHN
 A091078 001 Mar 22, 2011 Oct CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA

+ @ GILEAD 500MG
 + @ 1GM

N021526 002 Jan 27, 2006 Jan DISC
 N021526 001 Feb 12, 2007 Jan DISC

RANOLAZINE

AB NOVAST LABS 500MG
 AB 1GM
 AB PIRAMAL HLTHCARE UK 500MG
 AB 1GM
 AB RISING 500MG
 AB 1GM
 AB ! SUN PHARM 1GM
 @ UNICHEM 500MG
 AB 500MG
 @ 1GM
 AB 1GM

A210668 001 Sep 27, 2023 Sep NEWA
 A210668 002 Sep 27, 2023 Sep NEWA
 A213085 001 Jul 25, 2023 Jul NEWA
 A213085 002 Jul 25, 2023 Jul NEWA
 A212889 001 Jan 28, 2021 Aug CAHN
 A212889 002 Jan 28, 2021 Aug CAHN
 A211707 002 May 28, 2019 Jan CHRS
 A213083 001 Mar 16, 2023 Sep DISC
 A213083 001 Mar 16, 2023 Mar NEWA
 A213083 002 Mar 16, 2023 Sep DISC
 A213083 002 Mar 16, 2023 Mar NEWA

REGADENOSONSOLUTION; INTRAVENOUS
REGADENOSON

AP	BAXTER HLTHCARE CORP	0.4MG/5ML (0.08MG/ML)	A217455	001	May 23, 2023	May NEWA
AP	HIKMA	0.4MG/5ML (0.08MG/ML)	A215827	001	Feb 02, 2023	Jan NEWA
AP	IMS LTD	0.4MG/5ML (0.08MG/ML)	A214252	001	May 23, 2022	Apr CMFD

REPAGLINIDETABLET; ORAL
REPAGLINIDE

>D>	@ BOSCOGEN	0.5MG	A091517	001	Apr 24, 2015	Oct CAHN
>D>	@	1MG	A091517	002	Apr 24, 2015	Oct CAHN
>D>	@	2MG	A091517	003	Apr 24, 2015	Oct CAHN
>A>	@ KENTON	0.5MG	A091517	001	Apr 24, 2015	Oct CAHN
>A>	@	1MG	A091517	002	Apr 24, 2015	Oct CAHN
>A>	@	2MG	A091517	003	Apr 24, 2015	Oct CAHN
AB	MACLEODS PHARMS LTD	0.5MG	A207209	001	Mar 22, 2023	Mar NEWA
AB		1MG	A207209	002	Mar 22, 2023	Mar NEWA
AB		2MG	A207209	003	Mar 22, 2023	Mar NEWA

REZAFUNGIN ACETATEPOWDER; INTRAVENOUS
REZZAYO

+	!	CIDARA THERAPS	EQ 200MG BASE/VIAL	N217417	001	Mar 22, 2023	Mar NEWA
---	---	----------------	--------------------	---------	-----	--------------	----------

RIBOFLAVIN 5'-PHOSPHATESOLUTION/DROPS; OPHTHALMIC
PHOTREXA

+	!	GLAUKOS	0.146%	N203324	001	Apr 15, 2016	Jun CAIN
		PHOTREXA VISCOUS IN DEXTRAN 20%					
+	!	GLAUKOS	0.146%	N203324	002	Apr 15, 2016	Jun CAIN

RIFAMPINCAPSULE; ORAL
RIFAMPIN

AB	HIKMA	150MG	A065028	001	Mar 14, 2001	Sep CAHN
AB		300MG	A065028	002	Mar 14, 2001	Sep CAHN

INJECTABLE; INJECTION
RIFAMPIN

AP	EPIC PHARMA LLC	600MG/VIAL	A065502	001	Sep 21, 2010	Sep CAHN
----	-----------------	------------	---------	-----	--------------	----------

RIMEGEPANT SULFATETABLET, ORALLY DISINTEGRATING; ORAL
NURTEC ODT

+	!	PFIZER	EQ 75MG BASE	N212728	001	Feb 27, 2020	Feb CAHN
---	---	--------	--------------	---------	-----	--------------	----------

RIMEXOLONESUSPENSION/DROPS; OPHTHALMIC
VEXOL

>D>	@ EYEVANCE	1%	N020474	001	Dec 30, 1994	Oct CAHN
>A>	@ HARROW EYE	1%	N020474	001	Dec 30, 1994	Oct CAHN

RISPERIDONEFOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
RYKINDO

+	!	SHANDONG LUYE	12.5MG	N212849	001	Jan 13, 2023	Jan NEWA
+	!		25MG	N212849	002	Jan 13, 2023	Jan NEWA
+	!		37.5MG	N212849	003	Jan 13, 2023	Jan NEWA
+	!		50MG	N212849	004	Jan 13, 2023	Jan NEWA

SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS
UZEDY

+		TEVA	50MG/0.14ML (50MG/0.14ML)	N213586	001	Apr 28, 2023	Apr NEWA
+			75MG/0.21ML (75MG/0.21ML)	N213586	002	Apr 28, 2023	Apr NEWA
+			100MG/0.28ML (100MG/0.28ML)	N213586	003	Apr 28, 2023	Apr NEWA
+			125MG/0.35ML (125MG/0.35ML)	N213586	004	Apr 28, 2023	Apr NEWA
+			150MG/0.42ML (150MG/0.42ML)	N213586	005	Apr 28, 2023	Apr NEWA
+			200MG/0.56ML (200MG/0.56ML)	N213586	006	Apr 28, 2023	Apr NEWA
+	!		250MG/0.7ML (250MG/0.7ML)	N213586	007	Apr 28, 2023	Apr NEWA

TABLET;ORAL

RISPERIDONE

	@ DASH PHARMS	0.25MG	A076288	001	Sep 15, 2008	Feb CAHN
	@	0.5MG	A076288	002	Sep 15, 2008	Feb CAHN
	@	1MG	A076288	003	Sep 15, 2008	Feb CAHN
	@	2MG	A076288	004	Sep 15, 2008	Feb CAHN
	@	3MG	A076288	005	Sep 15, 2008	Feb CAHN
	@	4MG	A076288	006	Sep 15, 2008	Feb CAHN
AB	WESTMINSTER PHARMS	0.25MG	A078707	001	Dec 29, 2008	Aug CAHN
AB		0.5MG	A078707	002	Dec 29, 2008	Aug CAHN
AB		1MG	A078707	003	Dec 29, 2008	Aug CAHN
AB		2MG	A078707	004	Dec 29, 2008	Aug CAHN
AB		3MG	A078707	005	Dec 29, 2008	Aug CAHN
AB		4MG	A078707	006	Dec 29, 2008	Aug CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

	@ DASH PHARMS	0.25MG	A091537	006	Feb 12, 2013	Feb CAHN
	@	0.5MG	A091537	001	Mar 30, 2011	Feb CAHN
	@	1MG	A091537	002	Mar 30, 2011	Feb CAHN
	@	2MG	A091537	003	Mar 30, 2011	Feb CAHN
	@	3MG	A091537	004	Mar 30, 2011	Feb CAHN
	@	4MG	A091537	005	Mar 30, 2011	Feb CAHN

RITLACITINIB TOSYLATE

CAPSULE;ORAL

LITFULO

+	PFIZER	EQ 50MG BASE	N215830	001	Jun 23, 2023	Jun NEWA
---	--------	--------------	---------	-----	--------------	----------

RITONAVIR

SOLUTION;ORAL

NORVIR

+	@ ABBVIE	80MG/ML	N020659	001	Mar 01, 1996	Feb DISC
---	----------	---------	---------	-----	--------------	----------

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

EXELON

AB	+	SANDOZ	4.6MG/24HR	N022083	001	Jul 06, 2007	Sep CAHN
AB	+		9.5MG/24HR	N022083	002	Jul 06, 2007	Sep CAHN
AB	+		13.3MG/24HR	N022083	005	Aug 31, 2012	Sep CAHN

RIZATRIPTAN BENZOATE

FILM;ORAL

RIZAFILM

+	GENSCO	EQ 10MG BASE	N205394	001	Apr 14, 2023	Sep CAHN
+	INTELGENX CORP	EQ 10MG BASE	N205394	001	Apr 14, 2023	Apr NEWA

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB		CHARTWELL RX	EQ 5MG BASE	A077526	001	Mar 26, 2013	May CAHN
AB			EQ 10MG BASE	A077526	002	Mar 26, 2013	May CAHN
AB		CREEKWOOD PHARMS	EQ 5MG BASE	A202047	001	Dec 31, 2012	Aug CAHN
AB			EQ 10MG BASE	A202047	002	Dec 31, 2012	Aug CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

>D>	AB	UNICHEM	EQ 5MG BASE	A207835	001	Mar 07, 2017	Oct DISC
>A>		@	EQ 5MG BASE	A207835	001	Mar 07, 2017	Oct DISC
>D>	AB		EQ 10MG BASE	A207835	002	Mar 07, 2017	Oct DISC
>A>		@	EQ 10MG BASE	A207835	002	Mar 07, 2017	Oct DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP		CAPLIN	50MG/5ML (10MG/ML)	A216234	001	Mar 02, 2023	Feb NEWA
AP			100MG/10ML (10MG/ML)	A216234	002	Mar 02, 2023	Feb NEWA
AP		HIKMA	50MG/5ML (10MG/ML)	A217034	001	May 24, 2023	May NEWA
AP		HONG KONG	50MG/5ML (10MG/ML)	A213453	001	May 08, 2023	Apr NEWA
AP			100MG/10ML (10MG/ML)	A213453	002	May 08, 2023	Apr NEWA
AP		MEITHEAL	50MG/5ML (10MG/ML)	A213453	001	May 08, 2023	Aug CAHN
AP			100MG/10ML (10MG/ML)	A213453	002	May 08, 2023	Aug CAHN

ROFLUMILAST

TABLET;ORAL

ROFLUMILAST

	AB	ALKEM LABS LTD	250MCG	A212490	001	Apr 18, 2023	Apr NEWA
	AB		500MCG	A212490	002	Apr 18, 2023	Apr NEWA
	AB	AUROBINDO PHARMA LTD	500MCG	A213298	001	Apr 17, 2023	Apr NEWA
>A>	AB	BRECKENRIDGE	250MCG	A208236	002	Oct 19, 2023	Oct NEWA
	AB	HETERO LABS LTD III	250MCG	A208213	002	Apr 18, 2023	Apr NEWA
	AB	MICRO LABS	250MCG	A208180	002	Apr 18, 2023	Apr NEWA
	AB	STRIDES PHARMA	250MCG	A208247	002	Jun 20, 2023	Jun NEWA
>D>	AB	TORRENT	500MCG	A208272	001	Aug 06, 2018	Oct DISC
>A>		@	500MCG	A208272	001	Aug 06, 2018	Oct DISC
	AB	ZYDUS PHARMS	250MCG	A208303	002	Apr 18, 2023	Apr NEWA

ROMIDEPSIN

POWDER;INTRAVENOUS

ISTODAX

AP	+!	BRISTOL-MYERS	10MG/VIAL	N022393	001	Nov 05, 2009	Jul CAHN
----	----	---------------	-----------	---------	-----	--------------	----------

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB	CHARTWELL RX	EQ 0.25MG BASE	A079050	001	May 29, 2008	Jun CAHN
AB		EQ 0.5MG BASE	A079050	002	May 29, 2008	Jun CAHN
AB		EQ 1MG BASE	A079050	003	May 29, 2008	Jun CAHN
AB		EQ 2MG BASE	A079050	004	May 29, 2008	Jun CAHN
AB		EQ 3MG BASE	A079050	005	May 29, 2008	Jun CAHN
AB		EQ 4MG BASE	A079050	006	May 29, 2008	Jun CAHN
AB		EQ 5MG BASE	A079050	007	May 29, 2008	Jun CAHN
	@ MYLAN	EQ 0.25MG BASE	A078881	001	May 05, 2008	May DISC
	@	EQ 0.5MG BASE	A078881	002	May 05, 2008	May DISC
	@	EQ 1MG BASE	A078881	003	May 05, 2008	May DISC
	@	EQ 2MG BASE	A078881	004	May 05, 2008	May DISC
	@	EQ 3MG BASE	A078881	005	May 05, 2008	May DISC
	@	EQ 4MG BASE	A078881	006	May 05, 2008	May DISC
	@	EQ 5MG BASE	A078881	007	May 19, 2008	Mar DISC

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

AB	CHARTWELL RX	EQ 2MG BASE	A091395	001	Aug 27, 2012	Jun CAHN
AB		EQ 4MG BASE	A091395	002	Aug 27, 2012	Jun CAHN
AB		EQ 6MG BASE	A091395	003	Aug 27, 2012	Jun CAHN
AB		EQ 8MG BASE	A091395	004	Aug 27, 2012	Jun CAHN
AB		EQ 12MG BASE	A091395	005	Aug 27, 2012	Jun CAHN

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

	AP	AMNEAL	200MG/100ML (2MG/ML)	A216605	001	Mar 08, 2023	Feb NEWA
	AP		400MG/200ML (2MG/ML)	A216605	002	Mar 08, 2023	Feb NEWA
	AP		500MG/100ML (5MG/ML)	A216605	003	Mar 07, 2023	Feb NEWA
	AP		1GM/200ML (5MG/ML)	A216605	004	Mar 07, 2023	Feb NEWA
>A>	AP	MYLAN LABS LTD	200MG/100ML (2MG/ML)	A206091	001	Oct 26, 2023	Oct NEWA
>A>	AP		400MG/200ML (2MG/ML)	A206091	002	Oct 26, 2023	Oct NEWA

ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDIA

	+ @	WOODWARD	EQ 2MG BASE	N021071	002	May 25, 1999	Jun DISC
	+ @		EQ 4MG BASE	N021071	003	May 25, 1999	Jun DISC

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

AB	UMEDICA	EQ 5MG BASE	A207626	001	Apr 09, 2019	Jul CMFD
AB		EQ 10MG BASE	A207626	002	Apr 09, 2019	Jul CMFD
AB		EQ 20MG BASE	A207626	003	Apr 09, 2019	Jul CMFD
AB		EQ 40MG BASE	A207626	004	Apr 09, 2019	Jul CMFD

RUCAPARIB CAMSYLATE

TABLET;ORAL

RUBRACA

+	ZR PHARMA	EQ 200MG BASE	N209115	001	Dec 19, 2016	May CAHN
+		EQ 250MG BASE	N209115	003	May 01, 2017	May CAHN
+	!	EQ 300MG BASE	N209115	002	Dec 19, 2016	May CAHN

RUFINAMIDE

SUSPENSION;ORAL

RUFINAMIDE

AB	CHARTWELL RX	40MG/ML	A214009	001	Nov 07, 2022	May CAHN
----	--------------	---------	---------	-----	--------------	----------

TABLET;ORAL

RUFINAMIDE

AB	AUROBINDO PHARMA	200MG	A217230	001	Jun 16, 2023	Jun NEWA
AB		400MG	A217230	002	Jun 16, 2023	Jun NEWA
AB	MICRO LABS	200MG	A216688	001	May 15, 2023	May NEWA
AB		400MG	A216688	002	May 15, 2023	May NEWA

SAFINAMIDE MESYLATE

TABLET;ORAL

SAFINAMIDE MESYLATE

AB	@ AUROBINDO PHARMA	EQ 50MG BASE	A215902	001	Jun 14, 2023	Jun DISC
		EQ 50MG BASE	A215902	001	Jun 14, 2023	Jun NFTG
	@	EQ 100MG BASE	A215902	002	Jun 14, 2023	Jun DISC
AB		EQ 100MG BASE	A215902	002	Jun 14, 2023	Jun NFTG

XADAGO

	+	MDD US	EQ 50MG BASE	N207145	001	Mar 21, 2017	Jun CTEC
AB	+		EQ 50MG BASE	N207145	001	Mar 21, 2017	Jun CFTG
	+	!	EQ 100MG BASE	N207145	002	Mar 21, 2017	Jun CTEC
AB	+	!	EQ 100MG BASE	N207145	002	Mar 21, 2017	Jun CFTG

SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

ONGLYZA

>D>	AB	+	ASTRAZENECA AB	EQ 2.5MG BASE	N022350	001	Jul 31, 2009	Oct DISC
>A>		+	@	EQ 2.5MG BASE	N022350	001	Jul 31, 2009	Oct DISC
	AB	+		EQ 2.5MG BASE	N022350	001	Jul 31, 2009	Jul CFTG
>D>	AB	+	!	EQ 5MG BASE	N022350	002	Jul 31, 2009	Oct DISC
>A>		+	@	EQ 5MG BASE	N022350	002	Jul 31, 2009	Oct DISC
	AB	+	!	EQ 5MG BASE	N022350	002	Jul 31, 2009	Jul CFTG

SAXAGLIPTIN

	AB		AMNEAL	EQ 2.5MG BASE	A205941	001	Jul 31, 2023	Jul NFTG
	AB			EQ 5MG BASE	A205941	002	Jul 31, 2023	Jul NFTG
	AB		AUROBINDO PHARMA	EQ 2.5MG BASE	A205972	001	Jul 31, 2023	Jul NFTG
	AB			EQ 5MG BASE	A205972	002	Jul 31, 2023	Jul NFTG
	AB		GLENMARK PHARMS LTD	EQ 2.5MG BASE	A205994	001	Jul 31, 2023	Jul NFTG
	AB			EQ 5MG BASE	A205994	002	Jul 31, 2023	Jul NFTG
	AB		MYLAN	EQ 2.5MG BASE	A205980	001	Jul 31, 2023	Jul NFTG
>D>	AB			EQ 5MG BASE	A205980	002	Jul 31, 2023	Oct CHRS
>A>	AB		!	EQ 5MG BASE	A205980	002	Jul 31, 2023	Oct CHRS
	AB			EQ 5MG BASE	A205980	002	Jul 31, 2023	Jul NFTG
	AB		SUN PHARM	EQ 2.5MG BASE	A206078	001	Jul 31, 2023	Jul NFTG
	AB			EQ 5MG BASE	A206078	002	Jul 31, 2023	Jul NFTG

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

	@	BAYSHORE PHARMS LLC	5MG	A074912	001	Apr 30, 1998	Sep CAHN
	@	DASH PHARMS NATCO	5MG	A074866	001	Nov 26, 1997	Mar CAHN

SELENIUM SULFIDE

LOTION;SHAMPOO;TOPICAL

SELENIUM SULFIDE

	@	PHARMOBEDIENT CNSLTG	2.5%	A088228	001	Sep 01, 1983	Sep CAHN
	@	XTTRIUM LABS INC	2.5%	A088228	001	Sep 01, 1983	Mar CAHN

SELEXIPAGTABLET; ORAL
SELEXIPAG

AB	ALEMBIC	0.2MG	A214414	001	Oct 11, 2023	Sep NEWA
AB		0.4MG	A214414	002	Oct 11, 2023	Sep NEWA
AB		0.6MG	A214414	003	Oct 11, 2023	Sep NEWA
AB		0.8MG	A214414	004	Oct 11, 2023	Sep NEWA
AB		1.4MG	A214414	005	Oct 11, 2023	Sep NEWA
AB		1.6MG	A214414	006	Oct 11, 2023	Sep NEWA
	@ ZYDUS	0.2MG	A214302	001	Dec 21, 2022	May DISC
	@	0.4MG	A214302	002	Dec 21, 2022	May DISC
	@	0.6MG	A214302	003	Dec 21, 2022	May DISC
	@	0.8MG	A214302	004	Dec 21, 2022	May DISC
	@	1MG	A214302	005	Dec 21, 2022	May DISC
	@	1.2MG	A214302	006	Dec 21, 2022	May DISC
	@	1.4MG	A214302	007	Dec 21, 2022	May DISC
	@	1.6MG	A214302	008	Dec 21, 2022	May DISC
	UPTRAVI					
AB	+ ACTELION	0.2MG	N207947	001	Dec 21, 2015	Sep CTEC
	+	0.2MG	N207947	001	Dec 21, 2015	May CTEC
AB	+!	0.4MG	N207947	002	Dec 21, 2015	Sep CTEC
	+	0.4MG	N207947	002	Dec 21, 2015	May CTEC
AB	+	0.6MG	N207947	003	Dec 21, 2015	Sep CTEC
	+	0.6MG	N207947	003	Dec 21, 2015	May CTEC
AB	+	0.8MG	N207947	004	Dec 21, 2015	Sep CTEC
	+	0.8MG	N207947	004	Dec 21, 2015	May CTEC
	+	1MG	N207947	005	Dec 21, 2015	May CTEC
	+	1.2MG	N207947	006	Dec 21, 2015	May CTEC
AB	+	1.4MG	N207947	007	Dec 21, 2015	Sep CTEC
	+	1.4MG	N207947	007	Dec 21, 2015	May CTEC
AB	+	1.6MG	N207947	008	Dec 21, 2015	Sep CTEC
	+	1.6MG	N207947	008	Dec 21, 2015	May CTEC

SERTACONAZOLE NITRATECREAM; TOPICAL
ERTACZO

+!	LACER PHARMA	2%	N021385	001	Dec 10, 2003	Aug CAHN
----	--------------	----	---------	-----	--------------	----------

SERTRALINE HYDROCHLORIDETABLET; ORAL
SERTRALINE HYDROCHLORIDE

AB	HERITAGE PHARMA AVET	EQ 25MG BASE	A076465	001	Aug 11, 2006	Mar CMFD
AB		EQ 50MG BASE	A076465	002	Aug 11, 2006	Mar CMFD
AB		EQ 100MG BASE	A076465	003	Aug 11, 2006	Mar CMFD
	@ ZYDUS	EQ 25MG BASE	A077106	001	Feb 06, 2007	May CAHN
	@	EQ 50MG BASE	A077106	002	Feb 06, 2007	May CAHN
	@	EQ 100MG BASE	A077106	003	Feb 06, 2007	May CAHN

SETMELANOTIDE ACETATESOLUTION; SUBCUTANEOUS
IMCIVREE

+!	RHYTHM	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N213793	001	Nov 25, 2020	Aug CPOT
----	--------	-----------------------------------	---------	-----	--------------	----------

SEVELAMER CARBONATEFOR SUSPENSION; ORAL
SEVELAMER CARBONATE

AB	CHARTWELL RX	800MG/PACKET	A217319	001	Mar 02, 2023	Aug CAHN
AB		2.4GM/PACKET	A217319	002	Mar 02, 2023	Aug CAHN
AB	HANGZHOU ANPRIME	800MG/PACKET	A217319	001	Mar 02, 2023	Feb NEWA
AB		2.4GM/PACKET	A217319	002	Mar 02, 2023	Feb NEWA
AB	STRIDES PHARMA	800MG/PACKET	A211917	001	Sep 08, 2023	Sep NEWA
AB		2.4GM/PACKET	A211917	002	Sep 08, 2023	Sep NEWA
	TABLET; ORAL					
	SEVELAMER CARBONATE					
AB	MACLEODS PHARMS LTD	800MG	A206100	001	Apr 19, 2023	Apr NEWA

SEVELAMER HYDROCHLORIDE

TABLET; ORAL

SEVELAMER HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	400MG	A212599	001	Jul 11, 2023	Jun NEWA
AB		800MG	A212599	002	Jul 11, 2023	Jun NEWA
AB	MACLEODS PHARMS LTD	400MG	A206883	001	May 26, 2023	May NEWA
AB		800MG	A206883	002	May 26, 2023	May NEWA

SEVOFLURANE

LIQUID; INHALATION

SEVOFLURANE

AN	SHANDONG	100%	A214382	001	Aug 18, 2023	Aug NEWA
----	----------	------	---------	-----	--------------	----------

SILDENAFIL CITRATE

SUSPENSION; ORAL

LIQREV

+	CMP DEV LLC	EQ 10MG BASE/ML	N214952	001	Apr 28, 2023	Apr NEWA
---	-------------	-----------------	---------	-----	--------------	----------

TABLET; ORAL

SILDENAFIL CITRATE

AB	MACLEODS PHARMS LTD	EQ 25MG BASE	A202255	001	Apr 19, 2023	Apr NEWA
AB		EQ 50MG BASE	A202255	002	Apr 19, 2023	Apr NEWA
AB		EQ 100MG BASE	A202255	003	Apr 19, 2023	Apr NEWA
AB	NOVITIUM PHARMA	EQ 25MG BASE	A216383	001	Aug 29, 2023	Aug NEWA
AB		EQ 50MG BASE	A216383	002	Aug 29, 2023	Aug NEWA
AB		EQ 100MG BASE	A216383	003	Aug 29, 2023	Aug NEWA

SILODOSIN

CAPSULE; ORAL

SILODOSIN

@ CREEKWOOD PHARMS

@

@ ZYDUS PHARMS

@

4MG

8MG

4MG

8MG

A213230 001 Jan 03, 2022 Sep CAHN

A213230 002 Jan 03, 2022 Sep CAHN

A204816 001 Dec 08, 2022 May DISC

A204816 002 Dec 08, 2022 May DISC

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

@ WATSON LABS TEVA

@

@

@

@

5MG

10MG

20MG

40MG

80MG

A076685 001 Dec 20, 2006 Sep DISC

A076685 002 Dec 20, 2006 Sep DISC

A076685 003 Dec 20, 2006 Sep DISC

A076685 004 Dec 20, 2006 Sep DISC

A076685 005 Dec 20, 2006 Sep DISC

SIPONIMOD

TABLET; ORAL

MAYZENT

+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	May CAIN
---	----------	----------------	---------	-----	--------------	----------

+		EQ 1MG BASE	N209884	003	Aug 24, 2021	May CAIN
---	--	-------------	---------	-----	--------------	----------

+		EQ 2MG BASE	N209884	002	Mar 26, 2019	May CAIN
---	--	-------------	---------	-----	--------------	----------

SIROLIMUS

SOLUTION; ORAL

SIROLIMUS

AA	MSN	1MG/ML	A216728	001	Jan 19, 2023	Jan NEWA
----	-----	--------	---------	-----	--------------	----------

TABLET; ORAL

SIROLIMUS

AB	ZYDUS PHARMS	1MG	A201676	001	Feb 15, 2023	Feb NEWA
----	--------------	-----	---------	-----	--------------	----------

AB		2MG	A201676	002	Feb 15, 2023	Feb NEWA
----	--	-----	---------	-----	--------------	----------

>A> SITAGLIPTIN

>A> TABLET; ORAL

>A> ZITUVIO

>A>	+	ZYDUS	25MG	N211566	001	Oct 18, 2023	Oct NEWA
-----	---	-------	------	---------	-----	--------------	----------

>A>	+		50MG	N211566	002	Oct 18, 2023	Oct NEWA
-----	---	--	------	---------	-----	--------------	----------

>A>	+		100MG	N211566	003	Oct 18, 2023	Oct NEWA
-----	---	--	-------	---------	-----	--------------	----------

SODIUM ACETATE

INJECTABLE;INJECTION
SODIUM ACETATE

AP	FRESENIUS KABI USA	4MEQ/ML	A206687	001	Oct 30, 2017	Aug CTEC
AP	MILLA PHARMS	4MEQ/ML	A214805	002	Aug 25, 2023	Aug NEWA

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;INTRAVENOUS
SODIUM PHENYLACETATE AND SODIUM BENZOATE

AP	+! MAIA PHARMS INC	10%;10% (2GM/20ML;2GM/20ML)	N215025	001	Jun 10, 2021	Jul CFTG
AP	NAVINTA LLC	10%;10% (2GM/20ML; 2GM/20ML)	A217526	001	Jul 14, 2023	Jul NFTG

SODIUM BICARBONATE

INJECTABLE;INJECTION
SODIUM BICARBONATE

AP	OMNIVIVUM PHARMS	1MEQ/ML	A216364	001	Jun 15, 2023	Jun NEWA
AP	STERISCIENCE	1MEQ/ML	A217594	001	Jun 28, 2023	Jun NEWA

SODIUM CHLORIDE

INJECTABLE;INJECTION
SODIUM CHLORIDE 0.9%

	+ B BRAUN	9MG/ML	N019635	005	Aug 08, 2016	Mar CPOT
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	+ @ LIEBEL-FLARSHEIM	450MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Mar CPOT
	+ @ LIEBEL-FLARSHEIM	1.125GM/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Mar CPOT
	SODIUM CHLORIDE 0.9% IN PLASTIC THERMOJECT KIT FOR CARDIAC OUTPUT USE					
	+ @ ICU MEDICAL INC	9MG/ML	N019217	001	Jul 13, 1984	Jun CTNA
	SODIUM CHLORIDE 23.4%					
AP	FRESENIUS KABI USA	234MG/ML	A212248	001	Apr 28, 2021	Jun CTEC
AP		234MG/ML	A217796	001	Jul 11, 2023	Jun NEWA

SOLUTION;INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@ ABRAXIS PHARM	9MG/ML	A088909	001	Feb 07, 1985	Jun CDFR
	@ ABRAXIS PHARM	90MG/10ML (9MG/ML)	A088909	002	May 15, 1985	Jun CMS1
	@ ABRAXIS PHARM	270MG/30ML (9MG/ML)	A088909	001	Feb 07, 1985	Jun CPOT
AP	FRESENIUS KABI USA	9MG/ML	A088911	001	Feb 07, 1985	Jun CDFR
AP		90MG/10ML (9MG/ML)	A088911	002	May 17, 1985	Jun CMS1
AP		270MG/30ML (9MG/ML)	A088911	001	Feb 07, 1985	Jun CPOT
AP	+! HOSPIRA	9MG/ML	N018800	001	Oct 29, 1982	Jun CDFR
AP	+! HOSPIRA	90MG/10ML (9MG/ML)	N018800	001	Oct 29, 1982	Jun CPOT
AP	+! HOSPIRA	180MG/20ML (9MG/ML)	N018800	002	Oct 29, 1982	Jun CMS1
AP	+! HOSPIRA	270MG/30ML (9MG/ML)	N018800	003	Oct 29, 1982	Jun CMS1
	SODIUM CHLORIDE 0.9%					
	+ B BRAUN	9MG/ML	N019635	005	Aug 08, 2016	Jun CDFR
	+ B BRAUN	90MG/10ML (9MG/ML)	N019635	005	Aug 08, 2016	Jun CPOT
	HIKMA	9MG/ML	A201833	001	Sep 24, 2013	Jun CDFR
AP		9MG/ML	A201850	001	Jan 20, 2012	Jun CDFR
		18MG/2ML (9MG/ML)	A201833	001	Sep 24, 2013	Jun CPOT
AP		90MG/10ML (9MG/ML)	A201833	002	Jan 07, 2015	Jun CMS1
AP		90MG/10ML (9MG/ML)	A201850	001	Jan 20, 2012	Jun CPOT
AP	NEXUS PHARMS	90MG/10ML (9MG/ML)	A217535	001	Aug 23, 2023	Aug NEWA
AP		180MG/20ML (9MG/ML)	A217535	002	Aug 23, 2023	Aug NEWA
AP	SPECTRA MDCL DEVICES	9MG/ML	A206171	001	Jul 21, 2017	Jun CDFR
AP		45MG/5ML (9MG/ML)	A206171	001	Jul 21, 2017	Jun CPOT
AP		90MG/10ML (9MG/ML)	A206171	002	Jul 21, 2017	Jun CMS1
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	@ ABBOTT	9MG/ML	N019218	001	Jul 13, 1984	Jun CDFR
	@ ABBOTT	90MG/10ML (9MG/ML)	N019218	001	Jul 13, 1984	Jun CPOT
	@ ABBOTT	180MG/20ML (9MG/ML)	N019218	002	Apr 30, 1985	Jun CMS1
AP	+! BAXTER HLTHCARE	9MG/ML	N016677	004	Oct 30, 1985	Jun CDFR
AP	+ BAXTER HLTHCARE	9MG/ML	N020178	002	Dec 07, 1992	Jun CDFR
	+! BAXTER HLTHCARE	225MG/25ML (9MG/ML)	N016677	004	Oct 30, 1985	Jun CTEC
AP	+! BAXTER HLTHCARE	225MG/25ML (9MG/ML)	N016677	004	Oct 30, 1985	Jun CPOT
AP	+! BAXTER HLTHCARE	450MG/50ML (9MG/ML)	N016677	003		Jun CMS1
AP	+ BAXTER HLTHCARE	450MG/50ML (9MG/ML)	N020178	002	Dec 07, 1992	Jun CPOT
AP	+! BAXTER HLTHCARE	900MG/100ML	N016677	001		Jun CDFR
AP	+! BAXTER HLTHCARE	900MG/100ML	N020178	001	Dec 07, 1992	Jun CDFR
AP	! FRESENIUS KABI USA	9MG/ML	A088912	001	Jan 10, 1985	Jun CDFR
	! FRESENIUS KABI USA	18MG/2ML (9MG/ML)	A088912	004	Nov 29, 1985	Jun CMS1
AP	! FRESENIUS KABI USA	90MG/10ML (9MG/ML)	A088912	001	Jan 10, 1985	Jun CPOT
AP	! FRESENIUS KABI USA	180MG/20ML (9MG/ML)	A088912	002	Jan 10, 1985	Jun CMS1
AP	! FRESENIUS KABI USA	270MG/30ML (9MG/ML)	A088912	003	Jan 10, 1985	Jun CMS1

SOLUTION;INJECTION									
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
AP	+	!	HOSPIRA	90MG/10ML (9MG/ML)	N018803	001	Oct 29, 1982	Jun	CPOT
AP	+	!		9MG/ML	N018803	001	Oct 29, 1982	Jun	CDFR
AP	+			9MG/ML	N019465	002	Jul 15, 1985	Jun	CDFR
	+	@		18MG/2ML (9MG/ML)	N018803	004	Jan 22, 2015	Jun	CMS1
	+	@		27MG/3ML (9MG/ML)	N018803	005	Jan 22, 2015	Jun	CMS1
	+	@		45MG/5ML (9MG/ML)	N018803	006	Jan 22, 2015	Jun	CMS1
AP	+	!		180MG/20ML (9MG/ML)	N018803	002	Oct 29, 1982	Jun	CMS1
AP	+	!		450MG/50ML (9MG/ML)	N018803	003	Oct 29, 1982	Jun	CMS1
AP	+			450MG/50ML (9MG/ML)	N019465	002	Jul 15, 1985	Jun	CPOT
AP	+	!		900MG/100ML	N019465	001	Jul 15, 1985	Jun	CDFR
	+	@	ICU MEDICAL INC	45MG/5ML (9MG/ML)	N019217	002	Nov 18, 1998	Jun	CMS1
	+	@		90MG/10ML (9MG/ML)	N019217	003	Nov 18, 1998	Jun	CMS1
	+	@		360MG/40ML (9MG/ML)	N019217	004	Apr 01, 1999	Jun	CMS1
		@	JUBILANT CADISTA	9MG/ML	A203352	001	May 18, 2016	Jun	CDFR
		@		27MG/3ML (9MG/ML)	A203352	002	May 18, 2016	Jun	CMS1
		@		90MG/10ML (9MG/ML)	A203352	001	May 18, 2016	Jun	CPOT
		@	MILES	450MG/50ML (9MG/ML)	N018502	002		Jun	CMS1
		@		900MG/100ML	N018502	001		Jun	CDFR
AP			NEPHRON	9MG/ML	A211968	001	Apr 23, 2020	Jun	CDFR
AP				450MG/50ML (9MG/ML)	A211968	001	Apr 23, 2020	Jun	CPOT
AP				900MG/100ML	A211968	002	Apr 23, 2020	Jun	CMS1
AP	!		TARO	9MG/ML	A077407	001	Aug 11, 2006	Jun	CDFR
AP	!			45MG/5ML (9MG/ML)	A077407	001	Aug 11, 2006	Jun	CPOT
AP	!			90MG/10ML (9MG/ML)	A077407	002	Aug 11, 2006	Jun	CMS1
SODIUM CHLORIDE 0.9% IN PLASTIC THERMOJECT KIT FOR CARDIAC OUTPUT USE									
	+	@	ICU MEDICAL INC	9MG/ML	N019217	001	Jul 13, 1984	Jun	CDFR
	+	@		90MG/10ML (9MG/ML)	N019217	001	Jul 13, 1984	Jun	CPOT
<u>SODIUM NITROPRUSSIDE</u>									
INJECTABLE;INJECTION									
SODIUM NITROPRUSSIDE									
		@	CHARTWELL RX	25MG/ML	A209834	001	Jun 26, 2018	Sep	CAHN
AP			MYLAN	25MG/ML	A209584	001	Aug 10, 2018	Sep	CAHN
		@	VIRTUS	25MG/ML	A209834	001	Jun 26, 2018	Sep	CAHN
<u>SODIUM OXYBATE</u>									
FOR SUSPENSION, EXTENDED RELEASE;ORAL									
LUMRYZ									
	+	!	AVADEL CNS	4.5GM/PACKET	N214755	001	May 01, 2023	Jun	CHRS
	+			4.5GM/PACKET	N214755	001	May 01, 2023	May	NEWA
	+			6GM/PACKET	N214755	002	May 01, 2023	May	NEWA
	+			7.5GM/PACKET	N214755	003	May 01, 2023	May	NEWA
	+			9GM/PACKET	N214755	004	May 01, 2023	May	NEWA
<u>SODIUM PHENYLBUTYRATE</u>									
POWDER;ORAL									
BUPHENYL									
AB	+	!	HORIZON THERAP US	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Jan	CAHN
TABLET;ORAL									
BUPHENYL									
AB	+	!	HORIZON THERAP US	500MG	N020572	001	May 13, 1996	Jan	CAHN
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE</u>									
TABLET;ORAL									
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE									
	!		NOVEL LABS INC	0.398GM;1.102GM	A079247	001	Dec 30, 2011	Jul	CTEC
AB	!			0.398GM;1.102GM	A079247	001	Dec 30, 2011	Jul	CHRS
OSMOPREP									
	+	@	SALIX PHARMS	0.398GM;1.102GM	N021892	001	Mar 16, 2006	Jul	DISC
<u>SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS</u>									
INJECTABLE;INJECTION									
SODIUM PHOSPHATES									
AP	!		FRESENIUS KABI USA	142MG/ML;276MG/ML	A209997	001	Mar 30, 2022	Mar	CHRS

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA	UPSHER SMITH LABS	453.6GM/BOT	A090313	001	Dec 21, 2011	Sep CAHN
----	-------------------	-------------	---------	-----	--------------	----------

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB	CHARTWELL RX	5MG	A210582	001	May 20, 2019	May CAHN
AB		10MG	A210582	002	May 20, 2019	May CAHN
	@ CIPLA	5MG	A209839	001	May 20, 2019	Jul DISC
	@	10MG	A209839	002	May 20, 2019	Jul DISC
AB	LANNETT CO INC	5MG	A211622	001	Jun 06, 2023	May NEWA
AB		10MG	A211622	002	Jun 06, 2023	May NEWA
AB	RISING	5MG	A211423	001	Dec 11, 2019	Aug CAHN
AB		10MG	A211423	002	Dec 11, 2019	Aug CAHN

SORAFENIB TOSYLATE

TABLET;ORAL

SORAFENIB TOSYLATE

AB	TORRENT	EQ 200MG BASE	A217095	001	Apr 12, 2023	Mar NEWA
----	---------	---------------	---------	-----	--------------	----------

SOTAGLIFLOZIN

TABLET;ORAL

INPEFA

+	LEXICON PHARMS INC	200MG	N216203	001	May 26, 2023	May NEWA
+	!	400MG	N216203	002	May 26, 2023	May NEWA

SOTALOL HYDROCHLORIDE

TABLET;ORAL

SORINE

>A>	AB	AIPING PHARM INC	80MG	A075500	001	Apr 27, 2001	Oct CAHN
>A>	AB		120MG	A075500	004	Apr 27, 2001	Oct CAHN
>A>	AB		160MG	A075500	002	Apr 27, 2001	Oct CAHN
>A>	AB		240MG	A075500	003	Apr 27, 2001	Oct CAHN
>D>	AB	UPSHER SMITH LABS	80MG	A075500	001	Apr 27, 2001	Oct CAHN
>D>	AB		120MG	A075500	004	Apr 27, 2001	Oct CAHN
>D>	AB		160MG	A075500	002	Apr 27, 2001	Oct CAHN
>D>	AB		240MG	A075500	003	Apr 27, 2001	Oct CAHN

SOTALOL HYDROCHLORIDE

AB	AUROBINDO PHARMA USA	80MG	A077616	001	Feb 07, 2007	Jul CMFD
AB		120MG	A077616	002	Feb 07, 2007	Jul CMFD
AB		160MG	A077616	003	Feb 07, 2007	Jul CMFD
	@ NATCO PHARMA USA	80MG	A075237	001	May 01, 2000	Aug CAHN
	@	120MG	A075237	002	May 01, 2000	Aug CAHN
	@	160MG	A075237	003	May 01, 2000	Aug CAHN
	@	240MG	A075237	004	May 01, 2000	Aug CAHN

SOTORASIB

TABLET;ORAL

LUMAKRAS

+	AMGEN INC	120MG	N214665	001	May 28, 2021	Mar CHRS
+	!	320MG	N214665	002	Jan 20, 2023	Mar CHRS
+		320MG	N214665	002	Jan 20, 2023	Feb NEWA

SPARSENTAN

TABLET;ORAL

FILSPARI

+	TRAVERE	200MG	N216403	001	Feb 17, 2023	Feb NEWA
+	!	400MG	N216403	002	Feb 17, 2023	Feb NEWA

SPIRONOLACTONE

SUSPENSION;ORAL

CAROSPIR

AB	+! CMP DEV LLC	25MG/5ML	N209478	001	Aug 04, 2017	Aug CFTG
	SPIRONOLACTONE					
AB	AMNEAL	25MG/5ML	A215572	001	Sep 05, 2023	Aug NFTG

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

AP	AM REGENT	100% (10ML)	A217341	001	Aug 29, 2023	Aug NEWA
AP		100% (20ML)	A217341	002	Aug 29, 2023	Aug NEWA
AP	HIKMA	100%	A212735	001	Jan 31, 2023	Jan NEWA
AP	+! HOSPIRA	100% (20ML)	N018801	003	Oct 27, 1982	Jun CFTG
	+ @	100% (5.2ML)	N018801	006	May 02, 2023	Jun DISC
	+!	100% (5.2ML)	N018801	006	May 02, 2023	May NEWA

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

SUCCINYLCHOLINE CHLORIDE

>A> AP	@ BRECKENRIDGE	20MG/ML	A212638	001	Oct 09, 2019	Apr DISC
	EUGIA PHARMA	20MG/ML	A217808	001	Oct 16, 2023	Oct NEWA
	@ MANKIND PHARMA	20MG/ML	A216127	001	Feb 02, 2023	Aug DISC
AP		20MG/ML	A216127	001	Feb 02, 2023	Jan NEWA
AP	UMEDICA	20MG/ML	A211625	001	May 19, 2020	Sep CAHN

SUCRALFATE

TABLET;ORAL

SUCRALFATE

AB	ZYDUS LIFESCIENCES	1GM	A215705	001	May 03, 2023	Apr NEWA
----	--------------------	-----	---------	-----	--------------	----------

SUFENTANIL CITRATE

INJECTABLE;INJECTION

SUFENTA PRESERVATIVE FREE

AP	+! RISING	EQ 0.05MG BASE/ML	N019050	001	May 04, 1984	Sep CAHN
	TABLET;SUBLINGUAL					
	DSUVIA					
	+! VERTICAL PHARMS	EQ 0.03MG BASE	N209128	001	Nov 02, 2018	Apr CAHN

SUGAMMADEX SODIUM

SOLUTION;INTRAVENOUS

BRIDION

AP	+ MSD SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jul CAHN
AP	+!	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jul CAHN
AP	+ ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jun CFTG
AP	+!	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jun CFTG
	SUGAMMADEX SODIUM					
AP	ASPIRO	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214337	001	Jun 09, 2023	Jun NFTG
AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214337	002	Jun 09, 2023	Jun NFTG
AP	ZYDUS PHARMS	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214290	001	Oct 04, 2023	Sep NEWA
AP		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214290	002	Oct 04, 2023	Sep NEWA

SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM

	@ AKORN	10%	A040215	001	May 25, 1999	Jan DISC
	@ EPIC PHARMA LLC	30%	A040216	001	May 25, 1999	Sep CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	CHARTWELL MOLECULAR	200MG/5ML; 40MG/5ML	A077785	001	Jan 24, 2007	Jul CAHN
----	---------------------	---------------------	---------	-----	--------------	----------

SULINDAC

TABLET;ORAL

SULINDAC

	@ CHARTWELL RX	150MG	A072712	001	Aug 30, 1991	Jan CAHN
	@	200MG	A072713	001	Aug 30, 1991	Jan CAHN

SUMATRIPTANSPRAY;NASAL
TOSYMRA

+! TONIX MEDS 10MG/SPRAY N210884 001 Jan 25, 2019 Jul CAHN

SUMATRIPTAN SUCCINATEINJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

	@ BAXTER HLTHCARE CORP	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A207101	001	Jan 19, 2023	Aug DISC
AP		EQ 6MG BASE/0.5ML EQ 12MG BASE/ML	A207101	001	Jan 19, 2023	Jan NEWA
AP	SOMERSET	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A213998	001	Jul 13, 2021	Sep CAHN

SOLUTION;SUBCUTANEOUS
ZEMBRACE SYMTOUCH

+ TONIX MEDS EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) N208223 001 Jan 28, 2016 Jul CAHN

TABLET;ORAL
SUMATRIPTAN SUCCINATE

	@ SUN PHARM INDS LTD	EQ 25MG BASE	A076554	001	Aug 10, 2009	Aug DISC
	@	EQ 50MG BASE	A076554	002	Aug 10, 2009	Aug DISC
	@	EQ 100MG BASE	A076572	001	Feb 09, 2009	Aug DISC

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

>A>	AB	NATCO PHARMA	EQ 12.5MG BASE	A218024	001	Oct 24, 2023	Oct NEWA
>A>	AB		EQ 25MG BASE	A218024	002	Oct 24, 2023	Oct NEWA
>A>	AB		EQ 37.5MG BASE	A218024	003	Oct 24, 2023	Oct NEWA
>A>	AB		EQ 50MG BASE	A218024	004	Oct 24, 2023	Oct NEWA
	AB	NOVUGEN	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Aug NEWA
	AB		EQ 25MG BASE	A218012	002	Aug 21, 2023	Aug NEWA
	AB		EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Aug NEWA
	AB		EQ 50MG BASE	A218012	004	Aug 21, 2023	Aug NEWA

TACROLIMUS

CAPSULE;ORAL

TACROLIMUS

BX		ACCORD HLTHCARE	EQ 0.5MG BASE	A091195	001	Aug 31, 2011	Sep CTEC
BX			EQ 1MG BASE	A091195	002	Aug 31, 2011	Sep CTEC
BX			EQ 5MG BASE	A091195	003	Aug 31, 2011	Sep CTEC
AB		HANGZHOU ZHONGMEI	EQ 0.5MG BASE	A210929	001	Apr 17, 2023	Apr NEWA
AB			EQ 1MG BASE	A210929	002	Apr 17, 2023	Apr NEWA
AB			EQ 5MG BASE	A210929	003	Apr 17, 2023	Apr NEWA

OINTMENT;TOPICAL

TACROLIMUS

AB		ENCUBE	0.1%	A212387	001	Oct 10, 2023	Sep NEWA
AB		GLENMARK PHARMS LTD	0.03%	A210393	002	Aug 16, 2023	Aug NEWA

TADALAFIL

TABLET;ORAL

ALYQ

>D>		@ TEVA PHARMS INC	20MG	A216932	001	Oct 12, 2022	Oct CMFD
>A>	AB2		20MG	A216932	001	Oct 12, 2022	Oct CMFD
		@	20MG	A216932	001	Oct 12, 2022	Apr DISC

TADALAFIL

AB2		CHARTWELL RX	20MG	A210572	001	Feb 05, 2019	May CAHN
AB1		NOVITIUM PHARMA	5MG	A215949	001	Mar 03, 2023	Feb NEWA
AB1			10MG	A215949	002	Mar 03, 2023	Feb NEWA
AB1			20MG	A215949	003	Mar 03, 2023	Feb NEWA
AB1		UNICHEM	2.5MG	A209250	001	Mar 26, 2019	Jan CTEC
AB1			5MG	A209250	002	Mar 26, 2019	Jan CTEC
AB1			10MG	A209250	003	Mar 26, 2019	Jan CTEC
AB1			20MG	A209250	004	Mar 26, 2019	Jan CTEC
>D>		@ WATSON LABS INC	2.5MG	A205885	001	Mar 29, 2019	Oct CMFD
>A>	AB1		2.5MG	A205885	001	Mar 29, 2019	Oct CMFD
>D>		@	5MG	A205885	002	Mar 29, 2019	Oct CMFD
>A>	AB1		5MG	A205885	002	Mar 29, 2019	Oct CMFD
>D>		@	10MG	A205885	003	Mar 29, 2019	Oct CMFD
>A>	AB1		10MG	A205885	003	Mar 29, 2019	Oct CMFD
>D>		@	20MG	A205885	004	Mar 29, 2019	Oct CMFD
>A>	AB1		20MG	A205885	004	Mar 29, 2019	Oct CMFD

TABLET;ORAL							
TADALAFIL							
>D>	AB2	ZYDUS PHARMS	20MG	A212515	001	Jun 06, 2023	Oct DISC
>A>	@		20MG	A212515	001	Jun 06, 2023	Oct DISC
	AB2		20MG	A212515	001	Jun 06, 2023	May NEWA
<u>TALAZOPARIB TOSYLATE</u>							
CAPSULE;ORAL							
TALZENNA							
	+	PFIZER	EQ 0.1MG BASE	N211651	005	Jun 20, 2023	Jul NEWA
	+		EQ 0.35MG BASE	N211651	006	Jun 20, 2023	Jul NEWA
<u>TAMOXIFEN CITRATE</u>							
SOLUTION;ORAL							
SOLTAMOX							
	+	! MAYNE PHARMA COMMRL	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005	Feb CAHN
<u>TAMSULOSIN HYDROCHLORIDE</u>							
CAPSULE;ORAL							
TAMSULOSIN HYDROCHLORIDE							
	@	ASCENT PHARMS INC	0.4MG	A214730	001	May 04, 2022	Sep CAHN
AB		CHARTWELL RX	0.4MG	A211885	001	Oct 17, 2019	Sep CAHN
<u>TASIMELTEON</u>							
CAPSULE;ORAL							
TASIMELTEON							
AB		APOTEX	20MG	A211607	001	Dec 20, 2022	Jan CAHN
AB		MSN	20MG	A211654	001	Jan 12, 2023	Jan NEWA
<u>TAVABOROLE</u>							
SOLUTION;TOPICAL							
TAVABOROLE							
AB		ZYDUS LIFESCIENCES	5%	A212294	001	Apr 10, 2023	Mar NEWA
<u>TAZAROTENE</u>							
GEL;TOPICAL							
TAZAROTENE							
AB		PADAGIS ISRAEL	0.05%	A213079	001	Apr 25, 2023	Apr NEWA
AB			0.1%	A213079	002	Apr 25, 2023	Apr NEWA
AB		SOLARIS PHARMA CORP	0.05%	A213644	001	Mar 20, 2023	Mar NEWA
AB			0.1%	A213644	002	Mar 20, 2023	Mar NEWA
<u>TECHNETIUM TC-99M LABELED CARBON</u>							
AEROSOL;INHALATION							
TECHNEGAS KIT							
	+	! CYCLOMEDICA	N/A	N022335	001	Sep 29, 2023	Sep NEWA
<u>TECHNETIUM TC-99M MERTIATIDE KIT</u>							
POWDER;INTRAVENOUS							
TECHNETIUM TC 99M MERTIATIDE KIT							
	+	! JUBILANT DRAXIMAGE	N/A	N216820	001	Jan 30, 2023	Jan NEWA
>D>	<u>TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR</u>						
>D>	SOLUTION;INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC						
>D>	RADIOGENIX SYSTEM						
>D>	+	NORTHSTAR MEDICAL	30-1153mCi/GENERATOR	N202158	001	Feb 08, 2018	Oct DISC
>A>	+	@	30-1153mCi/GENERATOR	N202158	001	Feb 08, 2018	Oct DISC
<u>TELMISARTAN</u>							
TABLET;ORAL							
TELMISARTAN							
AB		CHARTWELL RX	20MG	A078710	001	Jan 08, 2014	May CAHN
AB			40MG	A078710	002	Jan 08, 2014	May CAHN
AB			80MG	A078710	003	Jan 08, 2014	May CAHN
<u>TEMAZEPAM</u>							
CAPSULE;ORAL							
TEMAZEPAM							
AB		ALKEM LABS LTD	7.5MG	A217875	001	Aug 24, 2023	Aug NEWA
AB			15MG	A217875	002	Aug 24, 2023	Aug NEWA
AB			22.5MG	A217875	003	Aug 24, 2023	Aug NEWA
AB			30MG	A217875	004	Aug 24, 2023	Aug NEWA

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

@ CHARTWELL MOLECULAR	5MG	A203898	001	Feb 10, 2016	Jul CAHN
@	20MG	A203898	002	Feb 10, 2016	Jul CAHN
@	100MG	A203898	003	Feb 10, 2016	Jul CAHN
@	140MG	A203898	004	Feb 10, 2016	Jul CAHN
@	180MG	A203898	005	Feb 10, 2016	Jul CAHN
@	250MG	A203898	006	Feb 10, 2016	Jul CAHN
@ HERITAGE	5MG	A078879	001	Mar 01, 2010	Aug DISC
@	20MG	A078879	002	Mar 01, 2010	Aug DISC
@	100MG	A078879	003	Mar 01, 2010	Aug DISC
@	140MG	A078879	005	Mar 01, 2010	Aug DISC
@	180MG	A078879	006	Mar 01, 2010	Aug DISC
@	250MG	A078879	004	Mar 01, 2010	Aug DISC

TENAPANOR HYDROCHLORIDE

TABLET;ORAL

XPHOZAH

>A>	XPHOZAH				
>A>	+ ARDELYX INC	EQ 10MG BASE	N213931	001	Oct 17, 2023 Oct NEWA
>A>	+	EQ 20MG BASE	N213931	002	Oct 17, 2023 Oct NEWA
>A>	+	EQ 30MG BASE	N213931	003	Oct 17, 2023 Oct NEWA

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

TENOFOVIR ALAFENAMIDE

AB	LUPIN LTD	EQ 25MG BASE	A214226	001	Mar 30, 2023 Mar NFTG
	VEMLIDY				
AB	+! GILEAD SCIENCES INC	EQ 25MG BASE	N208464	001	Nov 10, 2016 Mar CFTG

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB	REYOUNG	300MG	A211337	001	Mar 02, 2023 Aug CAHN
AB	REYOUNG PHARM	300MG	A211337	001	Mar 02, 2023 Feb NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

@ BIONPHARMA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Apr CAHN
@	EQ 2MG BASE	A075667	002	Jul 28, 2000	Apr CAHN
@	EQ 5MG BASE	A075667	003	Jul 28, 2000	Apr CAHN
@	EQ 10MG BASE	A075667	004	Jul 28, 2000	Apr CAHN

TABLET;ORAL

TERAZOSIN HYDROCHLORIDE

@ CHARTWELL RX	EQ 1MG BASE	A074657	001	Apr 28, 2000	May CAHN
@	EQ 2MG BASE	A074657	002	Apr 28, 2000	May CAHN
@	EQ 5MG BASE	A074657	003	Apr 28, 2000	May CAHN
@	EQ 10MG BASE	A074657	004	Apr 28, 2000	May CAHN

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

AB	AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018 Feb CMFD
AB		14MG	A209613	002	Sep 28, 2018 Feb CMFD
AB	APOTEX	7MG	A209601	001	Nov 02, 2018 Jan CMFD
AB		14MG	A209601	002	Nov 02, 2018 Jan CMFD
AB	AUROBINDO PHARMA	7MG	A209638	001	Oct 26, 2018 Jan CMFD
AB		14MG	A209638	002	Oct 26, 2018 Jan CMFD
AB	BIOCON PHARMA	7MG	A209639	001	Mar 13, 2023 Mar NEWA
AB		14MG	A209639	002	Mar 13, 2023 Mar NEWA
AB	HETERO LABS LTD V	7MG	A209598	001	Mar 13, 2023 Mar NEWA
AB		14MG	A209598	002	Mar 13, 2023 Mar NEWA
AB	MSN	7MG	A209623	001	Apr 24, 2019 Feb CMFD
AB		14MG	A209623	002	Apr 24, 2019 Feb CMFD
AB	MYLAN	7MG	A209702	001	Feb 28, 2020 Feb CMFD
AB		14MG	A209702	002	Feb 28, 2020 Feb CMFD
AB	NATCO	7MG	A209555	001	May 15, 2023 May NEWA
AB		14MG	A209555	002	May 15, 2023 May NEWA
AB	SOLA PHARMS	7MG	A209677	002	Sep 28, 2023 Sep NEWA
AB		14MG	A209677	001	Jun 17, 2020 Feb CMFD
AB	TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018 Feb CMFD

TABLET;ORAL
TERIFLUNOMIDE

AB		14MG	A209700	002	Sep 04, 2018	Feb CMFD
AB	ZYDUS PHARMS	7MG	A209668	001	Nov 30, 2018	Jan CMFD
AB		14MG	A209668	002	Nov 30, 2018	Jan CMFD

TESTOSTERONE

GEL, METERED;NASAL
NATESTO

+	!	ACERUS	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jan CHRS
+			5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jan CRLD

GEL, METERED;TRANSDERMAL
ANDROGEL

AB	+	!	BESINS HLTHCARE	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Feb CAHN
	+	@		12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Feb CAHN

AB			TESTOSTERONE					
			ENCUBE	1.62% (20.25MG/1.25GM ACTUATION)	A208620	001	Apr 10, 2019	Jan CAHN

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION
TESTOSTERONE CYPIONATE

>A>	AO		EUGIA PHARMA	100MG/ML	A211817	001	Oct 20, 2023	Oct NEWA
>A>	AO			200MG/ML	A211817	002	Oct 20, 2023	Oct NEWA
	AO		XIROMED	100MG/ML	A215351	001	Apr 13, 2023	Mar NEWA
	AO			200MG/ML	A215351	002	Apr 13, 2023	Mar NEWA

TETRABENAZINE

TABLET;ORAL
TETRABENAZINE

AB			CHARTWELL RX	12.5MG	A210544	001	Apr 20, 2018	May CAHN
AB				25MG	A210544	002	Apr 20, 2018	May CAHN
		@	SUN PHARM	12.5MG	A206129	001	Aug 17, 2015	Jan DISC
		@		25MG	A206129	002	Aug 17, 2015	Jan DISC

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL
ACHROMYCIN V

+	@	AVET	250MG	N050278	003		Sep DISC
+	@		500MG	N050278	001		Sep DISC

AB	!		AMNEAL PHARMS NY	500MG	A210674	002	Sep 18, 2018	Sep CHRS
	@		AUROBINDO PHARMA USA	250MG	A060783	001		Apr CAHN
	@			500MG	A060783	002		Apr CAHN

THALIDOMIDE

CAPSULE;ORAL
THALIDOMIDE

>D>	AB		NATCO	150MG	A213267	001	Apr 27, 2023	Oct DISC
>A>		@		150MG	A213267	001	Apr 27, 2023	Oct DISC
	AB			150MG	A213267	001	Apr 27, 2023	Apr NFTG
			THALOMID					
	+		BRISTOL-MYERS	50MG	N020785	001	Jul 16, 1998	Sep CAHN
	+			100MG	N020785	002	Jan 17, 2003	Sep CAHN
>D>	AB	+		150MG	N020785	004	Jan 10, 2007	Oct CTEC
>A>		+		150MG	N020785	004	Jan 10, 2007	Oct CTEC
	AB	+		150MG	N020785	004	Jan 10, 2007	Sep CAHN
		+		200MG	N020785	003	Jan 17, 2003	Sep CAHN
AB	+		CELGENE	150MG	N020785	004	Jan 10, 2007	Apr CFTG

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION
THALLOUS CHLORIDE TL 201

+	!	CURIUM	1mCi/ML	N018150	001		Aug CTEC
+	@	LANTHEUS MEDCL	1mCi/ML	N017806	001		Aug DISC

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL
THEO-24

>A>			AUXILIUM PHARMS LLC	100MG	A087943	002	Aug 22, 1983	Oct CMS1
>A>				300MG	A087943	003	Aug 22, 1983	Oct CMS1
>A>		!		400MG	A087943	004	Feb 28, 1992	Oct CMS1

INJECTABLE;INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

>D>	+!	B BRAUN	40MG/100ML	N019826	001	Aug 14, 1992	Oct DISC
>A>	+	@	40MG/100ML	N019826	001	Aug 14, 1992	Oct DISC
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER							
>D>	+!	B BRAUN	80MG/100ML	N019826	002	Aug 14, 1992	Oct DISC
>A>	+	@	80MG/100ML	N019826	002	Aug 14, 1992	Oct DISC
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER							
>D>	+!	B BRAUN	160MG/100ML	N019826	003	Aug 14, 1992	Oct DISC
>A>	+	@	160MG/100ML	N019826	003	Aug 14, 1992	Oct DISC
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER							
>D>	+!	B BRAUN	320MG/100ML	N019826	006	Aug 14, 1992	Oct DISC
>A>	+	@	320MG/100ML	N019826	006	Aug 14, 1992	Oct DISC

TABLET, EXTENDED RELEASE;ORAL

THEOCHRON

		NOSTRUM PHARMS LLC	100MG	A087400	003	Feb 21, 1985	Aug CMFD
			200MG	A087400	004	Feb 21, 1985	Aug CMFD
AB			300MG	A087400	002	Jan 11, 1983	Aug CMFD
AB			450MG	A087400	005	Aug 09, 2023	Aug NEWA
THEOPHYLLINE							
AB		AMNEAL	300MG	A216276	001	Mar 20, 2023	Mar NEWA
AB			450MG	A216276	002	Mar 20, 2023	Mar NEWA
AB		ANNORA PHARMA	300MG	A217422	001	Sep 08, 2023	Sep NEWA
AB			450MG	A217422	002	Sep 08, 2023	Sep NEWA
AB		BIONPHARMA	300MG	A216300	001	Apr 26, 2023	Apr NEWA
AB			450MG	A216300	002	Apr 26, 2023	Apr NEWA
>A>	AB	HARMAN FINOCHEM	300MG	A214806	001	Oct 24, 2023	Oct NEWA
>A>	AB		450MG	A214806	002	Oct 24, 2023	Oct NEWA
AB		LEADING	300MG	A214950	001	Jan 30, 2023	Jan NEWA
AB			450MG	A214950	002	Jan 30, 2023	Jan NEWA
AB		RHODES PHARMS	300MG	A214113	001	May 11, 2023	May NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

AP		CAPLIN	100MG/ML	A215692	001	Mar 06, 2023	Feb NEWA
AP		DR REDDYS	100MG/ML	A080571	001		Mar CMFD
	!		200MG/ML	A080571	002		Mar CMFD

THIOGUANINE

TABLET;ORAL

THIOGUANINE

	+!	WAYLIS THERAP	40MG	N012429	001		Sep CAHN
--	----	---------------	------	---------	-----	--	----------

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

@	CHARTWELL RX	10MG	A088131	001	Aug 30, 1983	Jan CAHN
@		15MG	A088132	001	Aug 30, 1983	Jan CAHN
@		25MG	A088133	001	Aug 30, 1983	Jan CAHN
@		50MG	A088134	001	Aug 30, 1983	Jan CAHN
@		100MG	A088135	001	Nov 20, 1984	Jan CAHN
@		150MG	A088136	001	Sep 17, 1986	Jan CAHN
@		200MG	A088137	001	Sep 17, 1986	Jan CAHN

THIOTEPA

INJECTABLE;INJECTION

THIOTEPA

AP		PENN LIFE	15MG/VIAL	A208242	001	Jan 10, 2020	May CAHN
POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL							
THIOTEPA							
AP		HIKMA	100MG/VIAL	A211755	001	Sep 05, 2023	Aug NEWA

THIOTHIXENE

CAPSULE;ORAL

THIOTHIXENE

AB		RISING	1MG	A071093	002	Jun 23, 1987	Feb CAHN
AB			2MG	A071093	003	Jun 23, 1987	Feb CAHN
AB			5MG	A071093	004	Jun 23, 1987	Feb CAHN
AB			10MG	A071093	001	Jun 23, 1987	Feb CAHN

TICAGRELORTABLET;ORAL
TICAGRELOR

AB	ALKEM LABS LTD	90MG	A208567	001	Apr 21, 2023	Apr NEWA
----	----------------	------	---------	-----	--------------	----------

TICLOPIDINE HYDROCHLORIDETABLET;ORAL
TICLOPIDINE HYDROCHLORIDE

!	APOTEX	250MG
		250MG
@	TEVA	250MG

A075089	001	Jul 01, 1999	Sep CHRS
A075089	001	Jul 01, 1999	Sep CTEC
A075149	001	Aug 20, 1999	Sep DISC

TIMOLOLSOLUTION/DROPS;OPHTHALMIC
BETIMOL

+	THEA PHARMA	EQ 0.25% BASE
+		EQ 0.5% BASE

N020439	001	Mar 31, 1995	Jan CTEC
N020439	002	Mar 31, 1995	Jan CTEC

TIMOLOL

>D>	@ AKORN	EQ 0.25% BASE
	@	EQ 0.25% BASE
>D>	@	EQ 0.5% BASE
	@	EQ 0.5% BASE
>A>	@ EPIC PHARMA LLC	EQ 0.25% BASE
>A>	@	EQ 0.5% BASE

A205309	001	Sep 30, 2016	Oct CAHN
A205309	001	Sep 30, 2016	Jan DISC
A205309	002	Sep 30, 2016	Oct CAHN
A205309	002	Sep 30, 2016	Jan DISC
A205309	001	Sep 30, 2016	Oct CAHN
A205309	002	Sep 30, 2016	Oct CAHN

TIMOLOL MALEATESOLUTION, GEL FORMING/DROPS;OPHTHALMIC
TIMOLOL MALEATE

AB	EUGIA PHARMA	EQ 0.5% BASE
AB	GLAND PHARMA LTD	EQ 0.5% BASE

A213540	001	Mar 23, 2023	Mar NEWA
A214645	002	Feb 14, 2023	Feb NEWA

SOLUTION/DROPS;OPHTHALMIC
TIMOLOL MALEATE

	@ AKORN	EQ 0.5% BASE
AT1	MICRO LABS	EQ 0.25% BASE
AT1		EQ 0.5% BASE
AT3	SENTISS PHARMA	EQ 0.5% BASE

A074466	001	Mar 25, 1997	Jan DISC
A217343	001	May 26, 2023	May NEWA
A217343	002	May 26, 2023	May NEWA
A217195	001	May 08, 2023	Apr NEWA

TABLET;ORAL

TIMOLOL MALEATE

AB	RISING	5MG
AB		10MG
AB		20MG

A207556	001	May 02, 2019	Aug CAHN
A207556	002	May 02, 2019	Aug CAHN
A207556	003	May 02, 2019	Aug CAHN

TINIDAZOLETABLET;ORAL
TINIDAZOLE

AB	CHARTWELL RX	250MG
AB		500MG

A202044	001	Apr 30, 2012	Apr CAHN
A202044	002	Apr 30, 2012	Apr CAHN

TIOPRONINTABLET, DELAYED RELEASE;ORAL
THIOLA EC

	+	MISSION PHARMACAL	100MG
AB	+		300MG
AB	+	MISSION PHARMACAL CO	100MG
	+		300MG
AB	+		300MG

N211843	001	Jun 28, 2019	Apr CTEC
N211843	002	Jun 28, 2019	Aug CTEC
N211843	001	Jun 28, 2019	Feb CFTG
N211843	002	Jun 28, 2019	Apr CTEC
N211843	002	Jun 28, 2019	Feb CFTG

TIOPRONIN

AB	AMNEAL	300MG
	@ PAR PHARM	100MG
AB		100MG
	@	300MG
AB		300MG

A216278	001	Aug 15, 2023	Aug NEWA
A217219	001	Feb 24, 2023	Apr DISC
A217219	001	Feb 24, 2023	Feb NFTG
A217219	002	Feb 24, 2023	Apr DISC
A217219	002	Feb 24, 2023	Feb NFTG

TIOTROPIUM BROMIDEPOWDER;INHALATION
SPIRIVA

AB	+	BOEHRINGER INGELHEIM	EQ 0.018MG BASE/INH
		TIOTROPIUM BROMIDE	
AB		LUPIN	EQ 0.018MG BASE/INH

N021395	001	Jan 30, 2004	Jun CFTG
A211287	001	Jun 20, 2023	Jun NFTG

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINETABLET; ORAL
LONSURF

AB	+	TAIHO ONCOLOGY	EQ 6.14MG BASE;15MG	N207981	001	Sep 22, 2015	Jun CFTG
AB	+	!	EQ 8.19MG BASE;20MG	N207981	002	Sep 22, 2015	Jun CFTG
TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE							
AB		NATCO	EQ 6.14MG BASE;15MG	A214008	001	Jun 13, 2023	Jun NFTG
AB			EQ 8.19MG BASE;20MG	A214008	002	Jun 13, 2023	Jun NFTG

TIROFIBAN HYDROCHLORIDESOLUTION; INTRAVENOUS
AGGRASTAT

AP	+	MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002	Jan CFTG
TIROFIBAN HYDROCHLORIDE							
AP		EUGIA PHARMA	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	A216379	001	May 01, 2023	Apr NEWA
AP			EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	A216379	002	May 01, 2023	Apr NEWA

TIZANIDINE HYDROCHLORIDECAPSULE; ORAL
ZANAFLEX

AB	+	LEGACY PHARMA USA	EQ 2MG BASE	N021447	001	Aug 29, 2002	Jul CAHN
AB	+		EQ 4MG BASE	N021447	002	Aug 29, 2002	Jul CAHN
AB	+	!	EQ 6MG BASE	N021447	003	Aug 29, 2002	Jul CAHN

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

		@ AUROBINDO PHARMA USA	EQ 2MG BASE	A076282	001	Dec 16, 2003	Apr CAHN
		@	EQ 4MG BASE	A076282	002	Dec 16, 2003	Apr CAHN
ZANAFLEX							
		+ @ LEGACY PHARMA USA	EQ 2MG BASE	N020397	002	Feb 04, 2000	Jul CAHN
AB		+	EQ 4MG BASE	N020397	001	Nov 27, 1996	Jul CAHN

TOBRAMYCINSOLUTION; INHALATION
TOBRAMYCIN

AN		MANKIND PHARMA	300MG/5ML	A214478	001	Jun 30, 2023	Jun NEWA
AN		MICRO LABS	300MG/5ML	A217344	001	Jul 27, 2023	Jul NEWA

SOLUTION/DROPS; OPHTHALMIC

AKTOB

		@ AKORN	0.3%	A064096	001	Jan 31, 1996	Feb DISC
TOBRAMYCIN							
>A>	AT	CHARTWELL RX	0.3%	A065026	001	Sep 11, 2001	Oct CAHN
>D>	AT	FERA PHARMS	0.3%	A065026	001	Sep 11, 2001	Oct CAHN

TOBRAMYCIN SULFATEINJECTABLE; INJECTION
TOBRAMYCIN SULFATE

>D>		@ AKORN	EQ 40MG BASE/ML	A205179	001	Sep 16, 2014	Oct CAHN
>A>		@ EPIC PHARMA LLC	EQ 40MG BASE/ML	A205179	001	Sep 16, 2014	Oct CAHN
AP		EUGIA PHARMA	EQ 1.2GM BASE/VIAL	A217519	001	Jun 21, 2023	Jun NEWA
AP	!	FRESENIUS KABI USA	EQ 10MG BASE/ML	A065122	001	Nov 29, 2002	Sep CHRS
AP		HAINAN POLY	EQ 1.2GM BASE/VIAL	A217029	001	Feb 01, 2023	Jan NEWA
		@ HOSPIRA	EQ 10MG BASE/ML	A063112	001	Apr 30, 1991	Sep DISC
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
		@ HOSPIRA	EQ 1.2MG BASE/ML	A063081	003	Jul 31, 1990	Sep DISC
		@	EQ 1.6MG BASE/ML	A063081	006	Jun 02, 1993	Sep DISC
		@	EQ 80MG BASE/100ML	A063081	001	Jul 31, 1990	Sep DISC

TOFACITINIB CITRATE

SOLUTION; ORAL

TOFACITINIB CITRATE

AA		SLAYBACK PHARMA LLC	EQ 1MG BASE/ML	A216878	001	Sep 25, 2023	Sep NFTG
XELJANZ							
AA	+	PFIZER	EQ 1MG BASE/ML	N213082	001	Sep 25, 2020	Sep CFTG
	+	!	EQ 1MG BASE/ML	N213082	001	Sep 25, 2020	Aug CPOT

TABLET; ORAL

TOFACITINIB CITRATE

		@ MICRO LABS	EQ 5MG BASE	A209738	001	Mar 13, 2023	Mar DISC
AB			EQ 5MG BASE	A209738	001	Mar 13, 2023	Mar NFTG

TABLET;ORAL							
TOFACITINIB CITRATE							
AB	@ ZYDUS PHARMS	EQ 5MG BASE	A209829	001	Mar 13, 2023	Sep	DISC
		EQ 5MG BASE	A209829	001	Mar 13, 2023	Mar	NEWA
XELJANZ							
AB	+ PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	Sep	CTEC
	+	EQ 5MG BASE	N203214	001	Nov 06, 2012	Mar	CFTG
<u>TOFERSEN</u>							
SOLUTION;INTRATHECAL							
QALSODY							
	+! BIOGEN MA	100MG/15ML (6.7MG/ML)	N215887	001	Apr 25, 2023	Apr	NEWA
<u>TOLMETIN SODIUM</u>							
CAPSULE;ORAL							
TOLMETIN SODIUM							
	RISING	EQ 400MG BASE	A073393	001	May 27, 1993	Jul	CMFD
TABLET;ORAL							
TOLMETIN SODIUM							
	! RISING	EQ 600MG BASE	A074473	001	Aug 30, 1994	May	CMFD
<u>TOLTERODINE TARTRATE</u>							
TABLET;ORAL							
TOLTERODINE TARTRATE							
AB	ELYSIUM	1MG	A210775	001	Dec 30, 2019	Sep	CAHN
AB		2MG	A210775	002	Dec 30, 2019	Sep	CAHN
<u>TOLVAPTAN</u>							
TABLET;ORAL							
TOLVAPTAN							
AB	MSN	15MG	A216949	001	Jun 21, 2023	Jun	NEWA
AB		30MG	A216949	002	Jun 21, 2023	Jun	NEWA
<u>TOPIRAMATE</u>							
CAPSULE;ORAL							
TOPIRAMATE							
AB	AUROBINDO PHARMA LTD	15MG	A215449	001	Sep 27, 2023	Sep	NEWA
AB		25MG	A215449	002	Sep 27, 2023	Sep	NEWA
	@ WATSON LABS	15MG	A077868	001	Apr 15, 2009	Sep	DISC
	@	25MG	A077868	002	Apr 15, 2009	Sep	DISC
CAPSULE, EXTENDED RELEASE;ORAL							
TOPIRAMATE							
AB1	ACTAVIS LABS FL	25MG	A206210	001	Mar 10, 2023	Mar	NEWA
AB1		50MG	A206210	002	Mar 10, 2023	Mar	NEWA
AB1		100MG	A206210	003	Mar 10, 2023	Mar	NEWA
AB1		200MG	A206210	004	Mar 10, 2023	Mar	NEWA
AB1	AJANTA PHARMA LTD	25MG	A215663	001	Aug 15, 2023	Aug	NEWA
AB1		50MG	A215663	002	Aug 15, 2023	Aug	NEWA
AB1		100MG	A215663	003	Aug 15, 2023	Aug	NEWA
AB1		200MG	A215663	004	Aug 15, 2023	Aug	NEWA
AB1	ALKEM LABS LTD	25MG	A217248	001	Jun 20, 2023	Jun	NEWA
AB1		50MG	A217248	002	Jun 20, 2023	Jun	NEWA
AB1		100MG	A217248	003	Jun 20, 2023	Jun	NEWA
AB1		200MG	A217248	004	Jun 20, 2023	Jun	NEWA
AB1	PAR PHARM	25MG	A205976	002	May 04, 2023	Apr	NEWA
AB1		50MG	A205976	003	May 04, 2023	Apr	NEWA
AB1		100MG	A205976	004	May 04, 2023	Apr	NEWA
AB1		200MG	A205976	001	Mar 01, 2023	Feb	NEWA
AB1	ZYDUS	25MG	A207382	001	Nov 24, 2017	Jan	CAHN
AB2		25MG	A208949	001	Nov 29, 2022	Jan	CAHN
AB1		50MG	A207382	002	Nov 24, 2017	Jan	CAHN
AB2		50MG	A208949	002	Nov 29, 2022	Jan	CAHN
AB1		100MG	A207382	003	Nov 24, 2017	Jan	CAHN
AB2		100MG	A208949	003	Nov 29, 2022	Jan	CAHN
AB2		150MG	A208949	004	Nov 29, 2022	Jan	CAHN
>A> AB1		200MG	A207382	004	Oct 30, 2023	Oct	NEWA
AB2		200MG	A208949	005	Nov 29, 2022	Jan	CAHN
	@ ZYDUS PHARMS	200MG	A216167	001	Feb 09, 2023	Aug	DISC
AB1		200MG	A216167	001	Feb 09, 2023	Jan	NFTG
TROKENDI XR							
AB1	+! SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013	Jan	CFTG

TABLET;ORAL
TOPIRAMATE

@ TEVA	25MG	A076317	001	Mar 27, 2009	Sep	DISC
@	50MG	A076317	002	Mar 27, 2009	Sep	DISC
@	100MG	A076317	003	Mar 27, 2009	Sep	DISC
@	200MG	A076317	004	Mar 27, 2009	Sep	DISC

TOPOTECAN HYDROCHLORIDE

CAPSULE;ORAL
HYCANTIN

+ SANDOZ	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	May	CAHN
+!	EQ 1MG BASE	N020981	002	Oct 11, 2007	May	CAHN

INJECTABLE;INJECTION
HYCANTIN

AP	+! SANDOZ	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	May	CAHN
----	-----------	------------------	---------	-----	--------------	-----	------

SOLUTION;INTRAVENOUS
TOPOTECAN HYDROCHLORIDE

>A> AP	@ DASH PHARMS	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Mar	CAHN
>D> AP	HONG KONG	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N022453	001	Dec 20, 2012	Oct	CAHN
	TEVA PHARMS USA	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N022453	001	Dec 20, 2012	Oct	CAHN

TORSEMIDE

TABLET;ORAL
SOAANZ

+ @ SARFE PHARMS	20MG	N213218	001	Jun 14, 2021	Jun	DISC
+ @	60MG	N213218	002	Jun 14, 2021	Jun	DISC

TORSEMIDE

@ TEVA	5MG	A076110	001	May 14, 2002	Sep	DISC
@	10MG	A076110	002	May 14, 2002	Sep	DISC
@	20MG	A076110	003	May 14, 2002	Sep	DISC
@	100MG	A076110	004	May 14, 2002	Sep	DISC

TRAMADOL HYDROCHLORIDE

TABLET;ORAL
TRAMADOL HYDROCHLORIDE

@ PLIVA	50MG	A075982	001	Jul 01, 2002	Sep	DISC
---------	------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL
TRAMADOL HYDROCHLORIDE

@ ACTAVIS ELIZABETH	100MG	A091609	001	Jun 27, 2012	Sep	DISC
@	200MG	A091609	002	Jun 27, 2012	Sep	DISC
@	300MG	A091609	003	Jun 27, 2012	Sep	DISC
! SUN PHARM	100MG	A091607	001	Dec 30, 2011	Sep	CTEC
	200MG	A091607	002	Dec 30, 2011	Sep	CTEC
	300MG	A091607	003	Dec 30, 2011	Sep	CTEC

TRAMETINIB DIMETHYL SULFOXIDE

SOLUTION;ORAL
MEKINIST

+! NOVARTIS	EQ 0.05MG BASE/ML	N217513	001	Mar 16, 2023	Mar	NEWA
-------------	-------------------	---------	-----	--------------	-----	------

TRANDOLAPRIL

TABLET;ORAL
TRANDOLAPRIL

@ TEVA PHARMS	1MG	A077489	001	Dec 12, 2006	Sep	DISC
@	2MG	A077489	002	Dec 12, 2006	Sep	DISC
@	4MG	A077489	003	Dec 12, 2006	Sep	DISC

TRANEXAMIC ACID

INJECTABLE;INJECTION
TRANEXAMIC ACID

>D> AP	AKORN	100MG/ML	A202373	001	Nov 17, 2011	Oct	CAHN
	@ CHARTWELL RX	100MG/ML	A202755	001	Feb 25, 2016	Sep	CAHN
>A> AP	EPIC PHARMA LLC	100MG/ML	A202373	001	Nov 17, 2011	Oct	CAHN
	@ VIRTUS	100MG/ML	A202755	001	Feb 25, 2016	Sep	CAHN

SOLUTION;INTRAVENOUS
TRANEXAMIC ACID

>A> AP	AMNEAL	1GM/100ML (10MG/ML)	A217155	001	Oct 16, 2023	Oct	NFTG
>D>	+! EXELA PHARMA	1GM/100ML (10MG/ML)	N212020	001	Apr 15, 2019	Oct	CFTG
>A> AP	+!	1GM/100ML (10MG/ML)	N212020	001	Apr 15, 2019	Oct	CFTG

TRAVOPROSTSOLUTION/DROPS;OPHTHALMIC
TRAVATAN Z

AT	+	!	SANDOZ	0.004%	N021994	001	Sep 21, 2006	Sep CAHN
----	---	---	--------	--------	---------	-----	--------------	----------

TRAZODONE HYDROCHLORIDETABLET;ORAL
TRAZODONE HYDROCHLORIDE

AB			AUROBINDO PHARMA	50MG	A204852	001	Feb 05, 2020	Jan CAHN
AB				100MG	A204852	002	Feb 05, 2020	Jan CAHN
AB				150MG	A204852	003	Feb 05, 2020	Jan CAHN
AB				300MG	A204852	004	Feb 05, 2020	Jan CAHN

TREPROSTINILINJECTABLE;IV (INFUSION), SUBCUTANEOUS
REMODULIN

>A>	+	!	UNITED THERAP	0.1MG/ML	N021272	006	Sep 28, 2023	Oct NEWA
>A>	+	!		0.2MG/ML	N021272	007	Sep 28, 2023	Oct NEWA
>A>	+	!		0.4MG/ML	N021272	008	Sep 28, 2023	Oct NEWA
			TREPROSTINIL					
AP			DR REDDYS	1MG/ML	A210214	001	May 22, 2020	Feb CMFD
AP				2.5MG/ML	A210214	002	May 22, 2020	Feb CMFD
AP				5MG/ML	A210214	003	May 22, 2020	Feb CMFD
AP				10MG/ML	A210214	004	May 22, 2020	Feb CMFD

TRETINOINCREAM;TOPICAL
RETIN-A

AB	+	!	BAUSCH	0.025%	N019049	001	Sep 16, 1988	Jan CAHN
			GEL;TOPICAL					
			AVITA					
			@ MYLAN	0.025%	N020400	001	Jan 29, 1998	May DISC
			RETIN-A-MICRO					
AB	+	!	VALEANT INTL	0.08%	N020475	003	Jan 28, 2014	Aug CFTG
			TRETINOIN MICROSPHERE					
AB			ENCUBE	0.08%	A215609	001	Aug 22, 2023	Aug NFTG

TRIAMCINOLONE ACETONIDECREAM;TOPICAL
TRIAMCINOLONE ACETONIDE

AT			CHARTWELL RX	0.025%	A208763	001	Feb 01, 2017	May CAHN
AT				0.1%	A208763	002	Feb 01, 2017	May CAHN
AT				0.5%	A208763	003	Feb 01, 2017	May CAHN
>D> AT			ENCUBE	0.1%	A208848	001	Sep 18, 2017	Oct CAHN
>A> AT				0.1%	A208848	001	Sep 18, 2017	Oct CAHN

LOTION;TOPICAL
TRIAMCINOLONE ACETONIDE

>D> AT			AKORN	0.025%	A202374	001	May 08, 2013	Oct CAHN
>D> AT				0.1%	A202374	002	May 08, 2013	Oct CAHN
>A> AT			EPIC PHARMA LLC	0.025%	A202374	001	May 08, 2013	Oct CAHN
>A> AT				0.1%	A202374	002	May 08, 2013	Oct CAHN
			@ PAI HOLDINGS PHARM	0.025%	A204608	001	Jul 07, 2016	Aug DISC
			@	0.1%	A204606	001	Jul 07, 2016	Aug DISC

OINTMENT;TOPICAL
TRIAMCINOLONE ACETONIDE

AT			CHARTWELL RX	0.05%	A214532	001	Jan 27, 2023	May CAHN
AT				0.1%	A207365	001	Oct 12, 2018	Apr CAHN
>D> AT			ENCUBE	0.1%	A205373	001	May 13, 2016	Oct CAHN
>A> AT				0.1%	A205373	001	May 13, 2016	Oct CAHN
AT			GLASSHOUSE PHARMS	0.05%	A214532	001	Jan 27, 2023	Jan NEWA
AT			MACLEODS PHARMS LTD	0.05%	A216625	001	Aug 18, 2023	Aug NEWA
			@ PAI HOLDINGS PHARM	0.5%	A208590	001	Mar 03, 2017	Aug DISC

SPRAY;TOPICAL

KENALOG

	+	@	SUN PHARM INDS INC	0.147MG/GM	N012104	001		Jun DISC
			TRIAMCINOLONE ACETONIDE					
AT	!		PADAGIS ISRAEL	0.147MG/GM	A205782	001	Apr 13, 2015	Jun CHRS

TRIAMTERENE

CAPSULE;ORAL
 TRIAMTERENE
 @ EYWA
 @

50MG
 100MG

A214768 001 Jul 06, 2022 Jan DISC
 A214768 002 Jul 06, 2022 Jan DISC

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL
 TRIENTINE HYDROCHLORIDE

AB MSN 250MG
 RISING 500MG

A211134 001 May 22, 2019 Mar CTEC
 A212238 002 Sep 22, 2023 Sep NEWA

TROFINETIDE

SOLUTION;ORAL
 DAYBUE

+! ACADIA PHARMS INC 200MG/ML

N217026 001 Mar 10, 2023 Mar NEWA

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC
 TROPICACYL

AT EPIC PHARMA LLC 0.5%

A040314 001 Sep 29, 2000 Sep CAHN

TROSPIMUM CHLORIDE

TABLET;ORAL
 TROSPIMUM CHLORIDE

AB CHARTWELL RX 20MG

A215781 001 Feb 16, 2022 Sep CAHN

UBROGEPANT

TABLET;ORAL
 UBRELVI

+ ABBVIE 50MG
 +! 100MG

N211765 001 Dec 23, 2019 Jan CAHN
 N211765 002 Dec 23, 2019 Jan CAHN

UREA, C-14

CAPSULE;ORAL
 PYTEST KIT

+ @ AVENT 1uCi

N020617 002 May 09, 1997 Sep DISC

URIDINE TRIACETATE

GRANULE;ORAL
 VISTOGARD

+! BTG INTL 10GM/PACKET
 XURIDEN

N208159 001 Dec 11, 2015 Jul CAHN

+! BTG INTL 2GM/PACKET

N208169 001 Sep 04, 2015 Jul CAHN

URSODIOL

CAPSULE;ORAL
 URSODIOL

AB @ MYLAN 300MG
 RK PHARMA 300MG
 @ TEVA PHARMS 300MG
 AB VGYAAN 300MG

A090530 001 Feb 17, 2010 Jan DISC
 A214329 001 Jul 28, 2021 Jun CAHN
 A075592 001 May 25, 2000 Sep DISC
 A214329 001 Jul 28, 2021 Apr CMFD

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL
 VALACYCLOVIR HYDROCHLORIDE

>A> AB ADAPTIS EQ 500MG BASE
 >A> AB EQ 1GM BASE
 AB CHARTWELL RX EQ 500MG BASE
 AB EQ 1GM BASE
 >D> AB YAMPA EQ 500MG BASE
 AB EQ 500MG BASE
 >D> AB EQ 1GM BASE
 AB EQ 1GM BASE

A079012 001 May 24, 2010 Oct CAHN
 A079012 002 May 24, 2010 Oct CAHN
 A090216 001 May 24, 2010 Jan CAHN
 A090216 002 May 24, 2010 Jan CAHN
 A079012 001 May 24, 2010 Oct CAHN
 A079012 001 May 24, 2010 Sep CAHN
 A079012 002 May 24, 2010 Oct CAHN
 A079012 002 May 24, 2010 Sep CAHN

VALGANCICLOVIR HYDROCHLORIDEFOR SOLUTION;ORAL
VALCYTE

AB	+	CHEPLAPHARM	50MG/ML	N022257	001	Aug 28, 2009	Mar CAHN
VALGANCICLOVIR HYDROCHLORIDE							
AB		APPCO	50MG/ML	A216317	001	Apr 11, 2023	Mar NEWA
TABLET;ORAL							
VALCYTE							
AB	+	CHEPLAPHARM	EQ 450MG BASE	N021304	001	Mar 29, 2001	Mar CAHN
VALGANCICLOVIR HYDROCHLORIDE							
	@	CIPLA	EQ 450MG BASE	A209672	001	Nov 09, 2018	Aug DISC

VALPROATE SODIUMINJECTABLE;INJECTION
VALPROATE SODIUM

AP		SAGENT	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Aug CAHN
----	--	--------	------------------	---------	-----	--------------	----------

VALPROIC ACIDSYRUP;ORAL
VALPROIC ACID

AA		HIKMA	250MG/5ML	A074060	001	Jan 13, 1995	Sep CAHN
	@	PHARMOBEDIENT CNSLTG	250MG/5ML	A070868	001	Jul 01, 1986	Sep CAHN
AA		QUAGEN	250MG/5ML	A090517	001	May 28, 2010	Apr CAHN
AA		SCIEGEN PHARMS INC	250MG/5ML	A090517	001	May 28, 2010	Sep CAHN
	@	XTTRIUM LABS INC	250MG/5ML	A070868	001	Jul 01, 1986	Mar CAHN

VALSARTANSOLUTION;ORAL
VALSARTAN

! NOVITIUM PHARMA 20MG/5ML

A214102 001 Nov 02, 2021 Jan CHRS

TABLET;ORAL
VALSARTAN

@ IVAX PHARMS 40MG
 @ 80MG
 @ 160MG
 @ 320MG

A077530 001 Jan 04, 2016 Sep DISC
 A077530 002 Jan 04, 2016 Sep DISC
 A077530 003 Jan 04, 2016 Sep DISC
 A077530 004 Jan 04, 2016 Sep DISC

VAMOROLONESUSPENSION;ORAL
AGAMREE

>A>	+	CATALYST PHARMS	40MG/ML	N215239	001	Oct 26, 2023	Oct CAHN
-----	---	-----------------	---------	---------	-----	--------------	----------

VANCOMYCINSOLUTION;INTRAVENOUS, ORAL
VANCOMYCIN

>D>	+	XELLIA PHARMS APS	5GM/100ML (50MG/ML)	N213895	001	Aug 26, 2021	Oct DISC
>A>	+	@	5GM/100ML (50MG/ML)	N213895	001	Aug 26, 2021	Oct DISC

VANCOMYCIN HYDROCHLORIDECAPSULE;ORAL
VANCOMYCIN HYDROCHLORIDE

>D>	AB	AKORN	EQ 125MG BASE	A065478	001	Apr 09, 2012	Oct CAHN
>D>	AB		EQ 250MG BASE	A065478	002	Apr 09, 2012	Oct CAHN
>A>	AB	PAI HOLDINGS PHARM	EQ 125MG BASE	A065478	001	Apr 09, 2012	Oct CAHN
>A>	AB		EQ 250MG BASE	A065478	002	Apr 09, 2012	Oct CAHN
	@	WATSON LABS	EQ 125MG BASE	A065510	001	Apr 09, 2012	Sep DISC
	@		EQ 250MG BASE	A065510	002	Apr 09, 2012	Sep DISC

FOR SOLUTION;ORAL

VANCOCIN HYDROCHLORIDE

AA	!	ANI PHARMS	EQ 250MG BASE/5ML	A061667	002	Jul 13, 1983	Jun CTEC
----	---	------------	-------------------	---------	-----	--------------	----------

VANCOMYCIN HYDROCHLORIDE

AA		AMNEAL	EQ 250MG BASE/5ML	A215338	001	Jun 23, 2023	Jun NEWA
----	--	--------	-------------------	---------	-----	--------------	----------

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

AP		GLAND PHARMA LTD	EQ 5GM BASE/VIAL	A205694	003	Jun 06, 2023	May NEWA
AP			EQ 10GM BASE/VIAL	A205694	004	Jun 06, 2023	May NEWA
AP		HIKMA	EQ 1GM BASE/VIAL	A203300	002	Aug 11, 2020	Jan CMFD

POWDER;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

AP		EUGIA PHARMA	EQ 1.25GM BASE/VIAL	A217401	001	Aug 04, 2023	Jul NEWA
----	--	--------------	---------------------	---------	-----	--------------	----------

POWDER; INTRAVENOUS
VANCOMYCIN HYDROCHLORIDE

AP		EQ 1.5GM BASE/VIAL	A217401	002	Aug 04, 2023	Jul NEWA
AP	HIKMA	EQ 1.25GM BASE/VIAL	A217489	001	Jun 29, 2023	Jun NFTG
AP		EQ 1.5GM BASE/VIAL	A217489	002	Jun 29, 2023	Jun NFTG
AP	+! MYLAN LABS LTD	EQ 1.25GM BASE/VIAL	N209481	003	Jul 10, 2018	Jun CFTG
AP	+!	EQ 1.5GM BASE/VIAL	N209481	004	Jul 10, 2018	Jun CFTG

POWDER; INTRAVENOUS, ORAL
VANCOMYCIN HYDROCHLORIDE

+!	ZHEJIANG NOVUS PHARM	EQ 500MG BASE/VIAL	N210274	001	Jan 20, 2023	Jan NEWA
+!		EQ 1GM BASE/VIAL	N210274	002	Jan 20, 2023	Jan NEWA
+!		EQ 5GM BASE/VIAL	N210274	003	Jan 20, 2023	Jan NEWA
+!		EQ 10GM BASE/VIAL	N210274	004	Jan 20, 2023	Jan NEWA

VARENICLINE TARTRATETABLET; ORAL
VARENICLINE TARTRATE

AB	ALKEM LABS LTD	EQ 0.5MG BASE	A214557	001	Aug 23, 2023	Aug NEWA
AB		EQ 1MG BASE	A214557	002	Aug 23, 2023	Aug NEWA
AB	APOTEX	EQ 0.5MG BASE	A201962	001	Jan 25, 2023	Jan NEWA
AB		EQ 1MG BASE	A201962	002	Jan 25, 2023	Jan NEWA
>A>	AB	EQ 0.5MG BASE	A214571	001	Oct 23, 2023	Oct NEWA
>A>	AB	EQ 1MG BASE	A214571	002	Oct 23, 2023	Oct NEWA
AB	LEADING PHARMA	EQ 0.5MG BASE	A217151	001	Jul 25, 2023	Sep CAHN
AB		EQ 1MG BASE	A217151	002	Jul 25, 2023	Sep CAHN
AB	MANKIND PHARMA	EQ 0.5MG BASE	A214255	001	Aug 01, 2023	Jul NEWA
AB		EQ 1MG BASE	A214255	002	Aug 01, 2023	Jul NEWA
AB	MEDLEY PHARMS	EQ 0.5MG BASE	A217151	001	Jul 25, 2023	Jul NEWA
AB		EQ 1MG BASE	A217151	002	Jul 25, 2023	Jul NEWA
AB	PAR PHARM INC	EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Jan CTEC
AB	!	EQ 1MG BASE	A201785	002	Aug 11, 2021	Jan CTEC
AB	ZYDUS	EQ 0.5MG BASE	A216723	001	Jun 12, 2023	Jun CAHN
AB		EQ 1MG BASE	A216723	002	Jun 12, 2023	Jun CAHN
AB	ZYDUS PHARMS	EQ 0.5MG BASE	A216723	001	Jun 12, 2023	Jun NEWA
AB		EQ 1MG BASE	A216723	002	Jun 12, 2023	Jun NEWA

VASOPRESSINSOLUTION; INTRAVENOUS
VASOPRESSIN

+!	AM REGENT	200UNITS/10ML (20UNITS/ML)	N212593	002	Jun 09, 2023	Jul NEWA
AP	FRESENIUS KABI USA	20UNITS/ML (20UNITS/ML)	A213206	001	May 26, 2023	May NEWA
		VASOPRESSIN IN SODIUM CHLORIDE 0.9%				
+!	BAXTER HLTHCARE CORP	20UNITS/100ML (0.2UNITS/ML)	N217569	001	Sep 29, 2023	Sep NEWA
+!		40UNITS/100ML (0.4UNITS/ML)	N217569	002	Sep 29, 2023	Sep NEWA
		VASOSTRICT				
+!	PAR STERILE PRODUCTS	50UNITS/50ML (1UNITS/ML)	N204485	006	Apr 12, 2023	Apr NEWA

VECURONIUM BROMIDEINJECTABLE; INJECTION
VECURONIUM BROMIDE

>A>	AP	HONG KONG	10MG/VIAL	A074688	001	Aug 25, 1999	Oct CAHN
>A>	AP		20MG/VIAL	A074688	002	Aug 25, 1999	Oct CAHN
>D>	AP	TEVA PHARMS USA	10MG/VIAL	A074688	001	Aug 25, 1999	Oct CAHN
>D>	AP		20MG/VIAL	A074688	002	Aug 25, 1999	Oct CAHN

VENLAFAXINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
VENLAFAXINE HYDROCHLORIDE

AB	GRANULES	EQ 37.5MG BASE	A217390	001	May 18, 2023	May NEWA
AB		EQ 75MG BASE	A217390	002	May 18, 2023	May NEWA
AB		EQ 150MG BASE	A217390	003	May 18, 2023	May NEWA
AB	NOSTRUM PHARMS LLC	EQ 37.5MG BASE	A200430	001	Apr 04, 2023	Mar NEWA
AB		EQ 75MG BASE	A200430	002	Apr 04, 2023	Mar NEWA
AB		EQ 150MG BASE	A200430	003	Apr 04, 2023	Mar NEWA
	@ TORRENT	EQ 37.5MG BASE	A090899	001	Jun 01, 2011	Aug DISC
	@	EQ 75MG BASE	A090899	002	Jun 01, 2011	Aug DISC
	@	EQ 150MG BASE	A090899	003	Jun 01, 2011	Aug DISC

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

@	CHARTWELL RX	EQ 25MG BASE	A077515	001	Jun 13, 2008	Jan CAHN
@		EQ 37.5MG BASE	A077515	002	Jun 13, 2008	Jan CAHN
@		EQ 50MG BASE	A077515	003	Jun 13, 2008	Jan CAHN

TABLET;ORAL						
VENLAFAXINE HYDROCHLORIDE						
	@	EQ 75MG BASE	A077515	004	Jun 13, 2008	Jan CAHN
	@	EQ 100MG BASE	A077515	005	Jun 13, 2008	Jan CAHN
TABLET, EXTENDED RELEASE;ORAL						
VENLAFAXINE HYDROCHLORIDE						
AB	AJANTA PHARMA LTD	EQ 37.5MG BASE	A214691	001	Apr 12, 2023	Mar NEWA
AB		EQ 75MG BASE	A214691	002	Apr 12, 2023	Mar NEWA
AB		EQ 150MG BASE	A214691	003	Apr 12, 2023	Mar NEWA
AB		EQ 225MG BASE	A214691	004	Apr 12, 2023	Mar NEWA
<u>VERAPAMIL HYDROCHLORIDE</u>						
TABLET, EXTENDED RELEASE;ORAL						
CALAN SR						
	+ @ PFIZER	120MG	N019152	003	Mar 06, 1991	Mar DISC
	+ @	240MG	N019152	001	Dec 16, 1986	Mar DISC
VERAPAMIL HYDROCHLORIDE						
AB	CADILA PHARMS LTD	120MG	A206173	003	Nov 14, 2022	Mar NEWA
AB	! GLENMARK GENERICS	120MG	A090700	001	Aug 03, 2011	Mar CHRS
AB	!	240MG	A078906	001	Sep 17, 2009	Mar CHRS
	@ IVAX SUB TEVA PHARMS	120MG	A073568	002	Oct 10, 1997	Sep DISC
	@	180MG	A074330	001	Jan 31, 1994	Sep DISC
	@	240MG	A073568	001	Jul 31, 1992	Sep DISC
<u>VIGABATRIN</u>						
FOR SOLUTION;ORAL						
VIGABATRIN						
	@ ACCORD HLTHCARE	500MG/PACKET	A214425	001	Nov 13, 2020	Mar DISC
	@ CHARTWELL RX	500MG/PACKET	A211790	001	Mar 10, 2022	May CAHN
	@ ZYDUS	500MG/PACKET	A214671	001	Mar 02, 2023	Jul DISC
AA		500MG/PACKET	A214671	001	Mar 02, 2023	Feb NEWA
TABLET;ORAL						
VIGABATRIN						
AB	PROPEL PHARMA	500MG	A215519	001	Apr 28, 2023	Apr NEWA
AB	UPSHER SMITH LABS	500MG	A214749	001	Jun 29, 2023	Sep CAHN
AB	ZENARA	500MG	A214749	001	Jun 29, 2023	Jun NEWA
<u>VILAZODONE HYDROCHLORIDE</u>						
TABLET;ORAL						
VIIBRYD						
AB	+! ABBVIE	10MG	N022567	001	Jan 21, 2011	Jan CAHN
AB	+	20MG	N022567	002	Jan 21, 2011	Jan CAHN
AB	+	40MG	N022567	003	Jan 21, 2011	Jan CAHN
VILAZODONE HYDROCHLORIDE						
AB	APOTEX	10MG	A208228	001	Jul 07, 2023	Jun NEWA
AB		20MG	A208228	002	Jul 07, 2023	Jun NEWA
AB		40MG	A208228	003	Jul 07, 2023	Jun NEWA
<u>VINCRIStINE SULFATE</u>						
INJECTABLE;INJECTION						
VINCRIStINE SULFATE PFS						
	! HOSPIRA	1MG/ML	A071484	001	Apr 19, 1988	Sep CTEC
	@ TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999	Sep DISC
<u>VORICONAZOLE</u>						
INJECTABLE;INTRAVENOUS						
VORICONAZOLE						
	@ EUGIA PHARMA	200MG/VIAL	A212162	001	Feb 02, 2023	Aug DISC
AP		200MG/VIAL	A212162	001	Feb 02, 2023	Jan NEWA
AP	SLATE RUN PHARMA	200MG/VIAL	A211661	001	Nov 30, 2018	Sep CAHN
AP	UBI	200MG/VIAL	A211264	001	Mar 09, 2023	Mar NEWA
AP	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Mar CDFR
TABLET;ORAL						
VORICONAZOLE						
AB	CHARTWELL RX	50MG	A207371	001	May 24, 2016	Apr CAHN
AB		200MG	A207371	002	May 24, 2016	Apr CAHN

VUTRISIRAN SODIUMSOLUTION; SUBCUTANEOUS
AMVUTTRA

+!	ALNYLAM PHARMS INC	EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML)	N215515	001	Jun 13, 2022	Feb CPOT
+!		25MG/0.5ML (25MG/0.5ML)	N215515	001	Jun 13, 2022	Feb CAIN

WARFARIN SODIUMTABLET; ORAL
WARFARIN SODIUM

@	AUROBINDO PHARMA USA	1MG	A040415	001	Sep 27, 2004	May CAHN
@		2MG	A040415	002	Sep 27, 2004	May CAHN
@		2.5MG	A040415	003	Sep 29, 2004	May CAHN
@		3MG	A040415	004	Sep 27, 2004	May CAHN
@		4MG	A040415	005	Sep 27, 2004	May CAHN
@		5MG	A040415	006	Sep 27, 2004	May CAHN
@		6MG	A040415	007	Sep 27, 2004	May CAHN
@		7.5MG	A040415	008	Sep 27, 2004	May CAHN
@		10MG	A040415	009	Sep 27, 2004	May CAHN

XENON XE-129 HYPERPOLARIZEDGAS; INHALATION
XENOVUE

+!	POLAREAN	N/A	N214375	001	Dec 23, 2022	Jan NEWA
----	----------	-----	---------	-----	--------------	----------

ZAVEGEPANT HYDROCHLORIDESPRAY, METERED; NASAL
ZAVZPRET

+!	PFIZER	EQ 10MG BASE/SPRAY	N216386	001	Mar 09, 2023	Mar NEWA
----	--------	--------------------	---------	-----	--------------	----------

ZILEUTONTABLET, EXTENDED RELEASE; ORAL
ZILEUTON

AB	AIZANT	600MG	A211390	001	Oct 23, 2020	Aug CAHN
AB	! RISING	600MG	A204929	001	Mar 17, 2017	Jan CHRS
	ZYFLO CR					
+	@ CHIESI	600MG	N022052	001	May 30, 2007	Jan DISC

>A> ZILUCOPLAN SODIUM>A> SOLUTION; SUBCUTANEOUS
>A> ZILBRYSQ

>A>	+!	UCB INC	EQ 16.6MG BASE/0.416ML (EQ 16.6MG BASE/0.416ML)	N216834	001	Oct 17, 2023	Oct NEWA
>A>	+!		EQ 23MG BASE/0.574ML (EQ 23MG BASE/0.574ML)	N216834	002	Oct 17, 2023	Oct NEWA
>A>	+!		EQ 32.4MG BASE/0.81ML (EQ 32.4 BASE/0.81ML)	N216834	003	Oct 17, 2023	Oct NEWA

ZINC SULFATESOLUTION; INTRAVENOUS
ZINC SULFATE

AP	FRESENIUS KABI USA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A216145	001	Dec 27, 2022	May CAIN
AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216145	002	Dec 27, 2022	May CAIN
AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216145	003	Dec 27, 2022	May CAIN
AP	GLAND PHARMA LTD	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A216249	003	Sep 01, 2023	Aug NEWA
AP	ZYDUS PHARMS	EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A217074	003	Aug 22, 2023	Aug NEWA
AP		EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A217074	001	Aug 22, 2023	Aug NEWA
AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A217074	002	Aug 22, 2023	Aug NEWA

ZOLEDRONIC ACIDINJECTABLE; INTRAVENOUS
RECLAST

AP	+!	SANDOZ	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	May CAHN
		ZOLEDRONIC ACID					
AP		AVET LIFESCIENCES	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Sep CMFD
	@	BRECKENRIDGE	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Sep DISC
AP		CHARTWELL RX	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Aug CAHN
AP			EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Aug CAHN
AP		HONG KONG	EQ 5MG BASE/100ML	A213371	001	Jun 05, 2023	May NEWA
AP	+	INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Jul CRLD
	@	INGENUS PHARMS LLC	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Jun DISC
AP		MEITHEAL	EQ 5MG BASE/100ML	A213371	001	Jun 05, 2023	Aug CAHN

INJECTABLE;INTRAVENOUS

ZOLEDRONIC ACID

	@ NOVAST LABS	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Sep CAHN
AP	PII	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Jul CAHN
AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Jul CAHN

ZOLMITRIPTAN

SPRAY;NASAL

ZOMIG

AB	+ AMNEAL	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Jan CAHN
AB	+!	5MG/SPRAY	N021450	004	Sep 30, 2003	Jan CAHN

TABLET;ORAL

ZOLMITRIPTAN

AB	! AJANTA PHARMA LTD	5MG	A204041	002	May 20, 2016	Jun CHRS
	ZOMIG					
	+ @ IPR	2.5MG	N020768	001	Nov 25, 1997	Jun DISC
	+ @	5MG	N020768	002	Nov 25, 1997	Jun DISC

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

AB	! ZYDUS PHARMS USA INC	5MG	A202890	002	May 15, 2013	Jun CHRS
	ZOMIG-ZMT					
	+ @ ASTRAZENECA	2.5MG	N021231	001	Feb 13, 2001	Jun DISC
	+ @	5MG	N021231	002	Sep 17, 2001	Jun DISC

ZOLPIDEM TARTRATE

CAPSULE;ORAL

ZOLPIDEM TARTRATE

	+! ALMATICA	7.5MG	N215721	001	May 09, 2023	May NEWA
--	-------------	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

	@ ACTAVIS LABS FL INC	6.25MG	A090153	001	Mar 25, 2013	Sep DISC
	@	12.5MG	A090153	002	Mar 25, 2013	Sep DISC
	@ ANCHEN PHARMS	6.25MG	A078148	002	Apr 14, 2011	May DISC
	@	12.5MG	A078148	001	Dec 03, 2010	May DISC
	@ BRECKENRIDGE	6.25MG	A213592	001	Jun 04, 2020	Aug DISC
	@	12.5MG	A213592	002	Jun 04, 2020	Aug DISC

>A> ZURANOLONE

CAPSULE;ORAL

ZURZUVAE

>A>	+ BIOGEN INC	20MG	N217369	001	Oct 31, 2023	Oct NEWA
>A>	+	25MG	N217369	002	Oct 31, 2023	Oct NEWA
>A>	+!	30MG	N217369	003	Oct 31, 2023	Oct NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

EXCEDRIN (MIGRAINE RELIEF)

+! GLAXOSMITHKLINE CONS 250MG; 250MG; 65MG

N020802 001 Jan 14, 1998 Apr CTNA

ACETAMINOPHEN; IBUPROFEN

TABLET; ORAL

ACETAMINOPHEN AND IBUPROFEN

BIONPHARMA 250MG; 125MG

A216999 001 Aug 01, 2023 Jul NEWA

GRANULES 250MG; 125MG

A216592 001 Jul 13, 2023 Jul NEWA

L PERRIGO CO 250MG; 125MG

A214836 001 Feb 28, 2023 Feb NEWA

MARKSANS PHARMA 250MG; 125MG

A216994 001 Jul 10, 2023 Jun NEWA

ALCAFTADINE

SOLUTION/DROPS; OPHTHALMIC

ALCAFTADINE

EUGIA PHARMA 0.25%

A210659 001 Jun 23, 2023 Jun NEWA

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

@ PERRIGO R AND D 800MG; 10MG; 165MG

A204782 001 Aug 29, 2016 Aug DISC

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ APOTEX 10MG

A207235 001 Aug 12, 2016 Aug DISC

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD 5MG; 120MG

A212409 001 Mar 08, 2023 Sep DISC

5MG; 120MG

A212409 001 Mar 08, 2023 Feb NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION; TOPICAL

SOLUPREP S

+! 3M HEALTH CARE 2%; 70%

N208288 001 Aug 08, 2018 Mar CTNA

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ IVAX SUB TEVA PHARMS 200MG

A075345 001 Jun 16, 1999 Sep DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

DR REDDYS 30MG; 600MG

A217340 001 Aug 01, 2023 Jul NEWA

60MG; 1.2GM

A217340 002 Aug 01, 2023 Jul NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

COREPHARMA 25MG; 220MG

A211830 001 Aug 22, 2019 Feb CAHN

DOCOSANOL

CREAM; TOPICAL

DOCOSANOL

TARO PHARMS 10%

A214454 001 Oct 26, 2023 Oct NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

ANDA REPOSITORY EQ 20MG BASE

A216149 001 Mar 15, 2023 Sep CAHN

GUARDIAN DRUG EQ 20MG BASE

A216149 001 Mar 15, 2023 Mar NEWA

@ HETERO LABS LTD III EQ 20MG BASE

A208939 001 May 28, 2020 Aug DISC

TABLET, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

AUROBINDO PHARMA LTD EQ 20MG BASE

A214473 001 Jul 12, 2023 Jun NEWA

>A>

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

MARKSANS PHARMA

10MG

A217543 001 Mar 08, 2023 Feb NEWA

20MG

A217543 002 Mar 08, 2023 Feb NEWA

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

FEXOFENADINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 30MG/5ML

A213466 001 May 23, 2023 May NEWA

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

>A>

AUROBINDO PHARMA LTD 30MG

A202039 001 Nov 19, 2014 Oct CAHN

>D>

AUROBINDO PHARMA USA 30MG

A202039 001 Nov 19, 2014 Oct CAHN

30MG

A202039 001 Nov 19, 2014 Apr CAHN

FEXOFENADINE HYDROCHLORIDE ALLERGY

>A>

AUROBINDO PHARMA LTD 60MG

A202039 002 Nov 19, 2014 Oct CAHN

>A>

180MG

A202039 003 Nov 19, 2014 Oct CAHN

>D>

AUROBINDO PHARMA USA 60MG

A202039 002 Nov 19, 2014 Oct CAHN

60MG

A202039 002 Nov 19, 2014 Apr CAHN

180MG

A202039 003 Nov 19, 2014 Oct CAHN

180MG

A202039 003 Nov 19, 2014 Apr CAHN

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

MARKSANS PHARMA

600MG

A217780 001 Aug 21, 2023 Aug NEWA

1.2GM

A217780 002 Aug 21, 2023 Aug NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ GRANULES

600MG; 60MG

A216082 001 Aug 22, 2022 Feb DISC

@

1.2GM; 120MG

A216082 002 Aug 22, 2022 Feb DISC

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

AUROBINDO PHARMA LTD

EQ 200MG FREE ACID AND POTASSIUM SALT

A215777 001 Sep 14, 2023 Sep NEWA

SUSPENSION; ORAL

IBUPROFEN

@ ARISE

100MG/5ML

A200457 001 Aug 18, 2011 Jun DISC

SUSPENSION/DROPS; ORAL

IBUPROFEN

TARO PHARMS

40MG/ML

A217261 001 Aug 08, 2023 Jul NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD

200MG; 30MG

A213565 001 Mar 10, 2023 Sep DISC

200MG; 30MG

A213565 001 Mar 10, 2023 Mar NEWA

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

KETOTIFEN FUMARATE

SENTISS

EQ 0.025% BASE

A077958 001 Jul 26, 2007 Aug CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

@ MYLAN

15MG

A203187 001 Jun 01, 2016 Aug DISC

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

@ GRANULES

2MG; 125MG

A215981 001 Aug 29, 2022 Feb DISC

LORATADINE

CAPSULE;ORAL

LORATADINE

@ AUROBINDO PHARMA

10MG

A211900 001 Mar 24, 2023 Sep DISC

10MG

A211900 001 Mar 24, 2023 Mar NEWA

TABLET;ORAL

LORATADINE

GUARDIAN DRUG

10MG

A207569 001 Mar 12, 2019 Sep CAHN

HETERO LABS LTD V

10MG

A211718 001 Jul 28, 2023 Jul NEWA

MINOXIDIL

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

AUROBINDO PHARMA LTD 2%

A074767 001 Feb 28, 1997 Sep CAHN

MINOXIDIL EXTRA STRENGTH (FOR MEN)

AUROBINDO PHARMA LTD 5%

A075438 001 Feb 27, 2003 Sep CAHN

MOMETASONE FUROATE

SPRAY, METERED;NASAL

MOMETASONE FUROATE

@ AMNEAL

0.05MG/SPRAY

A217460 001 Jun 14, 2023 Sep DISC

0.05MG/SPRAY

A217460 001 Jun 14, 2023 Jun NFTA

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL

NALOXONE HYDROCHLORIDE

PADAGIS ISRAEL

4MG/SPRAY

A211951 001 Jun 21, 2022 Jul CMKT

NARCAN

+! EMERGENT

4MG/SPRAY

N208411 001 Nov 18, 2015 Mar CMKT

RIVIVE

+! HARM REDUCTION THERP

3MG/SPRAY

N217722 001 Jul 28, 2023 Jul NEWA

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

@ STRIDES PHARMA

EQ 200MG BASE

A215472 001 Aug 17, 2022 Feb DISC

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

@ FERTIN PHARMA

EQ 4MG BASE

A214354 001 Dec 21, 2022 Jun DISC

NORGESTREL

TABLET;ORAL

OPILL

+ @ LABORATOIRE HRA

0.075MG

N017031 001 Jul CMKT

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

@ AKORN

EQ 0.1% BASE

A204532 001 Jan 10, 2017 Jan DISC

@

EQ 0.2% BASE

A204723 001 Dec 05, 2017 Jan DISC

OMEPRazole MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRazole MAGNESIUM

AUROBINDO PHARMA LTD

EQ 20MG BASE

A213201 001 Apr 28, 2023 Oct DISC

@

EQ 20MG BASE

A213201 001 Apr 28, 2023 Oct DISC

EQ 20MG BASE

A213201 001 Apr 28, 2023 Apr NEWA

OMEPRazole; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRazole AND SODIUM BICARBONATE

AUROBINDO PHARMA

20MG;1.1GM

A204923 001 Nov 07, 2016 Jun CAHN

ZYDUS

20MG;1.1GM

A203345 001 Mar 16, 2018 May CAHN

>D>

>A>

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

ELYSIUM

17GM/SCOOPFUL

A202071 001 Dec 28, 2012 Sep CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER 2023

NO OCTOBER 2023 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO OCTOBER 2023 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	8129385	Oct 05, 2027	DS DP		M-294	Jun 15, 2026
	8129385*PED	Apr 05, 2028			PED	Dec 15, 2026
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ PD</u>						
N 215413 001	8129385	Oct 05, 2027	DS DP		NPP	Jun 15, 2026
	8129385*PED	Apr 05, 2028			PED	Dec 15, 2026
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	11680942	Jan 10, 2040	U-3322		I-907	Dec 19, 2025
	>A> 11782041	Apr 30, 2038	DP U-2009			
	>A> 11782041	Apr 30, 2038	DP U-3543			
	8748382	Oct 03, 2027	U-2009			
	8748382	Oct 03, 2027	U-3543			
	RE49444	Apr 28, 2031	U-2009			
	RE49444	Apr 28, 2031	U-3543			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
	7855211	Dec 15, 2029	DS DP U-3265			
	7855211	Dec 15, 2029	DS DP U-3546			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 001	11091459	Mar 27, 2038	DS DP		>A> NP	Aug 11, 2026
	11207311	Jul 28, 2037	U-2830			
	11673877	Mar 27, 2038	DS DP			
	8071579	Aug 12, 2027	U-2830			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2830			
	8436185	Apr 24, 2029	DS DP			
	8859562	Aug 04, 2031	U-2830			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	11091459	Mar 27, 2038	DS DP		>A> NP	Aug 11, 2026
	11207311	Jul 28, 2037	U-2830			
	11673877	Mar 27, 2038	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	8071579	Aug 12, 2027	U-2830			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2830			
	8436185	Apr 24, 2029	DS DP			
	8859562	Aug 04, 2031	U-2830			
<u>ABROCITINIB - CIBINQO</u>						
N 213871 001					NPP	Feb 09, 2026
<u>ABROCITINIB - CIBINQO</u>						
N 213871 002					NPP	Feb 09, 2026
<u>ABROCITINIB - CIBINQO</u>						
N 213871 003					NPP	Feb 09, 2026
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001 >A>	11771696	Jan 21, 2035	U-3710			
<u>ACALABRUTINIB MALEATE - CALQUENCE</u>						
N 216387 001 >A>	11771696	Jan 21, 2035	U-3710			
<u>ACETAMINOPHEN; IBUPROFEN - COMBOGESIC</u>						
N 209471 001	10532036	Sep 22, 2025	U-3553		NP	Mar 01, 2026
	11197830	Feb 27, 2039	DP U-3553			
	11534407	Feb 27, 2039	DP U-3553			
<u>ACETAMINOPHEN; IBUPROFEN SODIUM - COMBOGESIC IV</u>						
N 215320 001					>A> NP	Oct 17, 2026
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001					NCE ODE-352	Dec 12, 2027 Dec 12, 2029
<u>ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CABTREO</u>						
N 216632 001 >A>	10220049	Jun 03, 2029	DP U-3713			
	>A> 10624918	Jun 03, 2029	U-3713			
	>A> 11389467	Dec 28, 2040	DP U-3713			
	>A> 8288434	Aug 05, 2029	DP U-3713			
	>A> 9561208	Jun 03, 2029	DP U-3713			
<u>ALBUTEROL SULFATE; BUDESONIDE - AIRSUPRA</u>						
N 214070 001	9415009	May 28, 2030	U-3509		NP	Jan 10, 2026
<u>ALENDRONATE SODIUM - ALENDRONATE SODIUM</u>						
A 214512 001					CGT	Nov 20, 2023
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001					M-300	Jul 27, 2026
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002					M-300	Jul 27, 2026
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003					M-300	Jul 27, 2026
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001					M-300	Jul 27, 2026
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002					M-300	Jul 27, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALPELISIB - PIQRAY</u>						
N 212526 001	8227462	Apr 29, 2033	DS DP U-2539			
<u>ALPELISIB - PIQRAY</u>						
N 212526 002	8227462	Apr 29, 2033	DS DP U-2539			
<u>ALPELISIB - PIQRAY</u>						
N 212526 003	8227462	Apr 29, 2033	DS DP U-2539			
<u>ALPELISIB - VIJOICE</u>						
N 215039 001	8227462	Apr 29, 2033	DS DP		ODE-396	Apr 05, 2029
<u>ALPELISIB - VIJOICE</u>						
N 215039 002	8227462	Apr 29, 2033	DS DP		ODE-396	Apr 05, 2029
<u>ALPELISIB - VIJOICE</u>						
N 215039 003	8227462	Apr 29, 2033	DS DP		ODE-396	Apr 05, 2029
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	11571478	Jan 12, 2038	U-3163			
	11690914	Jan 12, 2038	U-3163			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	11540981	Feb 07, 2028	DP			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	11701326	Oct 06, 2037	DP			
<u>AMLODIPINE BESYLATE - NORLIQVA</u>						
N 214439 001	11723866	Feb 24, 2041	DP U-3309			
	11723866	Feb 24, 2041	DP U-3310			
	11723866	Feb 24, 2041	DP U-3311			
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004 001					>A> NP	Nov 01, 2022
					>A> GAIN	Nov 01, 2027
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANA VEL XR</u>						
N 208147 001	11590228	Sep 07, 2036	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANA VEL XR 5</u>						
N 210526 001	11590081	Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANA VEL XR 10</u>						
N 210526 002	11590081	Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANA VEL XR 15</u>						
N 210526 003	11590081	Sep 24, 2038	DP U-3538			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANA VEL XR 20</u>						
N 210526 004	11590081	Sep 24, 2038	DP U-3538			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	11559559	Dec 18, 2034	U-3514			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	11559559	Dec 18, 2034	U-3514			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 003	11559559	Dec 18, 2034	U-3514			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	10052314	Sep 23, 2033	U-2381	Y		
	10052314	Sep 23, 2033	U-2382	Y		
	9481663	Jun 04, 2033	DS DP U-2237			
	9481663	Jun 04, 2033	DS DP U-2624			
	RE49353	Sep 23, 2033	U-2381			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	10702508	Apr 30, 2038	U-3012			
	10849888	Sep 23, 2033	U-3013			
	8445507	Sep 15, 2030	DS DP U-2237			
	8445507	Sep 15, 2030	DS DP U-2624			
	8802689	Mar 27, 2027	U-2237			
	8802689	Mar 27, 2027	U-2624			
	9388159	Mar 27, 2027	DS DP			
	9481663	Jun 04, 2033	DS DP U-2237			
	9481663	Jun 04, 2033	DS DP U-2624			
	9884054	Sep 23, 2033	U-2237			
	9987261	Mar 27, 2027	DP			
	RE49353	Sep 23, 2033	U-2381			
<u>APREMILAST - OTEZLA</u>						
N 205437 001					M-299	Jul 20, 2026
<u>APREMILAST - OTEZLA</u>						
N 205437 002					M-299	Jul 20, 2026
<u>APREMILAST - OTEZLA</u>						
N 205437 003					M-299	Jul 20, 2026
<u>APREPITANT - CINVANTI</u>						
N 209296 001	11744800	Sep 18, 2035	DP			
<u>APREPITANT - APONVIE</u>						
N 216457 001	11744800	Sep 18, 2035	DP U-3690			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	11648347	Apr 06, 2034	DP			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	11648347	Apr 06, 2034	DP			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	11648347	Apr 06, 2034	DP			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	11648347	Apr 06, 2034	DP			
<u>ARIPIRAZOLE - ABILIFY ASIMTUFI</u>						
N 217006 001	10517951	Apr 23, 2033	DP U-3245			
	10517951	Apr 23, 2033	DP U-814			
	11097007	Apr 23, 2033	DP U-3245			
	11097007	Apr 23, 2033	DP U-814			
	11638757	Apr 23, 2033	DP U-3245			
	11638757	Apr 23, 2033	DP U-814			
	8338427	Mar 15, 2025	DP U-1530			
	8338428	Aug 06, 2023	DP U-1530			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
<u>ARIPIRAZOLE - ABILIFY ASIMTUFI</u>						
N 217006 002	10517951	Apr 23, 2033	DP U-3245			
	10517951	Apr 23, 2033	DP U-814			
	11097007	Apr 23, 2033	DP U-3245			
	11097007	Apr 23, 2033	DP U-814			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY ASIMTUFI</u>						
N 217006 002	11638757	Apr 23, 2033	DP U-3245			
	11638757	Apr 23, 2033	DP U-814			
	8338427	Mar 15, 2025	DP U-1530			
	8338428	Aug 06, 2023	DP U-1530			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
<u>ASPIRIN - VAZALORE</u>						
N 203697 001	10646431	Sep 29, 2032	DP			
	10786444	Sep 29, 2032	U-3559			
<u>ASPIRIN - VAZALORE</u>						
N 203697 002	10646431	Sep 29, 2032	DP			
	10786444	Sep 29, 2032	U-3559			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 001	8754096	Jul 19, 2032	DS DP U-3534		I-909	Apr 17, 2026
	9499545	Nov 10, 2031	DS DP U-3534			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 002	8754096	Jul 19, 2032	DS DP U-3534		I-909	Apr 17, 2026
	9499545	Nov 10, 2031	DS DP U-3534			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 003	8754096	Jul 19, 2032	DS DP U-3534		I-909	Apr 17, 2026
	9499545	Nov 10, 2031	DS DP U-3534			
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260 001	11369567	Jun 07, 2037	DP			
	11654106	Jun 07, 2037	DP U-3612			
	11654106	Jun 07, 2037	DP U-3613			
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	10947544	Feb 14, 2025	DS U-3673			
	11273171	Jul 11, 2034	U-3673			
	11491176	Jul 11, 2034	U-3673			
	7538211	Feb 14, 2025	DS			
	7579456	Feb 14, 2025	DS			
	7803931	Feb 14, 2025	DS			
	8236773	Nov 11, 2026	U-3673			
	9617546	Feb 14, 2025	DS U-3673			
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	11603356	May 29, 2041	DS DP U-3558			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001					ODE-434	May 22, 2030
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002					ODE-434	May 22, 2030
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003					ODE-434	May 22, 2030
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004	9200002	Oct 15, 2034	DS DP U-3168		I-912	May 22, 2026
	9200002	Oct 15, 2034	DS DP U-3506		ODE-434	May 22, 2030
	9944651	Oct 15, 2034	DS DP U-3168			
	9944651	Oct 15, 2034	DS DP U-3506			
	9994575	Oct 15, 2034	DS DP U-3168			
	9994575	Oct 15, 2034	DS DP U-3506			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 005					ODE-434	May 22, 2030
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001					NPP	Dec 20, 2025
<u>AZACITIDINE - VIDAZA</u>						
N 050794 001					ODE-399	May 20, 2029
<u>AZACITIDINE - ONUREG</u>						
N 214120 001	11571436	May 14, 2029	DP			
<u>AZACITIDINE - ONUREG</u>						
N 214120 002	11571436	May 14, 2029	DP			
<u>BACLOFEN - BACLOFEN</u>						
A 217252 001					PC	Dec 16, 2023
<u>BACLOFEN - LYVISPAH</u>						
N 215422 001	11654124	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 002	11654124	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 003	11654124	Jul 29, 2039	DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	9737469	Nov 02, 2031	U-3500			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	9737469	Nov 02, 2031	U-3500			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	9737469	Nov 02, 2031	U-3500			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	11559637	Jul 21, 2039	DP			
	11583643	Aug 19, 2041	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	11559637	Jul 21, 2039	DP			
	11583643	Aug 19, 2041	DP			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	11613511	Jun 19, 2040	DS			
	11760714	Jun 19, 2040	DP			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	11613511	Jun 19, 2040	DS			
	11744816	Mar 14, 2036	U-3692			
	11760714	Jun 19, 2040	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11541026	Feb 19, 2040	U-3356			
	11628155	Dec 27, 2040	U-3356			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>						
A 208683 001				>A> PC		Mar 30, 2024
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	11618733	Nov 01, 2039	U-3300			
	11708333	Mar 09, 2035	U-3300			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	11618733	Nov 01, 2039	U-3300			
	11708333	Mar 09, 2035	U-3300			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - WYNZORA</u>						
N 213422 001	11696919	Mar 18, 2039	DP			
<u>BEXAGLIFLOZIN - BRENZAVVY</u>						
N 214373 001	10533032	Jul 03, 2031	U-2214		NCE	Jan 20, 2028
	10981942	Jun 13, 2031	DS DP			
	7838499	Jan 30, 2029	DS DP U-2214			
	8106021	Aug 22, 2028	U-2214			
	8802637	Aug 22, 2028	DS DP U-2214			
	8987323	May 14, 2032	DS DP			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	11744802	Nov 08, 2036	DP			
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2024	DS DP			
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE - BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE</u>						
A 217511 001					CGT	Dec 29, 2023
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 001	11679119	Sep 23, 2042	U-3632			
	11679119	Sep 23, 2042	U-3633			
	11752164	Sep 23, 2042	U-3632			
	11752164	Sep 23, 2042	U-3633			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 002	11679119	Sep 23, 2042	U-3632			
	11679119	Sep 23, 2042	U-3633			
	11752164	Sep 23, 2042	U-3632			
	11752164	Sep 23, 2042	U-3633			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001	11103497	Feb 28, 2034	U-3216		>A> I-923	Sep 26, 2026
	11103497	Feb 28, 2034	U-3217		ODE-163	Dec 19, 2024
	11103497*PED	Aug 28, 2034			>A> ODE-444	Sep 26, 2030
	>A> 7417148	Dec 11, 2025	U-1283		PED	Jun 19, 2025
	>A> 7417148	Dec 11, 2025	U-3707		>A> PED	Mar 26, 2027
	>A> 7417148	Dec 11, 2025	U-3708		>A> PED	Mar 26, 2031
	>A> 7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001	RE42376	Apr 13, 2024	DS			
	RE42376*PED	Oct 13, 2024				
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002	11103497	Feb 28, 2034	U-3216		>A> I-923	Sep 26, 2026
	11103497	Feb 28, 2034	U-3217		ODE-163	Dec 19, 2024
	11103497*PED	Aug 28, 2034			>A> ODE-444	Sep 26, 2030
>A>	7417148	Dec 11, 2025	U-1283		PED	Jun 19, 2025
>A>	7417148	Dec 11, 2025	U-3707		>A> PED	Mar 26, 2027
>A>	7417148	Dec 11, 2025	U-3708		>A> PED	Mar 26, 2031
>A>	7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
	RE42376	Apr 13, 2024	DS			
	RE42376*PED	Oct 13, 2024				
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	11103497	Feb 28, 2034	U-3216		>A> I-923	Sep 26, 2026
	11103497	Feb 28, 2034	U-3217		ODE-163	Dec 19, 2024
	11103497*PED	Aug 28, 2034			>A> ODE-444	Sep 26, 2030
>A>	7417148	Dec 11, 2025	U-1283		PED	Jun 19, 2025
>A>	7417148	Dec 11, 2025	U-3707		>A> PED	Mar 26, 2027
>A>	7417148	Dec 11, 2025	U-3708		>A> PED	Mar 26, 2031
>A>	7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
	RE42376	Apr 13, 2024	DS			
	RE42376*PED	Oct 13, 2024				
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 217729 001	>A> 11103497	Feb 28, 2034	U-3216		>A> NP	Sep 26, 2026
	>A> 11103497	Feb 28, 2034	U-3217		>A> ODE-444	Sep 26, 2030
	>A> 11103497*PED	Aug 28, 2034			>A> PED	Mar 26, 2027
	>A> 7417148	Dec 11, 2025	U-3707		>A> PED	Mar 26, 2031
	>A> 7417148	Dec 11, 2025	U-3708			
	>A> 7417148*PED	Jun 11, 2026				
	>A> 7767678	Nov 23, 2026	DS DP			
	>A> 7767678*PED	May 23, 2027				
	>A> 7919625	Dec 11, 2025	DP			
	>A> 7919625*PED	Jun 11, 2026				
	>A> RE42376	Apr 13, 2024	DS DP			
	>A> RE42376*PED	Oct 13, 2024				
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 217729 002	>A> 11103497	Feb 28, 2034	U-3216		>A> NP	Sep 26, 2026
	>A> 11103497	Feb 28, 2034	U-3217		>A> ODE-444	Sep 26, 2030
	>A> 11103497*PED	Aug 28, 2034			>A> PED	Mar 26, 2027
	>A> 7417148	Dec 11, 2025	U-3707		>A> PED	Mar 26, 2031
	>A> 7417148	Dec 11, 2025	U-3708			
	>A> 7417148*PED	Jun 11, 2026				
	>A> 7767678	Nov 23, 2026	DS DP			
	>A> 7767678*PED	May 23, 2027				
	>A> 7919625	Dec 11, 2025	DP			
	>A> 7919625*PED	Jun 11, 2026				
	>A> RE42376	Apr 13, 2024	DS DP			
	>A> RE42376*PED	Oct 13, 2024				
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	11590209	Apr 29, 2041	U-3539			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001					I-913	May 10, 2026
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002					I-913	May 10, 2026
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003					I-913	May 10, 2026
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004					I-913	May 10, 2026
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005					I-913	May 10, 2026
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006					I-913	May 10, 2026
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001	11596600	Jul 27, 2029	U-2222			
<u>BRINZOLAMIDE - BRINZOLAMIDE</u>						
A 211914 001					>A> CGT	Apr 07, 2024
<u>BUDESONIDE - BUDESONIDE</u>						
A 215328 001					CGT	Oct 24, 2023
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001					ODE-389	Dec 15, 2028
<u>BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT AEROSPHERE</u>						
N 216579 001	10716753	May 28, 2030	DP U-3203			
	9415009	May 28, 2030	U-3203			
<u>BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE</u>						
N 212122 001	11331442	Oct 05, 2038	DP			
<u>BUPIVACAINE - POSIMIR</u>						
N 204803 001	>A> 11771624	Jan 12, 2041	U-3724			
<u>BUPIVACAINE HYDROCHLORIDE - XARACOLL</u>						
N 209511 001	11746141	Jan 09, 2033	DP			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 001	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 002	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 003	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 004	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 005	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 006	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 007	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11534414	Nov 05, 2034	DP U-3419			
	11541021	Nov 05, 2034	U-3419			
	11541048	Nov 05, 2034	U-3419			
	11596627	Nov 05, 2034	U-3419			
	11617728	Nov 05, 2034	U-3419			
	11617747	Nov 05, 2034	U-3563			
	11717518	Jan 20, 2043	U-3419			
	11730706	Jan 23, 2043	U-3419			
	11752144	Feb 23, 2043	U-3419			
	>A> 11779579	Nov 05, 2034	U-3419			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	>A> 11801253	Sep 07, 2030	DP U-3721			
	>A> 11801253	Sep 07, 2030	DP U-3722			
	>A> 11801253	Sep 07, 2030	DP U-3723			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE</u>						
A 216541 001				>A> CGT		Apr 30, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
A 217174 001					CGT	Mar 10, 2024
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
A 217174 002					CGT	Mar 10, 2024
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE</u>						
A 217689 001					>A> CGT	Apr 17, 2024
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	11554102	Jan 11, 2033	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	11576894	Jul 06, 2030	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	11576894	Jul 06, 2030	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	11576894	Jul 06, 2030	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	11576894	Jul 06, 2030	DP			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	11633369	Jun 17, 2035	DP U-2780			
	11633369	Jun 17, 2035	DP U-2781			
	11633369	Jun 17, 2035	DP U-3071			
	11701330	Jun 17, 2035	U-2780			
	11701330	Jun 17, 2035	U-2781			
>A>	11766411	Jun 17, 2035	U-2781			
<u>CANTHARIDIN - YCANTH</u>						
N 212905 001	11052064	May 28, 2035	DP U-3663			
	11052064	May 28, 2035	DP U-3665			
	11147790	Aug 22, 2038	DP U-3663			
	11147790	Aug 22, 2038	DP U-3664			
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	11529357	Jan 31, 2040	DP			
<u>CARBIDOPA; LEVODOPA - DHIVY</u>						
N 214869 001	11439613	Mar 28, 2039	U-3557			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	RE49302	Jul 16, 2029	U-2543		I-904	Dec 16, 2025
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	RE49302	Jul 16, 2029	U-2543		I-904	Dec 16, 2025
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 001	11654133	Jun 16, 2039	U-3610			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 002	11654133	Jun 16, 2039	U-3610			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 003	11654133	Jun 16, 2039	U-3610			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 004	11654133	Jun 16, 2039	U-3610			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 005	11654133	Jun 16, 2039	U-3610			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 006	11654133	Jun 16, 2039	U-3610			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - SOLUPREP S</u>						
N 208288 001					M-292	Jan 20, 2026
<u>CHLOROPROCAINE HYDROCHLORIDE - IHEEZO</u>						
N 216227 001					NP	Sep 27, 2025
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	6706276	Mar 06, 2024	DP			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	8143240	Jan 12, 2024	U-2942			
	8865690	Jul 24, 2024	U-2942			
	9211295	Jul 24, 2024	DP			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 001	11541002	Jan 31, 2040	DP U-724			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 002	11541002	Jan 31, 2040	DP U-724			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 003	11541002	Jan 31, 2040	DP U-724			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	11597699	Oct 05, 2026	U-3554		ODE-416	Oct 28, 2029
<u>COCAINE HYDROCHLORIDE - NUMBRINO</u>						
N 209575 001	10016407	Feb 07, 2037	U-2225			
	10016407	Feb 07, 2037	U-2226			
	10016407	Feb 07, 2037	U-2329			
	10149843	Feb 07, 2037	U-2478			
	10149843	Feb 07, 2037	U-2479			
	10231961	Feb 07, 2037	DP			
	10413505	Feb 07, 2037	U-3014			
	10420760	Feb 07, 2037	U-2478			
	10857095	Feb 07, 2037	U-3014			
	10894012	Feb 07, 2037	U-3014			
	10933060	Feb 07, 2037	U-2478			
	10933060	Feb 07, 2037	U-3014			
	10973811	Feb 07, 2037	U-3680			
	11040032	Feb 07, 2037	DP			
	9867815	Feb 07, 2037	U-2225			
	9867815	Feb 07, 2037	U-2226			
	9867815	Feb 07, 2037	U-2227			
	9867815	Feb 07, 2037	U-2329			
<u>COLCHICINE - COLCHICINE</u>						
A 208678 001					>A> PC	Apr 29, 2024
<u>COLCHICINE - LODOCO</u>						
N 215727 001	10130585	Dec 31, 2034	U-3642			
	10206891	Jan 22, 2035	U-3641			
	10265281	Jan 22, 2035	U-3639			
	10842762	Jan 22, 2035	U-3640			
	11026899	Jan 22, 2035	U-3639			
	11026900	Jan 22, 2035	U-3639			
	11026901	Jan 22, 2035	U-3638			
	9744144	Jan 22, 2035	U-3643			
<u>CORTICOTROPIN - ACTHAR GEL</u>						
N 008372 008	11752199	Feb 25, 2041	U-3686			
	11752199	Feb 25, 2041	U-3687			
	11752199	Feb 25, 2041	U-3688			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001					>A> D-191	Apr 03, 2026
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					ODE-407	Jul 14, 2029
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					ODE-407	Jul 14, 2029
<u>CRIZOTINIB - XALKORI</u>						
N 217581 001	7230098	Aug 26, 2025	DS			
	7825137	May 12, 2027	U-3057			
	7825137	May 12, 2027	U-3058			
	7825137	May 12, 2027	U-3403			
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS			
	8785632	Mar 01, 2025	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CRIZOTINIB - XALKORI</u>						
N 217581 002	7230098	Aug 26, 2025	DS			
	7825137	May 12, 2027			U-3057	
	7825137	May 12, 2027			U-3058	
	7825137	May 12, 2027			U-3403	
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS			
	8785632	Mar 01, 2025	DS DP			
<u>CRIZOTINIB - XALKORI</u>						
N 217581 003	7230098	Aug 26, 2025	DS			
	7825137	May 12, 2027			U-3057	
	7825137	May 12, 2027			U-3058	
	7825137	May 12, 2027			U-3403	
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS			
	8785632	Mar 01, 2025	DS DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210852 001	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210852 002	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210852 003	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
<u>CYCLOSPORINE - VERKAZIA</u>						
N 214965 001	11612658	Jan 27, 2026		U-3560	NP	Jun 23, 2024
<u>CYCLOSPORINE - VEVYE</u>						
N 217469 001	10813976	Sep 22, 2037	DP		NP	May 30, 2026
	11154513	Nov 20, 2038	DP	U-1900		
	11413323	Oct 11, 2039		U-3627		
	8614178	Dec 13, 2030	DP			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	11642370	Jan 15, 2039	DP			
	11648262	Jan 15, 2039	DP			
	11679125	Jan 15, 2039	DP			
	11684636	Jan 15, 2039	DP			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	11510941	Mar 02, 2039	DP			
	11510942	Jan 15, 2039	DP	U-2752		
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Oct 15, 2032	DP	U-3149		
	10028912	Oct 15, 2032	DP	U-3150		
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	10869869	Aug 30, 2033		U-3185	I-894	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP	U-1406	ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP	U-2031	ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP	U-2032	ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP	U-2296	ODE-428	Mar 16, 2030
	7994185*PED	Jul 20, 2030			PED	Dec 22, 2024
	8415345	Jan 20, 2030	DS DP	U-1406	PED	Oct 30, 2025
	8415345	Jan 20, 2030	DS DP	U-2031	PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP	U-2032	PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP	U-2296		
	8415345*PED	Jul 20, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-428	Mar 16, 2030
	7994185*PED	Jul 20, 2030			PED	Dec 22, 2024
	8415345	Jan 20, 2030	DS DP U-1406		PED	Oct 30, 2025
	8415345	Jan 20, 2030	DS DP U-2031		PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP U-2032		PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 217514 001	11504333	Jun 29, 2038	DP		NP	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP		ODE-428	Mar 16, 2030
	8415345	Jan 20, 2030	DS DP			
	8703781	Oct 15, 2030	DS DP U-3565			
	8835443	Jun 10, 2025	U-3565			
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001	6900175	May 23, 2028	U-3499			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001					M-298	May 08, 2026
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002					M-298	May 08, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPRODUSTAT - JESDUVROQ</u>						
N 216951 001	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROQ</u>						
N 216951 002	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROQ</u>						
N 216951 003	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROQ</u>						
N 216951 004	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPRODUSTAT - JESDUVROQ</u>						
N 216951 005	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 217415 001	11759497	Aug 28, 2038	DP			
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 217415 002	11759497	Aug 28, 2038	DP			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	8975254	Mar 25, 2033	DS DP U-2605			
<u>DARUNAVIR - DARUNAVIR</u>						
A 202073 002					PC	Nov 28, 2023
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001					ODE-417	Apr 30, 2028
					ODE-420	Apr 30, 2028
					ODE-421	Apr 30, 2028
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002					ODE-417	Apr 30, 2028
					ODE-420	Apr 30, 2028
					ODE-421	Apr 30, 2028
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 001					ODE-417	Apr 30, 2028
					ODE-418	Apr 30, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030	001				ODE-419	Apr 30, 2028
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030	002				ODE-417 ODE-418 ODE-419	Apr 30, 2028 Apr 30, 2028 Apr 30, 2028
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269	001	11723874	Oct 25, 2038	U-3083	ODE-417 ODE-420 ODE-421	Apr 30, 2028 Apr 30, 2028 Apr 30, 2028
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114	001	11746348	Jun 22, 2032	DP		
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201	001	>A> 11766468	Apr 27, 2032	U-1978		
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201	002	>A> 11766468	Apr 27, 2032	U-1978		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	001	11446291	Mar 07, 2036	U-1995		
		11446291*PED	Sep 07, 2036			
		11564917	Mar 07, 2036	U-1995		
		11564917*PED	Sep 07, 2036			
		11648244	Mar 07, 2036	U-1995		
		11648244*PED	Sep 07, 2036			
		11666566	Sep 18, 2033	DP		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	002	11446291	Mar 07, 2036	U-1995		
		11446291*PED	Sep 07, 2036			
		11564917	Mar 07, 2036	U-1995		
		11564917*PED	Sep 07, 2036			
		11648244	Mar 07, 2036	U-1995		
		11648244*PED	Sep 07, 2036			
		11666566	Sep 18, 2033	DP		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	003	11446291	Mar 07, 2036	U-1995		
		11446291*PED	Sep 07, 2036			
		11564917	Mar 07, 2036	U-1995		
		11564917*PED	Sep 07, 2036			
		11648244	Mar 07, 2036	U-1995		
		11648244*PED	Sep 07, 2036			
		11666566	Sep 18, 2033	DP		
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354	001	10959996	Mar 07, 2036	U-3055		
		10959996*PED	Sep 07, 2036			
		11179386	Mar 15, 2038	DP U-1995		
		11179386	Mar 15, 2038	DP U-3055		
		11179386*PED	Sep 15, 2038			
		11311488	Jun 10, 2041	DP U-1995		
		11311488	Jun 10, 2041	DP U-3055		
		11357772	Mar 07, 2036	U-1995		
		11357772	Mar 07, 2036	U-3055		
		11357772*PED	Sep 07, 2036			
		11446291	Mar 07, 2036	U-1995		
		11446291*PED	Sep 07, 2036			
		11564917	Mar 07, 2036	U-1995		
		11564917*PED	Sep 07, 2036			
		11648244	Mar 07, 2036	U-1995		
		11648244*PED	Sep 07, 2036			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 001	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	10959996	Mar 07, 2036			U-3055	
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036			U-1995	
	11357772	Mar 07, 2036			U-3055	
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036			U-1995	
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036			U-1995	
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036			U-1995	
	11648244*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 003	10959996	Mar 07, 2036			U-3055	
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036			U-1995	
	11357772	Mar 07, 2036			U-3055	
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036			U-1995	
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036			U-1995	
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036			U-1995	
	11648244*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004					NPP	Dec 16, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 005					NPP	Dec 16, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	11497711	Jun 26, 2039	DP U-3645			
	11517524	Jun 26, 2039	DP U-3645			
>A>	11786508	Dec 29, 2037	U-3698			
>A>	11806334	Jan 12, 2043	U-3725			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	11497711	Jun 26, 2039	DP U-3645			
	11517524	Jun 26, 2039	DP U-3645			
>A>	11786508	Dec 29, 2037	U-3698			
>A>	11806334	Jan 12, 2043	U-3725			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 001	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 002	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 003	11559501	Jan 06, 2042	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 004	11559501	Jan 06, 2042	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001 >A>	11793786	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002 >A>	11793786	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003 >A>	11793786	Mar 27, 2029	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 215813 001	10398785	Mar 14, 2036	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 215813 002	10398785	Mar 14, 2036	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 215813 003	10398785	Mar 14, 2036	DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 002	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 003	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOLUTEGRAVIR SODIUM - TIVICAY PD</u>						
N 213983 001	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192 001	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 001	11648214	Sep 23, 2037	DP U-3334			
	11679086	May 26, 2037	U-3334			
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 002	11648214	Sep 23, 2037	DP U-3334			
	11679086	May 26, 2037	U-3334			
<u>DOXEPIN HYDROCHLORIDE - DOXEPIN HYDROCHLORIDE</u>						
A 215408 001					CGT	Aug 16, 2023
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	>A> 11793760	Jun 17, 2036	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	11617751	Jul 17, 2030	DP U-1			
	11617751	Jul 17, 2030	DP U-3572			
	11617751	Jul 17, 2030	DP U-3573			
	11617751	Jul 17, 2030	DP U-3574			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574 001	11617751	Jul 17, 2030	DP U-1			
	11617751	Jul 17, 2030	DP U-3572			
<u>DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM - XACDURO (COPACKAGED)</u>						
N 216974 001	10376499	Nov 17, 2035	DP U-2840		NCE	May 23, 2028
	9309245	Apr 02, 2033	DS		GAIN	May 23, 2033
	9623014	Apr 02, 2033	U-2840			
	9968593	Nov 17, 2035	DP U-2840			
<u>EDETATE CALCIUM DISODIUM - EDETATE CALCIUM DISODIUM</u>						
A 216435 001					CGT	Jan 08, 2024
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	11654139	Oct 02, 2034	U-1969			
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639 001	10071066	Oct 10, 2034	U-3524		NCE	Jan 27, 2028
	10385008	Jan 05, 2038	DS DP			
	10420734	Oct 10, 2034	U-3524			
	10745343	Jan 05, 2038	U-3523			
	>A> 11779552	Oct 10, 2034	U-3524			
	7612114	Aug 18, 2026	DS DP U-3523			
	>A> 8399520	Dec 25, 2024	DS DP U-3523			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELACESTRANT DIHYDROCHLORIDE - ORSERDU</u>						
N 217639 002	10071066	Oct 10, 2034	U-3524		NCE	Jan 27, 2028
	10385008	Jan 05, 2038	DS DP			
	10420734	Oct 10, 2034	U-3524			
	10745343	Jan 05, 2038	U-3523			
>A>	11779552	Oct 10, 2034	U-3524			
	7612114	Aug 18, 2026	DS DP U-3523			
>A>	8399520	Dec 25, 2024	DS DP U-3523			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	11542239	Jul 23, 2039	DS DP			
	11690845	Aug 27, 2040	U-3654			
	11690854	Apr 19, 2038	U-3653			
	11707464	Mar 14, 2034	U-3672			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	11542239	Jul 23, 2039	DS DP			
	11690845	Aug 27, 2040	U-3654			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	11542239	Jul 23, 2039	DS DP			
	11690845	Aug 27, 2040	U-3655			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	11564916	Aug 13, 2029	U-3525			
	11578062	Mar 25, 2031	DP U-3544			
	11639347	Apr 09, 2027	DS DP U-3587			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	11564916	Aug 13, 2029	U-3525			
	11578062	Mar 25, 2031	DP U-3544			
	11639347	Apr 09, 2027	DS DP U-3587			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 001	10022352	Apr 09, 2027	DP U-3596		NCE	Oct 21, 2024
	10081621	Mar 25, 2031	DP U-3600		NP	Apr 26, 2026
	10239867	Apr 09, 2027	DS DP U-3590		ODE-433	Apr 26, 2030
	10272046	Feb 27, 2033	DP U-3599			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-3589			
	10793547	Dec 08, 2037	DS DP U-3588			
	11147770	Feb 27, 2033	DP U-3598			
	11179367	Dec 08, 2037	DP U-3597			
	11426407	Oct 06, 2035	DS DP U-3595			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3586			
	11564916	Aug 13, 2029	U-3585			
	11578062	Mar 25, 2031	DP U-3584			
	11639347	Apr 09, 2027	DS DP U-3583			
	11752106	Feb 27, 2033	DP U-3696			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3589			
	8354427	Jul 06, 2026	U-3593			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3589			
	8598181	May 01, 2027	U-3589			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3592			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-3591			
	9974781	Apr 09, 2027	DP U-3589			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	10022352	Apr 09, 2027	DP U-3596		NCE	Oct 21, 2024
	10081621	Mar 25, 2031	DP U-3600		NP	Apr 26, 2026
	10239867	Apr 09, 2027	DS DP U-3590		ODE-433	Apr 26, 2030
	10272046	Feb 27, 2033	DP U-3599			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-3589			
	10793547	Dec 08, 2037	DS DP U-3588			
	11147770	Feb 27, 2033	DP U-3598			
	11179367	Dec 08, 2037	DP U-3597			
	11426407	Oct 06, 2035	DS DP U-3595			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3586			
	11564916	Aug 13, 2029	U-3585			
	11578062	Mar 25, 2031	DP U-3584			
	11639347	Apr 09, 2027	DS DP U-3583			
	11752106	Feb 27, 2033	DP U-3696			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3589			
	8354427	Jul 06, 2026	U-3593			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3589			
	8598181	May 01, 2027	U-3589			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3592			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-3591			
	9974781	Apr 09, 2027	DP U-3589			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	10258637	Apr 03, 2034	U-2290		I-869	Aug 18, 2024
	10258637*PED	Oct 03, 2034			>A> I-922	Sep 21, 2026
	11090323	Apr 03, 2034	U-3191		M-82	Feb 24, 2025
	11090323*PED	Oct 03, 2034			NPP	Jun 20, 2026
	11666590	Apr 03, 2034	U-3691		PED	Aug 24, 2025
	7579449	Aug 01, 2028	DS		PED	Dec 20, 2026
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	U-1651			
	8551957*PED	Apr 14, 2030				
	9949997	May 17, 2034	U-2292			
	9949997	May 17, 2034	U-3199			
	9949997	May 17, 2034	U-3325			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	11090323	Apr 03, 2034	U-3191			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	U-1651			
	8551957*PED	Apr 14, 2030				
	9949997	May 17, 2034	U-2292			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	10258637	Apr 03, 2034	U-2290			
	10258637*PED	Oct 03, 2034				
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				
	11090323	Apr 03, 2034	U-3191			
	11090323*PED	Oct 03, 2034				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-1651			
	8551957*PED	Apr 14, 2030				
	8673927	May 04, 2027	U-1652	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	10258637	Apr 03, 2034	U-2290			
	10258637*PED	Oct 03, 2034				
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				
	11090323	Apr 03, 2034	U-3191			
	11090323*PED	Oct 03, 2034				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-1651			
	8551957*PED	Apr 14, 2030				
	8673927	May 04, 2027	U-1652	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	10258637	Apr 03, 2034	U-2731			
	10258637*PED	Oct 03, 2034				
	11090323	Apr 03, 2034	U-3192			
	11090323*PED	Oct 03, 2034				
	11564886	Mar 07, 2032	DP U-3531			
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-2730			
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
9949998	9949998	Jun 11, 2034	U-2731			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	10258637	Apr 03, 2034	U-2731			
	10258637*PED	Oct 03, 2034				
	11090323	Apr 03, 2034	U-3192			
	11090323*PED	Oct 03, 2034				
	11564886	Mar 07, 2032	DP U-3531			
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
7579449	7579449	Aug 01, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029		DP	U-2730	
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9949998	Jun 11, 2034		U-2731		
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	10258637	Apr 03, 2034		U-2731		
	10258637*PED	Oct 03, 2034				
	11090323	Apr 03, 2034		U-3192		
	11090323*PED	Oct 03, 2034				
	11564886	Mar 07, 2032		DP	U-3531	
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029		DP	U-2730	
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9949998	Jun 11, 2034		U-2731		
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	10258637	Apr 03, 2034		U-2731		
	10258637*PED	Oct 03, 2034				
	11090323	Apr 03, 2034		U-3192		
	11090323*PED	Oct 03, 2034				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029		DP	U-2730	
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9949998	Jun 11, 2034		U-2731		
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	10258637	Apr 03, 2034		U-2290	NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034		U-3193		
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034		U-3532		
	9949997	May 17, 2034		U-3533		
	9949997*PED	Nov 17, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	10258637	Apr 03, 2034		U-2290	NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034			U-3532	
	9949997	May 17, 2034			U-3533	
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	8501758	Aug 27, 2030	DS DP			
	RE49556	Feb 27, 2030	DS DP			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 001	11571398	May 16, 2040	U-3183			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 002	11464752	May 16, 2040	DP			
	11571398	May 16, 2040	U-3183			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	11590286	Dec 12, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	11590286	Dec 12, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	11590286	Dec 12, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 001	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 002	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 003	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 004	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 005	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	11578044	Oct 19, 2037	DS			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 002	11578044	Oct 19, 2037	DS			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	11684620	Feb 09, 2036	U-2518			
	11684620	Feb 09, 2036	U-3065			
	11684620	Feb 09, 2036	U-3066			
	11684620	Feb 09, 2036	U-3067			
	8895601	Apr 12, 2033	DS DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	11684620	Feb 09, 2036	U-2518			
	11684620	Feb 09, 2036	U-3065			
	11684620	Feb 09, 2036	U-3066			
	11684620	Feb 09, 2036	U-3067			
	8895601	Apr 12, 2033	DS DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	11684620	Feb 09, 2036	U-2518			
	11684620	Feb 09, 2036	U-3065			
	11684620	Feb 09, 2036	U-3066			
	11684620	Feb 09, 2036	U-3067			
	8895601	Apr 12, 2033	DS DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 001					NPP	May 12, 2026
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 002					NPP	May 12, 2026
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 003					NPP	May 12, 2026
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021365 001					NPP	May 12, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	>A> 11793812	May 03, 2038	U-2360		M-289	Jan 27, 2026
	>A> 11795178	Sep 27, 2033	DS DP			
<u>ETRASIMOD ARGININE - VELSIPITY</u>						
N 216956 001					>A> NCE	Oct 12, 2028
<u>FEDRATINIB HYDROCHLORIDE - INREBIC</u>						
N 212327 001	7528143	Nov 16, 2031	DS DP			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	>A> 11759440	Aug 02, 2037	U-3694		ODE-393 PED	Mar 25, 2029 Sep 25, 2029
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	8895612	Jan 08, 2027	U-3635			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	11633489	Jun 22, 2036	U-3594			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 002	11633489	Jun 22, 2036	U-3594			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 003	11633489	Jun 22, 2036	U-3594			
<u>FEZOLINETANT - VEOZAH</u>						
N 216578 001	10836768	Mar 28, 2034	U-3621		NCE	May 12, 2028
	8871761	Apr 04, 2031	DS			
	9422299	Mar 28, 2034	DS DP U-3622			
	9987274	Mar 28, 2034	U-3622			
<u>FLOTUFOLASTAT F-18 GALLIUM - POSLUMA</u>						
N 216023 001	11413360	Nov 22, 2038	DS U-3614		NCE	May 25, 2028
	11413360	Nov 22, 2038	DS U-3615			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUORESCHEIN SODIUM - FLUORESCHEIN SODIUM</u>						
A 215709	001				>A> CGT	Apr 21, 2024
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625	001	8113199	Oct 23, 2027	DP		
		8113199*PED	Apr 23, 2028			
		8161968	Feb 05, 2028	DP		
		8161968*PED	Aug 05, 2028			
		8534281	Mar 08, 2030	DP		
		8534281*PED	Sep 08, 2030			
		8746242	Oct 11, 2030	DP		
		8746242*PED	Apr 11, 2031			
		9333310	Oct 02, 2027	DP		
		9333310*PED	Apr 02, 2028			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625	002	8113199	Oct 23, 2027	DP		
		8113199*PED	Apr 23, 2028			
		8161968	Feb 05, 2028	DP		
		8161968*PED	Aug 05, 2028			
		8534281	Mar 08, 2030	DP		
		8534281*PED	Sep 08, 2030			
		8746242	Oct 11, 2030	DP		
		8746242*PED	Apr 11, 2031			
		9333310	Oct 02, 2027	DP		
		9333310*PED	Apr 02, 2028			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625	003	8113199	Oct 23, 2027	DP	M-290	Mar 01, 2026
		8113199*PED	Apr 23, 2028			
		8161968	Feb 05, 2028	DP		
		8161968*PED	Aug 05, 2028			
		8534281	Mar 08, 2030	DP		
		8534281*PED	Sep 08, 2030			
		8746242	Oct 11, 2030	DP		
		8746242*PED	Apr 11, 2031			
		9333310	Oct 02, 2027	DP		
		9333310*PED	Apr 02, 2028			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275	001	11116721	Feb 26, 2029	DP U-1401	NPP	May 13, 2026
		11116721	Feb 26, 2029	DP U-1691		
		11116721	Feb 26, 2029	DP U-3623		
		11116721*PED	Aug 26, 2029			
		7439393	May 21, 2025	DS DP U-1401		
		7439393	May 21, 2025	DS DP U-1691		
		7439393	May 21, 2025	DS DP U-2099		
		7439393	May 21, 2025	DS DP U-2100		
		7439393	May 21, 2025	DS DP U-3623		
		7439393*PED	Nov 21, 2025			
		8113199	Oct 23, 2027	DP		
		8113199*PED	Apr 23, 2028			
		8161968	Feb 05, 2028	DP		
		8161968*PED	Aug 05, 2028			
		8511304	Jun 14, 2027	DP U-1424		
		8511304	Jun 14, 2027	DP U-1691		
		8511304	Jun 14, 2027	DP U-3623		
		8511304*PED	Dec 14, 2027			
		8534281	Mar 08, 2030	DP		
		8534281*PED	Sep 08, 2030			
		8746242	Oct 11, 2030	DP		
		8746242*PED	Apr 11, 2031			
		9333310	Oct 02, 2027	DP		
		9333310*PED	Apr 02, 2028			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	11116721	Feb 26, 2029	DP U-1691			
	11116721	Feb 26, 2029	DP U-3623			
	11116721*PED	Aug 26, 2029				
	7439393	May 21, 2025	DS DP U-1691			
	7439393	May 21, 2025	DS DP U-2099			
	7439393	May 21, 2025	DS DP U-2100			
	7439393	May 21, 2025	DS DP U-3623			
	7439393*PED	Nov 21, 2025				
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8511304	Jun 14, 2027	DP U-1691			
	8511304	Jun 14, 2027	DP U-3623			
	8511304*PED	Dec 14, 2027				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 003	11116721	Feb 26, 2029	DP U-3623		NS	May 13, 2026
	7439393	May 21, 2025	DS DP U-3623			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-3623			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	11554229	Feb 23, 2036	U-2133			
	11602603	Oct 27, 2028	DP U-2133			
	8327844	Oct 24, 2023	U-2133			
	8522778	Apr 20, 2024	DP			
<u>FOSAPREPITANT DIMEGLUMINE - FOCINVEZ</u>						
N 216686 001	>A> 11065265	Jan 11, 2039	DP			
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001					M-286	Oct 27, 2025
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	11529362	Jun 02, 2037	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	11529362	Jun 02, 2037	DP			
<u>FUTIBATINIB - LYTGobi</u>						
N 214801 001					ODE-410	Sep 30, 2029
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 001	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 002	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 003	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 004	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 005	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 006	11590246	Jan 17, 2040	DP			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 007	11590246	Jan 17, 2040	DP			
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001					ODE-395	Jun 01, 2029
<u>GEPIRONE HYDROCHLORIDE - EXXUA</u>						
N 021164 001	>A> 7538116	Sep 02, 2025	U-3699		>A> NCE	Sep 22, 2028
<u>GEPIRONE HYDROCHLORIDE - EXXUA</u>						
N 021164 002	>A> 7538116	Sep 02, 2025	U-3699		>A> NCE	Sep 22, 2028
<u>GEPIRONE HYDROCHLORIDE - EXXUA</u>						
N 021164 003	>A> 7538116	Sep 02, 2025	U-3699		>A> NCE	Sep 22, 2028
<u>GEPIRONE HYDROCHLORIDE - EXXUA</u>						
N 021164 004	>A> 7538116	Sep 02, 2025	U-3699		>A> NCE	Sep 22, 2028
<u>GIVOSIRAN SODIUM - GIVLAARI</u>						
N 212194 001	9133461	Nov 30, 2033	DS DP U-2672			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 214874 001					>A> CGT	Apr 15, 2024
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097 003	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097 004	11590205	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE KIT</u>						
N 212097 005	11590205	Apr 22, 2036	DP U-2742			
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	10456354	Oct 25, 2038	DP			
	11110054	Oct 25, 2038	DP			
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354 001	11648256	Jun 06, 2036	DP U-2625			
	11679115	Jun 06, 2036	DP U-2625			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 006	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>IBREXAFUNGERP CITRATE - BREXAFEMME</u>						
N 214900 001	11534433	Jun 10, 2039	U-3159		I-903	Nov 30, 2025
	11534433	Jun 10, 2039	U-3508			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10478439	Jun 03, 2031	U-1650		ODE-109	Mar 04, 2023
	10478439	Jun 03, 2031	U-1684		ODE-117	May 06, 2023
	10478439	Jun 03, 2031	U-1946		ODE-152	Aug 02, 2024
	10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10478439	Jun 03, 2031	U-2242		PED	Feb 02, 2025
	10478439	Jun 03, 2031	U-2665		PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8952015*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9540382*PED	Feb 18, 2034				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10478439	Jun 03, 2031	U-1650		ODE*	Mar 04, 2023
	10478439	Jun 03, 2031	U-1684		ODE*	May 06, 2023
	10478439	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10478439	Jun 03, 2031	U-2242		PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10478439	Jun 03, 2031	U-1650		ODE*	Mar 04, 2023
	10478439	Jun 03, 2031	U-1684		ODE*	May 06, 2023
	10478439	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10478439	Jun 03, 2031	U-2242		PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10478439	Jun 03, 2031	U-1650		ODE*	Mar 04, 2023
	10478439	Jun 03, 2031	U-1684		ODE*	May 06, 2023
	10478439	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10478439	Jun 03, 2031	U-2242		PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10478439	Jun 03, 2031	U-1650		ODE*	Mar 04, 2023
	10478439	Jun 03, 2031	U-1684		ODE*	May 06, 2023
	10478439	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10478439	Jun 03, 2031	U-2242		PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004					ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Aug 02, 2024
					ODE-405	Aug 24, 2029
					PED	Feb 24, 2030
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10106548	Jun 03, 2033	DS DP		ODE-405	Aug 24, 2029
	10106548*PED	Dec 03, 2033			PED	Feb 24, 2030
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	11717504	Apr 29, 2030	U-3669			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	11717504	Apr 29, 2030	U-3669			
<u>INCLISIRAN SODIUM - LEQVIO</u>						
N 214012 001	10125369	Aug 18, 2034	DS DP U-3652			
	10131907	Aug 24, 2028	DS DP U-3652			
	10266825	Nov 04, 2023	U-3652			
	10851377	Aug 25, 2036	U-3652			
	11078485	Nov 04, 2023	DS U-3652			
	8106022	Dec 12, 2029	DS DP U-3652			
	8222222	Dec 29, 2027	U-3652			
	8809292	May 10, 2027	DS DP U-3652			
	8828956	Dec 04, 2028	DS DP U-3652			
	9370582	Dec 04, 2028	DS DP U-3652			
	9708610	Jan 01, 2024	DS DP U-3652			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INCLISIRAN SODIUM - LEQVIO</u>						
N 214012 001	10125369	Aug 18, 2034	DS DP U-3652			
	10131907	Aug 24, 2028	DS DP U-3652			
	10266825	Nov 04, 2023	U-3652			
	10851377	Aug 25, 2036	U-3652			
	11078485	Nov 04, 2023	DS U-3652			
	8106022	Dec 12, 2029	DS DP U-3652			
	8222222	Dec 29, 2027	U-3652			
	8809292	May 10, 2027	DS DP U-3652			
	8828956	Dec 04, 2028	DS DP U-3652			
	9370582	Dec 04, 2028	DS DP U-3652			
	9708610	Jan 01, 2024	DS DP U-3652			
<u>INDOCYANINE GREEN - SPY AGENT GREEN KIT</u>						
N 211580 001	11712320	Jul 14, 2039	DP		I-911	Jun 05, 2026
<u>INDOMETHACIN - INDOMETHACIN</u>						
A 216184 001					CGT	Jan 30, 2024
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 002	6812238	Oct 31, 2025	DS			
<u>ISTRADEFYLLINE - NOURIANZ</u>						
N 022075 001	7727993	Jan 28, 2028	DP U-2623			
<u>ISTRADEFYLLINE - NOURIANZ</u>						
N 022075 002	7727993	Jan 28, 2028	DP U-2623			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	11564916	Aug 13, 2029	U-3530			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	11564916	Aug 13, 2029	U-3528		ODE-435	May 03, 2030
	11752106	Feb 27, 2033	DP U-3697			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	11564916	Aug 13, 2029	U-3528		ODE-435	May 03, 2030
	11752106	Feb 27, 2033	DP U-3697			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	11564916	Aug 13, 2029	U-3528		ODE-435	May 03, 2030
	11752106	Feb 27, 2033	DP U-3697			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 004	10272046	Feb 27, 2033	DP U-3605		NPP	May 03, 2026
	10646481	Aug 13, 2029	DP		ODE-435	May 03, 2030
	11147770	Feb 27, 2033	DP U-3604			
	11564916	Aug 13, 2029	U-3603			
	11752106	Feb 27, 2033	DP U-3697			
	7495103	May 20, 2027	DS DP			
	8324242	Aug 05, 2027	U-3609			
	8354427	Jul 06, 2026	U-3608			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-3607			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3606			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 005	10272046	Feb 27, 2033	DP U-3605		NPP	May 03, 2026
	10646481	Aug 13, 2029	DP		ODE-435	May 03, 2030
	11147770	Feb 27, 2033	DP U-3604			
	11564916	Aug 13, 2029	U-3603			
	11752106	Feb 27, 2033	DP U-3697			
	7495103	May 20, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFITOR - KALYDECO</u>						
N 207925 005	8324242	Aug 05, 2027	U-3609			
	8354427	Jul 06, 2026	U-3608			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-3607			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3606			
<u>IVACAFITOR; IVACAFITOR, TEZACAFITOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	11564916	Aug 13, 2029	U-3527			
	11578062	Mar 25, 2031	DP U-3545			
	11639347	Apr 09, 2027	DS DP U-2569			
<u>IVACAFITOR; IVACAFITOR, TEZACAFITOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	11564916	Aug 13, 2029	U-3527			
	11578062	Mar 25, 2031	DP U-3545			
	11639347	Apr 09, 2027	DS DP U-2569			
<u>IVACAFITOR; LUMACAFITOR - ORKAMBI</u>						
N 206038 001	11564916	Aug 13, 2029	U-3529			
<u>IVACAFITOR; LUMACAFITOR - ORKAMBI</u>						
N 206038 002	11564916	Aug 13, 2029	U-3529			
<u>IVACAFITOR; LUMACAFITOR - ORKAMBI</u>						
N 211358 001	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>IVACAFITOR; LUMACAFITOR - ORKAMBI</u>						
N 211358 002	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>IVACAFITOR; LUMACAFITOR - ORKAMBI</u>						
N 211358 003	11564916	Aug 13, 2029	U-3526		ODE-408	Sep 02, 2029
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001					D-188	Apr 28, 2026
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002					D-188	Apr 28, 2026
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003					D-188	Apr 28, 2026
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004					D-188	Apr 28, 2026
<u>LACOSAMIDE - VIMPAT</u>						
N 022254 001					D-188	Apr 28, 2026
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001					D-188	Apr 28, 2026
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 001	11337943	Jun 05, 2040	DP U-3660			
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 002	11337943	Jun 05, 2040	DP U-3660			
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 003	11337943	Jun 05, 2040	DP U-3660			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	11191766	Apr 04, 2037	U-2471			
	11484535	Apr 04, 2037	U-2470			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	7423050	Feb 17, 2028	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	7423050	Feb 17, 2028	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 003	7423050	Feb 17, 2028	DS DP U-1719			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	11618748	Jan 27, 2030	U-1524			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001					ODE*	Aug 28, 2026
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002					ODE*	Apr 07, 2024
					ODE*	Aug 28, 2026
					PED	Oct 07, 2024
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 001					M-293	Apr 20, 2026
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 002					M-293	Apr 20, 2026
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973 001	10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
	10654827	Aug 17, 2037	U-3507			
	11267799	Aug 16, 2038	DS			
	9951043	Feb 28, 2034	DS DP U-3507			
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215974 001	10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
	10654827	Aug 17, 2037	U-3507			
	11267799	Aug 16, 2038	DS			
	9951043	Feb 28, 2034	DS DP U-3507			
<u>LENIOLISIB PHOSPHATE - JOENJA</u>						
N 217759 001	8653092	Feb 19, 2032	DS DP		NCE	Mar 24, 2028
					ODE-430	Mar 24, 2030
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	11090386	Feb 23, 2036	U-3519			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	11090386	Feb 23, 2036	U-3519			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001					D-189	Aug 02, 2026
					I-916	Jun 05, 2026
					ODE-423	Jun 05, 2030
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002					D-189	Aug 02, 2026
					I-916	Jun 05, 2026
					ODE-423	Jun 05, 2030

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001					D-189 I-916 ODE-423	Aug 02, 2026 Jun 05, 2026 Jun 05, 2030
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002					D-189 I-916 ODE-423	Aug 02, 2026 Jun 05, 2026 Jun 05, 2030
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED KIT</u>						
N 020263 009	8921326	Feb 05, 2031	DP		NS	Apr 14, 2026
	9617303	Mar 22, 2028	U-3611			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021343 001	>A> 11771841	Dec 22, 2041	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021379 001	>A> 11771841	Dec 22, 2041	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021488 001	>A> 11771841	Dec 22, 2041	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021731 001	>A> 11771841	Dec 22, 2041	DS DP			
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001	>A> 11771841	Dec 22, 2041	DS DP			
<u>LEUPROLIDE MESYLATE - CAMCEVI KIT</u>						
N 211488 001	11717555	Jan 01, 2039	DP			
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001					ODE-385	Dec 30, 2028
<u>LEVOLEUCOVORIN - KHAPZORY</u>						
N 211226 001	11541012	Mar 25, 2039	DP			
<u>LEVOLEUCOVORIN - KHAPZORY</u>						
N 211226 002	11541012	Mar 25, 2039	DP			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	11628088	Feb 07, 2027	DP			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	11571328	Sep 07, 2040	DP		I-917	Jun 29, 2026
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	11628088	Feb 07, 2027	DP			
<u>LIDOCAINE - ZTLIDO</u>						
N 207962 001	>A> 11786455	May 10, 2031	DP	U-2267		
	>A> 11793766	May 10, 2031		U-2267		
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001					I-921	Jun 12, 2026
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	10702576	Aug 11, 2031		U-1516	I-921	Jun 12, 2026
	10702576	Aug 11, 2031		U-3644		
	7304036	Aug 30, 2026	DS DP	U-1516		
	7304036	Aug 30, 2026	DS DP	U-3644		
	8110553	Jan 28, 2024		U-1516		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	8110553	Jan 28, 2024	U-3644			
	8933030	Feb 17, 2031	DP U-1516			
	8933030	Feb 17, 2031	DP U-3644			
	9708371	Aug 16, 2033	DP U-1516			
	9708371	Aug 16, 2033	DP U-3644			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	10034877	Aug 05, 2029	U-2347		M-295	Jun 20, 2026
	10034877*PED	Feb 05, 2030			PED	Dec 20, 2026
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503	Y		
	8846695*PED	Dec 04, 2030				
	8853156	Mar 05, 2031	DP U-1642			
	8853156*PED	Sep 05, 2031				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9486526	Aug 05, 2029	U-1915			
	9486526*PED	Feb 05, 2030				
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	10973827	Apr 02, 2029	DP			
	10973827*PED	Oct 02, 2029				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503			
	8846695*PED	Dec 04, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	10973827	Apr 02, 2029	DP			
	10973827*PED	Oct 02, 2029				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503			
	8846695*PED	Dec 04, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	10973827	Apr 02, 2029	DP			
	10973827*PED	Oct 02, 2029				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503	Y		
	8846695*PED	Dec 04, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9173859	May 04, 2027	DP U-1503	Y		
	9173859*PED	Nov 04, 2027				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
	9555001*PED	Sep 06, 2033				
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9173859	May 04, 2027	DP U-1503	Y		
	9173859*PED	Nov 04, 2027				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
	9555001*PED	Sep 06, 2033				
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	11771733	Nov 06, 2035	DP			
<u>LITHIUM CITRATE - LITHIUM CITRATE</u>						
A 218036 001					CGT	Mar 18, 2024
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001 >A>	8828356	Oct 17, 2024	U-3070			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002 >A>	8828356	Oct 17, 2024	U-3070			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001	11534395	Jan 26, 2036	DP U-2764			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11642317	May 03, 2033	DP			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11596599	May 03, 2033	U-2985			
	11642317	May 03, 2033	DP			
<u>LOTILANER - XDEMVY</u>						
N 217603 001	10835517	Dec 14, 2038	U-3674		NCE	Jul 24, 2028
	11197847	Dec 14, 2038	U-3674			
	11690826	Dec 14, 2038	U-3674			
	11690827	Dec 14, 2038	U-3674			
	11752137	Dec 14, 2038	DP			
	8383659	Jan 17, 2030	DS DP			
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103 001					ODE-415	Oct 06, 2029
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	11690842	Aug 30, 2039	DP U-3362			
	11690842	Aug 30, 2039	DP U-3363			
	11753419	Dec 10, 2040	DP			
	RE48839	Aug 19, 2033	U-3271			
	RE48839	Aug 19, 2033	U-814			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	11690842	Aug 30, 2039	DP U-3362			
	11690842	Aug 30, 2039	DP U-3363			
	11753419	Dec 10, 2040	DP			
	RE48839	Aug 19, 2033	U-3271			
	RE48839	Aug 19, 2033	U-814			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	11690842	Aug 30, 2039	DP U-3362			
	11690842	Aug 30, 2039	DP U-3363			
	11753419	Dec 10, 2040	DP			
	RE48839	Aug 19, 2033	U-3271			
	RE48839	Aug 19, 2033	U-814			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE</u>						
N 215344 001					NP	Jun 15, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB</u>						
N 213135 001	11638697	Aug 04, 2037	DP			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001					NPP ODE-429	Mar 13, 2026 Mar 13, 2030
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001	11684632	Jan 04, 2032	U-3650		ODE-388	Nov 23, 2028
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 001					M-297 ODE-398	Jun 15, 2026 Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 002					M-297 ODE-398	Jun 15, 2026 Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003					M-297 ODE-398	Jun 15, 2026 Apr 28, 2029
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004					M-297 ODE-398	Jun 15, 2026 Apr 28, 2029
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001	6992207	Jun 25, 2024	DS DP U-3093			
<u>MELPHALAN HYDROCHLORIDE - HEPZATO</u>						
N 201848 001	10098997	Nov 07, 2032	DP		NP	Aug 14, 2026
	10195334	Jan 16, 2033	DP		ODE-438	Aug 14, 2030
	10369264	Nov 07, 2032	DP			
	10569004	Nov 07, 2032	U-3680			
	10569004	Nov 07, 2032	U-3683			
	11083831	Dec 30, 2032	DP			
	11241522	Nov 07, 2032	DP			
	11633528	Nov 07, 2032	U-3675			
	9314561	Feb 07, 2034	DP			
	9707331	Sep 17, 2034	DP			
<u>MELPHALAN HYDROCHLORIDE - MELPHALAN HYDROCHLORIDE</u>						
N 217110 001	10537520	Jun 29, 2036	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	11684723	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	11684723	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	11684723	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	11684723	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	11684723	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	11684723	Mar 10, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	11684723	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	11684723	Mar 10, 2029	DP			
<u>METHOTREXATE - JYLAMVO</u>						
N 212479 001	11129833	Oct 28, 2035	DP			
	>A> 11771701	Oct 29, 2034	DP U-3700			
	>A> 11771701	Oct 29, 2034	DP U-3701			
	>A> 11771701	Oct 29, 2034	DP U-3702			
	>A> 11771701	Oct 29, 2034	DP U-3703			
	>A> 11771701	Oct 29, 2034	DP U-3704			
<u>METHSUXIMIDE - METHSUXIMIDE</u>						
A 217213 001					CGT	Oct 28, 2023
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	11633389	Aug 14, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	11633389	Aug 14, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	11633389	Aug 14, 2033	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	11628150	Dec 22, 2029	DP U-2843			
<u>METRONIDAZOLE - LIKMEZ</u>						
N 216755 001	>A> 11541035	Oct 04, 2039	DP			
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
A 216159 001					PC	Jan 02, 2024
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
A 216159 002					PC	Jan 02, 2024
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11612593	May 30, 2038	DS			
	11612594	May 30, 2038	DS			
	11622962	Mar 17, 2039	DS			
	11633387	May 30, 2038	DS			
	11633388	Mar 25, 2039		U-2371		
	11642334	Feb 20, 2039		U-2371		
	11666564	May 30, 2038		U-2371		
	>A> 11786516	May 30, 2038	DS			
<u>MIGLUSTAT - OPFOLDA</u>						
N 215211 001	>A> 10208299	Sep 30, 2035	DS DP U-3726		>A> NP	Sep 28, 2026
	>A> 10512677	Mar 07, 2033	U-3726			
	>A> 10857212	Aug 12, 2037	U-3726			
	>A> 10961522	Sep 30, 2035	U-3726			
	>A> 11278599	Mar 07, 2033	U-3726			
	>A> 11278601	Dec 29, 2036	DP U-3726			
	>A> 11753632	Sep 30, 2035	U-3726			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	10842780	Sep 28, 2029	DP U-2996			
	10842780	Sep 28, 2029	DP U-3670			
	10842780*PED	Mar 28, 2030				
	11707451	Sep 28, 2029	U-2996			
	11707451	Sep 28, 2029	U-3670			
	11707451*PED	Mar 28, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	10842780	Sep 28, 2029	DP U-2996			
	10842780	Sep 28, 2029	DP U-3670			
	10842780*PED	Mar 28, 2030				
	11707451	Sep 28, 2029	U-2996			
	11707451	Sep 28, 2029	U-3670			
	11707451*PED	Mar 28, 2030				
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	10842780	Sep 28, 2029	DP U-2996			
	10842780	Sep 28, 2029	DP U-3670			
	10842780*PED	Mar 28, 2030				
	11707451	Sep 28, 2029	U-2996			
	11707451	Sep 28, 2029	U-3670			
	11707451*PED	Mar 28, 2030				
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001 >A>	11793806	Apr 12, 2033	U-3320		ODE-392	Feb 17, 2029
	RE49582	Feb 24, 2031	DS DP			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002 >A>	11793806	Apr 12, 2033	U-3320		ODE-392	Feb 17, 2029
	RE49582	Feb 24, 2031	DS DP			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003 >A>	11793806	Apr 12, 2033	U-3320		ODE-392	Feb 17, 2029
	RE49582	Feb 24, 2031	DS DP			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 001	8486941	Jan 03, 2030	DS DP U-1201		NCE	Sep 15, 2028
	9809559	Jun 11, 2035	U-1201		ODE-441	Sep 15, 2030
	RE48285	Jun 11, 2035	DS DP U-1201			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 002	8486941	Jan 03, 2030	DS DP U-1201		NCE	Sep 15, 2028
	9809559	Jun 11, 2035	U-1201		ODE-441	Sep 15, 2030
	RE48285	Jun 11, 2035	DS DP U-1201			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 003	8486941	Jan 03, 2030	DS DP U-1201		NCE	Sep 15, 2028
	9809559	Jun 11, 2035	U-1201		ODE-441	Sep 15, 2030
	RE48285	Jun 11, 2035	DS DP U-1201			
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001	11679210	Sep 03, 2038	DP			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	11590095	Mar 18, 2036	U-1384			
<u>MOTIXAFORTIDE ACETATE - APHEXDA</u>						
N 217159 001					ODE-442	Sep 08, 2030
<u>NALMEFENE HYDROCHLORIDE - OPVEE</u>						
N 217470 001	11458091	Jul 10, 2038	DP U-3630		NP	May 22, 2026
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	11590286	Dec 12, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - REXTOVY</u>						
N 208969 001					NP	Mar 07, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	11590286	Dec 12, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001	11617713	Aug 26, 2034	DP U-3110			
	11628139	Aug 26, 2034	DP U-3110			
<u>NALOXONE HYDROCHLORIDE - ZIMHI</u>						
N 212854 001	11571518	Jun 14, 2041	DP U-3515			
	11571518	Jun 14, 2041	DP U-3516			
	11571518	Jun 14, 2041	DP U-3517			
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)</u>						
N 215457 001	11590286	Dec 12, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - RIVIVE</u>						
N 217722 001	11020343	May 11, 2032	U-3671			
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 001	>A> 10351854	Oct 09, 2035	DS DP		>A> NCE	Sep 29, 2028
	>A> 10738311	Oct 09, 2035	DS DP U-3709		>A> ODE-443	Sep 29, 2030
	>A> 11053502	Oct 29, 2035	DS DP			
	>A> 11286488	Oct 12, 2038	DS DP U-3709			
	>A> 11359203	Oct 09, 2035	DS DP U-3709			
	>A> 11661604	Oct 12, 2038	DS DP U-3709			
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 002	>A> 10351854	Oct 09, 2035	DS DP		>A> NCE	Sep 29, 2028
	>A> 10738311	Oct 09, 2035	DS DP U-3709		>A> ODE-443	Sep 29, 2030
	>A> 11053502	Oct 29, 2035	DS DP			
	>A> 11286488	Oct 12, 2038	DS DP U-3709			
	>A> 11359203	Oct 09, 2035	DS DP U-3709			
	>A> 11661604	Oct 12, 2038	DS DP U-3709			
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 003	>A> 10351854	Oct 09, 2035	DS DP		>A> NCE	Sep 29, 2028
	>A> 10738311	Oct 09, 2035	DS DP U-3709		>A> ODE-443	Sep 29, 2030
	>A> 11053502	Oct 29, 2035	DS DP			
	>A> 11286488	Oct 12, 2038	DS DP U-3709			
	>A> 11359203	Oct 09, 2035	DS DP U-3709			
	>A> 11661604	Oct 12, 2038	DS DP U-3709			
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	11618748	Jan 27, 2030	U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	11559523	Nov 18, 2030	DP U-3522			
<u>NICARDIPINE HYDROCHLORIDE - NICARDIPINE HYDROCHLORIDE</u>						
A 215377 001					CGT	Mar 20, 2024
<u>NICARDIPINE HYDROCHLORIDE - NICARDIPINE HYDROCHLORIDE</u>						
A 215377 002					CGT	Mar 20, 2024
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	11547758	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	11547758	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	11547758	Apr 18, 2027	U-1029			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	11517563	Apr 16, 2038	DP	Y		
	11759457	Apr 16, 2038	U-2804			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	>A> 10105323	Jun 04, 2029	DP		>A> ODE-261	Sep 06, 2026
	>A> 10105323*PED	Dec 04, 2029			>A> PED	Mar 06, 2027
	>A> 10154990	Jan 08, 2026	U-2620			
	>A> 10154990*PED	Jul 08, 2026				
	>A> 6762180	Oct 01, 2025	DS DP			
	>A> 6762180*PED	Apr 01, 2026				
	>A> 9907756	Jun 07, 2029	DP			
	>A> 9907756*PED	Dec 07, 2029				
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	>A> 10105323	Jun 04, 2029	DP		>A> ODE-261	Sep 06, 2026
	>A> 10105323*PED	Dec 04, 2029			>A> PED	Mar 06, 2027
	>A> 10154990	Jan 08, 2026	U-2620			
	>A> 10154990*PED	Jul 08, 2026				
	>A> 6762180	Oct 01, 2025	DS DP			
	>A> 6762180*PED	Apr 01, 2026				
	>A> 9907756	Jun 07, 2029	DP			
	>A> 9907756*PED	Dec 07, 2029				
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	11673877	Mar 27, 2038	DP U-3646			
	11673877	Mar 27, 2038	DP U-3647			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 001	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP U-3646			
	11673877	Mar 27, 2038	DP U-3647			
	11730725	Jan 04, 2039	DP			
	8071579	Aug 12, 2027	U-2655			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2655			
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031	U-2655			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 002	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP U-3646			
	11673877	Mar 27, 2038	DP U-3647			
	11730725	Jan 04, 2039	DP			
	8071579	Aug 12, 2027	U-2655			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2655			
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031	U-2655			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 003	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP U-3646			
	11673877	Mar 27, 2038	DP U-3647			
	11730725	Jan 04, 2039	DP			
	8071579	Aug 12, 2027	U-2655			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2655			
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031	U-2655			
<u>NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)</u>						
N 217188 001	11351149	Aug 05, 2041	DS DP U-3629		NCE	May 25, 2028
	11541034	Oct 31, 2041	U-3629			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)</u>						
N 217188 002					NCE	May 25, 2028
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	11511252	Sep 21, 2029	DP			
	11554241	Aug 18, 2025	U-3037			
	11672938	Jul 22, 2040	U-3037			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 001	11602508	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 002	11602508	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 003	11602508	Jan 30, 2038	DP			
<u>NORGESTREL - OPILL</u>						
N 017031 001					RTO	Jul 13, 2026
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	10011633	Nov 08, 2031	U-3186		I-918	Jun 13, 2026
	10011633	Nov 08, 2031	U-3187		ODE-436	Jun 13, 2030
	10011633	Nov 08, 2031	U-3648			
	10011633	Nov 08, 2031	U-3649			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3187			
	11732006	Nov 08, 2031	U-3648			
	11732006	Nov 08, 2031	U-3649			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	10011633	Nov 08, 2031	U-3186		I-918	Jun 13, 2026
	10011633	Nov 08, 2031	U-3187		ODE-436	Jun 13, 2030
	10011633	Nov 08, 2031	U-3648			
	10011633	Nov 08, 2031	U-3649			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE	
ODEVIXIBAT - BYLVAY							
N 215498 002	10981952	Nov 08, 2031	U-3649				
	11365182	Jun 20, 2039	U-3186				
	11365182	Jun 20, 2039	U-3187				
	11365182	Jun 20, 2039	U-3648				
	11365182	Jun 20, 2039	U-3649				
	11583539	Nov 12, 2041	U-3186				
	11732006	Nov 08, 2031	U-3186				
	11732006	Nov 08, 2031	U-3187				
	11732006	Nov 08, 2031	U-3648				
	11732006	Nov 08, 2031	U-3649				
	9694018	Nov 08, 2031	U-3186				
	9694018	Nov 08, 2031	U-3187				
	9694018	Nov 08, 2031	U-3648				
	9694018	Nov 08, 2031	U-3649				
	ODEVIXIBAT - BYLVAY						
	N 215498 003	10011633	Nov 08, 2031	U-3186		I-918	Jun 13, 2026
10011633		Nov 08, 2031	U-3187		ODE-436	Jun 13, 2030	
10011633		Nov 08, 2031	U-3648				
10011633		Nov 08, 2031	U-3649				
10093697		Nov 08, 2031	U-3186				
10093697		Nov 08, 2031	U-3187				
10093697		Nov 08, 2031	U-3648				
10093697		Nov 08, 2031	U-3649				
10487111		Nov 08, 2031	U-3186				
10487111		Nov 08, 2031	U-3187				
10487111		Nov 08, 2031	U-3648				
10487111		Nov 08, 2031	U-3649				
10981952		Nov 08, 2031	U-3186				
10981952		Nov 08, 2031	U-3187				
10981952		Nov 08, 2031	U-3648				
10981952		Nov 08, 2031	U-3649				
11365182		Jun 20, 2039	U-3186				
11365182		Jun 20, 2039	U-3187				
11365182		Jun 20, 2039	U-3648				
11365182		Jun 20, 2039	U-3649				
11583539		Nov 12, 2041	U-3186				
11732006		Nov 08, 2031	U-3186				
11732006		Nov 08, 2031	U-3187				
11732006		Nov 08, 2031	U-3648				
11732006		Nov 08, 2031	U-3649				
9694018		Nov 08, 2031	U-3186				
9694018		Nov 08, 2031	U-3187				
9694018		Nov 08, 2031	U-3648				
9694018		Nov 08, 2031	U-3649				
ODEVIXIBAT - BYLVAY							
N 215498 004		10011633	Nov 08, 2031	U-3186		I-918	Jun 13, 2026
		10011633	Nov 08, 2031	U-3187		ODE-436	Jun 13, 2030
		10011633	Nov 08, 2031	U-3648			
		10011633	Nov 08, 2031	U-3649			
	10093697	Nov 08, 2031	U-3186				
	10093697	Nov 08, 2031	U-3187				
	10093697	Nov 08, 2031	U-3648				
	10093697	Nov 08, 2031	U-3649				
	10487111	Nov 08, 2031	U-3186				
	10487111	Nov 08, 2031	U-3187				
	10487111	Nov 08, 2031	U-3648				
	10487111	Nov 08, 2031	U-3649				
	10981952	Nov 08, 2031	U-3186				
	10981952	Nov 08, 2031	U-3187				
	10981952	Nov 08, 2031	U-3648				
	10981952	Nov 08, 2031	U-3649				
	11365182	Jun 20, 2039	U-3186				
	11365182	Jun 20, 2039	U-3187				
	11365182	Jun 20, 2039	U-3648				
	11365182	Jun 20, 2039	U-3649				
	11583539	Nov 12, 2041	U-3186				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3187			
	11732006	Nov 08, 2031	U-3648			
	11732006	Nov 08, 2031	U-3649			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	11707466	Nov 12, 2041	DP			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	11707466	Nov 12, 2041	DP			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	11707466	Nov 12, 2041	DP			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	11707466	Nov 12, 2041	DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	11633396	Oct 07, 2029	DP		I-914	May 31, 2026
	>A> 8071579	Aug 12, 2027	U-2480			
	>A> 8071579	Aug 12, 2027	U-2482			
	>A> 8071579	Aug 12, 2027	U-2483			
	>A> 8071579	Aug 12, 2027	U-2716			
	>A> 8071579	Aug 12, 2027	U-2819			
	>A> 8071579	Aug 12, 2027	U-2820			
	>A> 8071579	Aug 12, 2027	U-2821			
	>A> 8071579	Aug 12, 2027	U-2822			
	>A> 8071579	Aug 12, 2027	U-2823			
	>A> 8071579	Aug 12, 2027	U-2824			
	>A> 8071579	Aug 12, 2027	U-2832			
	>A> 8071579	Aug 12, 2027	U-2833			
	>A> 8071579	Aug 12, 2027	U-3333			
	>A> 8071579	Aug 12, 2027	U-3631			
	>A> 8071579	Aug 12, 2027	U-3695			
	>A> 8143241	Aug 12, 2027	U-2480			
	>A> 8143241	Aug 12, 2027	U-2482			
	>A> 8143241	Aug 12, 2027	U-2483			
	>A> 8143241	Aug 12, 2027	U-2716			
	>A> 8143241	Aug 12, 2027	U-2819			
	>A> 8143241	Aug 12, 2027	U-2820			
	>A> 8143241	Aug 12, 2027	U-2821			
	>A> 8143241	Aug 12, 2027	U-2822			
	>A> 8143241	Aug 12, 2027	U-2823			
	>A> 8143241	Aug 12, 2027	U-2824			
	>A> 8143241	Aug 12, 2027	U-2832			
	>A> 8143241	Aug 12, 2027	U-2833			
	>A> 8143241	Aug 12, 2027	U-3333			
	>A> 8143241	Aug 12, 2027	U-3631			
	>A> 8143241	Aug 12, 2027	U-3695			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8859562	Aug 04, 2031	U-3333			
	8859562	Aug 04, 2031	U-3631			
	8859562	Aug 04, 2031	U-3695			
	>A> 8912187	Mar 12, 2024	U-2480			
	>A> 8912187	Mar 12, 2024	U-2482			
	>A> 8912187	Mar 12, 2024	U-2483			
	>A> 8912187	Mar 12, 2024	U-2819			
	>A> 8912187	Mar 12, 2024	U-2820			
	>A> 8912187	Mar 12, 2024	U-2821			
	>A> 8912187	Mar 12, 2024	U-2822			
	>A> 8912187	Mar 12, 2024	U-2823			
	>A> 8912187	Mar 12, 2024	U-2824			
	>A> 8912187	Mar 12, 2024	U-3333			
	>A> 8912187	Mar 12, 2024	U-3695			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9169235	Mar 12, 2024	U-3631			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	11633396	Oct 07, 2029	DP		I-914	May 31, 2026
	>A> 8071579	Aug 12, 2027	U-2480			
	>A> 8071579	Aug 12, 2027	U-2482			
	>A> 8071579	Aug 12, 2027	U-2483			
	>A> 8071579	Aug 12, 2027	U-2716			
	>A> 8071579	Aug 12, 2027	U-2819			
	>A> 8071579	Aug 12, 2027	U-2820			
	>A> 8071579	Aug 12, 2027	U-2821			
	>A> 8071579	Aug 12, 2027	U-2822			
	>A> 8071579	Aug 12, 2027	U-2823			
	>A> 8071579	Aug 12, 2027	U-2824			
	>A> 8071579	Aug 12, 2027	U-2832			
	>A> 8071579	Aug 12, 2027	U-2833			
	>A> 8071579	Aug 12, 2027	U-3333			
	>A> 8071579	Aug 12, 2027	U-3631			
	>A> 8071579	Aug 12, 2027	U-3695			
	>A> 8143241	Aug 12, 2027	U-2480			
	>A> 8143241	Aug 12, 2027	U-2482			
	>A> 8143241	Aug 12, 2027	U-2483			
	>A> 8143241	Aug 12, 2027	U-2716			
	>A> 8143241	Aug 12, 2027	U-2819			
	>A> 8143241	Aug 12, 2027	U-2820			
	>A> 8143241	Aug 12, 2027	U-2821			
	>A> 8143241	Aug 12, 2027	U-2822			
	>A> 8143241	Aug 12, 2027	U-2823			
	>A> 8143241	Aug 12, 2027	U-2824			
	>A> 8143241	Aug 12, 2027	U-2832			
	>A> 8143241	Aug 12, 2027	U-2833			
	>A> 8143241	Aug 12, 2027	U-3333			
	>A> 8143241	Aug 12, 2027	U-3631			
	>A> 8143241	Aug 12, 2027	U-3695			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8859562	Aug 04, 2031	U-3631			
	8859562	Aug 04, 2031	U-3695			
	>A> 8912187	Mar 12, 2024	U-2480			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	>A> 8912187	Mar 12, 2024	U-2482			
	>A> 8912187	Mar 12, 2024	U-2483			
	>A> 8912187	Mar 12, 2024	U-2819			
	>A> 8912187	Mar 12, 2024	U-2820			
	>A> 8912187	Mar 12, 2024	U-2821			
	>A> 8912187	Mar 12, 2024	U-2822			
	>A> 8912187	Mar 12, 2024	U-2823			
	>A> 8912187	Mar 12, 2024	U-2824			
	>A> 8912187	Mar 12, 2024	U-3333			
	>A> 8912187	Mar 12, 2024	U-3695			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9169235	Mar 12, 2024	U-3631			
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001	11723905	Nov 12, 2039	DP		NCE	Dec 01, 2027
	11738018	Jul 17, 2039	U-3684		ODE-413	Dec 01, 2029
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	7553828	Jun 02, 2024	DS			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	7553828	Jun 02, 2024	DS			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001	11091430	Apr 20, 2029	U-3552		NCE	Feb 28, 2028
	8124799	Dec 03, 2029	DS		ODE-427	Feb 28, 2030
	8440854	Apr 20, 2029	DP			
	8993640	Apr 24, 2033	DS DP			
	9670147	Apr 20, 2029	DS			
	9701709	Apr 24, 2033	DS DP			
<u>OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001	11633478	Jul 16, 2039	DP			
	>A> 11771686	Mar 01, 2040	U-623			
<u>OMIDENEPAG ISOPROPYL - OMLONTI</u>						
N 215092 001	11666563	Jul 16, 2039	U-3454			
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ</u>						
N 212520 001	>A> 11701343	Dec 16, 2039	U-2849			
<u>PACRITINIB CITRATE - VONJO</u>						
N 208712 001					ODE-397	Feb 28, 2029
<u>PAFOLACIANINE SODIUM - CYTALUX</u>						
N 214907 001					I-905	Dec 16, 2025
					ODE-390	Nov 29, 2028
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	11065250	Aug 19, 2036	DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	11065250	Aug 19, 2036	DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	11065250	Aug 19, 2036	DP			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005	11666697	Nov 24, 2041	U-3626			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006	11666697	Nov 24, 2041	U-3626			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 001	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676		ODE-439	Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 002	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676		ODE-439	Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 003	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676		ODE-439	Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 004	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676		ODE-439	Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 005	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676		ODE-439	Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	11661441	Jan 13, 2033	DS U-3124		M-288	Feb 08, 2026
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	10035822	Nov 15, 2033	DS		NCE	May 14, 2026
	10125171	Aug 02, 2033	DS		NP	Feb 22, 2026
	10875893	Nov 15, 2033	DS U-3540			
	11292815	Nov 15, 2033	DS DP U-3540			
	11661441	Jan 13, 2033	DS U-3540			
	7888323	Dec 04, 2027	DS			
	7989589	Dec 04, 2027	DS			
	8168584	Apr 07, 2027	U-3540			
	8168584	Apr 07, 2027	U-3542			
	9056076	Oct 25, 2026	U-3540			
	9169307	Nov 18, 2027	DS U-3541			
<u>PEMETREXED - PEMFEXY</u>						
N 209472 001	>A> 11793813	Feb 19, 2036	DP			
<u>PEMETREXED DISODIUM - PEMETREXED</u>						
N 215179 001	11147817	Mar 26, 2035	DP			
<u>PEMETREXED DISODIUM - PEMETREXED</u>						
N 215179 002	11147817	Mar 26, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEMETREXED DISODIUM - PEMETREXED</u>						
N 215179 003	11147817	Mar 26, 2035	DP			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	11628162	Aug 30, 2040	U-3568		ODE-404	Aug 26, 2029
	11628162	Aug 30, 2040	U-3569			
	11628162	Aug 30, 2040	U-3570			
	11628162	Aug 30, 2040	U-3571			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002	11628162	Aug 30, 2040	U-3568		ODE-404	Aug 26, 2029
	11628162	Aug 30, 2040	U-3569			
	11628162	Aug 30, 2040	U-3570			
	11628162	Aug 30, 2040	U-3571			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003	11628162	Aug 30, 2040	U-3568		ODE-404	Aug 26, 2029
	11628162	Aug 30, 2040	U-3569			
	11628162	Aug 30, 2040	U-3570			
	11628162	Aug 30, 2040	U-3571			
<u>PENCICLOVIR - PENCICLOVIR</u>						
A 216981 001					CGT	Feb 28, 2024
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
<u>PERFLUOROHEXYLOCTANE - MIEBO</u>						
N 216675 001	10058615	Sep 12, 2033	U-1900		NCE	May 18, 2028
	10369117	Sep 12, 2033	U-1900			
	10449164	Sep 12, 2033	U-1900			
	10507132	Jun 21, 2037	U-1900			
	10576154	Sep 12, 2033	U-1900			
	11357738	Sep 29, 2036	DP			
<u>PHENOBARBITAL SODIUM - SEZABY</u>						
N 215910 001					ODE-414	Nov 17, 2029
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001	7229630	Jul 31, 2023	DP			
	7575757	Jul 31, 2023	DP			
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001					>A> NP	Sep 25, 2026
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
A 216496 001					CGT	Jul 17, 2023
<u>PHENYLEPHRINE HYDROCHLORIDE - IMMPHENTIV</u>						
N 203826 004	11213480	Sep 26, 2036	DP			
	11471400	Aug 05, 2036	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - IMMPHENTIV</u>						
N 203826 005	11213480	Sep 26, 2036	DP			
	11471400	Aug 05, 2036	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI</u>						
N 215352 001	10839960	Jul 15, 2031	U-3685		NP	May 05, 2026
	11398306	Jul 15, 2031	U-3685			
<u>PILOCARPINE HYDROCHLORIDE - VUITY</u>						
N 214028 001	10610518	Apr 24, 2039	U-3252		D-187	Mar 28, 2026
	10610518	Apr 24, 2039	U-3561			
	10610518	Apr 24, 2039	U-3562			
	11285134	Apr 24, 2039	U-3252			
	11285134	Apr 24, 2039	U-3561			
	11285134	Apr 24, 2039	U-3562			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	10464905	Dec 16, 2036	U-3518		ODE-424	Jan 27, 2030
	10695323	Dec 16, 2036	DS DP U-3518			
	10918622	Dec 16, 2036	U-3518			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	10464905	Dec 16, 2036	U-3518		ODE-424	Jan 27, 2030
	10695323	Dec 16, 2036	DS DP U-3518			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002	10918622	Dec 16, 2036	U-3518			
<u>POSACONAZOLE - POSACONAZOLE</u>						
A 208768 001					PC	Dec 26, 2023
<u>POTASSIUM CHLORIDE - POTASSIUM CHLORIDE</u>						
A 217704 001					CGT	Mar 11, 2024
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES</u>						
A 216274 001				>A>	CGT	Apr 13, 2024
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES</u>						
A 216274 002				>A>	CGT	Apr 10, 2024
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES</u>						
A 216274 003				>A>	CGT	Apr 10, 2024
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	10030005	Nov 01, 2036	DS DP U-2952			
	10030005	Nov 01, 2036	DS DP U-3002			
<u>PREDNISOLONE - PREDNISOLONE</u>						
A 215673 001					CGT	Nov 18, 2023
<u>QUIZARTINIB DIHYDROCHLORIDE - VANFLYTA</u>						
N 216993 001	7820657	Sep 26, 2028	DS		NCE	Jul 20, 2028
	7968543	Aug 15, 2029	DP U-3661		ODE-437	Jul 20, 2030
	8129374	Mar 16, 2027	U-3661			
	8357690	Feb 26, 2031	U-3661			
	8557810	Mar 16, 2027	DP			
	8836218	Mar 23, 2030	U-3661			
	8865710	Aug 15, 2029	DP			
	8883783	Mar 16, 2027	DS			
	9555040	May 14, 2030	U-3661			
	9585892	Mar 16, 2027	U-3661			
	9675549	Sep 30, 2033	DP			
<u>QUIZARTINIB DIHYDROCHLORIDE - VANFLYTA</u>						
N 216993 002	7820657	Sep 26, 2028	DS		NCE	Jul 20, 2028
	7968543	Aug 15, 2029	DP U-3661		ODE-437	Jul 20, 2030
	8129374	Mar 16, 2027	U-3661			
	8357690	Feb 26, 2031	U-3661			
	8557810	Mar 16, 2027	DP			
	8836218	Mar 23, 2030	U-3661			
	8865710	Aug 15, 2029	DP			
	8883783	Mar 16, 2027	DS			
	9555040	May 14, 2030	U-3661			
	9585892	Mar 16, 2027	U-3661			
	9675549	Sep 30, 2033	DP			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001	8771733	Jun 02, 2030	DS DP U-257			
	8852632	Jan 28, 2028	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145 002	8771733	Jun 02, 2030	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 002	8771733	Jun 02, 2030	DS DP U-257			
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	11583526	Sep 29, 2037	U-3020			
>A>	11795178	Sep 27, 2033	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	11583526	Sep 29, 2037	U-3020			
>A>	11795178	Sep 27, 2033	DS DP			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001					M-301	Jul 13, 2026
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002					M-301	Jul 13, 2026
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	11691948	Jul 14, 2030	DP			
<u>REZAFUNGIN ACETATE - REZZAYO</u>						
N 217417 001	10702573	Mar 14, 2033	DS DP U-3566		NCE	Mar 22, 2028
	11197909	Jul 14, 2038	DS DP U-3566		ODE-426	Mar 22, 2030
	11654196	Mar 02, 2032	DS DP U-3566		GAIN	Mar 22, 2033
	11712459	Mar 15, 2037	DP U-3566		GAIN	Mar 22, 2035
	8722619	Mar 02, 2032	DS DP U-3566			
	9526835	Mar 14, 2033	DS DP U-3566			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	11564912	Feb 26, 2029	U-3511			
	11564912	Feb 26, 2029	U-3512			
>A>	11779571	Feb 26, 2029	U-3706			
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728 001	8314117	Mar 09, 2030	DS DP U-2718			
	8314117	Mar 09, 2030	DS DP U-3142			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11529336	Aug 12, 2040	U-3382			
	11534432	Aug 12, 2040	U-3442			
	11576903	Dec 30, 2040	DP			
	11576904	Aug 12, 2040	U-3537			
	11612591	Dec 30, 2040	DP			
>A>	11779572	Oct 06, 2042	U-3714			
>A>	11793795	Dec 30, 2040	DP			
>A>	8461179	May 15, 2034	DS DP			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001	11534444	Oct 04, 2038	U-1943		>A> M-270	Oct 03, 2026
					ODE-400	May 27, 2029
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 001	11712475	Feb 13, 2028	U-3135			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 002	11712475	Feb 13, 2028	U-3135			
<u>RISPERIDONE - RYKINDO</u>						
N 212849 001	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
<u>RISPERIDONE - RYKINDO</u>						
N 212849 002	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RYKINDO</u>						
N 212849 003	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
<u>RISPERIDONE - RYKINDO</u>						
N 212849 004	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
<u>RISPERIDONE - UZEDY</u>						
N 213586 001	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
<u>RISPERIDONE - UZEDY</u>						
N 213586 002	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
<u>RISPERIDONE - UZEDY</u>						
N 213586 003	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
<u>RISPERIDONE - UZEDY</u>						
N 213586 004	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
<u>RISPERIDONE - UZEDY</u>						
N 213586 005	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - UZEDY</u>						
N 213586 005	9925268	Jan 12, 2025	DP			
<u>RISPERIDONE - UZEDY</u>						
N 213586 006	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
<u>RISPERIDONE - UZEDY</u>						
N 213586 007	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
<u>RITECITINIB TOSYLATE - LITFULO</u>						
N 215830 001	9617258	Dec 03, 2034	DS DP		NCE	Jun 23, 2028
<u>RIZATRIPTAN BENZOATE - RIZAFILM</u>						
N 205394 001	9301948	Jul 30, 2034	DS DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 001	>A> 11129818	Aug 25, 2037	U-3408			
	>A> 11129818	Aug 25, 2037	U-3712			
	>A> 11793796	Jun 07, 2037	DP			
	>A> 9907788	Jun 07, 2037	U-3408			
	>A> 9907788	Jun 07, 2037	U-3712			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005					M-285 PED	Dec 19, 2025 Jun 19, 2026
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	11510923	Sep 04, 2040	U-3505			
	11571425	May 20, 2031	DP			
	11590136	May 20, 2031	U-3229			
	11590136	May 20, 2031	U-3404			
	11590137	Sep 04, 2040	U-3505			
	11590138	Jun 10, 2040	U-3551			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	11602536	May 05, 2041	U-3550			
<u>SAXAGLIPTIN HYDROCHLORIDE - SAXAGLIPTIN</u>						
A 205941 001					PC	Jan 27, 2024
<u>SAXAGLIPTIN HYDROCHLORIDE - SAXAGLIPTIN</u>						
A 205941 002					PC	Jan 27, 2024
<u>SAXAGLIPTIN HYDROCHLORIDE - SAXAGLIPTIN</u>						
A 205972 001					PC	Jan 27, 2024
<u>SAXAGLIPTIN HYDROCHLORIDE - SAXAGLIPTIN</u>						
A 205972 002					PC	Jan 27, 2024
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	11602522	Sep 04, 2035	DP U-3169			
	11602522	Sep 04, 2035	DP U-3302			
	11684607	Sep 16, 2035	DP U-2583			
	11684607	Sep 16, 2035	DP U-3169			
	11684607	Sep 16, 2035	DP U-3270			
	11684607	Sep 16, 2035	DP U-3302			
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	8999996	Jul 03, 2033	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 002	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	8999996	Jul 03, 2033	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 003	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	8999996	Jul 03, 2033	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 004	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	8999996	Jul 03, 2033	DS DP			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001					ODE-409 ODE-412	Sep 21, 2029 Sep 21, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMO</u>						
N 213246	002				ODE-409 ODE-412	Sep 21, 2029 Sep 21, 2029
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756	001	7425637	Mar 13, 2024	DS		
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756	002	7425637	Mar 13, 2024	DS		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051	001	11759501	Mar 15, 2033	DP		
		11759502	Mar 15, 2033	DP		
		11759503	Mar 15, 2033	DP		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051	002	11759501	Mar 15, 2033	DP		
		11759502	Mar 15, 2033	DP		
		11759503	Mar 15, 2033	DP		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051	003	11759501	Mar 15, 2033	DP		
		11759502	Mar 15, 2033	DP		
		11759503	Mar 15, 2033	DP		
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256	001	11752198	Aug 24, 2038	DP U-3162	NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256	002	11752198	Aug 24, 2038	DP U-3162	NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256	003	11752198	Aug 24, 2038	DP U-3162	NPP	Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256	004	11752198	Aug 24, 2038	DP U-3162	D-190 NPP	Jul 21, 2026 Dec 23, 2025
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256	005	11752198	Aug 24, 2038	DP U-3162	NPP	Dec 23, 2025
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793	001				ODE-402	Jun 16, 2029
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845	001				M-287	Jan 31, 2026
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473	001				M-287	Jan 31, 2026
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109	001				M-287	Jan 31, 2026
<u>SILDENAFIL CITRATE - LIOREV</u>						
N 214952	001	11337979	Dec 24, 2038	DP U-3582		
		11464778	Dec 24, 2038	DP U-3582		
		11759468	Dec 24, 2038	DP U-3582		
<u>SINCALIDE - SINCALIDE</u>						
N 210850	001	11737983	Apr 20, 2038	DP U-3482		
		11737983	Apr 20, 2038	DP U-3689		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIROLIMUS - FYARRO</u>						
N 213312	001				ODE-386	Nov 22, 2028
<u>SIROLIMUS - HYFTOR</u>						
N 213478	001				ODE-391	Mar 22, 2029
<u>SODIUM BENZOATE; SODIUM PHENYLACETATE - SODIUM PHENYLACETATE AND SODIUM BENZOATE</u>						
A 217526	001				CGT	Mar 17, 2024
<u>SODIUM CHLORIDE - SODIUM CHLORIDE 23.4%</u>						
A 217796	001				CGT	Jan 23, 2024
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444	001	11753301	Feb 10, 2030	DS DP U-3681		
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755	001	10272062	Jul 21, 2037	DP	NP	May 01, 2026
		10736866	Jul 21, 2037	DP	ODE-431	May 01, 2030
		10925844	Feb 28, 2040	DP		
		10952986	Jul 21, 2037	U-3601		
		10973795	Jul 21, 2037	DP		
		11000498	Jul 21, 2037	DP U-3580		
		11052061	Jul 21, 2037	DP		
		11065224	Jul 21, 2037	DP		
		11400065	Jul 21, 2037	U-3579		
		11504347	Jul 21, 2037	DP		
		11583510	Feb 07, 2042	U-3578		
		11602512	Jul 21, 2037	U-3577		
		11602513	Jul 21, 2037	U-3576		
		11766418	Jul 21, 2037	DP		
	>A>	11779557	Mar 16, 2042	U-3705		
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755	002	10272062	Jul 21, 2037	DP	NP	May 01, 2026
		10736866	Jul 21, 2037	DP	ODE-431	May 01, 2030
		10925844	Feb 28, 2040	DP		
		10952986	Jul 21, 2037	U-3601		
		10973795	Jul 21, 2037	DP		
		11000498	Jul 21, 2037	DP U-3580		
		11052061	Jul 21, 2037	DP		
		11065224	Jul 21, 2037	DP		
		11400065	Jul 21, 2037	U-3579		
		11504347	Jul 21, 2037	DP		
		11583510	Feb 07, 2042	U-3578		
		11602512	Jul 21, 2037	U-3577		
		11602513	Jul 21, 2037	U-3576		
		11766418	Jul 21, 2037	DP		
	>A>	11779557	Mar 16, 2042	U-3705		
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755	003	10272062	Jul 21, 2037	DP	NP	May 01, 2026
		10736866	Jul 21, 2037	DP	ODE-431	May 01, 2030
		10925844	Feb 28, 2040	DP		
		10952986	Jul 21, 2037	U-3601		
		10973795	Jul 21, 2037	DP		
		11000498	Jul 21, 2037	DP U-3580		
		11052061	Jul 21, 2037	DP		
		11065224	Jul 21, 2037	DP		
		11400065	Jul 21, 2037	U-3579		
		11504347	Jul 21, 2037	DP		
		11583510	Feb 07, 2042	U-3578		
		11602512	Jul 21, 2037	U-3577		
		11602513	Jul 21, 2037	U-3576		
		11766418	Jul 21, 2037	DP		
	>A>	11779557	Mar 16, 2042	U-3705		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
	11766418	Jul 21, 2037	DP			
>A>	11779557	Mar 16, 2042	U-3705			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 001	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 002	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 003	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 004	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 005	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 006	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE; TAURURSODIOL - RELYVRIO</u>						
N 216660 001	11583542	Jul 27, 2040	DP		ODE-411	Sep 29, 2029
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	11753301	Feb 10, 2030	DS DP U-3682			
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937 001	10596190	Jan 05, 2038	U-3443	Y	ODE-384	Sep 20, 2029
	11617793	Jul 01, 2039	DP			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	11738044	Oct 14, 2035	U-2312			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	11738044	Oct 14, 2035	U-2312			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 001	11707479	Jan 30, 2034	DP U-1470			
	11707479*PED	Jul 30, 2034				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 002	11707479	Jan 30, 2034	DP U-1470			
	11707479*PED	Jul 30, 2034				
<u>SOLIFENACIN SUCCINATE - VESICARE LS</u>						
N 209529 001					NP W	May 26, 2023 Nov 26, 2023
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	11160779	Mar 19, 2040	U-3521			
	11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP U-3520			
	11648232	Jun 01, 2038	U-3602			
	11753368	Jun 07, 2026	U-2548			
	11771666	Dec 30, 2042	U-3693			
	11771667	Dec 30, 2042	U-3693			
>A>	11779554	Dec 30, 2042	U-3693			
>A>	11793776	Dec 30, 2042	U-3693			
	8440715	Jun 11, 2031	U-2548			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11160779	Mar 19, 2040	U-3521			
	11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP U-3520			
	11648232	Jun 01, 2038	U-3602			
	11753368	Jun 07, 2026	U-2548			
	11771666	Dec 30, 2042	U-3693			
	11771667	Dec 30, 2042	U-3693			
>A>	11779554	Dec 30, 2042	U-3693			
>A>	11793776	Dec 30, 2042	U-3693			
	8440715	Jun 11, 2031	U-2548			
<u>SOTAGLIFLOZIN - INPEFA</u>						
N 216203 001	7781577	May 04, 2028	DS DP U-3628		NCE	May 26, 2028
	8217156	Oct 07, 2030	DS DP			
	8476413	May 29, 2028	DS DP U-3628			
<u>SOTAGLIFLOZIN - INPEFA</u>						
N 216203 002	7781577	May 04, 2028	DS DP U-3628		NCE	May 26, 2028
	8217156	Oct 07, 2030	DS DP			
	8476413	May 29, 2028	DS DP U-3628			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	10512620	Aug 14, 2038	U-2769			
	10512620	Aug 14, 2038	U-3547			
	10799138	Apr 05, 2039	U-3125			
	10799138	Apr 05, 2039	U-3549			
	11583216	Aug 21, 2039	U-3549			
	11696902	Aug 14, 2038	U-2769			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001	11426404	Sep 15, 2040	U-3306			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 002	10519146	May 21, 2038	DS DP		NCE	May 28, 2026
	11236091	May 20, 2040	DS DP U-3306		ODE-352	May 28, 2028
	11426404	Sep 15, 2040	U-3306			
<u>SPARSENTAN - FILSPARI</u>						
N 216403 001	9993461	Mar 29, 2030	U-3269		NCE ODE-389	Feb 17, 2028 Feb 17, 2030

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SPARSENTAN - FILSPARI</u>						
N 216403 001	9993461	Mar 29, 2030	U-3269		NCE ODE-389	Feb 17, 2028 Feb 17, 2030
<u>SPARSENTAN - FILSPARI</u>						
N 216403 002	9993461	Mar 29, 2030	U-3269		NCE ODE-389	Feb 17, 2028 Feb 17, 2030
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 001					ODE-403	Jul 14, 2029
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 002					ODE-403	Jul 14, 2029
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223 001					ODE-403	Jul 14, 2029
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223 002					ODE-403	Jul 14, 2029
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	11672738	Feb 02, 2038	DP			
	11676691	Mar 16, 2030	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001					M-291	Jan 22, 2024
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002					M-291	Jan 22, 2024
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	11723869	May 15, 2039	DP U-3666			
	11723869	May 15, 2039	DP U-3667			
	11723869	May 15, 2039	DP U-3668			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	11571531	Feb 23, 2026	U-1809			
<u>TADALAFIL - TADLIO</u>						
N 214522 001	11666576	Dec 24, 2038	DP U-3397			
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	11744828	Dec 02, 2035	U-2582			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 001	10780088	Jul 27, 2029	U-3651		I-920	Jun 20, 2026
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 003	10780088	Jul 27, 2029	U-3651		I-920	Jun 20, 2026
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 005	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651		NCE	Oct 16, 2023
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 006	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 006	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 001					NPP	Jul 03, 2026
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 002					NPP	Jul 03, 2026
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 003					NPP	Jul 03, 2026
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 203794 001					NPP	Jul 03, 2026
<u>TAPINAROF - VTAMA</u>						
N 215272 001	11590088	Nov 13, 2039		U-2625		
	11597692	Nov 13, 2038	DS DP			
	11612573	May 19, 2036		U-2625		
	11617724	May 19, 2036	DP			
	11622945	May 19, 2036	DP			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	11566011	Feb 12, 2035	DS DP			
	11633377	Jan 25, 2033		U-2149		
	11633377	Jan 25, 2033		U-3003		
>A>	11759446	Feb 21, 2041		U-3003		
>A>	11760740	Feb 12, 2035	DS DP			
<u>TASIMELTEON - HETLIOZ LQ</u>						
N 214517 001	11566011	Feb 12, 2035	DS DP			
	11633377	Jan 25, 2033		U-3003		
>A>	11759446	Feb 21, 2041		U-3003		
>A>	11760740	Feb 12, 2035	DS DP			
<u>TAZAROTENE - ARAZLO</u>						
N 211882 001	11679116	Jun 06, 2036	DP			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	8410088	Jan 23, 2034	DS DP			
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209549 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209549 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209601 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209601 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209613 001					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209613 002					PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209638 001					PC	Sep 08, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209638	002				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209663	001				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209663	002				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209668	001				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209668	002				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209690	001				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209690	002				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209700	001				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209700	002				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209710	001				PC	Sep 08, 2023
<u>TERIFLUNOMIDE - TERIFLUNOMIDE</u>						
A 209710	002				PC	Sep 08, 2023
<u>TERIPARATIDE - FORTEO</u>						
N 021318	001				>A> M-302	Nov 16, 2023
<u>TERIPARATIDE - FORTEO</u>						
N 021318	002				>A> M-302	Nov 16, 2023
<u>TERLIPRESSIN ACETATE - TERLIVAZ</u>						
N 022231	001	>A> 10335452	Apr 05, 2037	U-3711	ODE-406	Sep 14, 2029
<u>TESTOSTERONE CYPIONATE - TESTOSTERONE CYPIONATE</u>						
N 216318	001	11642355	Mar 25, 2039	DP		
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863	001	>A> 11771646	Apr 10, 2034	DP		
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863	002	>A> 11771646	Apr 10, 2034	DP		
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863	003	>A> 11771646	Apr 10, 2034	DP		
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089	001	11564933	Apr 12, 2039	U-1103		
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089	002	11564933	Apr 12, 2039	U-1103		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	11564933	Apr 12, 2039	U-1103			
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	11559530	Nov 28, 2037	U-1500			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 001	11590146	Dec 31, 2030	DP			
	11617758	Mar 15, 2033	DP U-2506			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 002	11590146	Dec 31, 2030	DP			
	11617758	Mar 15, 2033	DP U-2506			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 003	11590146	Dec 31, 2030	DP			
	11617758	Mar 15, 2033	DP U-2506			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	10456399	Feb 03, 2037	U-3657			
	10456399	Feb 03, 2037	U-3658			
	10960004	Feb 03, 2037	U-3657			
	10960004	Feb 03, 2037	U-3658			
	9943537	Sep 05, 2034	U-3659			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
	RE46284	Sep 22, 2029	U-3656			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	10456399	Feb 03, 2037	U-3657			
	10456399	Feb 03, 2037	U-3658			
	10960004	Feb 03, 2037	U-3657			
	10960004	Feb 03, 2037	U-3658			
	9943537	Sep 05, 2034	U-3659			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
	RE46284	Sep 22, 2029	U-3656			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2024	DS DP U-3100			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2024	DS DP U-3100			
<u>TOFENSEN - QALSODY</u>						
N 215887 001	10385341	Apr 01, 2035	DS DP		NCE	Apr 25, 2028
	10669546	Apr 01, 2035	U-3575		ODE-432	Apr 25, 2030
	10968453	Apr 01, 2035	U-3575			
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	11633374	Aug 21, 2040	DP			
<u>TRAMADOL HYDROCHLORIDE - ODOLO</u>						
N 214044 001	11752103	Sep 01, 2040	DP U-3197			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025			U-1581	
	8835443	Jun 10, 2025			U-1582	
	8835443	Jun 10, 2025			U-2020	
	8835443	Jun 10, 2025			U-2037	
	8835443	Jun 10, 2025			U-2302	
	8835443	Jun 10, 2025			U-2305	
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030			U-2020	
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	10869869	Aug 30, 2033		U-3184	I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025			U-1581	
	8835443	Jun 10, 2025			U-1582	
	8835443	Jun 10, 2025			U-2020	
	8835443	Jun 10, 2025			U-2037	
	8835443	Jun 10, 2025			U-2302	
	8835443	Jun 10, 2025			U-2305	
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030			U-2020	
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	10869869	Aug 30, 2033		U-3184	I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025			U-1581	
	8835443	Jun 10, 2025			U-1582	
	8835443	Jun 10, 2025			U-2020	
	8835443	Jun 10, 2025			U-2037	
	8835443	Jun 10, 2025			U-2302	
	8835443	Jun 10, 2025			U-2305	
	8835443*PED	Dec 10, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 217513 001	7378423	May 29, 2027	DS DP		NP	Mar 16, 2026
	8703781	Oct 15, 2030	DS DP U-3564		ODE-428	Mar 16, 2030
	8835443	Jun 10, 2025	U-3564			
<u>TRANEXAMIC ACID - TRANEXAMIC ACID</u>						
A 217155 001					>A> CGT	Apr 16, 2024
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 005	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 006	>A> 11723887	Dec 15, 2028	DS			
	>A> 7999007	Mar 29, 2029	DP U-1437			
	>A> 8653137	Sep 05, 2028	U-1437			
	>A> 8658694	Sep 05, 2028	U-1437			
	>A> 9199908	May 24, 2024	U-1771			
	>A> 9593066	Dec 15, 2028	DS			
	>A> 9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 007	>A> 11723887	Dec 15, 2028	DS			
	>A> 7999007	Mar 29, 2029	DP U-1437			
	>A> 8653137	Sep 05, 2028	U-1437			
	>A> 8658694	Sep 05, 2028	U-1437			
	>A> 9199908	May 24, 2024	U-1771			
	>A> 9593066	Dec 15, 2028	DS			
	>A> 9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 008	>A> 11723887	Dec 15, 2028	DS			
	>A> 7999007	Mar 29, 2029	DP U-1437			
	>A> 8653137	Sep 05, 2028	U-1437			
	>A> 8658694	Sep 05, 2028	U-1437			
	>A> 9199908	May 24, 2024	U-1771			
	>A> 9593066	Dec 15, 2028	DS			
	>A> 9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	11723887	Dec 15, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	11723887	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	11723887	Dec 15, 2028	DS			
<u>TRETINOIN - TRETINOIN MICROSPHERE</u>						
A 215609 001					CGT	Mar 06, 2024
<u>TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR</u>						
N 215760 001					ODE-401	Apr 28, 2029
<u>TRIFAROTENE - AKLIEF</u>						
N 211527 001	7807708	Jul 19, 2031	DS DP			
<u>TRIHEPTANOIN - DOJOLVI</u>						
N 213687 001	>A> 8697748	Apr 28, 2029	DP			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	11529352	Jul 23, 2039	U-3504			
	11717523	Mar 14, 2034	U-3678			
	11717523	Mar 14, 2034	U-3679			
<u>TROFINETIDE - DAYBUE</u>						
N 217026 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	9212204	Jan 27, 2032	U-3556		ODE-425	Mar 10, 2030
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324	Apr 27, 2038	U-3510		I-906 ODE-422	Jan 19, 2026 Jan 19, 2030
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3510		I-906 ODE-422	Jan 19, 2026 Jan 19, 2030
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	11717515	Dec 22, 2041	U-3677			
	8912210	Dec 23, 2033	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	8912210	Dec 23, 2033	DS DP			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	11524964	Oct 17, 2036	U-3371		I-919	May 18, 2026
	11535624	Oct 17, 2036	U-3255			
	11535625	Oct 17, 2036	U-3298			
	11564922	Mar 09, 2038	U-3624			
	11607411	Mar 09, 2038	U-3341			
	11661425	Oct 17, 2036	DS DP			
	11680069	Oct 17, 2036	DS DP			
	11718627	Oct 17, 2036	DS DP			
>A>	11767326	Oct 17, 2036	U-3298			
>A>	11773105	Oct 17, 2036	DS DP			
>A>	11773106	Oct 17, 2036	U-3275			
>A>	11773106	Oct 17, 2036	U-3371			
>A>	11773106	Oct 17, 2036	U-3487			
	8962629	Jan 15, 2031	DS U-3255			
	8962629	Jan 15, 2031	DS U-3275			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3371			
	8962629	Jan 15, 2031	DS U-3624			
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	11535626	Oct 17, 2036	U-3298		I-919	May 18, 2026
	11564922	Mar 09, 2038	U-3624			
	11607411	Mar 09, 2038	U-3341			
	11661425	Oct 17, 2036	DS DP			
	11680069	Oct 17, 2036	DS DP			
	11718627	Oct 17, 2036	DS DP			
>A>	11767326	Oct 17, 2036	U-3298			
>A>	11773105	Oct 17, 2036	DS DP			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3624			
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	11564922	Mar 09, 2038	U-3624		I-919	May 18, 2026
	11607411	Mar 09, 2038	U-3341			
	11661425	Oct 17, 2036	DS DP			
	11680069	Oct 17, 2036	DS DP			
	11718627	Oct 17, 2036	DS DP			
>A>	11773105	Oct 17, 2036	DS DP			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3624			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	10065952	Oct 28, 2036	DS DP U-1995		ODE-440	Aug 18, 2030
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	10065952	Oct 28, 2036	DS DP U-1995		ODE-440	Aug 18, 2030
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	10065952	Oct 28, 2036	DS DP U-1995		ODE-440	Aug 18, 2030
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 003	10065952	Oct 28, 2036	DS DP U-1995		ODE-440	Aug 18, 2030
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 003	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VANCOMYCIN - VANCOMYCIN</u>						
N 213895 001	11517609	Nov 06, 2035	U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
A 214913 001					PC	Feb 25, 2024
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
A 214913 002					PC	Feb 25, 2024
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
A 215338 001					CGT	Dec 20, 2023
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
A 217489 001					CGT	Feb 12, 2024
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
A 217489 002					CGT	Feb 12, 2024
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001	11638692	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002	11638692	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 005	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 006	11628200	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 007	11628200	Nov 06, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 006	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	11590128	Sep 06, 2033	U-3548			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	11590128	Sep 06, 2033	U-3548			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	11590128	Sep 06, 2033	U-3548			
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	11622991	Dec 07, 2037	U-3056			
	>A> 7332472	Oct 17, 2024	DS DP U-3056			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	11458134	Jun 15, 2027	DP U-3463		M-232	Aug 23, 2026
	11458134*PED	Dec 15, 2027			PED	Feb 23, 2027
	7144884	Jun 17, 2026	DS DP U-1439			
	7144884*PED	Dec 17, 2026				
	8722684	Jun 30, 2031	DS DP			
	8722684*PED	Dec 30, 2031				
	8969355	Jun 15, 2027	U-1668			
	8969355*PED	Dec 15, 2027				
	9125908	Jun 15, 2027	U-2309			
	9125908*PED	Dec 15, 2027				
	9125909	Jun 15, 2027	U-2309			
	9125909*PED	Dec 15, 2027				
	9125910	Jun 15, 2027	U-2309			
	9125910*PED	Dec 15, 2027				
	9227946	Jun 15, 2027	U-1668			
	9227946*PED	Dec 15, 2027				
	9278096	Mar 21, 2032	U-2436			
	9278096*PED	Sep 21, 2032				
	9861630	Jun 15, 2027	U-1668			
	9861630*PED	Dec 15, 2027				
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	11458134	Jun 15, 2027	DP U-3463		M-232	Aug 23, 2026
	11458134*PED	Dec 15, 2027			PED	Feb 23, 2027
	7144884	Jun 17, 2026	DS DP U-1439			
	7144884*PED	Dec 17, 2026				
	8722684	Jun 30, 2031	DS DP			
	8722684*PED	Dec 30, 2031				
	8969355	Jun 15, 2027	U-1668			
	8969355*PED	Dec 15, 2027				
	9125908	Jun 15, 2027	U-2309			
	9125908*PED	Dec 15, 2027				
	9125909	Jun 15, 2027	U-2309			
	9125909*PED	Dec 15, 2027				
	9125910	Jun 15, 2027	U-2309			
	9125910*PED	Dec 15, 2027				
	9227946	Jun 15, 2027	U-1668			
	9227946*PED	Dec 15, 2027				
	9278096	Mar 21, 2032	U-2436			
	9278096*PED	Sep 21, 2032				
	9861630	Jun 15, 2027	U-1668			
	9861630*PED	Dec 15, 2027				
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	11458134	Jun 15, 2027	DP U-3463		M-232	Aug 23, 2026
	11458134*PED	Dec 15, 2027			PED	Feb 23, 2027
	7144884	Jun 17, 2026	DS DP U-1439			
	7144884*PED	Dec 17, 2026				
	8722684	Jun 30, 2031	DS DP			
	8722684*PED	Dec 30, 2031				
	8969355	Jun 15, 2027	U-1668			
	8969355*PED	Dec 15, 2027				
	9125908	Jun 15, 2027	U-2309			
	9125908*PED	Dec 15, 2027				
	9125909	Jun 15, 2027	U-2309			
	9125909*PED	Dec 15, 2027				
	9125910	Jun 15, 2027	U-2309			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9125910*PED	Dec 15, 2027				
	9227946	Jun 15, 2027	U-1668			
	9227946*PED	Dec 15, 2027				
	9278096	Mar 21, 2032	U-2436			
	9278096*PED	Sep 21, 2032				
	9861630	Jun 15, 2027	U-1668			
	9861630*PED	Dec 15, 2027				
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	11458134	Jun 15, 2027	DP U-3463		M-232	Aug 23, 2026
	11458134*PED	Dec 15, 2027			PED	Feb 23, 2027
	7144884	Jun 17, 2026	DS DP U-1439			
	7144884*PED	Dec 17, 2026				
	8722684	Jun 30, 2031	DS DP			
	8722684*PED	Dec 30, 2031				
	8969355	Jun 15, 2027	U-1668			
	8969355*PED	Dec 15, 2027				
	9125908	Jun 15, 2027	U-2309			
	9125908*PED	Dec 15, 2027				
	9125909	Jun 15, 2027	U-2309			
	9125909*PED	Dec 15, 2027				
	9125910	Jun 15, 2027	U-2309			
	9125910*PED	Dec 15, 2027				
	9227946	Jun 15, 2027	U-1668			
	9227946*PED	Dec 15, 2027				
	9278096	Mar 21, 2032	U-2436			
	9278096*PED	Sep 21, 2032				
	9861630	Jun 15, 2027	U-1668			
	9861630*PED	Dec 15, 2027				
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001					ODE-387	Nov 19, 2028
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002					ODE-387	Nov 19, 2028
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003					ODE-387	Nov 19, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001					ODE-394	Dec 17, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002					ODE-394	Dec 17, 2028
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001					ODE-394	Dec 17, 2028
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001					ODE-212	Jun 13, 2029
<u>XENON XE-129 HYPERPOLARIZED - XENOVUE</u>						
N 214375 001	10583205	Feb 20, 2035	DP		NCE	Dec 23, 2027
	11052161	Dec 29, 2035	DP			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-817	Jan 19, 2026
	10570139	Apr 22, 2034	U-2145		ODE-274	Jan 19, 2030
	10570139	Apr 22, 2034	U-2537			
	10570139	Apr 22, 2034	U-2666			
	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11591340	Aug 15, 2037	U-1745			
	11591340	Aug 15, 2037	U-2145			
	11591340	Aug 15, 2037	U-2537			
	11591340	Aug 15, 2037	U-2666			
	11591340	Aug 15, 2037	U-3063			
	11591340	Aug 15, 2037	U-3486			
	>A> 11786531	Jan 19, 2043	U-3715			
	>A> 11786531	Jan 19, 2043	U-3716			
	>A> 11786531	Jan 19, 2043	U-3717			
	>A> 11786531	Jan 19, 2043	U-3718			
	>A> 11786531	Jan 19, 2043	U-3719			
	>A> 11786531	Jan 19, 2043	U-3720			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
<u>ZAVEGEPANT HYDROCHLORIDE - ZAVZPRET</u>						
N 216386 001	7220862	Jan 21, 2024	DS DP		NCE	Mar 09, 2028
	7314883	Dec 05, 2023	U-3555			
	8481546	Oct 07, 2031	DS DP U-3555			
<u>ZINC SULFATE - ZINC SULFATE</u>						
A 216145 001					CGT	Aug 14, 2023
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001				>A>	NCE	Oct 31, 2028
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002				>A>	NCE	Oct 31, 2028
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003				>A>	NCE	Oct 31, 2028

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 43rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm